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The respiratory tract lining fluid (RTLF) is the first physical interface with which inhaled 
materials and aerosolised drugs come into contact in the airways. Surrounding the 
underlying epithelial cells, the RTLFs are composed of a thin amphipathic layer, 
providing crucial physiological and protective roles across the airways. The aim of this 
thesis was to investigate the composition of this extracellular compartment using human 
lavage samples from healthy volunteers, asthmatics and patients with Chronic Obstructive 
Pulmonary Disease (COPD) to guide the development of a series of lung lining fluid 
simulants for the testing of inhaled drugs. Analysis across nasal, bronchial and alveolar 
compartments revealed marked compositional differences throughout the respiratory tract 
in healthy individuals, with significant differences also observed with age, smoking status 
and the presence of established respiratory disease. Within the asthmatic group I observed 
evidence of an impaired microbicidal defense network at the air-lung interface, with 
significant depression of innate immunity proteins in the bronchial RTLFs associated 
with elevated concentrations of bacterial cell wall components. In the lavage samples 
obtained from healthy aged populations a general dysregulation of immunity and 
inflammatory processes was observed, alongside a pro-oxidant shift in the redox balance. 
In COPD, characteristic pathological changes were identified, from evidence of chronic 
inflammation, to protease-antiprotease imbalance and oxidative stress. In addition, I 
obtained preliminary evidence of dysregulated metal homeostasis, superimposed on 
compositional protein signatures characteristic of normal physiologic ageing. Clear 
differences in the composition of the RTLF could be attributed to smoking; with the 
greatest number of proteins identified (234) in the RTLFs of COPD smokers, in stark 
contrast to only 58 proteins accounted for within the COPD ex-smoking proteome. This 
extensive characterization of the RTLFs was used to successfully develop a 
physiologically representative ‘base model’; the suitability of which was assessed in a 
series of preliminary studies, focusing on particle and cellular interactions (nanoparticle 
characterization and biocompatibility with in vitro cell lines). These fundamental 
applications will be significant in evolving both understanding the behaviour of inhaled 
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The lung has long been targeted for the localized delivery of pulmonary 
medicines in the treatment of respiratory diseases, particularly asthma and COPD. 
However with new pharmaceutical technologies and the development of novel classes of 
therapeutic agents (e.g. peptides), which are delivered less effectively through common 
routes of administration, pulmonary drug delivery is an increasingly attractive target for 
the systemic delivery of medicines (Forbes and Erhadt, 2005; Takizawa, 2009; Agu and 
Ugwoke, 2011). The various advantages of the inhaled delivery route include the large 
alveolar surface area for drug absorption, the extensive vascularization, low epithelial 
barrier thickness, low enzymatic metabolic activity and absence of the first-pass 
metabolism effect of the liver (Courrier et al., 2002; El-Sherbiny, 2010).  Accordingly, 
the delivery of drugs via the lungs has undergone significant development, both in terms 
of delivery devices and formulation. Thus there is an urgent need to develop and improve 
in vitro testing systems that reflect the in vivo interactions between inhaled drugs and 
components of the respiratory tract lining fluid that represent the interface between 
inhaled air and the respiratory epithelium (Forbes et al., 2010).  
These in vitro investigations are necessary to improve our understanding of the 
behaviour (aggregation, solubility, chemical modification) of inhaled particles at the air-
lung barrier. In vitro cell culture systems despite their well-documented limitations, allow 
investigations into the underlying mechanisms of action of inhaled medicines and 
particulates at the cellular and molecular level. Several cellular in vitro systems of the 
airways have been developed and are employed in investigations of drug absorption, 
transport, metabolism and toxicity. These include primary cultures and the 16HBE14o- 
and Calu-3 bronchial epithelial cell lines, considered to have representative airway barrier 
properties and commonly used to investigate drug permeability (Forbes, 2000; Mathias et 
al., 2002; Forbes et al., 2005). Whilst the development of in vitro cell culture models is 
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continuously evolving, models are often too simplistic and fail to replicate the complex 
interaction and behaviour of inhaled drugs and particles within the airways. 
The first physical interactions between materials inhaled into the airways are with 
the respiratory tract lining fluids (RTLFs) that overlay the underlying epithelial cells. The 
lungs consist of heterogeneous cell populations, both epithelial and inflammatory, which 
significantly influence the local composition of the RTLFs, through their secreted 
products resulting in dramatically differing compositional profiles throughout the 
respiratory tract, from the nasal to the alveolar regions. In the upper, mucus secreting 
airways, the RTLF exists as a double layer compartment comprised of an aqueous sol and 
an overlying gel layer, with the mucus layer promoting the trapping and clearance of 
microorganisms and particles via the operation of the mucociliary escalator. This 
contrasts significantly from the alveolar region where surfactant is secreted from Type II 
pneumocytes to prevent collapse. The composition of human RTLFs has also been shown 
to vary significantly in different airway pathologies from COPD, asthma, and various 
interstitial lung diseases, though the available data is often relatively scant due to the 
difficulty in obtaining lavage samples from patients with chronic airway diseases (Hatch, 
1992). 
With aerosol particle size used to target drug deposition to specific, 
therapeutically relevant regions of the airways, an understanding of drug interactions at 
the air-lung interface requires an appreciation of the variation in RTLF composition both 
regionally within the respiratory tract and in different target patient groups. Drug particles 
targeting the respiratory tract are within a narrow size range, typically 0.5-5µm, 
sufficiently small to pass through the conducting airways (not trapped by the mucus layer 
as occurs for larger particle sizes), but large enough in aerodynamic diameter to ensure 
their efficient deposition in the airways without significant losses due to exhalation or 
swallowing after impaction in the oropharyngeal region (Barnes and Liew, 1995; Bao and 
Zhao, 2010; Agu and Ugwoke, 2011). Of those particles depositing, the mucociliary 
escalator is the dominant mechanism of clearance in the upper respiratory tract. Those 
that deposit deeper within the distal airways may be cleared by the process of dissolution 
in addition to other processes, including clearance by alveolar macrophages (Ahsan et al., 
2002; Davies and Feddah, 2003; Makino et al., 2003). In addition to particle 
characteristics, patient variables such as airway morphometry, breathing pattern, age and 
disease will also influence the deposition and effectiveness of inhaled medicines (Fischer 
et al., 2009; Agu and Ugwoke, 2011).  
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In vitro methods to establish the fate and interactions of inhaled particles 
depositing within the airways are therefore vital to an improved understanding of their 
likely therapeutic or toxicological impacts upon the lung. It is consequently important that 
in vitro models of the airways are truly reflective of what occurs in vivo, focusing on 
interactions with the lung lining fluids, as well as the subsequent cellular interactions to 
permit the most accurate and realistic testing of particulate behavior. The complexity and 
regional heterogeneity of the lung however presents challenges to both in vitro and in vivo 
testing methods (Agu and Ugwoke, 2011). Currently no single standardized in vitro test 
for inhaled formulations simulating the interactions with human RTLFs has been put into 
place (Son and McConville, 2009). 
Interestingly, in the research fields of medical geochemistry and environmental 
sciences, the use of simulated extracellular lung fluids has become an integral part of in 
vitro investigations (Plumlee et al., 2006). The importance of using simulated lung fluids 
for the in vitro testing of dust soils, earth materials, metals, uranium, silica and asbestos to 
assess particulate behaviour - dissolution, solubility, bioavailability and influence on 
oxidative rate in the lung, have been well described in the literature (De Meringo et al., 
1994; Herting et al., 2006; Sdraulig et al., 2007). Although the majority of studies have 
used a relatively simplistic model for the simulated lung fluid, they also illustrate the 
importance of the use of biorelevant in vitro models in assessing inhaled particulate 
behaviour (De Meringo et al., 1994). 
In addition, the development of simulated intestinal fluids to evaluate the 
disintegration, dissolution and solids transfer of orally administered drugs in vitro, has 
demonstrated the importance of biorelevant media use throughout the drug development 
process. If such tests are not performed under appropriate conditions the drug release 
profiles obtained are often erroneous (Dressman et al., 1998). With in vitro testing 
methods required as part of the development of new formulations, quality control 
purposes and, in determining bioequivalence, the more physiologically relevant the 
media, the more likely in vitro in vivo correlation can be achieved. There is therefore an 
urgent need to develop simulant models better able to predict the in vivo performance of 
inhaled medicines and inform the development of pharmaceutical preparations. The great 
complexity and regional variation of the human RTLFs present many challenges to the 
design of such simulant models, requiring a detailed characterisation of RTLF 
components in both health and disease. This is the main objective of the work described 
in this thesis; with the ultimate aim of providing information relevant to the design of 
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disease specific simulated models for the testing of inhaled drug behavior at the surface of 
the lung.  
 
The specific aims of this study are therefore three-fold: 
 First to investigate the composition of the major components of the RTLFs, across the 
nasal, bronchial and alveolar compartments of the respiratory tract, to inform the 
production of realistic simulants for the screening of drug behaviour at the surface of 
the lung. 
 Further, to investigate compositional differences in the RTLF between patient groups 
likely to be the end users of inhaled medicines: aged individuals, asthmatics, and 
patients with COPD. 
 Finally, to construct a base RTLF simulant and assess both its impact on particulate 
behaviour and biocompatibility with commonly used pulmonary cell lines 
 
2: The respiratory tract lining fluids 
2.1: Sampling methods:  
 
A considerable body of information on RTLF composition has been published 
since the 1970s. However, to fully evaluate these data it is both necessary to understand 
the methodologies employed to obtain these samples from the human lung, as well as the 
conventions employed in expressing the measured concentrations of RTLF constituents. 
By the use of various catheters and bronchoscopes (Jackson, 1904; Carlens, 1942; Ikeda, 
1968), washings to obtain various secretions and cellular components of the airways have 
been performed for many decades. Retrieving samples and washings of RTLFs continues 
to be routinely performed in the clinical setting as a therapeutic tool, as part of the 
diagnosis and monitoring of airway disorders. Early studies described the use of large 
volume saline instillations and segmental washing of the airways as a means to remove 
‘material’ from the lungs as part of the therapeutic strategy for respiratory failure 
(Ramirez et al., 1963; Rogers et al., 1972; Reynolds, 2011). In addition, sampling 
procedures have also provided researchers a way in which to investigate the various 
extracellular (and the cellular) components of the RTLF, and consequently develop a 
more comprehensive understanding of its composition (Reynolds, 2011). The assumption 
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being that fluid instilled into the airways interacts with the fluid compartment overlaying 
the respiratory epithelium, such that the retrieved aspirate effectively represents a dilute 
sample of these fluids (Walters and Gardiner, 1991).  
 
2.2:  Bronchoalveolar lavage and bronchial wash  
 
The method of bronchoalveolar lavage (BAL) was first used in the treatment of 
several airway diseases (including alveolar proteinosis, cystic fibrosis and bronchitis) to 
‘wash out’ purulent secretions accumulated within the lung with large volumes of saline. 
Subsequently it has become the most common approach used to sample the RTLF 
samples from the distal lung. Samples obtained with this method were used to achieve the 
first real descriptions of the cellular and non cellular composition of the lower respiratory 
tract (Finley et al., 1967; Reynolds and Newball, 1974; Reynolds, 2008). The most 
common BAL procedure routinely employs a fiber-optic bronchoscope gently wedged,  
into a subsegmental bronchus, through which a volume of buffered saline (37oC) is 
instilled into the airway and recovered by aspiration and suction (Walters and Gardiner, 
1991). Large volume lavages (150-180 mL) to sample distal airway secretions are usually 
achieved by consecutive instillations of 50-60 mLs of buffered saline, with aspiration 
after each aliquot and the consecutive returns pooled to provide a single highly dilute 
sample. The procedural factors that are considered to cause most significant variability in 
the concentration of lavage cellular and non-cellular components include lavage dwell 
time, the volume of saline instilled, the number of instilled aliquots and the 
inclusion/exclusion of the first lavage instillment (Shields and Riedler, 2000). Notably 
lavage methods vary noticeably between research groups (as Table 1.1 illustrates) and a 
standardised procedure for BAL and the reporting of solute concentrations has yet to be 
put in place (Merrill et al., 1982; Walters and Gardiner, 1991; Reynolds, 2000). 
Bronchial airway lining fluid samples may also be sampled using small fixed 
volume aliquots (Kelly et al., 1987). Alternatively the first aliquot of saline recovered 
during the BAL procedure can be collected as a separate sample to reflect more proximal 
airway secretions (Shields and Riedler, 2000). The subsequent mixing of instilled saline 
during the lavage procedure within the respiratory compartments has been described as a 
complicating factor worth consideration, with the majority of research groups using BAL 
pooling aspirated aliquots (Duddridge et al., 1988; Walters and Gardiner, 1991). It has 
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been suggested that cellular indicators (ciliated bronchial cells vs. squamous cells) can be 
used to separate aspirated aliquots on the basis of region of the airway sampled (Haslam 
and Baughman, 1999), with samples retrieved from bronchial wash typically displaying a 
low total cell count and a high percentage ratio of neutrophils to macrophages (Shields, 
2000). 
 
2.3: Lavage dilution correction methods – determining and reporting ELF 
concentrations 
 
Despite the wealth of information that has been provided using lavage-based 
techniques, the considerable dilution of the sampled RTLF remains a great problem. The 
instillation of large volume aliquots of saline results in what is essentially a dilution of an 
unknown volume of RTLFs, preventing the accurate quantification of soluble 
components. In addition, poor lavage recoveries, 20-60%, present an additional cause for 
uncertainty (Baughman, 1997; Shields and Riedler, 2000). Consequently, there is the 
need to implement an appropriate marker to correct for the dilution produced by lavage. 
The use of a reliable markers would greatly increase the quantitative robustness of data 
gathered (Feng et al., 1992), however as of yet no standardized inter-laboratory method 
for doing so has been implemented (Haslam and Baughman, 1999). Previously proposed 
and investigated markers of dilution have included external compounds: methylene blue, 
helium, radioactively labelled markers - 99mTc-diethylenetriaminepentaacetic acid, 
51Cr-ETDA, introduced into the instilled saline into the lung; or endogenous compounds 
including urea, albumin, or total protein. The use of such ‘internal’ markers requires prior 
knowledge of marker concentrations; both in the blood and lavage aspirate, and require 
that the marker in question should be freely permeable between the blood plasma and 
extra-vascular spaces with equivalent concentrations in these two fluids (Baughman, 
1997).  
The use of methylene blue as an exogenous marker for lavage correction was 
short lived, on account of its loss via diffusion from the airway surface and it’s binding to 
airway cells (Baughman, 1997; Rennard et al., 1986). To date no other external marker 
has been demonstrated to have the required characteristics for an effective dilution 
marker: safety, resistance to degradation, or uptake by calls, as well as displaying an even 
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distribution throughout the airway (Haslam and Baughman, 1999). Whilst various 
corrections for lavage dilution have been implemented, the use of the small molecular 
weight molecule urea has been the most commonly and widely adopted approach. 
 
 
Figure 1.1: A schematic illustration of lavage procedure and the use of external (EM) 
and internal markers (IM) in correcting for lavage dilution. This figure illustrates how 
the introduction of an external marker with saline instilled as part of the lavage process can 
thus be analysed from within aspirated fluid collected to determine the resulting dilution. 
Additionally the figure describes how the measurement of an internal marker present within 
RTLF of known concentration can be analysed in aspirated fluid as an alternative way in 
which to determine and correct for the lavage dilution.  
 
 
2.3.1: The Urea correction method  
Rennard et al (1986) were the first group to suggest the use of urea as an effective 
marker for the correction of lavage dilution. With no net charge at physiological pH, urea 
is neither used, nor produced by the cells of the respiratory tract and on account of the 
high permeability of the blood-air barrier, this 60Da molecule would in theory have 
equivalent concentrations in the RTLF and blood plasma. Thus, Rennard et al (1986) 
proposed that by the comparison of both plasma and lavage urea concentrations and the 
application of basic principles of dilution, one could determine with reasonable accuracy 
the dilution of the RTLF produced by airway lavage, which could then be used to 
estimate the concentrations of solutes within the RTLF. 
Since the use of urea as a marker of dilution was originally suggested, this 
relatively convenient method has become the most extensively applied for nornalising 
lavage solute concentrations. However it’s use in this manner relies heavily on the 
assumption that the concentrations of urea in plasma and the RTLF remain equivalent 
with no source of urea influx throughout the lavage procedure. Several studies have 
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however demonstrated the rapid influx of urea from blood plasma into the air-spaces, due 
to the combination of solute flux, passive diffusion and the increased epithelial and 
endothelial permeability created as a result of the lavage procedure itself (Marcy et al., 
1987; Duddridge et al., 1988; Effros et al., 1990; van de Graaf et al, 1991; Feng et al., 
1992). The reliability of the urea method of correcting for lavage dilution has therefore 
come into question, as urea influx into the lavage fluid complicates the interpretation of 
solute concentrations resulting in the underestimation of RTLF solute concentrations 
(Marcy et al., 1987; Walters and Gardiner, 1991). Clearly, therefore the length of time 
between saline instillation and aspiration, the  ‘dwell’ time will strongly influence lavage 
urea concentrations. The consensus view however is that using urea to normalise lavage 
dilutions is valid as long as dwell time is kept minimal (van de Graaf et al, 1991). Studies 
performed by van der Vliet et al (1999) further demonstrated increasing urea 
concentrations in successive saline instillations when a sequential lavage procedure was 
employed, and they proposed the use of a single-cycle lavage procedure to minimize urea 
influx to obtain more accurate and reliable determinations of RTLF solute concentrations. 
The reliability of urea correction has also been investigated with nasal lavage methods. 
Kaulbach et al (1993) have suggested it a reliable approach as a result of the minimal 
dwell time (30-60 seconds) associated with the procedure. However few investigators 
explicitly describe the lavage procedure followed when using this method or the RTLF 
dilution determined (as illustrated in Table 1.1). This time dependence in the diffusion of 
urea in lavage and the lack of a standardized procedure ultimately results in the wide 
range of RTLF solute concentrations that have been reported in the literature. 
 
2.3.2: Other correction methods 
In addition to the significant dilution problem associated with lavage, the varying 
methods for reporting RTLF solute concentrations often hinders the interpretation and 
understanding of the composition of the RTLF, both at baseline and in response to an 
acute insult. Reports of the cellular data retrieved from sampling methods have been 
remarkably consistent; however the concentrations of acellular components are greatly 
affected by variable dilutions produced by lavage (Haslam and Baughman, 1999). An 
approach for the standardised reporting of RTLF solute concentrations has often been 
proposed (Dargaville et al., 1999; Ward et al., 1993; Walters and Gardiner, 1991), but to 
date the reporting of lavage data in the literature remains inconsistent.  
The presentation of lavage data using RTLF volume as a denominator has been 
much discussed, however direct methods (including the urea method) used to determine 
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RTLF volume have tended to overestimate it considerably, for the reasons outlined 
previously (Rennard et al., 1986). A report carried out by the ERS task force suggested 
that concentrations per volume of lavage fluid cannot be correctly extrapolated to in vivo 
concentrations found in RTLF (Haslam and Baughman, 1999). Surface area and lining 
thickness measurements of each section of the airways via morphometric methods 
(Weibel, 1963; Crapo et al., 1983; Hatch, 1992) have been made and it has been 
suggested the calculation of morphological volumes using this data may allow for 
superior interpretation of RTLF solute concentration, though the data on which this is 
based on is rather limited (Hatch, 1992) and this approach requires an appreciation of the 
total area of the airway sampled. It is also likely to be limited due to unknown differences 
in RTLF volumes in disease, as well as simply in relation to inter-individual variation in 
airway structure and volume.   
The use of albumin, or total protein (predominately albumin in RTLFs) as 
denominators to which RTLF solute concentrations are expressed has also been proposed. 
As with urea, albumin diffuses into the lung lining fluid from the blood plasma (although 
less rapidly, due to its size) and is easily measurable (Baughman, 1997; Ward et al., 
1993). However the use of albumin has a number of limitations, as similar to urea, its use 
as a marker of sample dilution is based on its equilibrium across the blood-air barrier.  
With many pulmonary diseases associated with altered epithelial permeability, the use of 
albumin becomes questionable (Walters and Gardiner, 1991; Ward et al., 1993; 
Baughman, 1997; Dargaville et al, 1999; Haslam and Baughman, 1999). It has also been 
recommended that lavage solute concentrations could be exprerssed relative to another 
component, e.g. individual protein concentrations relative to the total protein 
measurements. This semi quantitative method may provide the best way to sensibly 
compare the concentrations of RTLF solute concentrations as it’s unaffected by dilution 
(Haslam and Baughman, 1999). It is noteworthy that very little has been published since 
the ERS task force lead by Haslam and Baughman (1999) fifteen years ago, probably 
reflecting the change in direction from invasive RTLF sampling procedures to a variety of 
less invasive ones, as discussed in the next section. 
 
2.4:  Nasal lavage, exhaled breath condensate and induced sputum collection 
Historically sampling of the distal airways required the use of invasive lavage 
procedures; however more recently less invasive methods have become more widely 
employed. In addition to being less expensive, both in absolute personal and equipment 
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costs, these methods are more amenable to volunteers and patients and also permit for 
more detailed time course investigations to be performed (Kelly and Mudway, 2003). 
Nasal lavage has been routinely employed in studies wishing to selectively sample the 
nasal airways. Similarly induced sputum has also become popular as a relatively non-
invasive method for obtaining bronchial airway lining fluids (Mutlu et al., 2001; Ratto et 
al., 2006). In addition the collection of exhaled breath condensate (EBC) to provide 
samples derived from the distal RTLFs has also become widespread. Critically, 
bronchoscopy-based lavage remains the gold standard of sampling methods and newer 
methods such as bronchoscopic microsampling have been developed that aim to sample 
the RTLFs directly.  
Non-invasive techniques to sample the RTLFs have been developed to counteract 
problems faced with lavage procedures. The collection of EBC has been developed as an 
inexpensive sampling procedure, as a potential substitute for BAL (in the research and 
clinical settings) based on the collection of ‘respiratory fluid droplets’ in exhaled air. 
Condensate samples are typically collected through exhalation into commercially 
available condensators, cooled with ice water and then dripped into polycarbonate tubes, 
with approximately one hour required to collect ~ 10ml (Effros et al., 2002; Effros et al., 
2003). Measured parameters from condensate samples have included: pH, total protein 
and phospholipid components of the airway lining fluids (Mutlu et al., 2001; Jackson et 
al., 2007). 
Limitations of this technique have however come to light. Concentrations of 
solutes found within EBC are greatly influenced by their physical properties (solubility, 
hydrophobicity etc.), in addition to their relative concentrations in the RTLFs. The site of 
origin of components recovered from these ‘respiratory droplets’ is also not fully clear, 
and it has been suggested that this approach provides a sample reflective of the whole of 
the respiratory tract from the mouth to the alveoli. With EBC said to sample a much 
larger area of the lung than BAL, the relative contributions of different regions of the lung 
to solute concentrations can therefore not be specified using this technique. EBC may also 
be contaminated by salivary components since it is collected orally, but to what extent 
this occurs is unclear and has lead to much contention within the published literature 
(Mutlu et al., 2001; Hunt, 2007; Jackson et al., 2007; Effros, 2010).  











Calculated ELF dilution 
Rennard et al., 1986 BAL 
5x20ml for 3 
sites 
30-45 seconds Urea 100 fold 
    
Albumin 8 fold 
Ward et al., 1993 BAL 3x60ml - Albumin n/d 
van de Graaf et al.,  1991 BAL 7x20ml - Urea n/d 
van der Vliet et al., 1999 BAL 5x20ml 2-3 minutes each Urea 
100 fold in initial fraction 
~30-40 fold in final 
 
BAL 1x60ml <1 minute 
 
100 fold in initial fraction 
~30-40 fold in final 
Baldwin et al.,  1991 BAL 1x20ml 20 seconds Urea and Total Protein n/d 
  
4x50ml 4 minutes total Urea and Total Protein n/d 
Dargaville et al.,  1999 BAL 3x1ml/kg 60-90 seconds 
Albumin, Total Protein, 
Urea 
n/d 
Sutinen  et al.,  1995 BAL 4x50ml - Urea n/d 
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To fully assess the potential of EBC, investigations comparing measured components to 
those obtained using bronchoscopy-based lavage are required. Jackson et al (2007) compared 
several biomarkers between EBC and BAL fluids, including various markers of inflammation 
(eNO, NOx and pH), as well as total protein, cytokine and phospholipid concentrations. They 
found no correlation, before or after dilution corrections were applied. Total protein 
concentrations were found to be much higher in BAL whereas phospholipid content was higher 
in EBC suggesting that solutes measured in EBC could not be directly compared to BAL 
samples. The potential application of EBC is also seriously hindered by the dilution of 
respiratory droplets by water vapour. The dilution created by this process has been estimated to 
vary from 5,000 to 25,000 fold (Effros et al., 2002; Effros et al., 2003; Dwyer, 2003). As with 
BAL a dilution marker would therefore also be required in the quantification of RTLF solutes 
from retrieved condensate samples (Effros, 2010).  
Urea has therefore also been investigated as a marker to correct for EBC dilution.Since 
no fluid is instilled into the airways with this technique the issue of urea movement from the 
blood into the RTLF down an artificial concentration gradient is no longer a complicating factor 
and yet the results obtained demonstrated great variability (Effros et al., 2003).  Conversly in a 
study performed by Esther et al. (2009) investigating urea as a dilution marker for this 
procedure, the authors were able to demonstrate correlation between EBC urea and EBC 
electrolyte concentrations and thus concluded that a biomarker to urea ratio may be effective to 
control for condensate dilution. The use of electrolytes (K+, Cl-, Na+ and NH4
+) to correct for 
dilution in condensate samples has also been investigated (Effros et al., 2002; Effros et al., 
2003; Esther et al., 2009), but as with lavage based methods a standardized reporting approach 
is absent. 
Bronchoscopic microsampling (BMS) has been described in recent years as a novel 
procedure to tackle the problems outlined above, permitting the direct measurement of 
molecules in the RTLF. This approach makes use of the flexible fibreoptic bronchoscope, 
through which a bronchoscopic microsampling probe is inserted. This probe first described by 
Ishizaka et al (2001), consists of a polyester fibre rod (1.2mm diameter) attached to a stainless 
steel wire for guidance, covered by a polyethylene sheath (2.5mm outer diameter). The probe is 
placed gently onto the surface of the central or peripheral airways for approximately 10 seconds, 
sampling the RTLF directly by adsorption. The protocol for this procedure requires the inner 
probe to be cut and frozen at -80oC, prior to subsequent dilution into 1ml of saline, to produce a 
solution for the purpose of solute measurement (Ishizika et al., 2001; Yamazaki et al., 2003; 
Kodama et al., 2009). Bypassing the problems encountered with lavage dilution, this method has 
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been suggested to provide a more reliable method by which to sample and quantify RTLF 
components (Kodama et al., 2009). To date this technique has been employed in studies 
investigating the pharmacokinetics of antimicrobials and their concentrations in the respiratory 
tract (Yamazaki et al., 2003) and investigations into pulmonary biochemical markers in 
pathological conditions of the airways (Ishizaka et al., 2001; Watanabe et al., 2003; Kodama et 
al., 2009). Yamazaki et al. (2003) compared BAL (using the urea correction) and BMS RTLF 
sampling procedures in the pharmacokinetic determination of levofloxacin concentrations, 
demonstrating significantly different concentrations between the two methods. Nevertheless, the 
use of this relatively non invasive technique could potentially solve one of the major issues 
faced by RTLF sampling procedures and futher investigations are require to assess its use in 
vivo. 
 
2.5:  Compositional differences along the respiratory passages: nasal passages, 
tracheobronchial and bronchoalveolar compartments 
When considering the deposition pattern of inhaled particles in the lung and their 
interaction with the RTLFs, the regional variation in airway morphology and cell populations, 
from the nasal passages to the terminal alveolar region is of great importance (Chen et al., 2004; 
Darquenne et al., 2009). With the size and shape of medicinal particles determining their 
deposition site within the respiratory tract (Heyder, 2004), there is a need to understand how 
they interact with the RTLFs at various levels of the respiratory tree. The respiratory tract is 
often divided into three distinctive morphological areas: the nasal passages, the tracheobronchial 
airways and finally the bronchoalveolar regions. Investigations making use of airway casting 
techniques have reported the alveolar surface area to be 890,000 cm2, approximately 5,000 fold 
greater than that reported for the nasopharyngeal regions (178 cm2) (Hatch, 1992). Light and 
electron microscopic studies have been used to determine thickness of the RTLF along the 
respiratory tract; with the thickness in the upper airways estimated to be between 5-20 µM 
(Yoneda, 1976; Wanner; 1994; Widdicombe and Widdicombe, 1995). Rapid freeze techniques 
have also been applied in determinations of RTLF depth in more distal airways, resulting in 
estimated depth of 1.8 µM in the bronchioles (Mercer et al., 1992). Overall the available 
evidence suggestes that RTLF depth decreases from the nasal airways (5-10µM), contrasting 
with a thickness of approximately only 0.2-0.5µM in the distal alveolar regions (Sleigh et al., 
1988; Hatch, 1992; Kelly and Mudway, 2003). Using this quantitative information regarding the 
relative thickness of the RTLF in each respiratory tract compartment together with the 
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information on airway area, ‘morphological volumes’ of the RTLF surrounding these 
compartments have been estimated to be 142 µl in the nasal airways compared with 8.9 ml in 
the alveoli (Hatch, 1992; Mercer et al., 1992).  
The progressive increase in RTLF thickness from the distal to the proximal airways 
reflects changes in epithelial cell ion transport, as well as a number of passive factors, including 
evaporation and osmotic water flow (Widdicombe and Widdicombe, 1995). In the upper 
airways ciliated cells appear to determine the depth of the aqueous layer, and it has been 
suggested there may be some mechanical regulation via surface tension forces created by the 
presence of the cilia themselves (Widdicombe, 1997; Widdicombe and Widdicombe, 1995). 
Many of the epithelial cells of the upper airways, particularly submucosal glands, serous, goblet 
and Clara cells are secretory in nature and significantly contribute to RTLF composition, though 
their contribution is greatest in respiratory conditions associated with expansion of secretory cell 
populations, such as asthma and chronic obstructive pulmonary disease (COPD) (Widdicombe 
and Widdicombe, 1995; Finkbeiner, 1999). The variation in RTLF depth and composition 
throughout the respiratory tree is illustrated in Figure 1.2. 
In addition to changes in epithelial cell populations along the respiratory tract, the 
general composition of the RTLF varies in composition reflecting its different roles in the upper 
and lower airways. In the upper airways it is well established that the RTLF is composed of two 
layers: a perciliary watery sol layer covered and surrounded by a gel like mucous layer. The 
appearance of these two layers has been clearly demonstrated by electron microscopic studies of 
rapidly fixed tissues (Widdicombe and Widdicombe, 1995), see Figure 1.3. This mucus layer, 
secreted by underlying sub-mucosal glands allows the entrapment of inhaled particles, including 
microorganisms, and their subsequent removal by the mucociliary escalator.  The alveoli 
responsible for the majority of gaseous exchange that occurs in the lung does not contain mucus, 
but the RTLF in this region is enriched with surfactant secreted by alveolar type II cells, 





Figure 1.2: An illustration highlighting the differences in RTLF composition and thickness 
throughout the  respiratory tract. RTLF thickness alters dramatically from 1-10 µm in the upper 
airways to 0.2-0.5 µm in the distal airspaces. Additionally both the antioxidants (UA – urate, AA – ascorbate, 
GSH - glutathione), proteins (as named) and lipids present within the RTLFs alter in composition and 
concentration between different compartments of the airways, as is highlighted in the image, depending on 
their relative functional roles.  
 
 
Figure 1.3: The two layers (mucus gel and aqueous 
sol) of the RTLF as seen in rapidly frozen 
preparations from rabbit tracheal culture. 









2.6:  Major components of the respiratory tract lining fluids 
Having discussed and described the methods used to sample human RTLFs; the changes 
in its relative thickness and the roles it plays throughpout the respiratory tract, the proceeding 
section will focus on a detailed descriprion of its composition. Whilst the main focus of this 
section will be on the soluble components of the sol layer, attention is also paid to the gel phase. 
It should be noted up front that the great variability in the reporting of RTLF solute 
concentrations between different research groups, as well as the variety of sampling methods 
employed complicates such a discussion. 
 
2.6.1:  Mucus gel layer 
Mucus is pivotal in airway disease, the major function of the mucus gel phase is 
protective, trapping microorganisms and large particles which have been inhaled. Allied to 
mucociliary transport of this layer this provides an effective clearance mechanism, limiting the 
interaction of inhaled xenobiotics with the underlying epithelial cells. Within the 
tracheobronchial region of the airways, particles are said to be cleared within twenty four hours 
of deposition by this mechanism (Kreyling et al., 2002). As a result, the mucus layer is 
continually being turned over. The velocity of mucus transport in the human trachea is 
approximately 4mm/min (Sleigh et al., 1988), with the maximal submucosal gland secretion rate 
estimated at 60µl per cm2 per hour (Widdicombe and Widdicombe, 1995). The importance of 
this mucus barrier function is illustrated in the diseases of asthma and chronic bronchitis, in 
which mucus hypersecretion occurs (Fletcher and Peto, 1977; Vestbo et al., 1996; Vestbo et al., 
2002;) in paralell to decreased cilia beat frequency (Agius et al., 1998; Dalhamn, 1958), 
resulting in airway obstruction and increased airway infections. 
A basic description of the mucous layer is one of a high molecular weight 
glycoconjugate (molecular weights up to 15MDa) polymer matrix with a high affinity for water, 
various ions and proteins, varying in thickness between 2-20µM (Widdicombe and 
Widdicombe, 1995).  The high molecular weight glycoconjugates can be split into two groups: 
mucous glycoproteins (mucin) and proteoglycans, providing the characteristic mucoid properties 
of high viscosity and stringy gel like appearance (Hatch, 1992).  They are secreted 
predominately from the submucosal glands of the upper airways, estimated to occur at a density 
of 1 per mm2 in an adult human trachea; as well as by goblet and serous cells (Reid, 1960; 
Quinton, 1979). Ciliated cells are also responsible for the control of ionic and water 
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concentrations and for mucous secretions, as are alveolar macrophages and lymphocytes (Hatch, 
1992). 
Mucous glycoproteins have great inherent polydispersity. These acidic polyanionic 
mucins are composed of oligosaccharide chains attached to a core peptide region via o-
glycosidic linkages. Principle mucin glycoproteins, MUC5AC and MUC5B, are required for 
both mucociliary clearance and airway defence, with MUC5b found to be crucial in maintining 
the immune homeostasis of the airways (Roy et al., 2014).  The thiol content of mucins is 
reported to be between 1-2% with disulphide bridge formations playing an important role in the 
polymerization between cysteine rich regions of chains (Allen, 1983; Hatch, 1992). 
Proteoglycans in contrast are mainly composed of linear unbranched glycosaminoglycans (Reid, 
1978).  
2.6.2:  Low molecular weight antioxidants  
The lung, due to its anatomy and physiological function is exposed to a high oxidant 
burden both from the inhalation of environmental oxidants/pro-oxidants (tobacco smoke, 
ambient air pollution, pesticides etc.), or arising from the release of reactive oxygen species 
from activated phagocytic cells associated with acute respiratory insults or chronic 
inflammatory disease (Macnee, 2001). The antioxidant content of the RTLFs has therefore 
received much attention, due to their role in maintaining the reducing environment at the air-
lung interface (Skoza et al., 1983; Cross et al., 1994), limiting oxidative injury to the lung 
(Cantin et al., 1987; Gutteridge et al., 1996; Hernandez et al., 2009). It has therefore been 
argued that the capacity of the respiratory tract epithelium to transport and maintain the RTLF 
antioxidant pool represents a critical determinant of the protective ability of this compartment 
(Nel et al., 2006; Stone and Donaldson, 2006; Behndig et al., 2009). 
 The antioxidant milieu of the RTLFs includes a variety of components; the high 
molecular weight glycoproteins of mucus (described in the previous subsection), metal chelating 
proteins, antioxidant enzyme systems (including extracellular glutathione peroxidase and 
superoxide dismutase) and low molecular weight soluble antioxidants, which will be the focus 
of this sub-section.  
 
2.6.2.1:  Urate 
Urate (UA), an oxidized purine base, is a major low molecular weight antioxidant found 
throughout the RTLFs, with particularly high concentrations within the nasal lining fluids, 
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where it represents the predominant sacrificial antioxidant, present at concentrations equivalent 
to those in plasma, see Table 1.2 (Peden et al., 1990; Kaliner, 1991; Cross et al., 1998). Urate 
has been implicated as a highly potent scavenger of a variety of radicals and gaseous pollutants, 
particularly ozone in the nasal passages, and it has thus been speculated that its high 
concentrations within the upper airways may act as a mechanism to protect the distal airways 
from oxidative stress (Kaliner, 1991; Peden et al., 1993; Crosset al., 1992; Meadows and Smith, 
1986). Due to the high concentrations of urate observed within upper airway secretions and the 
apparent correlation with plasma concentrations, its presence within the RTLF is thought to 
occur as a result of passive transudation from the plasma pool (Kelly and Mudway, 2003). 
Additionally, it has been proposed that epithelial submucosal glands take up plasma or 
interstitial UA, concentrating and subsequently co-secreting this antioxidant alongside mucin in 
the nasal and upper RTLFs (Peden et al., 1990; Peden et al, 1993; Cross et al., 1994).   
 
2.6.2.2:  Ascorbate  
The highly water-soluble, reactive oxygen species scavenger ascorbic acid ( ascorbate, 
AA) is distributed throughout the RTLF, present in both its reduced (L-ascorbic acid) and 
oxidized form (dehydroascorbic acid).  Humans lack the ability to synthesize AA due to the lack 
of the enzyme gulonolactone oxidase, consequently its presence is entirely dietary dependent 
(Frei et al., 1989). RTLF AA concentrations have been attributed to passive pericellular 
diffusion from the plasma pool due to the similar concentrations observed between plasma and 
lavage dilution corrected nasal lavage samples (van der Vliet et al., 1999). However no 
association between AA concentrations in lavage and plasma samples has ever been clearly 
demonstrated (Blomberg et al., 1999; Mudway et al., 2004). Studies investigating the 
supplementation of Vitamin C (L-ascorbate) on RTLF concentrations have shown rapid 
movement of ascorbate into the RTLF, that is either rapidly lost from the airway surface by 
oxidation, or taken up into airway cells (Behndig et al., 2009). Whilst, the former would support 
the relatively high concentrations of dehydroascorbate that have been measured in the airway, 
such continual oxidative losses from the airway surface would present a significant drain on 
bodily vitamin C reserves. Consequently, some form of recycling or cellular salvaging system 
would be required, but to date none has been identified. A number of reports have demonstrated 
significantly reduced, or even absent AA concentrations within the RTLFs of  asthmatic patients 
which have been related to the presence of airway inflammation and oxidative stress in their 




Table 1.2: RTLF antioxidant concentrations as determined from BAL and NL, with plasma 
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Peden et al., 1990; 
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Frei et al., 1992; 
7
Svardal et al., 1990 
 
2.6.2.3:  Glutathione 
L-y-glutamyl-L-cysteinyl-glycine, or glutathione, is a sufhydryl containing tripeptide 
constituting the major component of the antioxidant network in the distal RTLFs (Cantin et al., 
1987; Kelly et al., 1999). Under normal physiological conditions > 95% is found in its reduced 
form (GSH), with the remainder present as glutathione disulfide (GSSG) (Meister and 
Anderson, 1983; Cantin et al., 1987; Kelly et al., 1999). GSH is found in all cells at mM 
concentrations, with reported RTLF concentrations approximately one hundred times (100-300 
µM) that found in the plasma pool (1-10 µM) in normal healthy RTLFs – see Table 1.2 (Van 
der Vliet et al., 1999). The increased GSH concentration in RTLF strongly suggest that the local 
concentrations do not arise by passive diffusion from the plasma pool, but suggest local 
synthesis, recycling and export from airway cells.  The majority of extracellular GSH is 
catabolized by y-glutamyl-transpeptidase, an enzyme expressed by type II epithelial cells, clara 
cells, mononuclear phagocytes, lymphocytes and fibroblasts, and is believed to play an 
important role in determining RTLF GSH concentrations (Griffith and Meister, 1979; Rahman 
and MacNee, 2000; Kelly and Mudway, 2003; Reynaert, 2011).  Elevated GSSG concentrations 
are a clear marker of oxidative stress, and have been reported in asthmatic RTLFs (Reynaert, 
2011; Kelly et al, 2003; Kelly et al, 1999). Higher total glutathione concentrations have also 
been observed within the RTLFs of asthma sufferers (Smith et al, 1993; Kelly et al., 1999), 
whilst decreased concentrations have been reported in sufferers of idiopathic pulmonary fibrosis 






2.6.2.3:  α-tocopherol 
This lipid soluble antioxidant is found integrated within biological membranes where it 
acts as a direct free radical scavenger terminating lipid peroxidation reactions at relatively low 
concentrations (Davis and Pacht, 1991; Rustow et al., 1993; Burton et al., 1983). In the lung it is 
believed to be secreted alongside surfactant by type II alveolar cells. Investigations have 
demonstrated the important oxidant protection this antioxidant provides to the airways, with 
lower concentrations demonstrated to result in increased lung injury (Pryor, 1991). Significantly 
lower concentrations of this antioxidant have been observed in the RTLFs sampled from 
asthmatic patients. A similar deficiency has been reported in the RTLFs of current smokers 
(Kelly et al., 1999; Pacht et al., 1986). 
 
2.6.3: Major protein components of human RTLFs  
The protein constituents of the RTLF are important when considering the potential 
biophysicochemical interactions occurring when inhaled particles deposit in the lung. 
Particularly the likely impact of the protein corona formed around particles interacting with 
biofluids has attracted considerable attention, as this is likely to modify surface properties, 
including charge, propensity to aggregate and hydrodynamic diameter, altering particle 
behaviour in vivo (Nel et al., 2009; Monopoli et al., 2011).  
The presence of protein within the RTLFs was first demonstrated electrophoretically by 
Warfvinge et al. (1955), since this initial study the protein components found within this extra-
cellular compartment have been extensively studied through the use of various techniques. The 
great complexity of the RTLF proteome is in part due to the large number of distinct individual 
proteins present but also a result of the variety in their source of origin (Noel-Georis et al., 
2002). Proteins may be derived from plasma transudation (e.g. albumin), or synthesized locally 
(e.g. surfactant protein A), with certain proteins unique to the airways (Stockley, 1984; Kim et 
al., 2002; Hermans et al., 1998). As described previously uncertainties regarding the 
interpretation of BAL solute concentration data, in addition to differences as a result of 
pathological airway conditions, complicate the quantitative description and interpretation of the 
RTLF proteome. The clearance of proteins from the airways also plays an important role in 
determining concentrations within this compartment. Protein clearance has been studied in both 
animal models and human participants, with protein tracers the most common procedure 
employed (Folkesson et al., 1996). Clearance mechanisms include elimination via the 
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mucociliarly escalator followed by swallowing, endocytosis by alveolar macrophages, 
degradation of proteins by peptidases within the airways or absorption across the airway 
epithelial cells into the circulation (Hastings et al., 1992; Phipps and Richardson, 1976; Matthay 
et al., 1996). To date RTLF proteome comparisons have only observed small differences across 
gender, age and ethnic groups (Hatch, 1992). 
Serum proteins found present in the RTLF generally have molecular weights <200, 000 
Da, corresponding to the significantly lower protein concentrations found within this 
compartment compared to plasma, and indicating a size dependent diffusional process at play 
(Bell et al., 1981; Feng et al., 1992). Of those proteins derived by transudative mechanisms, the 
most dominant plasma protein is albumin. Early experiments in which radiolabelled albumin 
was injected into the peripheral circulation, later to be detected within airway lavage samples, 
clearly demonstrated this process (Bonomo, 1964).  
 
Clear regional differences in protein concentrations have become apparent throughout 
the airway. Alveolar lining fluids have been reported to have higher total protein concentrations 
compared with bronchial and nasal compartments and it has been speculated that this might 
reflect difference in the relative leakiness of the blood-air barrier at various levels of the 
respiratory tree (Hatch, 1992). Additionally, surfactant-associated proteins were also reported to 
have their highest concentrations within the distal airways, a result of the selective secretion of 
surfactant by type II cells (Serrano and Perez-gil, 2006). Conversely, bronchial and nasal 
airways have been reported to contain higher concentrations of several secretory proteins, 
including proteoglycans found within mucin, lysozyme and lactoferrin, reflecting secretions 




Figure 1.4. An overview of the various sources of origin of proteins found within BAL samples. 
Proteins identified within BAL may be derived from plasma following transudation across the air-
blood barrier, secreted within the airways by inflammatory cells, and secretory cells composing the 
epithelium including Clara cells and serous cells. Reproduced from Wattiez et al., 2005. 
 
While the quantification of lavage total protein content is relatively straight forward 
using common methods (Lowry et al., 1951; Bradford, 1976; Smith et al., 1985), the 
quantification of individual protein components requires more sensive immunological or mass 
spectroscopy-based techniques, due to the low concentrations present in dilute RTLF samples 
(Boutten et al., 1998; Wattiez et al., 1999). High resolution techniques have been applied to 
‘map’ the RTLF proteome and to build up a detailed picture of the protein composition of this 
compartment in a variety of clinical conditions. Electrophoretic methods in particular, 2-
dimensional electrophoresis (2-DE), in which polypeptides are separated by both their 
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isoelectric point and molecular weight, are employed in the analysis of complex protein 
mixtures and have thus provided a vast wealth of information regarding the protein composition 
of various body fluids including those obtained from the respiratory tract (Wattiez et al., 1999; 
Magi et al., 2006), see Figure 1.4.With the first 2-DE map of proteins identified from a lung 
lavage sample published in 1979 by Bell and colleagues (1981).  The popularity of 2-DE 
techniques for the analysis of BAL fluid resulted in the production of a reference protein map, 
which currently comprises of over 1,200 silver stained spots (Noel-Georis et al., 2002). The 
comparison of 2-DE BAL protein maps to the human reference plasma protein 2-DE map and 
macrophage-like cell line maps have also helped identifying the source of origin of proteins 
present within human RTLFs (Wattiez et al., 1999).  
However many factors complicate 2-DE techniques, from the range in the magnitude of 
protein concentrations within human RTLFs, protein pIs, charge, molecular weight, relative 
hydrophobicity; all of which make the effective separation of all proteins within this 
compartment extremely challenging (Magi et al., 2006). Many alternative approaches are often 
used or combined with 2-DE techniques to maximize the number of identifiable spots, their 
accuracy, recovery, speed and separation (Magi et al., 2006). Currently, 1,500 different proteins 
have been identified in human BAL fluid using the combination of these approaches: affinity 
depletion of the most abundant BAL proteins, SDS PAGE fractionation, and protein in-gel 
digestion followed by nano-LC-MS/MS (Wu et al., 2005). 
Such techniques have identified the major soluble protein components of human RTLFs; 
in addition to permitting biomarker identification in relation to early airway disease and 
progression. The following section will discuss the major proteins identified within the RTLF, 
focusing on their concentrations, origins, and functions, in addition to differences observed 







Figure 1.5: A 2D-gel map of a lavage sample retrieved from a healthy human airway. 
Proteins (100 μg) were separated on pI 3-10 nonlinear IPG strips (first dimension) and on 
11-18%T SDS polyacrylamide gels (second dimension). The gel was stained with SYPRO 
Ruby, with a detection limit of about 10 ng protein. The proteins were identified by 2-DE and 
MALDI-TOF MS after tryptic cleavage and are indicated). Albumin has been removed from the 





Albumin is a single 585 amino acid polypeptide chain of 66.5 kDa molecular weight and 
represents the most abundant plasma protein (35-50 mg/mL). In addition to its role as an acute 
phase protein, it has also been proposed as the major antioxidant protein within plasma by virtue 
of its free thiol group. The majority of albumin synthesis occurs in the hepatocytes of the liver. 
It is a major protein component of the RTLF, found at concentrations approximately 10 fold 
lower than plasma, accounting for approximately half of total protein content (with 
concentrations of 2-5 mg/mL reported, See Table 1.3). Derived from passive plasma 
transudation across the airway epithelium it is a well established marker of vascular 
permeability (Webber and Widdicombe, 1989; Hatch, 1992; Greiff et al., 2003). Concentrations 
of albumin have been shown to be increased in lavages obtained from patients with  a range of 
acute and chronic inflammatory airway disease, including interstitial lung disease (Noel-Goeris 
et al., 2001); asthma (Nocker et al., 1999) and seasonal allergic rhinitis (Ghafouri et al., 2006). 
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Table 1.3: Major RTLF protein concentrations (mg/mL) as determined by the urea method for 
lavage dilution correction. 
 
1
Dargaville et al, 1999 (NL/BAL); 
2
Rennard et al, 1990 (BAL); 
3
Rennard et al, 1990 (BW); 
4
 Sutinen et al, 
1995 (BAL); 
5 
Thompson, 1990 (BAL); 
6 
Thompson et al, 1990 (BW); 
7
 Bell, 1981 (BAL); 
8
 Kaliner, 1991; 
9 
Raphael et al, 1989; 
10
 Bernard et al, 1992; 
11
Peterson et al, 1993 (BAL); 
12





 Holter et al, 1986, 
15
van der Vliet et al, 1999, 
16
Lenz et al, 1993. * denotes values are derived from a 
secretory component, denotes values are obtained from nasal   
 
2.6.3.2: Transferrin 
Transferrin is an 80kDa glycoprotein found abundantly within human RTLFs. It is 
predominately derived from the plasma, with additional local production by alveolar 
macrophages and lymphocytes. Transferrin represents a greater proportion of total protein 
within the RTLF (4-5.6% see Table 1.3) than it does within the plasma pool on account of local 
synthesis within the airways (Wesselius et al., 1994; Mateos et al., 1998). Transferrin is 
responsible for the transport of free iron by the reversible binding of two ferric ions. In this 
manner it has important antioxidant properties at the air-lung interface, preventing iron 
catalysed free radical production, as well as limiting iron availability to bacteria within the 
airway (Romero et al., 1993; Mateos et al., 1998). The greatest transferrin concentrations have 
been observed within the more distal airway compartments in healthy samples (Lindahl et al., 
1998). For patients with acute respiratory distress syndrome, a twenty fold increase in 
transferrin RTLF concentrations has been reported; related to its role in the removal of excess 
free iron following cell death (Holter et al., 1986; Pacht and Davis, 1988). Greater 
 RTLF protein 
concentrations (mg/mL) 
% contribution to total 
protein 
Total Protein 5.7















5, 0.0706 158 ,359  





concentrations have also been demonstrated in sarcoidiosis patients, likely due to increased 
transudation of protein from the plasma pool (Wattiez et al., 2000).  
 
 
2.6.3.3: Immunoglobulins: A, G, M  
The lungs have been described as one of the major ‘immunological organs’ in the body, 
reflecting their position as the first line of defence against inhaled xenobiotics. The production 
of immunoglobulins is central to this role, being involved in the recognition and binding to 
specific antigens and the activation of various immunological responses (Burnett, 1986). In 
contrast to plasma, in which IgG is the most predominant immunoglobulin, IgA forms the major 
class of immunoglobulin within RTLF (Daniele, 1990). The plasma form of this 
immunoglobulin exists as a 150kDa protein, and is found within the RTLF, a result of passive 
plasma transudative forces, the secretory form (sIgA), a dimer of 400kDa is synthesized by 
serous cells and submucosal glands of the respiratory epithelium of the upper airways (Hatch; 
1992; Raphael et al., 1989). The secretory form represents approximately 80% of IgA in 
secretions found of the nasal airways, as confirmed by 2D-gel work examining concentrations in 
NL versus BAL fluids (Hatch, 1992; Lindahl, et al. 1995; Lindahl et al., 1998), highlighting the 
extensive local synthesis that occurs. IgA producing plasma cells are most prominent within the 
major bronchioles of the airways, corresponding with the higher concentrations observed in 
samples obtained from the upper airways, at concentrations reported between 0.05-1.42 mg/mL 
(see Table 1.3), (Burnett, 1986). 
Whilst immunoglobulin G does not form the major immunoglobulin present within this 
compartment, its concentration remains considerable (concentrations of 0.64-0.89 mg/mL have 
been reported see Table 1.3), being derived from plasma via transduction, as well as by local 
production of specific subclasses, with IgG secreting plasma cells located in the bronchial 
mucosa (Burnett, 1986; Nijhuis-Heddes et al., 1982). 
Immunoglobulin M is the largest class of immunoglobulins with a molecular weight of 
900kDa, implying that movement from the plasma pool is limited, and as such is much less 
abundant than IgA and IgG: 0.028mg/mL (Table 1.3). Some local production is possible due to 
the presence of IgM plasma cells in the bronchial mucosa (Burnett, 1986; Nijhuis-Heddes et al., 
1982; Stockley et al., 1979). 
Concentrations of immunoglobulins are altered in several diseases of the airways; with 
interstitial diseases (sarcoidiosis, alveolitis, idiopathic pulmonary fibrosis) all associated with 
significant increases in IgG and IgA RTLF concentrations, presumably reflecting both increased 
local synthesis (increased T helper cells have been observed in BAL samples) and increased 
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permeability of the air blood barrier (Stockley and Burnett, 1980; Bauer et al., 1985; Rankin et 
al., 1983; Reynolds et al., 1977). Chronic bronchitis sufferers have also been observed to have 
significantly greater concentrations of IgA; however conflicting results have been reported 




This small 14kDa secretory antimicrobial protein is a hydrolytic enzyme which acts to 
degrade bacterial cell walls. It has been found in greater concentrations (approximately three to 
four fold greater according to 2-DE maps) in the proximal airways compared with the more 
distal alveolar airway (concentrations of 0.16-0.3mg/mL observed in BAL samples – Table 
1.3), as determined by NL versus BAL sampling techniques (Lindahl et al., 1998). The high 
levels of lysozyme in samples from nasal airways are presumably due to the secretion of this 
protein from the submucosal glands, specifically serous cells that constitute the bronchus and 
nasal epithelium (Raphael et al., 1989). Another possible, but minor source of this enzyme 
might occur through its release from neutrophils and alveolar macrophages. Increased lavage 
concentrations of lysozyme have been reported in allergic rhinitis and allergic extrinsic 
alveolitis (Ghafouri et al, 2006; Raphael et al., 1989; Perez-Arellano et al., 1996). Interestingly, 
lysozyme is often secreted alongside the bacteriostatic and bacteriocidal lactoferrin by serous 
cells (Revenis and Kaliner, 1992), an iron binding protein found particularly in glandular 
secretions of the upper airways and nasal passages (Mateos et al., 1998). The highest 
concentrations of both these proteins are observed within external secretions including tears and 
mucus, on account of their antimicrobial actions (Raphael et al., 1989). 
 
2.6.3.4: α-2-macroglobulin 
α-2-macroglobulin is one of the major protease inhibitors found within plasma, with its 
main action the inhibition of endopeptidase enzymes. The main site of synthesis in the body of 
this protein is the liver and due to its high molecular weight,700kDa its passive transudation 
onto the surface of the lung is unlikely. It’s presence in the RTLF is likely a result of its 
secretion by alveolar macrophages (White et al., 1980). Through the formation of complexes 
with serine proteases or metalloproteinase, these enzymes are recognized by macrophage α-2-
macroglobulin receptors, internalized and degraded (Moestrup et al., 1993). Its presence in 
RTLFs has been shown to increase in a variety of lung diseases, including asthma, pneumonia, 
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acute respiratory distress syndrome, sarcoidiosis and tuberculosis (Nocker et al., 1999; Holter et 
al., 1986; Titanian et al., 1987). 
 
2.6.3.5: α 1-antitrypsin 
This serine proteinase inhibitor is responsible for inactivating proteolytic enzymes, 
particularly neutrophil elastase, providing an important defence mechanism within the airways 
against uncontrolled enzyme mediated tissue injury (Ghafouri et al, 2006). The presence of α 1-
antitrypsin in RTLF is accordingly increased in inflammatory diseases of the lung (pneumonia, 
tuberculosis, sarcoidiosis, interstitial pulmonary fibrosis and allergic rhinitis) presumably a 
result of increased protease release from activated inflammatory cells within the airways (Gadek 
et al., 1981; Titaninan et al., 1987; Wattiez et al., 2000; Ghafouri et al., 2006). It has also been 
linked with a protective role in atopic asthma and deficiency of this enzyme has been associated 
with the development of emphysema (Boutten et al., 1998). The major source of this enzyme is 
from plasma, with hepatocytes being the major site of production. In addition pulmonary 
alveolar macrophages and alveolar epithelial cells are believed to be sources of this protein 
within the RTLFs (Takemura et al., 1986; Boutten et al., 1998). 
 
 
2.6.3.6: Clara cell secretory protein (CC16) 
CC16 is a 16kDa low molecular weight protein, uniquely synthesized in the airways by 
the Clara cells of the bronchial and alveolar epithelium, and reported to be a major protein 
constituent within BAL fluids (Bernard et al., 1992; Singh et al., 1988; Hermans and Bernard, 
1999). This protein is however also found in plasma, relefecting its retrograde diffusion across 
the air blood barrier from the airway surface. Consequently the plasma concentrations of CC16 
have been proposed as a sensitive biomarker of altered blood-air barrier permeability (Bernard 
et al., 1992; Hermans and Bernard, 1999; Broeckaert et al., 2000) and plasma concentrations 
have been shown to be elevated in a variety of respiratory diseases, (Bernard et al., 1992; 
Hermans and Bernard, 1996). Transient increases in serum CC16 concentration have been 
observed in response to several airway irritants such as ozone (Blomberg, et al. 2003), 
lipopolysaccharide (LPS) (Michel, et al. 2005) and smoke (Bernard, et al. 1997). Altered 
concentrations of this protein have been demonstrated in tobacco smokers (decrease in BAL) 
and patients with interstitial lung disease (increase in serum levels) (Bernard et al., 1992; 
Hermans and Bernard, 1996). Lower concentrations of CC16 have also been demonstrated in 
nasal lavage samples from children with allergic asthma and rhinitis (Lindahl et al., 1995; 
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Lindahl et al., 2001), as well as in severe COPD patients compared to those with moderate 
COPD or healthy controls (Braido et al., 2007). CC16 is believed to have anti-inflammatory 
actions in the airways. It is a potent inhibitor of PLA2 activity (Levin et al., 1986) and 
monocyte, neutrophil and fibroblast chemotaxis (Vasanthakumar et al., 1988; Lesur et al., 
1995). Higher susceptibility to airway inflammation and injury in response to irritants including 
ozone (Mango et al., 1998) and hyperoxia (Johnston et al., 1997) has been observed in CC16-
deficient mouse strains compared to wild type.  
 
2.6.4: Surfactant  
Secreted by type II alveolar cells, surfactant forms a crucial physiological component of 
RTLFs by reducing the surface tension of the alveoli, preventing their collapse during breathing 
(Hills, 1988; Creuwels et al., 1997). Investigations by Von Neergaard et. al (1929) initiated the 
research into this unique material, identifying a surface active substance which lowered the 
tension of the air water interface. Later studies by Pattle (1955) suggested a ‘surfactant’ was 
responsible for the maintenance and stability of low surface tension within the fluid lining the 
lung; with Macklin et al (1954, 1955) demonstrating that the material was specifically secreted 
by the epithelial cells lining the alveoli. Investigations carried out by Clements et al. (1972) 
were the first to identify the presence of phospholipids with surface tension lowering properties, 
with the actions of proteins in this surface active material later identified in studies performed 
by King et al. (1973). Since these initial investigations, the composition of surfactant has been 
extensively studied. Approximately 90% of surfactant is composed of lipid, wih the remaining 
fraction accounted for by the four surfactant associated proteins (A-D), with surfactant protein A 
the predominant form, representing approximately 5% of surfactant. 
Neutral lipids including cholesterol, triglycerides and free fatty acids contribute to the 
lipid fraction of surfactant; however it is phospholipids that comprise the major fraction, with 
phospathidycholine (PC) the predominant form. Approximately half (41-70%) of PC is in the 
form of dipamitoylphosphatidylcholine (DPPC), with the remainder including 
phosphotidylglycerol (~8-10%), phosphatidylethonanolamine (~5%), phosphatidylinositol 
(~3%), with sphingomyelin and phosphatidylserine also providing minor contributions. The 
analysis of these lipid fractions has predominantly involved the use of HPLC techniques 
(Creuwels et al., 1997; Goerke, 1998; Kahn et al., 1995). These lipids account for the main 
surface active properties of surfactant, DPPC is considered the chief tensoactive component 
responsible for lowering surface tension (Perez-Gil and Keough, 1998).  
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Proir to its secretion from type II alveolar cells surfactant is packaged and assembled 
into densely packed bilayers by lamellar bodies located within these cells. Following secretion, 
surfactant must cross the aqueous lining fluid surrounding cells, during which time it assumes a 
structure known as tubular myelin and finally, in order to transfer into the interface, where it 
must adsorb rapidly forming a monolayer film, it is compressed to facilitate its tensoactive 
properties (Sanders et al., 1980; Perez-Gil and Keough, 1998; Goerke; 1998). In vitro studies 
have suggested the continuous removal of subphase surfactant from the interface (Gross et al., 
1988; Putman et al., 1996), either by phagocytosis by alveolar macrophages or recycling by type 
II cells (Wright and Clements, 1987). 
 
2.6.4.1: Surfactant Proteins 
It is important to note that despite surfactant associated proteins (A, B, C and D) 
providing only a modest percentage contribution to surfactant (8-10%), they impart critical 
dynamic properties to surfactant, without which its full functionality could not be achieved 
(Perez-Gil and Keough, 1998).  Surfactant protein A (SP-A), is the predominant form, 
representing approximately 5% of surfactant. It was the first of the surfactant proteins identified 
and is a hydrophilic 26-38kDa mannose binding glycoprotein member of the collectin family 
(King et al., 1973; White et al., 1985; Weaver and Whitsett, 1991), with a high affinity for 
DPPC over other lipid components. Secreted in lamellar bodies of type II alveolar cells, it has an 
essential role in the formation of tubular myelin structures due to its ability to aggregate lipid 
vesicles in a calcium dependent manner, promoting movement of materials to surface films 
(Veldhuizen et al., 1996; Perez-Gil and Keough, 1998). It is also believed to be involved in the 
interfacial properties of surfactant, though the precise contribution of SP-A to the tensoactive 
properties of surfactant have yet to be fully clarified (Perez-Gil, 2008). In addition to its role in 
the modulation of phospholipid uptake and secretion by type II cells, it has also been 
implemented in immunological defense through the activation and chemotactic stimulation of 
alveolar macrophages, as well as in the binding and clearance of microorganisms (Kalina et al., 
1995; Van Iwaarden et al., 1992; Van Iwaarden et al., 1994; Creuwels et al., 1997). Whilst 
surfactant protein A is predominately found within the distal airways it has also been identified 
in lavages from the proximal conducting airways (Kuroki and Akino, 1991; Casals et al., 1993; 
Khoor et al., 1993). 
The 43Kda surfactant protein D (SP-D),  a hydrophilic member of the collectin family of 
proteins, also plays a role in host defence, binding to both bacteria and alveolar macrophages 
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(Kuan et al., 1992; Lim et al., 1994). This protein only accounts for ~0.5% of surfactant; with 
only 10% associated with surfactant phosphilipids, binding to phosphatidylinositol in a calcium 
dependent manner (Serrano, 2006; Persson, 1989; Persson, 1992; Ogasawara, 1992). Similiar to 
SP-A, SP-D contains a collagenous region and C-type lectin domain providing them the 
structural characteristics necessary to bind numerous ligands (inhaled particles and pathogens) 
within the alveolar RTLF permitting their function as part of the innate immune system (Serrano 
and Perez-Gil, 2006; Crouch and Wright, 2001). 
The hydrophobic anionic surfactant proteins B and C, with molecular weights 8.7kDa 
and 4.2kDa respectively, contribute approximately 1-1.5% to surfactant. They are both secreted 
by type II pneumocytes and are implicated in independently promoting the interfacial adsorption 
of surfactant lipids and stabilizing the films formed, vital for the full functionality of surfactant 
(Wang et al., 1996; Perez-Gil et al., 1992; Weaver and Conkright, 2001). It has been reported 
that only surfactant protein C can really be considered a specific surfactant associated protein, 
being found uniquely present within the alveolar compartment (Serrano and Perez-Gil, 2006). 
Conflicting results of the behaviour of surfactant proteins have been reported in 
asthmatics. Increased expression of surfactant proteins has been observed in allergic asthma 
(Magi et al., 2006; Noel-Goeris et al., 2002; Lenz et al., 1993; McCormack et al., 1991; Cheng 
et al., 2000), whilst van de Graaf et al (1992) reported a decrease in SP-A and Wright et al 
(2000) observed no apparent changes in SP-A concentration in asthmatic RTLFs. In IPF patients 
lower concentrations of surfactant proteins have been reported, possibly related to decreased 
synthesis from damaged alveolar type II cells (Magi et al., 2006; Noel-Goeris et al., 2002; Lenz 
et al., 1993; McCormack et al., 1991).  As with CC16, the circulating plasma concentrations of 
SP-A, SP-B and SP-D have been employed as retrograde biomarkers of air-blood barrier 
dysfunction, and have been shown to be elevated in several lung disorders (Hermans et al., 
1999; Hermans et al., 1998; Kuroki et al., 1993; Doyle et al., 1997). 
 
3: The evaluation of inhaled particles in vitro 
3.1:  Dissolution, solubility and bioavailability testing of inhaled particulates  
Only a small percentage of inhaled materials are deposited within the respiratory system, 
with a proportion exhaled immediately and others cleared through mechanical processes. 
Furthermore, the lung contains different location specific clearance mechanisms, the 
mucociliary escalator of the upper airways to alveolar macrophage clearance in the distal lung. 
Particle elimination by macrophages is believed to be slow within the human airways (Snipes et 
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al., 1989). Those inhaled particles/materials that evade these defenses accumulate, degrade or 
undergo dissolution within the RTLF (Borm et al., 2006). The deposition of inhaled particles 
and drugs within the RTLFs is therefore influenced by a variety of factors: deposition rate, 
clearance, retention, translocation and dissolution within this compartment. Thus the ‘retained 
dose’ may be quite different to the initial inhaled dose into the lung and this is greatly 
influenced by its physical properties of the inhaled material itself (Oberdorster et al., 1994; 
Sdraulig et al., 2008). The regional deposition of inhaled materials within the respiratory tract is 
also dependent on its aerodynamic diameter. For example, particulate materials deposited within 
the distal airways encounter large surface-to-volume ratios, in which even effectively insoluble 
particles can be cleared by the process of dissolution (Lippmann et al., 1980). Size, shape, 
composition and other physiochemical characteristics help determine the level of interaction 
between inhaled materials with the RTLF and underlying airway epithelial cells.  The precise 
nature of these interactions remains somewhat undefined and there is therefore the need for the 
development of physiologically relevant in vitro models that permit these interactions to be 
examined. The development of simulated lung lining fluids to model these initial interactions in 
vitro has therefore been identified as a critical requirement (Taunton et al., 2010).  
In vitro dissolution studies investigate the process by which a solid enters into a solvent, 
yielding a solution. The kinetics of this process are dependent on the affinity of the interaction 
between solutes and the solvent in question, including both physiochemical particle properties 
and the dissolution media (or solvent) that mediate this process. Dissolution profiles (a 
cumulative description of dissolved drug over time) and parameters which provide a summary 
of the process (the dissolution rate constant or dissolution rate coefficient) are determined to 
deliver predictive estimates of this process in vivo (Aulton, 2007). Dissolution studies are used 
as part of the characterization of inhaled materials, determining the rate of dispersion and the 
retention time in the body, major determinants of bioavailability (and therapeutic potential in the 
case of pharmaceutical compounds). The process of drug dissolution is dynamic and highly 
influenced by the properties of the solvent used, from pH, ionic strength and concentration 
(Borm et al., 2006). As this determines the dose of an inhaled material that can be absorbed into 
the systemic blood circulation, it is often considered the critical step in determining the fate of 
drugs. ‘Simulated lung lining fluids’ have been used in investigations as a proxy for the RTLF 
surrounding the respiratory tract cells, with this the primary dissolution environment of inhaled 
particulate materials. The use of such simulated lung fluids to assess the fraction of inhaled 
material made soluble and thus available for absorption has been employed in the assessment of 
a variety of inhaled materials. With dissolution described as an important element for the 
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characterization of inhaled materials, the use of representative dissolution media is an important 
part of this approach (Takaya et al., 2006).  
From a pharmaceutical perspective, there is a real need for the development of methods 
that accurately assess inhaled drug solubility and dissolution in vitro, since the proportion of 
inhaled drug that undergo the process of dissolution determines its therapeutic effect 
(Wiedmann et al., 2000). With in vitro testing providing crucial information at several stages of 
the drug development process; to the formulation scientist in the choice of appropriate 
formulation excipient; to the clinical scientist in helping determine in vitro in vivo correlation 
and to the regulatory scientist to ensure the product meets appropriate requirements. If 
dissolution testing is not performed under relevant and meaningful conditions, results from such 
studies will be invalid, increasing both the time and cost of product development (Dressman et 
al., 1998). Pharmacopoeias describe the official in vitro dissolution testing methods for 
conventional solid and semi solid drug delivery methods, specifying factors from the apparatus, 
solvent and volume used, since dissolution is an important predictor of the behaviour and 
bioavailiability of drugs in vivo. However no accepted dissolution method is currently available 
for inhaled medicines (Agu and Ugwoke, 2011).  As has been described by Forbes et al (2010) 
in order for this to be achieved the RTLFs must be fully characterized prior to the development 
of biological relevant simulant fluids and to establish appropriate modeling parameters. 
 
3.2: Composition and design of simulated lung fluids  
As the inclusion of complex biomolecules in simulant RTLFs provides a greater number 
of potential particle interactions, the majority of particle behaviour studies have limited the 
complexity of their simulant models to reflect only the electrolyte composition of this 
compartment. The complexity and variability in composition of lung lining fluids has also been 
used as justification for the use of simple in vitro fluids in these studies (Midander et al., 2007). 
Gambles solution, often referred to as simulated epithelial lung fluid (sELF) has been routinely 
employed for over 30 years as a simulant lung fluid. Originally this solvent comprised solely of 
inorganic salts, chlorides, carbonates, various phosphates, citrate and acetate, kept at 37oC, with 
a 5% CO2-air mixture bubbled through it (see Table 1.4). Whilst Gambles fluid has been used 
most often to mimic lung lining fluid in the study of  inhaled particle dissolution,it is considered 
an acceptable simulant. Various different modifications/adaptations are often applied (see Table 
1.5), though these have not resulted in significant differences in the solubility data obtained (de 
Meringo et al., 1994). Additionally, fluid simulating the acidic (pH 4.5-5) lysozymal 
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environment following particle ingestion by alveolar macrophages has also been used in similar 
investigations (Sebastien et al., 1990; Thelohan et al., 1993; Herting et al., 2006).  
Studies by Midander,et al. (2007) compared simpler models, including PBS to both 
Gambles solution and simulated lysosymal fluids and demonstrated clear differences between 
the magnitude and kinetics of particle dissolution. A more representative simulant model based 
on Hatch’s (1992) description of RTLF composition has also been used to evaluate particle 
solubility (Berlinger et al., 2008). The main difference in these simulant models is the inclusion 
of various physiologically relevant proteins and enzymes. Investigations by Harrington et al. 
(2012) studying the effects of Survanta on pyrite oxidative dissolution found marked effect. 
Other groups have considered the addition of RTLF antioxidants to create more realistic 
simulant models. Charrier and Anastasio (2010) demonstrated the significant effect the inclusion 
of ascorbate, citrate, glutathione and uric acid at physiological concentrations, on metal 
catalysed hydroxyl radical generation. 
However these approaches do not realistically mimic the complexity of in vivo RTLFS 
and whilst a simulant model should be relatively simple it should also aim to account for the 
major constituents present in the lung lining fluids in order to provide more accurate 
interpretations of particle behaviour from in vitro testing systems. The extent to which simulated 
lung fluids and in vitro testing systems are able to model the epithelial lining fluids of the 
airways would perhaps be best evaluated by in vitro in vivo correlations. Taunton et al (2010) 
concluded that the limited knowledge on the aqueous composition of RTLFs and their 
replenishment rates, limit our understanding of the fate of inhaled drugs. However this is not 
wholly the case, with a great wealth of information available regarding the composition of 
human RTLFs it is therefore feasible to create more detailed and realistic simulant models to 
allow for the realistic in vitro testing of particles in the airways. 
The influence of biorelevant in vitro simulants, were explored in investigations by 
Berlinger et al (2008) into the dissolution of welding fume particulates. In this study the authors 
employed both Gambles and Hatch’s solution (with the addition of defined protein and low 
molecular weight components – see Table 5.1) to study  the in vitro behavioural characteristics 
of welding fumes, concluding that the latter was the most appropriate choice as an in vitro 
dissolution media, producing the most biorelevant results. From the pharmaceutical perspective 
in vitro tissue culture models integrating inhaled particle deposition alongside particle 
dissolution in the sRTLFs (Simulated Respiratory Tract Lining Fluid) have attempted to mimic 
in vivo interactions at the lung surface following drug inhalation. In vitro dissolution studies of 
pharmaceutical compounds have utilised a sRTLF modified by the addition of DPPC (0.02% 
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w/v), based on the contention that surfactant phospholipids components of surfactant would 
enhance wettability, preventing the aggregation of hydrophobic drugs, resulting in an increased 
rate of dissolution (Sinswat et al., 2008; Agu and Ugwoke, 2011). Davies and Feddah (2003) 
investigated the effects of increasing DPPC concentrations (0.01, 0.02 and 0.05%) in simulant 
models and found increased solubility of the glucocorticoids under investigation with increasing 
lipid concentration. The results observed in vitro for the glucorticoid drug flutacisone 
propionate, correlated with data obtained in in vivo clinical studies (Davies and Feddah, 2003; 
Esmailpour et al., 1997). Wiedmann et al (2000) focused on the use of an artificial surfactant 
(Survanta) in their investigations into drug solubilization, observing that the addition of this 
commercial bovine lung surfactant increased glutocorticoid drug solubilization. These such 
examples from the literature further demonstrate the importance of using biorelevant simulant 
fluids with in vitro studies investigating inhaled particle behaviour, for the purposes of 
understanding inhaled drug and xenobiotic interaction at the surface of the human lung. 
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4,5 










3.3: Work plan 
The three major aims of my thesis are decribed in Section 1.1. These are addressed in 
the proceeding four experimental chapters (3, 4, 5 and 6). Chapters 3-4 present a detailed 
assessment of RTLF composition in healthy adults and mild asthmatics (Chapter 3), in aged 
healthy populations (Chapter 4) and in patients with COPD, including ex- and current smokers 
(Chapter 5). The data within these chapters represent the most up to date summary of RTLF 
composition in these conditions. In addition, data on the proteome of the bronchial RTLFs are 
presented for the first time. Based on this information I have designed a base model of human 
RTLFs, which can be modified to reflect regional and disease specific compositional profiles. In 
the final chapter, I present data characterizing particle behavior within this simulant model and 



















Table 1.5: Various simulated RTLF variants described in the literature  
sELF Variant Material investigated Author 
Gambles solution Welding fumes Berlinger et al., 2008; 
Ansoborlo et al., 1990; 
Midlander et al., 2007; 
Sdraulig et al., 2008 
Gambles + 0.02% DPPC Micronised hydrocortisone 
gelatin capsule dissolution 
Son and McConville, 
2009 
Gambles + 0.02% DPPC Amorphous or crystalline 
nanoparticles of tacrolimus 
Sinswat et al., 2008 
Gambles + 0.01, 0.02 and 
0.05% DPPC 
Various glucocorticoids Davies and Feddah, 
2003 
Gambles - pH3 and pH9 Various glucocorticoids Davies and Feddah, 
2003 
PBS + 100uM urate, 200uM 
ascorbate, 100uM reduced 
glutathione, 300uM citrate 
Mixed Transition metals Charrier and Anastasio, 
2010 
Gambles + aluminium 
(320uM), K+ (0.004M) 
Mineral particles Taunton et al., 2010 
Gambles - proteins Rare earth oxide dissolution 
rates 
Takaya et al., 2006 
PBS + Survanta Cationic drugs e.g. 
Amitriptylline, Imipramine 
Liao and Wiedmann, 
2003 
Hatches solution (glucose, 
DPPC, alpha tocopherol, uric 
acid, serum albumin, 
lysosyme, apo-transferrin, 
ascorbate, glutathione) 
Welding fumes (manual metal 
arc, metal inert gas and tungsten 
inert gas) 









General Materials and Methods 
 
2.1: Subjects and study design 
All subjects were recruited following advertisement at the Umea University campus and 
in the local newspapers. Informed written consent was obtained from all subjects prior to 
inclusion into the studies outlined in Chapters 3, 4 and 5. The studies described in this thesis 
were approved by the local ethics committee at the University Hospital, Umea, Sweden, in 
accordance with the Declaration of Helsinki.  
 
2.2: Sample Collection 
2.2.1: Plasma collection 
In all of the clinical studies reported in this thesis peripheral blood was collected into 
heparinized tubes and centrifuged at 2,000 g for 10 min at 4 oC. An aliquot of the plasma (450 
μL) was treated with 50 μL of 50% metaphosphoric acid (MPA) and centrifuged at 13,000 rpm 
for 5 minutes (4oC) to remove protein, with the resultant supernatant stored at -80 °C within 30 
minutes of blood collection until required for analysis. This sample was subsequently used for 
the determination of plasma ascorbate and urate concentrations. Further aliquots of unacidified 
plasma (~1ml) were frozen and stored at -80 °C for analysis of other markers (urea). All 
procedures and sample pre-treatment steps were performed by laboratory personal at Umea 
University. 
2.2.1: Nasal lavage 
Nasal lavage samples (Chapter 3) were collected using the metered nasal spray method, 
as previously described (Mudway et al., 1999). Briefly, five 1 ml volumes of 0.9% saline were 
sprayed into each nostril, with the recovered material pooled and transferred into a sterile plastic 
receptacle maintained on wet ice. The lavage was self administered by the subject after 
demonstration of the procedure, with the aspirates collected after each 1-ml instillation to limit 
the instilled volume and dwell time of the saline in the nose. In total the protocol took 
approximately 2 minutes per nostril, with a total instilled volume of 10 ml. The recovered 
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aspirate was filtered through a sterile 100-μm pore nylon filter to remove mucus aggregates 
before centrifugation at 400g for 15 minutes (4◦C) to isolate the cell free fraction. Nasal lavage 
samples were then similarly acidified with MPA for ascorbate and urate analysis as described 
for the plasma samples and the de-proteinated supernatant stored at −80◦C prior to analysis. The 
pH (5.4) of the saline used for the lavage procedure was slightly acidic, which acts to limit the 
extent of ascorbate auto-oxidation, during the lavage procedure. As with plasma, further 1ml 
aliquots of cell free nasal lavage were stored for protein and urea determinations. 
 
2.2.2: Bronchial wash and Broncholaveolar Lavage 
Bronchoscopy was performed, following an overnight fast. A flexible video 
bronchoscope (Olympus BF IT240, Tokyo, Japan) was inserted through the mouth with the 
subject in the supine position. Pre-medication with atropine (1 mg) was given subcutaneously 30 
minutes prior to bronchoscopy to reduce airway mucous secretion, with Lidocaine (5% and 1%) 
sprayed onto the airways to achieve topical anaesthesia. Bronchial wash (BW) was performed 
by infusing two aliquots of 20 mL sterile sodium chloride (NaCl), pH 7.3 at 37oC into the 
lingular or middle lobe, which was gently aspirated after each infusion. These recovered 
aspirates were kept as separate aliquots on wet ice. Bronchoalveolar lavage (BAL) was 
performed immediately after these small volume infusions by the instillation and immediate 
aspiration of 3 consecutive aliquots of 60 mL saline. The recovered aspirates were pooled and 
placed on wet ice prior to transport to the laboratory for processing. All lavage samples were 
passed through a nylon filter (pore diameter 100µm) and centrifuged at 400g for 15 minutes at 
4˚C. The BW and BAL supernatants for vitamin C and urate determinations were treated as 
previously outlined for the nasal lavage samples. Samples for GSH and GSSG determination 
were treated with the metal chelator desferoxamine mesylate and the synthetic antioxidant 
butylated hydroxytoluene both at 2 mM, 5 ml of each to 490 ml of lavage, prior to storage at -
80°. The remaining lavage was untreated, but immediately aliquoted and stored at -80°.  
2.3: Total and differential cell counts 
BW and BAL fluid cell pellets were suspended in saline at a concentration of 106 cells/ml, for 
total and differential cell counts. Total leukocyte numbers were determined using a Bürker 
chamber. Cyto-centrifuged specimens were prepared with 5x104 non-epithelial cells per slide 
using a Cytospin 3® (Shandon Southern Instruments Inc., Sewikly, PA, USA) at 1,000 rpm 
(96g) for 5 min. Differential cell counts were performed on slides stained with May-Grünwald 
Giemsa, with 500 cells counted per slide using a light microscope at 100 x magnification and 
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the proportion of non-epithelial cells including macrophages, neutrophils, eosinophils and 
lymphocytes was established. Cells were analyzed on slides stained with acid toluidine blue and 
counterstained with Mayer´s acid haematoxylin, counting a minimum of 12 visual fields at 20x 
magnification. Mast cells were counted in at least 10 visual fields at a magnification of x160 on 
slides stained with acid toluidine blue and counter stained with Mayer’s acid haematoxylin. 
Based on the total cell concentration and the differential cell counts, the concentration of each 
cell type was determined as cell/ml. Cell count data are expressed throughout as absolute cell 
numbers, to avoid artifacts related to proportional changes in cell populations, e.g. apparent 
increases in neutrophils due to a fall in lavage macrophages. Thus, absolute total cell counts are 
vital for the adequate interpretation of differential cell counts, avoiding interlaboratory 
variations and underestimations, as there is no evidence they are influenced by dilution, 
variability in total lavage volume or number of aliquots, permitting more accurate comparison 
across studies. 
 
2.4:  Antioxidant and oxidative damage markers determination 
2.4.1:  Vitamin C and urate analysis 
The concentrations of Vitamin C (ascorbate (AA), plus dehydroascorbate (DHA)) and 
uric acid (UA) were determined simultaneously in NL, BW and BAL samples via reverse phase 
HPLC with electrochemical detection (Iriyama et al., 1984). After thawing on ice the pre-
acidifed deproteinated samples were then lipid extracted by addition of 200µl of ice cold 
heptane, followed by vortexing for 60 seconds and centrifuging at 13,000 rpm for 5 minutes 
(4oC) (Behndig et al., 2009). The resultant lower layer was then carefully decanted into amber 
HPLC vials for analysis. All sample processing was performed on wet ice with care taken to 
protect the samples from light at all times. A Gilson 234 auto-sampler was used to inject 20µl 
aliquots of each sample for analysis onto a 5µm C18 column (4.6 x 150mm, Phenomenex) 
eluted with a 0.2mM K2HPO4-H3PO4 mobile phase (pH 2.1) containing 0.25mM 
octanesulphonic acid (pH 2.1) at a flow rate of 1.5 ml/min. An E&EG amperometric 
electrochemical detector (Jones Chromatography, Hengoed, Wales) was used for detection set at 
800mV and a sensitivity of 0.2µA for lavage samples and 0.5 µA for plasma samples. Ascorbate 
and urate concentrations were determined against appropriate standards. Typical standard curves 
for both compounds are shown in Figure 2.1.  
Total vitamin C was measured in all samples by pre-treating 400 µl aliquots of the 
acidified sample with 50 µl 50 mM Tris(2-carboxylethyl)phosphine (TCEP) in 5% MPA 
(Molecular Probes, Eugene, Oregon USA) for 15 minutes and then performing the lipid 
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extraction and HPLC analysis as described above. The DHA concentration was then calculated 
by subtracting the measured ascorbate concentration from the total vitamin C concentration. 
Urate S tandard C urve
y =  170450x +  22405
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Figure 2.1: Example ascorbate and urate calibration curves 
 
2.4.2:  Glutathione determinations 
Glutathione and glutathione disulfide (GSSG) concentrations were measured 
spectrophotometrically in NL, BW and BAL samples using the GSSG-reductase recycling assay 
(Baker et al.,1990),  a kinetic assay in which glutathione causes a continuous reduction of 5,5’-
dithiobis-(2-nitrobenzoic) acid (DTNB) to TNB. The samples used for this assay were those 
stored in BHT/DES.  Fifty µl aliquots of samples were transferred to a 96 well plate and 100µl 
of a DTNB-reaction mixture added to give final concentrations of 0.15mM DTNB, 0.2mM 
57 
 
NADPH and 1U glutathione reductase in each well. Immediately following addition of the 
reaction mixture the plate was analysed on a plate reader (SpectraMAX 190; Molecular 
Devices) with the rate of change in absorbance at 405 nm followed for two minutes at 30 °C, 
with absorbance read every 10 seconds with mixing between measurements. Glutathione 
concentrations in samples were measured by comparison with a set of standards (GSSG: 0-6.6 
μM). A typical standard curve for total glutathione is illustrated in Figure 2.2.This assay 
measures total glutathione (GSx). The concentration of GSSG was determined by combining 2-
vinyl pyridine (5 μL) and 130 μL of samples or controls in 2 mL micro-centrifuge tubes. This 
solution was vortexed for 5 seconds and incubated for 1 hour at room temperature. This reagent 
forms a conjugate with reduced glutathione (GSH) and prevents it from reacting with the 
DTNB. Once plated out, glutathione disulfide (GSSG) was measured using the same procedure 
as outlined for GSx.  GSSG produces two molecules of TNB when it reacts with DTNB whereas 
reduced GSH produces only one, consequently the reduced GSH concentration was calculated 
as: 
 
Total glutathione – (2 x GSSG) 
GSSG concentrations in samples were again measured by comparison with a set of 
standards (GSSG: 0-3.3 μM) also treated with 2-vinyl pyridine. A typical standard curve for 
GSSG ran with and without 2-vinyl pyridine treatment is shown in Figure 2.2. 
 
 
Figure 2.2: Typical standard curves of total glutathione. Total glutathione concentrations: 0, 30, 
60, 90, 120, 150, 180, 210, 240, 270, 300 and 330 ρmol/50 µl; n = 2) and glutathione disulphide 
concentrations: 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150 and 165 ρmol/50 µl). 
 
2.4.3:Protein carbonyl and 4HNE adduct formation 
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Oxidized protein concentrations were determined quantitatively using commercially 
available protein carbonyl and 4-HNE-HIS protein adduct ELISA kits. Protein carbonyl 
formation was measured spectrophotometrically using OxiSelect protein carbonyl 
spectrophotometric kit (Cell Biolabs, Inc., USA). The measurement is based on derivitization of 
protein carbonyl groups with 2,4-dinitrophenylhydrazine (DNPH). BSA standards (mixture of 
oxidized/reduced BSA)  and samples (10 μg/mL) were adsorbed in duplicate onto a 96-well 
plate for 2 hrs at 37ºC. After DNPH derivatization of the protein carbonyls present, the protein 
samples were incubated with an anti-DNP antibody and a horseradish peroxidase–conjugated 
secondary antibody according to the manufacturer's instructions.  The protein carbonyl contents 
were determined by colorimetric analysis at 450 nm using a standard curve prepared from 
predetermined reduced and oxidized BSA standards. Carbonyl levels are expressed as nmol/mg 
of protein. 
 The level of 4-HNE protein adducts was determined using the OxiSelect HNE Adduct 
ELISA Kit (Cell Biolabs, San Diego, CA, USA). BSA standards (mixture of oxidized/reduced 
BSA)  and samples (10 μg/mL) were adsorbed in duplicate onto a 96-well plate for 2 hrs at 
37ºC. 4-HNE adducts were detected at 450 nm after incubation with a mouse monoclonal anti-
HNE–His antibody followed by HRP-conjugated secondary anti-mouse antibody. HNE protein 
adduct concentration was then determined using a standard curve containing known amounts of 
HNE–BSA (0-10 μg/ml). 
 
 
2.5: Urea: Lavage dilution factor 
RTLF concentrations of each component were determined using the urea correction for lavage 
dilution. Urea was measured with the QuantiChrom urea assay kit (BioAssay Systems, 
Hayward) a spectrophotometric assay based on the complexation of urea with a chromogenic 
reagent, with a linear detection range of 0.00006 mg/mL (1μM) to 1 mg/mL (17mM) urea. For 
plasma, samples (5 μl) were incubated with 200 µl reagent for 20 minutes and for lavage fluid 
(200 μl), incubations with 200 µl reagent for 50 minutes, after which the absorbance was 
measured at at 520 nm. Concentrations were determined with reference to a standard curve  (8 
standards of 0, 0.0025,0.005,0.01,0.025,0.05,0.1, 0.125 mg/ml urea were used) made up in a 





Figure 2.3: Example of a typical Urea calibration curve. 
The dilution of RTLF fluids obtained from lavage procedures was estimated for a given 
individual from the ratio between the determined urea concentrations in parallel lavage and 
plasma samples obtained from the same subject: 
Dilution factor= ([urea]plasma/[urea]lavage) 
 The RTLF concentration of each solute was calculated by multiplying the values 
determined in the lavage returns by the  dilution factors calculated in this manner for each subject. 
The urea concentrations determined in each sample compartment together with the calculated 
dilution factor for each patient group included in this thesis are summarised in Table 2.2a (nasal 
lavage and bronchial wash) and 2.2b (bronchoalveolar lavage). No significant differences were 
observed between the groups. The results presented from this point forward will only discuss 
these urea corrected RTLF concentrations. Both urea concentrations and dilution factors 
determined are consistent with those reported in the literature for NL and BAL samples (van der 
Vliet, 1999; Marcy; 1986). Interestingly the dilution factors determined for BW were much 
greater than those seen with BAL.  
 
 
Table 2.1: Dilution factors determined in upper airway (nasal lavage and bronchial wash) lavage samples retrieved across all subject groups 







  Nasal Lavage Bronchial Wash 
  
Healthy Control  Mild asthmatic  Healthy Control  Mild asthmatic  
Healthy Aged 
Control 
Healthy Smoker COPD Smoker 
COPD Ex-
Smoker 
(n=16) (n=16) (n=16) (n=16) (n=14) (n=11) (n=14) (n=18) 
Lavage Urea 
(mg/ml) 
0.043 0.0503 0.0018 0.0016 0.0021 0.003 0.0017 0.0028 






0.705 0.7256 0.705 0.7256 0.7629 0.8366 0.6914 0.7021 
(0.603-0.779) (0.613-0.831) (0.603-0.779) (0.613-0.831) (0.543-0.878) (0.715-0.931) (0.546-0.762) (0.647-0.895) 
Dilution 
Factor 
15.5 11.1 417.7 364.4 348.4 277.5 397.1 269.7 
(11.2-24.5) (9.5-13.3) (307.6-572.2) (275.9-510.3) (245.1-427.8) (251.9-299.6) (158.1-524.9) (220.7-335.3) 
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Table 2.2: Dilution factors determined in bronchoalveolar lavage samples retrieved across all subject groups investigated in this thesis. 
Concentrations are presented as medians and the 25th and 75th percentiles. 
  Bronchoalveolar lavage 
 
Healthy Control Mild asthmatic 
Healthy Aged 
Control 
Healthy Smoker COPD Smoker COPD Ex-Smoker 
(n=16) (n=16) (n=14) (n=11) (n=14) (n=18) 
Lavage Urea  
(mg/ml) 
0.0039 0.0029 0.005 0.0051 0.0059 0.0038 
(0.004-0.006) (000.23-0.0046) (0.0045-0.0057) (0.0044-0.0077) (0.0054-0.0068) (0.003-0.004) 
Plasma Urea  
(mg/ml) 
0.7256 0.7629 0.8366 0.6914 0.7021 0.705 
(0.613-0.831) (0.543-0.878) (0.715-0.931) (0.546-0.762) (0.647-0.895) (0.603-0.779) 
Dilution Factor 
181.3 233.9 184.6 136.1 131.8 197.1 
(119.7-239.6) (133.4-336.9) (145.2-259.8) (89.1-160.3) (116.0-171.1) (155.5-216.9) 
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2.6: Total protein determination 
Total protein was measured by reaction with bicinchoninic acid (BCA) and 4% 
copper (II) sulphate, against a set of bovine serum albumin (BSA) standards (0-1 mg/mL) 
(Smith et al., 1985) in NL, BAL and BW samples. This method is based on the reduction 
of Cu2+ by proteins in an alkaline medium, with the highly sensitive and selective 
colourimetric detection of Cu+ using BCA. The chelation of two molecules of BCA with 
each Cu1+ ion forms a purple coloured product that exhibits a strong absorbance at 562 nm, 
linear with protein concentration. A typical standard curve is illustrated in Figure 2.4.  It 
should be noted that all measurements from the various samples fell within the range of the 
standard curve generated for each biomarker of interest. 
 
 
Figure 2.4: Typical standard curve of total protein concentration with BSA standard 
concentrations of 0, 0.025, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0 mg/mL. 
 
 
2.7: Quantification of individual proteins 
2.7.1: Albumin determination 
 BAL and BW samples were assayed for albumin concentration using the 
bromocresol green assay (Alpha Diagnostics, San Antonio). The absorbance was then read 
on a spectrophotometer set at a wavelength of 628 nm. Albumin binds to the dye 
bromocresol green at pH 4.3 to form a blue-green colored complex, directly proportional 





Figure 2.5:. Example of a typical BCG calibration curve for albumin determination. 
2.7.2: Antibody based quantification 
 Individual Enzyme-Linked Immunosorbent Assays (ELISAs) were performed 
according to the manufacturers instructions. The proteins asayed in each  sample type and 
subject groups, together  with all other relevant information are presented in Table 2.2. 
Representative standard curves from 4 of the 15 proteins assayed by ELISA (lactoferrin, 
IgA, IgG and α1-antitrypsin (A1AT)) are presented in Figure 2.6. 
 
 
Figure 2.6: Examples of typical standard curves obtained from ELISAs performed across 
samples.(A) Lactoferrin, (B) IgA, (C) IgM and (D) A1AT. 
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Table 2.3: List of ELISAs performed across different subject groups and sample types detailing the Vendor, the range of the standard curve and 






Subject groups investigated Vendor 
Standard curve 
range 













Lactoferrin BW HC, MA Merck 0-100 ng/ml 100 
Lactoperoxidase BW HC, MA Gentaur 0-10 ng/ml 50 
A1AT BAL and BW HC, MA, HAC, HS, CS, CES Bethyl Laboratories 0-250 ng/ml 100 
IgA BAL and BW HC, MA, HAC, HS, CS, CES Bethyl Laboratories 0-250 ng/ml 100 
IgG BAL and BW HC, MA, HAC, HS, CS, CES Bethyl Laboratories 0-250 ng/ml 100 
IgM BAL and BW HC, MA Bethyl Laboratories 0-250 ng/ml 100 
SP-A BAL and BW HC, MA, HAC, HS, CS, CES Biovendor 0-100 ng/ml 100 
SP-B BAL and BW HC, HAC, HS, CS, CES CusaBio 0-10 ng/ml 50 
Transferrin BAL and BW HC, MA, HAC, HS, CS, CES Alpha Diagnostic 0-200 ng/ml 50 
Haptoglobin BAL and BW HC, HAC, HS, CS, CES 
Immunology 
Consultants Lab, Inc. 
0-200 ng/ml 100 
α 2 Macrogloblin BAL and BW HC, HAC, HS, CS, CES Assaypro 0-320 ng/ml 50 
Caeruloplasmin BAL and BW HC, HAC, HS, CS, CES Assaypro 0-320 ng/ml 100 
Ferritin BAL and BW HC, HAC, HS, CS, CES Biovendor 0-800ng/ml n/a 
CC16  
 
BAL and BW 
 








Key: A1AT - alpha-1-antitrypsin; SP-A - surfactant protein A; SP-B - surfactant protein B; CC16 - Clara Cell secretory protein 16; BAL - 
bronchoalveolar lavage; BW - bronchial wash; HC - healthy controls; MA - mild asthmatics; HAC - healthy aged controls; HS - healthy aged smokers; 
CS - COPD current smokers; CES - COPD ex-smokers. (HC n= 16, MA n=16, HAC n=14, HS n=11, CS n=14, CES n=18).
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2.8: Proteomic analysis 
 
2.8.1 Desalting and lavage concentration  
 To overcome the large dilution and high salinity of the airway lavages (150mM 
NaCl), samples were concentrated using 9K MWCO iCON Pierce concentrators (Thermo 
Scientific). Twenty ml of each BAL sample was loaded into iCON concentrators prior to 
centrifugation at 4,000 rpm at 4oC, for 15 minute cycles until complete. This results in a 
filter retentate, corresponding to lavage components in excess of 9kDa, which was then 
resuspended in HBSS. The supernatant was retained to study components of the low 
molecular weight pool. This step was necessary as the high salt concentration of the saline 
used is incompatible with the downstream 1D PAGE and MS applications. It also helps 
reduce the great analytical complexity of the RTLF proteome, removing the low molecular 
weight proteome (> 9kDa). This large dynamic range of molecular weights creates a 
challenge for both the successful detection and relative quantification of BAL proteins, 
limiting the number of proteins successfully identified. The concentration protocol also 
increased the likelihood of detecting relatively low abundance proteins within the lavage 
samples. 
2.8.2: Albumin Depletion  
The highly abundant plasma protein albumin was removed from the concentrated BAL 
samples, using SwellGel Blue Albumin Removal Discs (Pierce) according to the 
manufacturer’s instructions. Each disc has a reported binding capacity of <2mg of 
albumin. The removal of albumin is necessary to identify proteins within a similar mass 
range, which would overwise be masked by the high concentration of this RTLF protein, 
allowing for improved separation in the subsequent 1D-PAGE analysis. 
 
2.8.3: 1D-PAGE 
Volumes equivalent to 100 µg protein per sample were lyophilized in a SpeedVac 
(Eppendorf), resuspended in sample loading buffer (63 mM Tris HCl, 10% glycerol, 2% 
SDS, 0.0025% bromophenol blue, pH 6.8)  in 50mM DTT (Sigma) and denatured at 87oC 
for 5 minutes prior to SDS-PAGE. Samples were loaded into 4-12% Precast Bis Tris gels 
(NuPAGE, life technologies) using MOPS SDS running buffer (NuPAGE, life 
technologies) in an XCell sure lock gel electrophoresis chamber (Life Technologies). 
HiMark™ Pre-Stained HMW Protein Standards were used as a molecular weight markers. 
A potential of 50v was applied for 15 minutes, increased to 150v and run for 1 hour. Gels 
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were removed and bands stained using InstantBlue Coomassie stain (Expedeon) on a 
rocker for one hour, finally gels were left to rinse with water overnight. 
 
2.8.4: Trypsin digestion and protein extraction 
Protein bands were excised from the polyacrylamide gel, reduced with DTT and  the 
cysteine residues carboxyamidated prior to digestion in situ with Trypsin according to a 
modification of the method of Shevchenko et al. (1996), as described below. 
 Ten protein bands were excised per sample, and washed sequentially with dH2O. 
Excised bands were cut into cubes (ca 1mm3), transferred into LoBind eppendorff tubes 
and centrifuged for 5 minutes on a bench top microcentrifuge. Fifty µl of Acetonitrile was 
then added to shrink the gel pieces and the samples dried in a Speed-Vac.  To reduce the 
protein, gel pieces were subsequently swollen with 50 µl ul DTT, 0.1M ammonium 
bicarbonate for 30 minutes at 56 oC. Following this, in order to derivatise cysteine resides 
in the protein, 50 µl iodoacetamide, 0.1M ammonium bicarbonate was added and samples 
incubated at room temperature for 20 minutes in the dark. All steps were performed on an 
orbital shaking platform. In order to destain gel pieces, residual liquid was removed and 
gel pieces washed with 200ul 0.1M ammonium bicarbonate for 15 minutes on an orbital 
shaker (Benchmark). Residual liquid was then removed and acetonitrile added to shrink 
gel pieces for ten minutes. Samples were then dried for 30 minutes by Speed-Vac. 
Dried gel pieces were then saturated with Trypsin digestion buffer (13 ng/ml Trypsin 
(Promega), 50mM ammonium bicarbonate) for 45 minutes on ice. Finally 10µl of this 
digestion buffer was added to samples and they were incubated at 37oC overnight. In order 
to ensure optimal protein extraction, digested samples were centrifuged and incubated with 
acetonitrile at 30 oC for 30 minutes. The supernatant then transferred to a new LoBind 
ependorff tube, whilst 50 µl of 1% formic acid was added to the digested gel pieces and 
incubated for a further 20 minutes. This supernatant was then transferred to the lobind 
ependorff tube described above and the process repeated. One-hundred and fifty µl of 
Acetonitrile was then added to shrink gel pieces and the supernatant again transferred. The 
supernatants were lyophilized in a SpeedVac and resuspended in 1% formic acid, 
 
2.8.5: Nano LC MS/MS 
Following the steps described (in 2:8.3 and 2.8.4): 1D PAGE separation, band 
excision, trypsin digestion and protein extraction, samples were analysed with an 
automated nanoLC MS/MS system. Samples were first separated using an easy nano-LC 
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1000 system (Thermo) with a 75um x 2cm reverse phase column (C18 3um 100 Å). 
Injection volumes of 2 µl were used with a flow rate of 300nl/min. The mobile phase 
consisted of solvents A (water with 0.1% formic acid) and B (ACN with 0.1% formic 
acid), and a linear gradient of 5% Solvent A to 40% Solvent B in 70 min then to 95% B in 
5 min which remained for 15 min prior to column re-equilibration at 5%. This was coupled 
to an LTQ Orbitrap XL mass spectrometer equipped with a nanoelectrospray ionization 
source (ThermoFinnigan, San Jose, CA). The mass spectrometer was set up in a data-
dependent mode for which every MS scan (m/z acquisition range from 300-1800) was 
followed by tandem (Collision induced dissociation (CID)) mass spectra scans (m/z 
acquisition range from 350-5000 Da) for the five most intense peaks in any full scan. 
 
2.8.6: Protein identification and database searching 
Tandem mass spectra were extracted by Proteome Discoverer version 1.3.0.339. 
Charge state deconvolution and deisotoping were not performed. All MS/MS samples 
were analyzed using Mascot (Matrix Science, London, UK; version 1.3.0.339) and X! 
Tandem (The GPM, thegpm.org; version CYCLONE (2010.12.01.1)). Mascot was set up 
to search Mascot5_swissprot_Homo sapiens (human) assuming the digestion enzyme 
trypsin. X! Tandem was set up to search a subset of the HUMAN database also assuming 
trypsin. Mascot and X! Tandem were searched with a fragment ion mass tolerance of 0.80 
Da and a parent ion tolerance of 10.0 PPM. Trypsin/P was set as the protease, allowing for 
one missed cleavage cysteine, oxidation of methionine, carbamidomethylaltion of cysteine 
and phosphorylation of serine, threonine and tyrosine were specified in Mascot and X! 
Tandem as variable modifications.The false discovery rate for automated interpretation of 
the MS/MS spectra was set between 0.01-0.05 when searched against a decoy database (a 
comparable database with all of the protein sequences reversed). 
Scaffold (version Scaffold_3.6.3, Proteome Software Inc., Portland, OR) was used to 
validate MS/MS based peptide and protein identifications. Stringent criteria were used for 
protein identification. Peptide identifications were accepted if they could be established at 
greater than 90.0% probability as specified by the Peptide Prophet algorithm (Keller et al., 
2002).  Protein identifications were accepted if they could be established at greater than 
99.0% probability and contained at least 2 identified peptides.  Protein probabilities were 
assigned by the Protein Prophet algorithm (Nesvizhskii, et al., 2003). Proteins that 
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contained similar peptides and could not be differentiated based on MS/MS analysis alone 
were grouped to satisfy the principles of parsimony. 
The abundance of an individual protein was calculated as the sum of the three most 
intense peptide precursor ions derived from that protein.  The normalization of peak areas 
was achieved by correcting values for total protein concentrations (see Section 2.6) 
determined for individual BAL samples, and further corrected for the lavage dilution using 
the urea method  (Section 2.5). The annotation of protein cellular localization and 
biological function were mapped to Gene Ontology (GO) biological process terms. Further 
to this, proteins were further excluded if not found present in at least 3 out of 5 subjects. 
The full proteomic analytical protocol is summarised in Figure 2.7. 
 
 
Figure 2.7: Scheme of the overall proteomics strategy. This approach permitted for both 




2.9: Assessment of bacterial load within the airways 
2.9.1: Limulus Amebocyte Lysate (LAL) assay 
In order to quantify the endotoxin content of BW and BAL fluid samples, as a 
biomarker of Gram-negative bacterial load, the kinetic Limulus Amebocyte Lysate (LAL) 
assay from Lonza (Walkersville, MD, USA) was performed according to manufacturer’s 
instructions. Endotoxin catalyzes the activation of the propeptide contained in LAL, 
within the provided Kinetic-QCL ReagentR (Lonza). The activated enzyme cleaves a 
peptide to yield a colored substrate, with the rate of proenzyme activation dependent on 
endotoxin concentration. Thus the rate of color change is dependent on sample endotoxin 
concentration. One-hundred μl of Kinetic-QCLR Reagent (Lonza) was added to all wells 
per 96 well plate, and incubated for 1 hour at 37oC in a spectrophotometer (Spectra Max 
190 Molecular Devices) set for a kinetic assay with readings every 30 seconds at 405 nm. 
SoftMax Pro 3.1.2 was used to determine Endotoxin concentrations in samples 
determined against known endotoxin standards (0.005- 5 EU from 50 EU endotoxin 
stock: E. Coli O55:B5 Endotoxin, Lonza). A representative standard curve is illustrated 
below (Figure 2.8). 
Concentration (EU/ml)












y = ( (A - D)/(1 + (x/C)^B ) ) + D: A B C D R^2
STD (Standards: Concentration vs Mean Time) 1.782 0.468 3.874 18.71 1  
Figure 2.8: Example of a typical LAL calibration curves 
 
2.9.1: Assessment of lipoteichoic acid  
Lipoteichoic acid (LTA) was employed as a marker of Gram-positive bacterial load. LTA 
concentrations within BW samples were determined quantitatively using a commercially 
available ELISA (UscnLife Science Inc., Wuhan, PR China), according to manufacturers 
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instructions. One hundred ul of standards and samples were added to a precoated 96 well 
plate with an antibody specific to LTA. Next a biotin-conjugated polyclonal antibody 
preparation specific for LTA and Avidin conjugated to Horseradish Peroxidase (HRP) 
was added to each well and incubated for 1 hour. Following this a TMB substrate solution 
was added to each well, with only those wells containing LTA, biotin-conjugated 
antibody and enzyme-conjugated Avidin exhibiting a change in color. The enzyme-
substrate reaction was terminated by the addition of a sulphuric acid stop solution and 
measured spectrophotometrically at 450 nm. The concentration of LTA in the samples 
could then be determined by comparing samples to the standard curve (0-20 ng/ml), see 
Figure 2.9. 
Concentration








y = ( (A - D)/(1 + (x/C)^B ) ) + D: A B C D R^2
Std (Standards: Concentration vs MeanValue) 0.31 1.12 6.347 3.666 1  
Figure 2.9: Example of a typical LTA calibration curves. 
 
2.10: Determination of lavage elemental composition by Inductively Coupled 
Plasma Mass Spectrometry (ICP-MS) 
Trace concentrations of biometals (44Ca, 52Cr, 65Cu, 57Fe, 39K, 24Mg, 55Mn, 95Mo, 
60Ni, 31P, 48S, 82Se and 66Zn) in BAL fluid samples were established using  inductively 
coupled plasma mass spectroscopy (ICP-MS) following an acid digestion in a solution 
prepared with 60% HNO3 and 30% HCl combined in a 1:3 ratio (in dH2
aliquots of lavage were added to 450 μL of this digesting medium in   acid washed (2% 
HNO3) Teflon vials. Each sample was additionally spiked with Yttrium (to a final 
concentration of 10 ppb), which was used as an internal standard to correct for any 
sample volume losses during the digestion process. Acidified samples were vortexed for 
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two minutes prior to heating in a hot water bath at 90 °C for 90 minutes. The resultant 
digests were then allowed to cool to room temperature overnight in a fume cupboard prior 
to centrifugation at 4,000 rpm for 10 minutes. Acid extracted solutions were stored at 4 
°C until analysis using an ICP-MS (ELAN DRC, MSF008) housed within the King’s 
College London mass spectrometry facility. The selected isotopes were chosen to avoid 
known potential isotopic interferences, with the instruments dynamic reaction cell (based 
on the reaction with ammonia) employed for 44Ca, 52Cr, 39K, 24Mg, 55Mn and 48SO. 
Digestion blanks (using 150mM NaCl) were also ran at regular intervals throughout the 
analytical runs with the mean concentrations substracted from those measured in the 
lavage samples. Trace metal calibrations were conducted using dilutions of a certified 
multi-elemental standard solution (VI CertiPUR Merck, Lot. No.OC529648). Typical 7 
point standard curves are illustrated in Figure 2.10.  
 
 
Figure 2.10: Typical elemental standard curves. Data points represent the mean intensity 





2.11: Statistical analysis 
All statistical analysis was performed using SPSS statistical program for Mac version 
22 (SPSS Inc., Chicago, IL, USA). Data were normally distributed (Shapiro-Wilks test) 
and are therefore expressed throughout as medians with the 25th and 75th percentiles 
(except when stated otherwise). Analysis between subjects was performed using a 
Kruskal-Wallis test with post-hoc Mann-Whitney U tests with the Bonferroni correction 
or using the Mann-Whitney U test with significance assumed at the 5% level. 
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Chapter 3  
 
Characterising the composition of the respiratory 





The RTLFs provide the first physical interface within the airways, surrounding 
the human respiratory tract from the proximal airways to the distal airspaces, playing an 
active and vital role as the first line of defence; possessing a robust antioxidant network, 
metal chelation proteins; as well as proteins with innate immune functions (Hatch, 1992; 
O’Neil et al., 2011). The composition of this extracellular compartment reflects both 
macromolecules derived by transduction from the plasma pool, as well as local secretory 
products arising from the various epithelial and resident inflammatory cells within the 
airways (reviewed in Chapter 1). Hence, any condition that alters the permeability of the 
air-blood barrier, stimulates secretory cells, or changes the cellular milieu of the airway is 
likely to have a profound impact on RTLF composition. In this chapter I have therefore 
investigated the compositional difference between the RTLF in healthy young adults with 
that observed in patients with mild atopic asthma, the latter group reflecting a major 
pharmaceutical market for inhaled drugs: anti-inflammatories and bronchodilators. The 
rationale for this approach is that when testing drug interactions and behaviors within 
airway lining fluids, it is necessary that any developed simulant is reflective of the 
underlying condition targeted for treatment.  
Asthma is a highly variable disease clinically, with multiple overlapping 
phenotypes associated with differing underlying mechanisms (Lötvall et al., 2011; Lin et 
al., 2013; Wenzel, 2013). Despite this heterogeneity, some pathophysiological features 
are characteristic of this disease including reversible airway obstruction, increased 
responsiveness of the airway to irritant stimuli, airway remodeling with expansion in 
mucus secreting cells (serous and goblet cells) smooth muscle in the conducting airways 
(Bai and Knight, 2005), the presence of allergic inflammation and impaired innate 
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immunity (Holgate, 2012) and evidence of elevated oxidative stress in the airways 
(Dozor, 2010).  
 These characteristic features of asthma are all inter-related, with the presence of 
episodes of allergic and neutrophilic inflammation associated with oxidative stress; 
evidenced by increased production of reactive oxygen species (Ranguelova et al., 2012; 
Murata et al., 2014), depressed antioxidant defenses (Smith et al., 1997; De Raeve et al., 
1997; Kelly et al., 1999) and the formation of oxidative damage markers (Aldridge et al., 
2002; Schock et al., 2003; Montuschi et al., 2004; Fitzpatrick et al., 2011).  In turn the 
oxidative stress induced in the airway, causes the activation of redox sensitive signaling 
pathways, triggering either antioxidant adaptations to protect the airway (Roth and Black, 
2006; Reynaert et al., 2011), or the upregulation of pro-inflammatory mediators via the 
transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells 
inflammation and oxidative stress, causing tissue injury, resulting in adaptive remodelling 
of the respiratory epithelium (Manuyakorn et al., 2013) and stimulating mucus 
hypersecretion (Voynow and Kummarapurugu, 2011).  
In addition it is now clear that asthma is not only a disease of the adaptive 
immune system but is associated with dysregulation of innate immunity (Hansel et al., 
2013), characterised by: neutrophilia in severe asthma (Fahy, 2009), impaired 
phagocytosis (Simpson et al., 2013; Brugha et al., 2014); decreased mucociliary clearence 
(Daviskas et al., 2005; Fahy and Dickey, 2010); impaired barrier function (Hansel et al., 
2013); the presence of alternatively activated macrophages (Byers and Holtzman et al., 
2011); and evidence of decreased innate immunity proteins (Balzar et al., 2006). These 
features of the asthmatic airway reflect the disordered airway microbial communities that 
have been reported in asthmatics (Hilty et al., 2010), as well their reported increased 
sensitivity to bacterial (Papadopoulos et al., 2011) and viral infections (Folkerts et al., 
1998; Rosenthal et al., 2010). 
All of the asthma phenotypes outlined above are likely to have profound effects 
on the composition of the RTLF, altering the behavior of inhaled materials at the air-lung 
interface, and their subsequent interaction with the underlying epithelial cells.  In this 
study I therefore performed a detailed compositional analysis of both upper and lower 
RTLFs, sampled by bronchial wash (BW) and bronchoalveolar lavage (BAL) 
respectively, in mild atopic asthmatic and non-allergic healthy controls. This analysis 
consisted of a detailed proteomic analysis (with antibody-based validation of selected 
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proteins), as well as an assessment of the antioxidant, elemental and lipid profile in the 
recovered aspirates. While the aim was simply to characterize the dominant RTLF 
components to permit the design of representative simulants of the upper and lower 
airways, representing the healthy and asthmatic lung, the data obtained also allowed an 
investigation into the underlying biology of the asthmatic RTLF, especially in relation to 






3.2.1: Subjects:  
Healthy and asthmatic subjects were invited to participate in the study through 
advertisement. Inclusion criteria were: age 18-40 years, no history of smoking, normal 
lung function (forced expiratory volume in 1 second (FEV1) and forced vital capacity 
(FVC) of at least 80% of predicted and a normal FEV1/FVC ratio) and absence of 
concomitant diseases, apart from allergy in the asthmatic group. All asthmatics had a 
positive history of allergy together with at least one positive skin prick test against a 
standard panel of common aeroallergens. In the asthmatic group, increased bronchial 
hyper-responsiveness to methacholine with a provocative concentration causing a 20% 
fall in FEV1 < 8 mg/mL was required. In total, 16 healthy and 16 age-matched asthmatics 
were included in the study. All participants were free of chest infection within 6 weeks 
prior to and during the study. No antioxidant supplementation or anti-inflammatory 
medication was allowed within 2 weeks prior to or during the study. Asthma severity was 
classified as intermittent according to GINA guidelines (GINA, 2006) with short-acting 
inhaled β2-agonists on demand as sole medication. Inhaled or nasal corticosteroids were 
terminated at least three months prior to the study. Informed consent was obtained from 
all volunteers after verbal and written information. The study was approved by the local 
ethical review board at Umeå University, and performed according to the declaration of 
Helsinki. Subject demographics are presented in Table 3.1. 
 
3.2.2: Lung function 
Lung function was measured using a Vitalograph spirometer (Vitalograph Ltd. 
Buckingham, UK). At least three satisfactorily performed and well-co-operated 
measurements of each variable were carried out, according to recommendations of the 
American Thoracic Society (1995). Methacholine challenge was carried out using the 
method described by Juniper et al. (1994).  
3.2.3: Nasal and Bronchoscopy-based lavages 
All airway sampling was performed outside the pollen season in Northern 
Sweden. Prior to the study visit, subjects fasted from midnight. All lavage procedures 
were performed in the morning and healthy and asthmatic participants were examined in 
a randomized order. Prior to pre-medication for the bronchoscopy procedures patients 
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provided a blood sample (see Section 2.2.1) and performed a self-administered nasal 
lavage; as outlined in Section 2.2.2. Pre-medication with 1.0 mg of atropine was given 
subcutaneously 30 minutes before the bronchoscopy procedure. Subjects with asthma 
inhaled 0.2 mg of salbutamol. Lidocaine was used for topical anesthesia. A flexible video 
bronchoscope (Olympus BF-1T160, Tokyo, Japan) was inserted through the mouth with 
the subject in the supine position. Bronchial wash (BW, 2x20 mL) and bronchoalveolar 
lavage (BAL, 3x60 mL) were carried out on the contralateral side using sterile sodium 
chloride. The aspirates were collected into separate siliconised containers and 
immediately placed on ice, with the three separate BAL aspirates pooled to provide a 
combined sample. All lavage samples were filtered through nylon (pore diameter 100 
Cell pellets derived from the BW (first aspirate) and the combined BAL aspirates were re-
suspended in phosphate buffered saline (PBS) at a cell concentration of 106 cells/mL. 
Differential cell counts were performed on cytocentrifuge preparations stained with May-
Grünwald Giemsa and 400 cells per slide were counted. Information on BW and BAL 
differential cell counts are presented in Table 3.2. Lavage supernatants for vitamin C 
at 13,000 rpm for 5 minutes (4oC). The resultant, deproteinated sample was then 
transferred into a new tube for storage at -80oC. This acidification protocol has previously 
been shown to prevent sample auto-oxidation during storage (Lykkesfeldt, 2007). The 
remaining cell free lavage was stored untreated as 1 mL aliquots. The second BW return 
was employed for all analysis of soluble mediators, according to previous convention 
(Blomberg et al., 1999; Mudway et al., 1999; Mudway et al., 2006). For the BAL fluid 
samples large volume aliquots were also stored (30-50 mL) to provide material for 
subsequent concentration. 
 
3.2.4: Antioxidant analysis 
Vitamin C, ascorbate, dehydroascorbate, total glutathione (GSx), glutathione 
(GSH), and glutathione disulphide (GSSG) concentrations were determined in nasal 
lavage, BW and BAL as previously described,(Mudway et al., 2001; Behndig et al., 
2009); further details are provided in Chapter 2 (Section 2.4). Glutathione, total protein 
and urea determinations were performed in untreated lavage samples. Lavage and plasma 
urea concentrations were determined using the QuantiChrom urea assay kit (BioAssay 
Systems, Hayward).  Urea dilution factors for BW and BAL for each subject were 
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calculated as [urea]plasma/[urea]lavage. Each subject's lavage measurements were 
multiplied by his/her unique dilution factors to correct for dilution to derive bronchial and 
alveolar RTLF concentrations. Total protein was determined using the bicinchoninic acid 
(BCA) method described by Smith et al (1985) in NL, BAL and BW samples (Section 
2.6). Acidified and deproteinated lavage samples for ascorbate determinations underwent 
lipid extraction with heptane prior to analysis by reverse phase HPLC, with 
electrochemical detection (500mV, 100nA). An identical protocol was followed for the 
determination of vitamin C (ascorbate plus dehydroascorbate), with the exception that the 
samples underwent a reduction step with Tris (2-carboxylethyl) phosphine (TCEP) 
(Molecular Probes, Eugene, Oregon USA) (Lykkesfeldt, 2000).The dehydroascorbate 
concentration was determined by subtracting the measured ascorbate from the vitamin C 
concentration. Glutathione and glutathione disulphide concentrations were determined 
using the glutathione disulphide reductase–dithiobisnitrobenzoic acid recycling assay 
(Baker et al., 1990; Mudway et al., 2006).  
 






n = 16 
 
Asthmatics 
n = 16 
 
Male/female 5F / 11M 10F / 6M 
Age (years) 25 (2) 26 (6) 
Methacholine PC20 
(mg/mL) - 1.1 (0.7-4.4) 
Skin Prick Test (SPT) Neg Pos 
 
Lung Function (mean, SD) 
 
FEV1  4.09 (0.77) 3.61 (0.69) 
FEV1 %pred 105 (8) 98 (10)* 








BMI=body mass index; FEV1=forced expiratory volume in one second; PC20=provocative 








3.2.5: Proteomic analysis 
 Five representative large volume cell free lavage sample from both the healthy 
and asthmatic groups were selected for concentration using 9K MWCO iCON Pierce 
concentrators (Thermo Scientific), as described in Section 2.8.1. This analysis was 
restricted to the bronchoalveolar lavage samples, as insufficient volume was available 
from the BW and nasal lavage procedures. The demographics of these two subgroups 
were as follows: for the healthy control population (n=5), 27±2 years, 4 females/1 male, 
with no significant differences noted in basal lung function, or differential cell counts 
relative to the full group (summarized in Tables 3.1 and 3.2). The mild asthmatic group 
was of a similar age (26±6 years) and gender distribution (4F/1M), again with no 
significant difference apparent in basal lung function and airway inflammatory status 
relative to the full group. 
 Following sample concentration, albumin removal was achieved using SwellGel 
Blue Albumin Removal Discs (Pierce) prior to sample separation using 1D-page (Section 
2.8.2, with equal protein loadings), with the subsequent protein bands excised (10 per 
sample) prior to trypsin digestion (Section 2.8.4) and analysis by nanoLC MS/MS 
(Section 2.8.5). A description of the protein identification and the bioinformatic strategies 
adopted in the analysis of the resulting spectra are provided in Section 2.8.6. Comparison 
of relative protein concentrations within each group and for specific proteins between 
groups was based on a semi-quantitative analysis using the area of the three major ion 
peaks as a proxy for protein concentration. Having identified the most abundant proteins, 
these concentrations were confirmed using commercially available ELISAs (see Section 
2.7.2, Table 2.3) in BW and BAL fluid samples from all 16 subjects in each group. All 
final protein concentrations were adjusted for the total protein concentration within the 
original concentrated lavage sample, as well as for the lavage dilution. 
 
3.2.6: Determination of bacterial lipopolysaccharide and lipoteichoic acid  
BAL fluid LPS concentrations were determined using the kinetic Limulus 
Amebocyte Lysate (LAL) assay from Lonza (Walkersville, MD, USA) according to 
manufacturer’s instructions. Lipoteichoic acid (LTA) concentrations were determined 





3.2.7: Elemental analysis 
Trace concentrations of biometals (44Ca, 52Cr, 65Cu, 57Fe, 39K, 24Mg, 55Mn, 95Mo, 
60Ni, 31P, 48S, 82Se and 66Zn) in BAL fluid were established using  inductively coupled 
plasma mass spectroscopy (ELAN DRC, MSF008) following an acid digestion in a 
solution prepared with 60% HNO3 and 30% HCl combined in a 1:3 ratio. Full details of 
the protocol are provided in Section 2.10. The instruments dynamic reaction cell was 
employed for the determination of 44Ca, 52Cr, 39K, 24Mg, 55Mn and 48SO to avoid common 
isotopic interferences.  
 
3.2.8: Statistics  
Antioxidant, inflammatory cell and immunohistochemistry data were not 
normally distributed and are therefore described as medians with 25th and 75th 
percentiles. Mann-Whitney U tests were employed to compare healthy and asthmatic 
data, with Spearman’s rank correlation employed for analysis of association. Statistical 
analyses were performed using the IBM SPSS software, version 20 (SPSS, Armonk, NY, 





3.3.1: Baseline characteristics 
BW and BAL were performed in all subjects. Median BW and BAL recoveries 
were 42% and 72%, with no significant differences between the two groups.  In the 
asthmatic group, predicted FEV1 was significantly lower than in the healthy controls 
(Table 3.1). Consistent with their allergic status, asthmatic subjects had increased 
eosinophil and mast cell numbers in their BW (Table 3.2).  
Table 3.2: Inflammatory cell counts in bronchial wash (BW) and bronchoalveolar lavage 
(BAL) fluid, obtained from mild asthmatic and healthy individuals.  
 





n = 16 
 
Asthmatics 





(×104 cells·mL−1)    
Macrophages 7.2 (5.2–12.3) 5.3 (4.6–9.2) NS  
Neutrophils 0.7 (0.3–1.0) 0.2 (0.1–0.6) NS (P=0.06) 
Lymphocytes 0.3 (0.2–0.7) 0.6 (0.3–0.9) NS 
Eosinophils 0.0 (0.0–0.1) 0.1 (0.0–0.3) * 
Mast cells 0.01 (0.00–0.02) 0.03 (0.01–0.04) * 
Bronchoalveolar Lavage 
(×104 cells·mL−1)    
Macrophages 13.9 (8.9–17.6) 12.0 (10.6–16.1) NS 
Neutrophils 0.1 (0.0–0.2) 0.1 (0.0–0.2) NS 
Lymphocytes 0.7 (0.5–1.0) 1.1 (0.6–1.4) NS 
Eosinophils 0.0 (0.0–0.1) 0.1 (0.0–0.2) NS 
Mast cells 0.01 (0.00–0.03) 0.02 (0.01–0.04) NS 
a
 = Data given as medians (interquartile range). Statistical comparisons between groups performed 
using the Mann-Whitney U-test. NS indicates results were not significant, * indicates significance at 
the 5% level. 
3.3.2: Low molecular weight antioxidants 
Lavage samples were analysed for the low molecular weight antioxidants 
ascorbate, urate, and glutathione (total, reduced and glutathione disulphide). Individual 
lavage correction factors based on the urea method were used to derive undiluted RTLF 
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concentrations, as illustrated in Table 3.1, overall no significant differences were 
observed between the concentrations of these antioxidants between the two groups, 
however analyses revealed clear regional differences in antioxidant concentrations 
between the alveolar, bronchial and nasal lining fluids sampled. For both healthy subjects 
and mild asthmatics, ascorbate concentrations were significantly greater within the 
alveolar RTLFs (122.1 (97.7-154.3) M and 79.4 (62.2-144.6) M respectively) 
compared with those of the bronchial and nasal passages (p<0.001) – Table 3.1. 
Conversely for urate, significantly (p<0.001) higher concentrations were observed in the 
nasal lining fluids (compared with the concentrations determined in the bronchial, or 
alveolar RTLFs (Table 3.1). Glutathione concentrations appeared greatest in the 
bronchial conducting airways, in both the  healthy and mild asthmatic subjects (p<0.001), 
being approximately four fold greater than alveolar and ten-fold greater than 
concentrations measured in the nasal compartment.  
 
3.3.3: The RTLF Proteome 
1D PAGE and Nano LC MS/MS analysis of the mild asthmatic and healthy 
BAL RTLF proteomes identified 217 and 199 proteins respectively, 140 of which were 
common across both groups (Figure 3.1).  Of the 77 proteins unique to the mild 
asthmatic proteome, CD151 antigen, a cell adhesion molecule implicated in the 
proliferation of T cells; Caveolin-1, essential in T-cell receptor mediated T-cell activation 
and HLA class II histocompatibility antigens, which have a responsibility in the binding 
of antigens for recognition by CD4 T-cells, in a Th1 specific response were identified. 
Ferritin, an intracellular iron storage protein and Protein AMBP, a protease inhibitor 
found which forms a complex with tryptase in mast cells were also found uniquely in the 
mild asthmatic proteome. 
Many of the proteins ‘missing’ from the asthmatic RTLFs, compared with the 
healthy controls, were related to antioxidant defense or innate immunity. Glutathione-S-
Transferase omega, glutathione peroxidase and thioredoxin like proteins were all absent 
from the RTLFs.  With LPLUNC1, neutrophil gelatinase associated lipocalin and CD59 




Table 3.3:  Dilution factors determined in nasal lavage, bronchial wash and bronchoalveolar samples retrieved. Values are Medians and IQR, 
n=16 for both healthy controls and mild asthmatics 
  Nasal Lavage Bronchial Wash Bronchoalveolar lavage 
  Healthy Control Mild asthmatic Healthy Control Mild asthmatic Healthy Control Mild asthmatic 
























































Table 3.4: RTLF Antioxidant and total protein concentrations determined from parallel BAL, BW, NL and Plasma samples obtained from both 
healthy and mild asthmatic subjects. Data are Medians with IQR values, n=16 for both asthmatics and healthy controls 
 Healthy RTLF Asthmatic RTLF 
 





















































































































Figure 3.1: A venn diagram illustrating the proteins shared and specific to mild 
asthmatic and healthy control subjects. (Data is based on data derived from five subjects for 
both mild asthmatics and healthy controls). 
 
Across both groups the identified proteins were predominantly classified, based 
on their gene ontological definitions as being related to five major categories: immunity 
and inflammation, metal handling, protease-antiprotease balance, transport and the 
oxidant-antioxidant balance of the airways. The largest category in both groups were 
proteins involved in immunity and inflammation, with 62 and 61 proteins identified in the 
healthy controls and mild asthmatics respectively (Figure 3.4). This was followed by 
proteins related to protease/antiprotease balance (24 and 25 proteins respectively) and 
metal handling (25 and 23 proteins respectively). Only 9 and 7 proteins were identified 
that were classified as being involved in oxidant-antioxidant balance within the young 
and asthmatic RTLFs (see Appendix A for the full protein lists classified by ontology).  
Additionally the source of each protein was annotated, with the majority of 
proteins classified as being extracellularly derived (101 and 94 for healthy controls and 
mild asthmatics respectively), but with the most abundant proteins largely of plasma 
origin: Serotransferrin, Serum albumin, Ig gamma chains, alpha-1-antrypsin and 
Haptoglobin, (see Table 3.4). Proteins were then ranked by relative abundance, based on 
the three most abundant ion peaks identified for each protein. Table.3.4 displays the top 
fifteen most abundant proteins from both the healthy controls and mild asthmatics, with 
additional annotation concerning their source of origin, ontological definition and the 
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relative fold difference between healthy and asthmatic RTLFs. The proteins listed were 
limited to those present within at least 3 out of 5 subjects investigated in each group. 
Considering these most abundant proteins, a general decline in expression of the majority 
of these proteins was observed within the mild asthmatic proteome with the exception of 
Haptoglobin, which demonstrated an increase (2.9 fold) in the mild asthmatics. 
Considering the full protein list a few prominent fold differences were noted 
between the healthy and asthmatic RTLFs, highlighted in Tables 3.5 and 3.6. The 
immunoglobulin chains (Ig lambda chain V region 4A, Ig lambda chain V-III region LOI, 
Ig kappa chain C region) were 10.6, 7.4, 5.9 lower, respectively in mild asthmatics. 
Lysozyme a key secretory protein involved in innate immunity, demonstrated a six fold 
decrease in asthmatic RTLFs. Whilst relatively few proteins were identified contributing 
to the oxidant/antioxidant balance, of the 6 proteins identified, Glutathione S-Transferase 
P and Protein DJ-1 were found 3.6 and 2.3 fold lower in mild asthmatics respectively. Of 
the proteins with roles in metal handling serotransferrin and the ferroxidase 
caeruloplasmin were found to have lower expression in the mild asthmatics subjects (2.8 
fold and 4.4 fold lower respectively). Interestingly only two proteins, Haptoglobin and 
Leucine rich alpha 2 glycoprotein were found to be increased in the asthmatic proteome, 
3 and 6-fold respectively. Neither has previously been implicated in the pathology of 
asthma. 
 
3.3.4: Protein quantification 
Analyses of urea corrected total protein in BAL, showed no significant differences 
between groups with values of 14.34 (11.8-24.6) and 17.46 (12.4-21.5) mg/mL in healthy 
controls and mild asthmatics respectively. Total protein concentrations determined in BW 
were 40.38 (28.9-51.4) and 27.99 (24.1-40.8) mg/mL for HC and MA groups respectively 
(no significant differences between the groups), approximately two fold greater than 
concentrations in alveolar samples (p<0.001). However prior to the application of the urea 
correction for lavage dilution, total protein values measured in BW (0.09 (0.06-0.12) and 
0.09 (0.07-0.10) mg/mL) were broadly similar to those of BAL (0.08 (0.06-0.11) and 0.09 
(0.07-0.12) mg/mL) in both HC and MA subgroups. 
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Table 3.5: The most abundant alveolar proteins identified in healthy and mild asthmatic RTLFs. The 15 most abundant proteins common to both 
young and aged subjects identified (out of 140) are listed alongside their source of origin, their ontological classification and their relative fold differences. In all 






















(healthy vs asthma) 
Serotransferrin Extracellular, Secreted 
Metal Handling and 
Transport 
1.28E+10 4.55E+09 
2.8 ↓ with asthma 
  
Serum albumin Extracellular, Secreted 
Metal Handling and 
Transport 
3.97E+09 3.32E+09 
1.19 ↓ with asthma 
  




4.1 ↓ with asthma 
  




3.7 ↓ with asthma 
  




4.1 ↓ with asthma 
  




5.9 ↓ with asthma 




1.9 ↓ with asthma 
  
α-1-antitrypsin Extracellular, Secreted Protease/antiprotease 
2.69E+09 7.42E+08 
3.6 ↓ with asthma 
  




2.3 ↓ with asthma 
  




3.0↑ with asthma 
  




4.4 ↓ with asthma 
  




2.4 ↓ with asthma 






2.5 ↓ with asthma 






2.4 ↓ with asthma 
  
Lactotransferrin Extracellular, Secreted 





1.9 ↓ with asthma 
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Table 3.6: Alveolar proteins demonstrating the largest relative fold decreases with Asthma. The proteins of the common 134 identified showing the greatest fold 
decrease with asthma are listed alongside their source of origin, their ontological classification and their relative fold differences. Data shown is a comparison of the mean of the 
three most abundant ion peaks of each protein identified, with an arbitrary fold change cut off threshold of 2.5 used. In all cases the proteins listed were identified in all five of 
the concentrated BAL fluid samples. References are indicated for those proteins identified that have previously been implicated in asthma. 
 
References: 1. Jeong et al., 2005, 2. Stockley and Burnett, 1980, 3. Soutar, 1977, 4. Lindmark et al., 1990, 5. Hoskins et al., 2013, 6. Fruth et al., 2011; 7. 















(healthy vs asthma) 
Rho GDP-dissociation inhibitor 2 
1 
Intracellular Cell morphology / interaction; signalling 1.36E+09 6.99E+06 194 ↓ with Asthma 
Ig lambda chain V-IV region Bau 
2,3
 Extracellular Immunity and Inflammation 4.40E+08 4.15E+07 10.6 ↓ with Asthma 
Ig lambda chain V region 4A 
2,3
 Extracellular Immunity and Inflammation 1.06E+08 9.96E+06 10.6 ↓ with Asthma 
14-3-3 protein epsilon Intracellular Signalling, Apoptosis 9.02E+07 1.49E+07 6.1 ↓ with Asthma 
Ig kappa chain C region 
2,3
 Extracellular Immunity and Inflammation 5.90E+09 1.00E+09 5.9 ↓ with Asthma 
Lysozyme C  Extracellular Immunity and Inflammation 2.75E+06 4.75E+05 5.8 ↓ with Asthma 
Alpha-1-antichymotrypsin 
4
 Extracellular Protease/antiprotease 1.49E+08 3.86E+07 3.9  ↓ with Asthma 




9.61E+07 1.95E+07 4.9 ↓ with Asthma 
Glutathione S-transferase P 
5,6,7
 Intracellular Antioxidant/oxidant balance 3.42E+07 9.57E+06 3.6 ↓ with Asthma 
Serpin B3  Intracellular Protease/antiprotease 3.01E+07 7.74E+06 3.9 ↓ with Asthma 
Antithrombin-III 
8.9
 Extracellular Blood coagulation cascade regulation 2.92E+07 7.80E+06 3.8 ↓ with Asthma 
Afamin Extracellular Vitamin E binding 2.55E+07 7.98E+06 3.2 ↓ with Asthma 
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 Table 3.7: Alveolar proteins demonstrating the largest relative fold increases with Asthma. The proteins of the common 124 identified showing the greatest fold 
increases with asthma are listed alongside their source of origin, their ontological classification and their relative fold differences. In all cases the proteins listed were identified 



























(healthy vs. asthma) 




Immunity and Inflammation 3.82E+08 1.13E+09 3.0 ↑ with Asthma 
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The contribution of albumin to the measured total protein content of the healthy 
and asthmatic alveolar RTLFs were equivalent, 49.19 (36.3-62.6) and 47.4 (36.0-61.3)% 
respectively (Figure 3.2): 8.16 (6.49-9.37) and 7.77 (5.34-10.04) mg/mL (Figure 3.3A), 
the greatest contribution of any individual protein. In the bronchial RTLF, albumin 
represented a significantly greater (p<0.001) proportion of the total protein pool, 54.54 
(49.6-85.5) and 71.70 (57.6-90.8)% (Figure 3.4) in both healthy volunteers and 
asthmatics:  24.09 (18.25-30.00) and 22.03 (14.73-30.60) mg/mL (Figure 3.5A).  
Following albumin the combined immunoglobulin contribution to the total protein 
pool was the second most dominant, with the total immunoglobulin (G, A and M) 
contribution to the alveolar RTLF protein pool being 15.7 and 17.9% in the healthy and 
asthmatic subjects, with IgG being the major contributor (Figure 3.2). No significant 
differences were observed between the two groups (Figure 3.3B). In the bronchial 
samples the combined immunoglobulin contribution to the protein pool was similar, 
representing 15.3% (healthy) and 13.5% (asthmatic) of total protein (Figure 3.4), 
although IgA was the major immunoglobulin. IgM was the least abundant of the three 
immunoglobulin classes investigated in all samples, both BAL and BW, with no 
significant differences observed between HC and MA (Figure 3.3C and 3.5C). 
The protease inhibitor α-1 antitrypsin (A1AT) represented the third most 
abundant protein in the alveolar RTLFs, contributing 6.87 (5.05-16) and 10.44 (7.7-
14.0)% to the total protein pool in the healthy and asthmatic subjects (Figure 3.2), with 
absolute concentrations of 0.94 (0.55-2.16) and 1.55 (1.37-21) mg/mL (Figure 3.3F). 
This contribution was significantly lower in the bronchial samples (P<0.05), in which 
A1AT comprised 2.66 (1.19-3.39) (healthy) and 2.40 (0.9-3.8)% (asthmatic) of the 
measured total protein (Figure 3.4), with absolute concentrations of 0.60 (0.38-1.07) and 
0.68 (0.26-1.43) mg/mL. No significant differences in A1AT concentration were 
observed between the two groups in either compartment (Figure 3.3F and 3.5G). 
Surfactant protein A, the only of the four surfactant proteins investigated, 
contributed 5.11 (3.7-8.1) and 3.39 (2.5-4.9)% to the alveolar RTLFs (Figure 3.2); 1.00 
(0.6-1.3) and 0.64 (0.5-0.8) mg/mL in the healthy and asthmatic subjects respectively 
(Figure 3.3H). A similar contribution was seen to the bronchial protein pool, representing 
2.87 (1.6-6.5) and 2.07 (1.3-4.0)% (Figure 3.4): 1.30 (0.7-3.1) and 0.99 (0.4-1.6) mg/mL 
in healthy and asthmatic samples respectively. No significant differences in protein 
concentration were noted between the two groups (Figure 3.3H and 3.5H). 
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Transferrin comprised 6.65 (4.4-10.4)% of alveolar lining fluid total protein in the 
healthy and 8.94 (6.0-11.3) % in the asthmatics (Figure 3.2): 1.09(0.6-1.7) and 1.5 (1.2-
1.9) mg/mL, respectively, representing the fourth most abundant protein (Figure 3.3E).  
In the bronchial RTLFs transferrin represented 5.26 (3.6-8.1) and 3.06 (2.2-4.4)% of total 
protein (Figure 3.4): 1.91(1.3-3.0) and 1.22 (0.7-1.5) mg/mL, in the healthy and 
asthmatic subjects respectively, with the measured concentration significantly lower 
(P<0.05) in the asthmatic group (Figure 3.5E). 
The antimicrobial protein lysozyme comprised a smaller proportion of the total 
protein content in the alveolar compartment, 0.22 (0.14-0.4) (healthy) and 0.27 (0.15-
0.50)% (asthmatic), Figure 3.2:  0.03(0.02-0.06) and 0.05 (0.03-0.07) mg/mL, 
respectively (Figure 3.3G). It's contribution to total protein in the bronchial lining fluids 
was significantly greater (P<0.001) in both healthy and asthmatic subjects, 0.74 (0.21-
1.53) and 0.35 (0.23-0.52)% (Figure 3.4): 0.22 (0.11-0.46) and 0.13 (0.08-0.15) mg/mL, 
in controls and asthmatics. In addition bronchial RTLF lysozyme concentrations were 
significantly greater (P<0.05) in the healthy subjects compared with the mild asthmatics 
(Figure 3.5J). 
Having established the significantly depressed concentrations of two proteins of 
related to innate airway immunity in the asthmatic bronchial RTLFs: transferrin and 
lysozyme, two further proteins involved in limiting Fe availability (lactoferrin) and 
maintaining airway sterility (lactoperoxidase) were also investigated. Neither of these 
proteins were significantly reduced in the asthmatic bronchial RTLFs, though there was a 
trend (P=0.054) suggestive of lower lactoperoxidase concentrations in the asthmatics: 








Figure 3.2: Percentage contributions of individual alveolar protein components relative to total alveolar RTLF protein. Values are represented as 


















Figure 3.3: The proteins of the alveolar RTLF in mild asthmatics and healthy controls. Values Corrected for  dilution using the urea method. First row 
from left to right: Albumin (A) , IgA (B), IgG (C), IgM (D); Second row:  Transferrin (E), A1AT (F), Lysozyme (G) and Surfactant Protein A (H). 
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Figure 3.4: Percentage contributions of individual bronchial protein components relative to total bronchial RTLF protein. Proportions are represented 











Figure 3.5: The proteins of the bronchial RTLF in mild asthmatics and healthy controls. Values corrected for lavage dilution using the urea approach. 
First row from left to right: Albumin (A) , IgA (B), IgG (C), IgM (D) Transferrin (E) Second row:  A1AT (E), Surfactant Protein A (G), Lactoferrin 
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3.3.5: Bacterial Load  
Concentrations of the Gram negative bacterial cell wall component LPS were 
significantly elevated (p<0.05) in the bronchial RTLFs of mild asthmatic patients (27.12 (8.7-
125.9) EU/ml) relative to healthy controls (4.1(1.6-13.3) EU/ml) – Figure 3.6. A quantitatively 
similar difference was also noted between both groups in the BAL RTLF (28.3 (9.2-76.0) and 
14.3(5.5-40.4) in MA and HC respectively). The gram positive cell wall component of bacteria 
LTA was additionally investigated within bronchial samples only (0.27 (0.15-0.36) and 0.19 
(0.15-0.29) mg/mL in MA and HC respectively). However, no significant difference was 










Figure 3.6: LTA (A) and LPS (B) concentrations in healthy and mild asthmatic bronchial 
wash samples. Values corrected for lavage dilution using the urea approach. Healthy controls 
n=16, 25.0±2.6 years, 6M/10F; Mild asthmatics n=16, 26.7±6.2 years, 5M/11F. * denotes a 
statistical difference where p<0.05     
 
 
3.3.6: Elemental analysis of BAL fluid 
Phosphorous (P), calcium (Ca) and potassium (K) were the most abundant elements 
within the digested BAL fluid samples in both groups. Of the 14 elements investigated 
significantly higher (p<0.05) concentrations of the following metals were found within the 
asthmatic samples: Zn, 2.0 (1.1-2.5) [asthmatics] vs. 1.3 (0.7-17) µM [healthy]; Fe, 2.4 (2.3-2.6) 
vs. 2.3 (2.3-2.4) µM); S, 7.3 (7.1-8.4) vs. 6.7 (6.4-7.0) µM; Ca, 66.7 (63.8-77.5) vs. 60.9 (56.3-
64.4) µM and K, 114.1 (90.5-132.9) vs. 91.3 (56.4-100.6) µM.  Correlation analysis (Spearman's 
rank order correlation for non-parametric data) was performed to examine the relationships 
between individual elements, with several significant positive correlations (P<0.05) observed 













Figure 3.7: ICP-MS results from healthy controls (A) and mild asthmatic (B) in 
bronchoalveolar lavage samples. Healthy controls n=16, 25.0±2.6 years, 6M/10F , Mild 
asthmatics n=16, 26.7±6.2 years, 5M/11F . * denotes a statistical difference where p<0.05     
 
3.3.6: Lipids of the RTLF 
Measurements of the most abundant surfactant phospholipid, phosphatidylcholine (PC) 
revealed no significant differences between mild asthmatic (3.8 (3.0-6.1) mg/mL) and healthy 
(4.8 (3.1-5.4) mg/mL) alveolar RTLFs. Using the previously determined phosphorous 
concentrations (186.4 (152.9-227.1) and 198.9 (159.6-219.4) µM)  in the asthmatic and healthy 
subjects as an approximate of total RTLF phospholipid, the % contribution of PC was 17.74 
(15.1-21.2)% and 17.28 (14.4-19.3)% in the asthmatics and healthy controls respectively. 
Alveolar RTLF cholesterol concentrations of 0.09 (0.07-0.12) mg/mL (asthmatic) and 0.10 (0.09-
0.14) mg/mL (control) were determined, with the Phospholipid to Cholesterol concentrations 
calculated at a % ratio of 4.2 (3.8-5.1) and 4.5 (3.9-5.4) for MA and HC respectively. No 






 The aim of this study was to characterise the composition of the healthy and mild 
asthmatics RTLFs, with the objective of using this information as a basis for the construction of 
disease-specific lung lining fluid simulants for the in vitro testing of drug interactions at the air 
lung interface (described in Chapter 6). To achieve this aim I focused on quantifying the key 
components of this physiologically important extracellular compartment; including a detailed 
description of the RTLF proteome, as well as the lipid, low molecular weight antioxidant and 
elemental composition. 
The RTLF represents the first line of defense at the air-lung interface, protecting the 
underlying airway epithelium from inhaled xenobiotics, in part through its robust extra-cellular 
antioxidant network (Skoza, 1983; Cross et al., 1994; Mudway and Kelly, 2000; van der Vliet and 
Cross, 2001). The antioxidant concentrations established in this study and adjusted for sample 
dilution using the urea method are generally consistent with previously published results (Cantin 
et al., 1987; Kelly et al., 1999; van der Vliet et al., 1999). This pre-existing literature has 
demonstrated significant regional differences in RTLF antioxidant composition throughout the 
human airway, with glutathione concentrations highest within the alveolar region (Hatch, 1992; 
Cross et al., 1994; van der Vliet et al., 1999), whilst urate concentrations dominate within the 
nasal passages and conducting airways (Peden et al., 1990; Davis and Pacht, 1991; Peterson et al., 
1993; Housley et al., 1995; Blomberg, et al., 1998). This study confirmed these previously 
reported regional variations.  
Alveolar RTLF ascorbate concentrations were similar to plasma levels, with lower 
concentrations determined in the nasal RTLFs, consistent with previous observations (van der 
Vliet et al., 1999). As outlined in previous studies there is still a great deal of uncertainty 
regarding the source and regulation of ascorbate within the RTLFs and the view that this simply 
reflects passive diffusion from the plasma pool is not strongly supported in the literature (Kelly 
and Mudway, 2003; van der Vliet et al., 1999). It was also notable that a significant proportion of 
the RTLF vitamin C pool was present as its oxidised product, dehydroascorbate, especially within 
the bronchial airways. As the samples used for vitamin C analysis were acidified and 
deproteinated to prevent erroneous sample oxidation, this is unlikely to reflect a storage artefact. 
In addition, GSSG concentrations in the bronchial wash samples were not similarly increased, 
relative to the levels seen in the alveolar samples. This suggests that the ascorbate moving onto 
the surface of the lung is subject to oxidation, partly explaining the absence of a clear association 
between plasma and RTLF pools previously reported (Blomberg et al., 1999; Mudway et al, 
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2001).  Previous supplementation studies have shown a rapid flux of ascorbate into the airways 
(Schock et al., 2004; Behndig et al., 2009), which is subsequently lost over a 24-hour period 
(Behndig et al., 2009). Schock and colleagues demonstrated that ascorbate in induced sputum is 
rapidly oxidised in an azide-inhibitable manner, suggesting that endogenous peroxidases 
contribute to the oxidative losses observed (Schock et al., 2004). The RTLF has also been shown 
to contain appreciable concentrations of non-transferrin-bound iron (NTBI), (Gutteridge et al., 
1996) consistent with a pro-oxidant environment. 
I found no significant differences in antioxidant concentrations between the two groups, 
despite reports of lower concentrations of ascorbate in bronchial wash, bronchoalveolar lavage 
and induced sputum obtained from asthmatic subjects (Chanez et al., 1988; Blomberg et al., 
1998; Kongerud et al., 2003). This discrepancy could reflect differences in airway neutrophilia 
between this and the earlier studies. In the former study, (Mudway et al., 2001) a pronounced 
airway neutrophilia was present in the asthmatics compared to healthy controls, which was absent 
here. Indeed in the present study there was a trend (P=0.06) suggestive of reduced neutrophil 
numbers in the bronchial compartment of asthmatic subjects. Given that there was clear evidence 
of allergic inflammation in the asthmatic airways in this study, this suggests that the previous 
observation of low ascorbate concentrations in asthmatics may in fact, more accurately, be 
interpreted as a function of on-going airway neutrophilia, rather than that of asthma or allergic 
inflammation per se. The difference in the inflammatory profile between the current and previous 
studies, likely reflects the clinical heterogeneity of asthma endotypes (Lötvall et al., 2011), with 
increasing evidence of different underlying pathophysiologies in asthma. Thus, whilst the current 
study failed to show evidence of enhanced oxidative stress in the asthmatic airway, this should be 
framed more accurately as mild allergic asthma, without concomitant neutrophilia. This caveat is 
applicable to all of the subsequent discussion of asthma RTLF composition, as the results can 
only reflect patients with mild disease and one of many potential underlying disease processes, 
not all asthma. 
Having established that the antioxidant composition of the healthy and asthmatic RTLFs 
was broadly equivalent, I next examined the proteome of this compartment in subsets (n=5) of the 
two groups. 2D-gel maps examining the protein composition of bronchoalveolar lavage fluids 
have existed for over 30 years ago (Bell and Hook, 1979), with approximately 900 protein spots 
(not corresponding to individual proteins) identified in previous investigations (Noel-Georis et 
al., 2001). In this study using the combination of 1D PAGE and nano-LC MS/MS I was able to 
resolve 353 unique proteins in both subsets of healthy control (n=5) and mild asthmatic subjects 
(n=5), using stringent identification algorithms (see Section 2.8.5).  In order to assign broad 
functional classes to the proteins identified, gene ontologies were employed. This identified 5 
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major functional groups related to: (1) immunity and inflammation, (2) metal handling, (3) 
transport, (4) antioxidant-oxidant balance, and (5) antiprotease- protease balance; consistent with 
the requirement of the surface of the airway to maintain a sterile, anti-inflammatory and reducing 
environment.  In general, based on the proteomic data alone, the majority of proteins identified in 
the alveolar lining fluids from mild asthmatics were found to be decreased relative to the control 
group (Tables 3.4 and 3.5), though these differences were not statistically significant, reflecting 
the small group sizes and the semi-quantitative analysis employed, based on the area of the three 
major ion peaks as a proxy of concentration. The proteomic analysis was therefore used as a 
guide to identify the most abundant proteins, perceived as being the most important in terms of 
simulant design, with validation of protein concentrations performed using ELISAs on all the 
subjects within each group (n=16). As my aim was to account for the major protein components a 
quasi-mass balance approach was adopted, with individual protein concentrations related to the 
total measured concentration. My overall aim was to account for >70% of the total protein pool. 
Previous studies using a similar approach have only accounted for approximately 30-50% of total 
protein (Hatch, 1992; Sutinen et al., 1995; Dargaville et al., 1999); whilst in the present study I 
was able to account for 88.3% and 83.8% of the measured total protein in the asthmatic and 
healthy control alveolar lining fluids, based on quantification of the 8 most abundant proteins 
(Figure 3.2). This figure was inflated to account for the all of the measured ‘total’ protein pool, 
104.3 and 111.7%, when the bronchial RTLFs were considered, based on the 10 determined 
proteins within this compartment (Figure 3.4).  
The RTLF total protein measurements, following urea correction (14.3 [healthy] and 17.5 
mg/mL [asthmatic]), were considerably in excess of previously published concentrations: 6 to 11 
mg/mL (Hatch, 1992; Cross et al., 1994; van der Vliet et al., 1999). Albumin represented the greatest 
contributor to the protein pool, consistent with numerous previous reports (Bell, 1981; Peterson, 
1993; Rennard et al., 1990), accounting for approximately 50% of total protein, with the 
concentrations, approximately 1.5 to 2 fold greater than previously quoted values:  8.2 and 7.8 
mg/mL in asthmatics and healthy alveolar RTLFs, respectively (Hatch, 1992; Cross et al., 1994; 
van der Vliet et al., 1999). Total protein concentrations in the bronchial RTLFs were significantly 
greater than those in the alveolar compartment: 40.4 (healthy) and 28 mg/mL (asthma) 
respectively, representing the first published estimates of urea corrected total protein 
concentrations in this compartment.   
Immunoglobulins provided the second greatest contribution to the alveolar lining fluid 
proteome, with the most abundant: IgG, IgA and IgM combined accounting for 15.7% and 17.9% 
of the total protein pool in healthy and asthmatic RTLFs respectively (Note: the least abundant 
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immunoglobulin IgE was not included on account of it’s low contribution to total RTLF protein). 
Previous reports of the immunoglobulin contribution to the RTLF proteome have been variable 
with both higher (30% of total protein) (Hatch, 1992; Lenz et al., 1993) and lower (5-10 fold) 
contributions reported (Rennard et al., 1990; Sutinen et al., 1995; Dargaville et al., 1999). As 
immunoglobin concentrations within the RTLFs are largely derived from plasma cells found 
within the airways, they are much more likely to vary in concentration across study populations, 
especially in conditions with a known inflammatory component, than albumin, which is derived 
exclusively from the plasma pool by transduction (Burnett, 1986; Raphael et al., 1988; Daniele, 
1990; Hatch, 1992).  
The immunoglobulin composition of the bronchial RTLFs was characterized by a 
significantly greater proportion of IgA relative to the alveolar compartment, corresponding to the 
higher density of IgA secreting plasma cells within the conducting bronchioles (Burnett, 1986).  
The concentration of the secretory protein lysozyme was also significantly greater in the 
bronchial lining fluids, consistent with a previous report by Rogan et al. (2006) who 
demonstrated lysozyme to be ten times more abundant in the aspirate from the first BAL aliquot 
instilled. They further noted the absence of a correlation with neutrophil numbers and suggested 
that this implied that bronchial airway submucosal glands were the likely source (Rogan et al., 
2006). A similar regional pattern of lactoperoxidase enrichment in the upper airways was also 
observed, with this secretory protein responsible for catalysing the production of the biocidal 
compound hypothiocynate (Gerson et al., 2000; Wijkstrom-Frei et al., 2003), however this failed 
to attain statistical significance (P=0.054). In contrast, concentrations of the 80kDa glycoprotein 
transferrin were greatest in the distal airway. This was consistent with previous reports in airway 
lavages from healthy subjects (Lindahl et al., 1998), where transferin concentrations constituted a 
greater proportion of RTLF protein (4-5.6%) than within the plasma pool, implying local 
synthesis within the airways themselves, from alveolar macrophages and lymphocytes (Wesselius 
et al., 1994; Mateos et al., 1998). This emphasizes the importance of Fe homeostasis at the air 
lung interface, both to limit metal catalyzed reactive oxygen species generation (Ghio, 2009; 
Vlasic et al., 2009; Quinlan et al., 2002), but also to limit metal availability to bacterial 
populations (Dehner et al., 2013). 
Proteins related to the innate immune system were strongly represented within the 
extracellular RTLFs, posessing intrinsic microbicidal, bacteriostatic, antiviral and antifungal 
properties, as has previously been shown (Bals and Hiemstra, 2004; Martin et al., 2005; Rogan et 
al., 2006). Fleming was the first to demonstrate the bactericidal effects of airway secretions in 
1922, with many of the above proteins actively secreted into the RTLF by serous cells of the 
upper airways, as well as by activated plasma cells, Clara cells and type II pneumocytes of the 
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more distal airspaces (Travis et al., 1999). The current data demonstrate that in the bronchial 
airways in particular, the RTLF provides a powerful ‘microbicidal barrier’, providing a relatively 
broad spectrum protection against gram positive and negative bacteria.  In addition to the 
independent antimicrobial activities of these proteins, many have been shown to act in a 
synergistic manner. Lysozyme a hydrolytic enzyme, is secreted alongside lactoferrin (Revenis 
and Kaliner, 1992), which acts to destabilize bacterial membranes, increasing the penetration of 
lysozyme into the gram negative bacteria where the enzyme can then disrupt the glycosidic 
linkages of the cell wall (Ellison and Giehl, 1991; Baveye et al., 1999; Rogan et al., 2006).  
Additionally lactoferrin acts as an iron binding protein, depriving bacteria of this essential 
nutrient (Ellison and Giehl, 1991).  
Considerable inter-individual variability was observed for all the determined proteins 
within both the alveolar and upper airway RTLFs. Overall no significant differences were noted 
between the determined protein concentrations in the alveolar RTLFs between the healthy and 
asthmatic subjects. In contrast antimicrobial proteins lysozyme and transferrin were both 
significantly lower in bronchial RTLFs of the asthmatic subjects, with a trend for reduced 
lactoperoxidase, consistent with an overall impairment of the microbicidal defense network at the 
air-lung interface of mild asthmatics. The low transferrin concentration was consistent with 
reduced synthesis within the airway, and contrasted with previous reports of increased airway 
concentrations under conditions of acute inflammation and airway injury.  In patients suffering 
from acute respiratory distress syndrome a twenty fold increase in transferrin RTLF concentration 
has been reported, likely reflective of both the breakdown in the air blood barrier and a protective 
response to the release of excess free iron from dying airway cells (Holter et al., 1986; Pacht and 
Davis, 1988). Greater concentrations have also been demonstrated in sarcoidiosis patients, likely 
due to the increased transduction of protein from the plasma pool (Wattiez et al., 2000). This data 
is therefore consistent with the absence of active inflammation in asthmatic subjects, but infers a 
basal reduction in innate immune defense.  
Before discussing this aspect of the results in detail it is worth noting that whilst the 
determined concentrations of RTLF proteins in this study varied from those in the literature, their 
relative contributions to the total protein pool appeared broadly similar. This implies that the 
higher concentrations likely reflect the application of different lavage dilution correction factors. 
Due to the scarcity of data on dilution factors in the published literature it is difficult to make 
meaningful comparisons between individual protein concentrations across studies. It should 
however be stated that in the present study we employed a high sensitivity urea method, as the 
implied dilution factors from the pre-existing literature suggested that the lavage urea 
concentrations were near the detection limit of the commercially available kits at the time of their 
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publication. It is therefore likely that these previous dilution estimates underestimated the true 
dilution of human RTLF during airway lavages and hence the RTLF protein concentration.  
It is now recognized that the airways of humans are not completely sterile environments 
(Huang et al., 2011), reflecting the presence of commensal bacterial populations (Beck et al., 
2012; Hansel et al., 2013; Huang, 2013), as well as the contribution from the large number of 
microbes inhaled every day. It is thus increasingly clear, that whilst asthma has often been framed 
as a disease of adaptive immune dysregulation, the innate immune system of the lung may play 
an important role in disease etiology and symptom exacerbation (Bals and Hiemstra, 2004; 
Holgate, 2012; Hansel et al., 2013; Huang, 2013). In light of the evidence of depressed immune 
defenses within the asthmatics RTLFs in the present study I hypothesized that their airways were 
likely to contain increased and potentially more diverse bacterial populations. In addition to such 
basal differences one would also expect an increased susceptibility to microbial infection in the 
asthmatic airway (Singh et al. 2000).  I therefore investigated whether there was evidence of 
increased gram negative and gram positive bacterial loads within the airway lining fluids of the 
mild asthmatics, employing lipopolysaccharide (LPS) and lipoteichoic acid (LTA) as indicative 
biomarkers. Consistent with this view I observed an approximate 7-fold increase in the 
concentration of the soluble gram negative bacterial cell wall component LPS in asthmatic 
bronchial wash. In agreement with these findings, a previous investigation demonstrated 
increased bacterial populations within the bronchial airways of asthmatics compared with healthy 
controls, with the most diverse microbial populations found in the most hyperresponsive 
asthmatics (Huang et al., 2011). In contrast, Dubin et al (1996) found similar concentrations of 
LPS in BAL fluid recovered from subjects with and without mild asthma, but reported that the 
asthmatic airway had increased sensitivity to LPS (bronchial hyperresponsiveness, neutrophilia 
and increased airway obstruction) compared with healthy controls. LPS has also been linked to 
the pathogenesis of asthma, with short exposures at high concentrations heavily implicated in the 
development of acute respiratory illnesses (Rylander and Haglind, 1984; Mamolen et al., 1993; 
Schwartz et al., 1995), and early exposure apparently protective against the development of 
allergic diseases (Michel, 2003). Chronic exposures to LPS have been reported to contribute to 
the development of chronic airway conditions, including asthma (Castellan et al, 1987; Niven et 
al., 1997; Pal et al, 1997). Specific bacterial infections have also been linked to asthmatic 
exacerbations, although the incidence of this has yet to be fully elucidated (Toews, 2005), to date 
no association between indoor LPS exposure and the clinical severity of asthma has been 
demonstrated (Michel et al., 1991). A similar increase in bronchial RTLF lipoteichoic acid, 




In addition to the low molecular weight antioxidant and protein components of the RTLF, 
I also examined the concentrations of the most abundant surfactant phospholipid, 
phosphatidylcholine (PC) and cholesterol in the alveolar RTLFs. It is only relatively recently that 
surfactant dysfunction has been implicated in asthma; with Wright et al (2000) suggesting that it 
may predispose the development and severity of the condition, and a report by Kurashima et al 
(1997) having described the successful treatment of asthma by exogenous surfactant treatment, 
also implicating its dysfunction in this disease. Further evidence comes from the exudation of 
plasma proteins into the airway lumen during inflammatory events in asthma, which has been 
shown to inhibit the action of surfactant, impairing its surface tension lowering ability (Van de 
Graaf et al., 1991). Reported differences observed in surfactant composition between the relative 
ratios of phospholipids within asthmatic RTLFs, including significant increases in 
phosphatidylcholine - phosphatidylglycerol ratio, were later identified to be the result of 
specifically increased levels of plasma derived PC after allergen induced inflammation and thus 
increased plasma infiltration into the airways (Heeley et al., 2000). Analyses of sputum samples 
from asthmatics have further revealed changes in % ratios of dipalmitoyl phosphatidylcholine in 
surfactant (Wright et al., 2000) with Kurashima et al. (1997) reporting that sputum samples 
obtained from asthmatics displayed lower surface activity, although these same studies revealed 
no such changes in BAL surfactant composition (Kurashima et al., 1997; Wright et al, 2000).  In 
the present study the concentrations of both PC and cholesterol in the alveolar lining fluids were 
equivalent in asthmatic and healthy populations.  
Elemental analysis was performed predominately as a means of obtaining a measurement 
of total phosphourous as a proxy for total lipid in the alveolar RTLFs. In addition a panel of 13 
elements were also considered: Mo (reflective of xanthine oxidase in the RTLF (Pinamonti et al., 
1998)), Zn (extra-cellular superoxide dismutase, plus other Zn containing proteins, including 
matrix metalloproteinases and S100 proteins (Heizmann and Cox et al., 1998; Mudway et al., 
2001; Ko et al., 2005)), Co (marker of smoking or environmental tobacco smoke (ETS) 
exposure), Cr (smoking, ETS), Mn (Mn-SOD as a marker of cell lysis in the absence of other 
known extracellular Mn containing protein in the lung), Ni (smoking, ETS), Cu (extra-cellular 
superoxide dismutase, caeruloplasmin (Schoonbrood et al., 1994; Mudway et al., 2001)), Fe 
(lactoferrin, ferritin and transferrin (Ghio et al., 2007)), Se (glutathione peroxidase (Fitzpatrick et 
al., 2009)), S (predominately glutathione and cysteine rich proteins (Mudway et al., 2001)), Mg 
(to inform ionic RTLF composition), Ca (ionic composition and concentration of Ca-binding 
proteins, such as  Calgranulin B (Bargagli et al., 2008) and K (ionic composition). Fe, Zn, Ca, K 
and S were all significantly elevated in asthmatic alveolar lining fluids. Whilst Fe was 
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significantly elevated in asthmatic RTLFs, the actual quantitative difference was negligible.  
Nevertheless this is the first observation of increased total iron (Fe) in the RTLFs of asthmatic 
subjects, with previous studies in plasma demonstrating conflicting results, with evidence of both 
enhanced plasma concentrations of total Fe in asthmatics (Kocyigit et al., 2004), or no overall 
difference compared with controls (Vural et al., 2000). This observation gains greater relevance 
when coupled with the significant decrease of transferrin observed within the mild asthmatic 
RTLFs, suggesting that Iron uptake and sequestration into cells might be impaired. Furthermore, 
significant correlations between BAL total Fe measurements and both bronchial and alveolar LPS 
concentrations that were restricted to the mild asthmatics only, suggest that the enhanced Iron 
pool might play a role in providing a favorable microbial growth environment. Whether this 
exists in a redox active form would require further investigation, but it would be consistent with 
previous reports (Gutteridge et al., 1996), as well as the evidence of extensive ascorbate oxidation 
within this compartment (Behndig et al., 2009).  
Increased concentrations of Cu have been previously reported in the plasma of asthmatics 
(Kadrabova et al., 1996; Vural et al., 2000; Ermis et al., 2004), where it has been argued to reflect 
the presence of acute or chronic inflammation within the airways. This is the first report of a 
similar increase within actual RTLFs; though attributing the elevated concentrations in asthmatics 
to the presence of inflammation is far too simplistic. The fact that this increase in Cu occurred in 
parallel to increased Zn concentrations in the asthmatic RTLFs, strongly implicates a possible 
upregulation of extra-cellular superoxide dismutase (EC-SOD), supported by the positive 
correlation between Cu and Zn.  It should be noted however that previous studies have reported 
decreased Zn concentrations in the plasma of asthmatics (el-Kholy et al., 1990; Kadrabova et al., 
1996; Soutar et al., 1997; Vural et al., 2000; Ermis et al., 2004) and there are no published reports 
demonstrating increased EC-SOD concentrations in the asthmatic RTLFs. Rather, there are a 
number of studies demonstrating SOD inactivation in asthma (De Raeve et al., 1997; Comhair et 
al., 2000; Comhair et al., 2005), though which isoform of this enzyme is implicated remains  an 
area of contention. Assuming the upregulation of Cu and Zn to reflect an increase in EC-SOD, 
though the Cu:Zn stoichiometry was not 1:1, this would imply a response to oxidative stress. One 
would thus expect a general upregulation of antioxidant enzyme expression in the asthmatic 
airway, with a parallel increase in plasma glutathione peroxidase to catalyze the reduction of the 
hydrogen peroxide formed by EC-SOD to water; as well as glutathione, which is an essential co-
factor for this enzymatic function. The elemental data however fails to provide a wholly coherent 
picture as Se, the catalytic metal at the active site of glutathione peroxidase was not increased, 
whilst S (used as a proxy for GSH due to its high concentrations in the RTLF) was. Previous 
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reports have actually associated low Se concentrations in airway lavages as a potential biomarker 
for asthma severity (Flatt et al., 1990; Misso et al., 1996; Hoffmann, 2008; Jacobson et al., 2007). 
In addition the concentration of sulphur within the RTLFs did not correlate with the actual 
measured glutathione concentrations, which was also not found to increase in the mild asthmatics, 
suggesting that the S measurement was strongly influenced by contributions from other thiol 
containing proteins.  
Calcium is essential in many cellular processes, with numerous Ca-binding or utilizing 
proteins identified within the RTLF during the proteomic analysis, including the S100 calgranulin 
proteins, surfactant proteins A and D, as well as the high molecular weight glycoconjugate mucin. 
However no differences in these proteins were observed within asthmatic RTLFs, based on the 
proteomic data, and no correlation could be established between calcium and surfactant protein-
A, which was measured in all 32 subjects by ELISA.. The basis for the increase in RTLF 
potassium in asthma remains similarly oblique.  
 
Summary and conclusions 
The aim of this study was to explore the major compositional features of the RTLFs, 
across the respiratory tract in both healthy subjects and mild asthmatics, with the aim of 
identifying the major components for inclusion in lung lining fluid simulants. Using a mass 
balance approach I was able to show that the proteome in both healthy and asthmatic subjects 
could be accounted for by a relatively small panel of abundant proteins identified by the 
proteomic screen; 8 for the alveolar RTLF and 10 for the lining fluids of the bronchial airways. 
This does not infer that these proteins are the most significant to the clinical phenotype, or the 
underlying disease process, only that they should be included within a designed simulant for it to 
be representative of RTLF composition in vivo. In the alveolar compartment there was little 
difference in the composition of the RTLF between the healthy and asthmatic subjects, when the 
low molecular weight antioxidant pool, proteins and lipids were considered, indicating that a 
common simulant could be designed for asthmatics and controls if drug delivery was to be 
targeted to this compartment. The situation was somewhat different in the bronchial lining fluids, 
where there was an enrichment of proteins related to innate immunity relative to the alveolar 
compartment with evidence that these defences were somewhat degraded in the asthmatic 
subjects. Following this result I was able to demonstrate that this depression in innate immune 
proteins in the asthmatics was associated with increased LPS concentrations in the recovered 
lavage fluids, consistent with increased basal bacterial populations in the lung and a potential 
heightened susceptibility to infection. This observation has to be placed in the context that the 
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mild asthmatics examined in this study were stable, with well controlled asthma symptoms, 
consistent with the absence of overt oxidative stress in their airways, or neutrophilia. Hence, these 
observations likely reflect an underlying deficiency related to the disease, rather than as a 







 Age-related changes in the composition of human 




Currently over a third of the UK population is over 50 years of age, with the number of 
people aged over 65 expected to rise by 65% in the next 25 years to over 16.4 million in 2033 
(age, UK London). Despite the shift toward a more aged population surprisingly little information 
is known regarding the normal biochemical changes that accompany the established age related 
decline in lung function (Sharma and Goodwin, 2006; Ito and Barnes, 2009), see Figure 4.1. This 
is a critical issue for inhaled drug development, as the aged population represents the single 
largest market for drugs worldwide and yet the in vitro models employed to evaluate drug 
efficacy and toxicity make no allowance for the affect of normal physiological ageing. The 
underlying causes for the observed changes in lung structure and function are likely 
multifactorial, from the presence of oxidative stress, an imbalance in protease-antiprotease 
regulation, the glycosylation of collagen and connective tissue supporting structures, to the 
presence of low grade chronic inflammation. All of these age-related declines likely contribute to 
the physiological loss of adaptability, making the aged lung not only more susceptible to 
infection, but also to other environmental stressors. This is reflected by the high prevalence of 
chronic and obstructive respiratory diseases and acute infections within the aged population 
where airway diseases constitute the second largest cause of severe disability (Dyer et al, 2012). 
As argued previously, these changes to the lung are likely to have a profound impact on the 
composition of airway RTLFs. In this chapter I used a similar strategy to that employed 
previously to investigate the RTLF composition in a healthy aged population. ‘Healthy’ in this 
context inferring the absence of repiratory disease and predicted lung function within the normal 
range.  
Ageing is an inevitable process defined by four basic principles; it is intrinsic, universal, 
progressive and ultimately detrimental to the host .The mechanisms driving ageing, remain fairly 
poorly understood, with numerous (over 300) theories proposed to explain the ageing process. 
Hayflick’s (1987) theory of cell senescence, Bjorkstens Cross-linking Theory (1968), the role of 
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changing immunity  (Walford, 1969), the mitochondrial- lysosomal axis theory of ageing (Brunk 
and Terman, 1989) and the ‘free radical hypothesis’ proposed by Harman (1956), describe events 
on both the cellular and molecular levels, all of which have greatly evolved our understanding 
into the phenomenon of ageing; however no one theory is generally accepted  (Medvedev, 1990; 
Weinert and Timiras, 2003).  
 
 
Figure 4.1: Age-related decline in forced expiratory volume in one second (FEV1) with 
increasing age. Adapted from Sharman and Goodwin and Ware JH, Dockery DW, Louis TA, et 
al. 1990.  
  
 The gradual functional deterioration in lung function with age (decreases in lung volume, 
maximum rates of airflow, forced vital capacity (FVC), FEV1 and diffusing lung capacity) reflect 
underlying structural and anatomical changes of the airways (Rode and Shephard, 1994; Brandli 
et al., 1996; Ito and Barnes 2009). The dilatation of the ageing alveolus, increasing alveolar dead 
space and reducing parenchymal support to the small airways is known as known as ‘senile 
emphysema’; with onset reported to occur after 50 years of age (Sobin et al., 1988; Gillooly and 
Lamb, 1993; Janssens et al., 1999). Changes in structural elastic fibers and collagen also contribute 
to the loss of elastic recoil, effectively resulting in non-uniform ventilation/blood flow ratios in 
the aged lung (John and Thomas, 1972). This deterioration in lung function is exacerbated by 
osteoporosis and age-related declines in diaphragmatic strength (McClaran et al., 1995; Sharma 
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and Goodwin, 2006). The decline in respiratory muscle strength may have a particularly important 
impact on cough, essential for airway clearance, resulting in an increased risk of airway infection 
(Dyer et al, 2012). Finally, detrimental effects of ageing have also been reported on the 
respiratory centre and peripheral chemoreceptors of the respiratory system, which become 
increasingly unresponsive to stimuli including hypoxia, increasing the vulnerability of the lungs 
in conditions such as pneumonia, heart failure and ventilatory failure (Kronenberg et al., 1973). 
 Animal models including the senescence associated mouse (SAM), developed from an 
AKR/J strain (Takeda et al., 1981), have been used to study ‘normal’ physiological ageing, in the 
absence of complicating environmental factors. These animals have shown to develop the 
morphological and mechanical changes consistent with senile lung with increasing age, including 
airspace enlargement (without the alveolar destruction as seen in emphysema), and loss of elastic 
recoil, in the absence of extrinsic factors  (Verbeken et al., 1992). In addition, minor but 
nevertheless statistically significant impairments of important physiological and protective 
functions of the airways have been observed: immunity, protease-antiprotease and oxidant-
antioxidant balance in these mouse models (Takeda et al., 1981). The normal physiological 
changes as seen in these models were further identified to be exacerbated by exposure to extrinsic 
factors such as inducers of inflammation, including tobacco smoke and LPS, suggesting that they 
accelerate the normal ageing process (Shock, 1962; Thurlbeck, 1967; Takeda et al., 1981).  
Sustained low-grade inflammation alongside dysregulation of respiratory immune 
systems may provide for a mechanism explaining the structural and functional changes occurring 
with age (Ito and Barnes, 2009). A study by Thompson et al (1992) demonstrated a considerable 
increase in the number of neutrophils in the airways with increasing age, associated with fewer, 
but still functionally active alveolar macrophages. The presence of chronic inflammation would 
contribute to the ageing associated changes occurring in the lung, through oxidant mediated and 
enhanced proteolytic damage to the airways (Ito and Barnes, 2009). Two further important 
components of innate immune defence in the airways, mucociliary clearance and bronchial 
secretions into the RTLFs, have both been shown to decline in the aged lung (Goodman et al., 
1978; Gyetko and Toews, 1993), consistent with an increased age-related susceptibility to acute 
respiratory infections, particularly pneumonia, the second most prevalent cause of death in the 
elderly. This would be further exacerbated by the reduction in neutrophil phagocytic activity 
observed in the very elderly (Meyer, 2004). Whilst this depression in innate immunity is well 
established in aged individuals (Shaw et al., 2013), there is a paucity of information regarding 
how this impacts the composition of human RTLFs. There is also evidence of changes to the  
adaptive immune system in aged populations, with T helper (CD4+) cells, essential in the activity 
of other immune cells of the airways (antibody secreting B cell class switching and the activation 
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and maturation of cytotoxic T cells), reported to increase relative to CD8+  lymphocytes. The 
accumulation of CD4+ cells within the distal alveolar airspaces, suggests a heightened presence 
of primed T cells in aged healthy RTLFs, which may be reflective of the large number of insults 
and repeated antigenic exposure occcuring over time. Immunoglobulin concentrations have been 
shown to increase in age, alongside increased levels of various cytokines (including IL-6 and IL-
8) across central and distal RTLFs (Meyer et al., 1998; Meyer, 2001). 
 The role of oxidative damage has been implicated in the pathogenesis of ageing, with 
advanced glycation end products (Simm, 2013), DNA oxidation (Evans et al., 2004; Siomek et 
al., 2007), protein oxidation (Levine, 2002; Stadtman et al., 2005; Baraibar et al., 2013) and lipid 
peroxidation  (Barreiro, 2005; Cruz et al., 2009; Benlloch-Navarro et al., 2013) products all 
observed to increase with age (Jacob et al., 2013). In many organs ageing is accompanied with 
increased concentrations of oxidatively modified proteins, reflected by the carbonylation of 
amino acids, tyrosine nitration and oxidation of cysteine residues, all of which have been shown 
to mark proteins for degradation, as well as alter protein function (Umstead et al., 2009; Oettl and 
Stauber, 2007). Importantly, ageing has also been shown to be associated with impaired lysomal 
and proteosomal function (Höhn et al. 2013), promoting the accumulation and aggregation of 
these oxidation products (Jung et al., 2007).  These changes have been related to both increased 
reactive oxygen species production (Ma et al., 2009; Wang et al., 2013), as well as diminished 
endogenous antioxidant defences (Teramoto et al., 1994; Kumawat et al., 2012; Currais and 
Maher, 2013), with evidence that antioxidant enzyme activites are significantly reduced with 
airway leukocytes from aged subjects (Behndig et al., 2009). This increased oxidative imbalance 
is further exacerbated by poorer diets deficient in antioxidants, in the aged population (Kelly and 
Mudway, 2003; Schwartz and Weiss, 1990). Table 4.1 highlights the types and consequence of 
the oxidative modifications that have been shown to occur in ageing. 
These intrinsic factors are however also exacerbated across the life course by exposure to 
external ‘insults’. The respiratory tract, and the respiratory tract lining fluids surrounding them 
are exposed to a huge array of lung ‘insults’ from environmental/occupational pollutants, tobacco 
smoke and exposure to infectious agents all of which  elicit inflammation and injury to the airway 
which effectively accelerate age-related functional declines (Ito and Barnes, 2009). Thus the 
literature examining age related changes in the airways is often complicated by factors such as 
smoking status or the presence of concomitant disease (Nicholas et al. 2010; Merkel et al., 2005; 
Ohlmeier et al., 2008). This consequently has blurred our understanding of the biochemical 
processes underpinning the age-related declines in lung function. Therefore in this study I have 
selected only healthy aged subjects; never smokers, with no significant lifetime exposures to 
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In this chapter I have investigated the composition of the aged RTLF, comparing BW and 
BAL samples obtained from non-smoking healthy aged subjects to their non-smoking younger 
counterparts; this latter group reflecting the control group from the previous chapter. The primary 
aim was to provide an understanding of the compositional changes occuring at the surface of the 
lung, attributable to ‘healthy’ ageing, to permit the design of simulants representative of the aged 
RTLF. In addition, I aimed to gain a greater insight into the biochemical changes associated with 
the aged lung, with a specific focus on impacts on the antioxidant and innate immune networks 
present within this extra-cellular compartment.  
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Table 4.1: Evidence of oxidative modifications occurring during ageing.




Influences protein synthesis, has mutagenic portential and interfers with gene expression and epigentic processes. Age related changes in proteins 
are regulated both at the transcriptional and translational levels, as well as post translational modifications and physiological cellular clearance 
mechanisms, that together determine the concentration, activity and stability of proteins 
Cheng et al., 1992; 
 Evans et al., 2004;  
Rattan, 1996 
Lipid  
Products inclusing (4-HNE and MDA) are 
capable of forming stable protein adducts  
HNE protein adduct formation, has been correlated with respiratory muscle function Barreiro et al., 2005 
MDA and HNE adducts of apolipoproteins B-100 lys residues implicated in atherosclerotic lesions 
Martinez-Vicente et al., 
2005 
Oxidative modification of LDL Resulting in their aggregation and uptake by mactophages has been crucially implicated in the development of atherosclerotic plaques 
Martinez-Vicente et al., 
2005; Shacter et al., 
2000 
Protein 
Protein oxidation: carbonyl, 4-HNE and MDA 
adducts 
Protein carbonyl derivatives are used as a marker of the free radical mediated effects on proteins, with carbonyl adducts added on to proteins either 
by reacting with aldehyde groups  (4-hydroxy-2-nonenal, malondialdehyde), products of lipid peroxidation, or reacting with reactive carbonyl 
derivatives, the products of glycation and glycoloxidation reactions. The presence of carbonyl groups has been used to establish the association 
between oxidatively damaged proteins with ageing. Oxidative modifications have been said to serve to either inactivate proteins or mark them for 
clearance. These modifications are typically irreversible and thought to be relatively nonspecific. Accumulation of oxidised and glycated proteins, 
could be attributed to defective autophagy, a consequence of age related alterations in proteolytic systems 
Berlett and Stadtman, 
1997; Levine, 2002; 
Bader and Grune, 2006; 
Cecarini et al., 2007; 
Levine and Stadtman, 
2006; Bito et al,  2005 
Formation of intra- or inter-molecular protein 
cross-linked derivatives.   
Ageing has been associated with the decreased efficiency of cellular protein degradation. The degradative processes, both lysosomal and 
proteasomal, impaired with ageing resulting in the accumulation of oxidised protein aggregates.  
Kirkwood, 2005;  
Terman and Brunk, 
2004; Ward et al., 2002; 
Szweda et al., 2003; 
Cuervo and Dice, 2000 
The susceptibility of specific proteins in the 
RTLFs to oxidation has previously been 
reported (Starosta and Griese, 2006). 
Oxidation of the most abundant plasma derived protein within RTLF, albumin, has been demonstrated to both inhibit its functional binding 
capacity and increase its degradation. Conformational changes to albumin also modify in its biological antioxidant functions.  
Oettl and Stauber., 2007; 
Iwao et al., 2006; Nagai 
et al., 2006 
Oxidation of fibrinogen, results in loss of function, clotting, correlates with carbonyl formation Shacter et al., 2000 
Oxidation of immunoglobulins, has been shown to result in aggregation observed in Rheumatoid arthritis Shacter et al., 2000 
Oxidation of alpha-1 antitrypsin, results in loss of function that can have severe physiological consequences contributing to tissue destruction 
Shacter et al., 2000; 
Beatty et al., 1980 
Positive correlation between loss of biological function and elevation of level of oxidised protein in brain in specific regions controlling cognitive 
function 
Carney et al., 1994; 
Forster et al., 1996 
Actin carbonylation, which has structural consequences Dalle-Donne et al., 2003 
Amino acid oxidation: tyrosine nitration and 
oxidation of cysteine residues 
Influences many signal transduction pathways. Oxidation of sulfide groups and the phosphorylation of tyrosine is crucual in  many signalling 
pathways. Oxidation of signalling proteins causes structural modifications, which in turn affects redox-sensitive signalling pathways. Oxidative 
modification of sulfhydryls has been observed in Altzhiemers disease. 
Dalle-Donne et al., 2003; 
Halliwell and Chirico, 
1993. 





4.2.1: Subjects:  
Selection criteria for the healthy young controls are as outlined in Section 3.2.1. 
Inclusion criteria for the aged healthy controls were: being between 50-75 years, never 
smokers with normal lung function. Subjects underwent a detailed medical consultation 
with ECG and chest X-ray prior to inclusion. Exclusion criteria for all groups were the 
use of any medications other than those specifically stated in the inclusion criteria and 
any use of antioxidant supplementation. All participants gave their informed consent and 
the local Ethics Committee of Umeå University approved the study, in accordance with 
the declaration of Helsinki. Subject demographics are presented in Table 4.2, showing 
the age related decline in absolute lung volumes, though the aged subjects test results 
were within the predicted range for their sex and age. 
 
Table 4.2: Demographics and clinical characteristics of the young and aged study 
populations. 
 
Characteristics Healthy controls (n=16) Aged Controls (n=13) 
 5F / 11M 6F / 7M Male/female 
Age (years) 25 (2) 67 (5)*** 
     
Lung Function (mean SD) 
  
FEV1  4.09 (0.77) 2.95 (0.80)*** 
FEV1 % 85 (7) 78 (4) 
FEV1 %pred 105 (8) 100 (18.5) 
FVC 4.81 (1.05) 4.07 (0.97)*** 
FVC %pred 106 (9) 104 (12) 
 
Data presented as mean values with standard deviation, BMI=body mass index; FEV1=forced 






4.2.2: Experimental proceedure:  
Spirometry was performed as outlined in Section 3.2.2. Bronchoscopy with 
bronchial wash and bronchoalveolar lavage was performed as described in Section 3.2.3. 
Nasal lavage was not performed on the aged subjects. Details of the total and differential 
cell counts have been decribed previously (Section 3.2.3). 
 
 
4.2.3: Antioxidant, total protein and urea determinations 
Vitamin C, (ascorbate and dehydroascorbate), urate, total glutathione (GSx), 
glutathione (GSH), and glutathione disulphide (GSSG) concentrations were determined in 
BW and BAL as previously described, (Mudway et al., 2001; Behndig et al., 2009); 
further details are provided in Chapter 2 (Section 2.4). Total protein determinations were 
made using the BCA assay (Smith et al., 1985), with paired plasma and lavage urea 
concentration assessed using the high sensitivity QuantiChrom urea assay kit (BioAssay 
Systems, Hayward). Protein carbonyl formation was measured spectrophotometrically 
using OxiSelect protein carbonyl spectrophotometric kit (Cell Biolabs, Inc., USA), with 
4-HNE protein adducts determined using the OxiSelect HNE Adduct ELISA Kit (Cell 
Biolabs, San Diego, CA, USA).  
 
 
4.2.4: Proteomic analysis 
 The strategy employed was identical to that outlined in the previous chapter 
(Section 3.2.5), with analysis performed on a subset of 5 individuals drawn from each of 
the young and aged groups. For the young group, (n=5), 27±2 years 1M/4F; and for the 
aged population, (n=5) ,67±9 years, 3M/2F.  
 
 
4.2.5: Elemental analysis 
ICP-MS was performed on acid digested BAL fluid samples by inductively 
coupled plasma mass spectroscopy (ELAN DRC, MSF008) as described previously in 




4.2.6: Statistics  
Inflammatory cell numbers, plus urea adjusted protein, elemental and antioxidant 
concentration data were not normally distributed and are therefore described as medians 
with 25th and 75th percentiles throughout. Mann-Whitney U tests were employed to 
compare data derived from the healthy and aged populations, with Spearman’s rank 
correlation employed for analysis of association. Statistical analyses were performed 
using the IBM SPSS software, version 20 (SPSS, Armonk, NY, USA). A p-value <0.05 






















4.3.1: Baseline characteristics 
 All subjects tolerated the lavage procedure well with mean returns for the young 
population of 17.2/40mL and 132.4/180mL for the bronchial wash and bronchoalveolar 
lavage respectively. These returns were significantly decreased within the aged 
population (lavage return thus appears to be associated with airflow limitation): 9.8/40mL 
(bronchial wash) and 86.4/180mL (bronchoalveolar lavage). No evidence of increased 
inflammation was seen in either the upper or lower airway lavages from the aged 
individuals (Table 4.3). 
 
 
Table 4.3: Inflammatory cell counts in bronchial wash (BW) and bronchoalveolar lavage 
(BAL) fluid, obtained from young and aged populations.  
 





n = 16 
 
Aged 





(×104 cells·mL−1)    
Macrophages 7.2 (5.2–12.3) 6.2 (3.4–9.3) NS 
Neutrophils 0.7 (0.3–1.0) 1.1 (0.3–1.4) NS 
Lymphocytes 0.3 (0.2–0.7) 0.6 (0.3–0.8) NS 
Eosinophils 0.0 (0.0–0.1) 0.0 (0.0–0.1) NS 
Mast cells 0.01 (0.00–0.02) 0.00 (0.00–0.01) NS 
BAL-fluid 
(×104 cells·mL−1)    
Macrophages 13.9 (8.9–17.6) 14.1 (9.8–16.6) NS 
Neutrophils 0.1 (0.0–0.2) 0.1 (0.1–0.2) NS 
Lymphocytes 0.7 (0.5–1.0) 1.7 (0.9–3.9) NS 
Eosinophils 0.0 (0.0–0.1) 0.0 (0.0–0.1) NS 
Mast cells 0.01 (0.00–0.03) 0.01 (0.01–0.02) NS 
a
 = Data given as medians (interquartile range). Statistical comparisons between groups performed 





4.3.2: The Ageing RTLF Proteome: 1D PAGE and nano -LC MS/MS  
 1D PAGE and nano LC MS/MS proteomic analysis identified 199 and 163 
proteins within young and aged RTLFs respectively. One hundred and twenty-four were 
common to both proteomes, (Figure 4.2, see Appendix B for a detailed description of all 
the proteins identified), with the majority, 63 and 78 % of the total proteome in young and 
aged RTLFs, respectively, being of extra-cellular, or secretory origin. Only 38 proteins 
were attributed an intra-cellular designation.  
 
Figure 4.2: Venn diagram illustrating the proteins common and unique to healthy young 
and aged alveolar RTLFs, as organised by the most common ontological classifications. 
Classifications include: Inflammation and immunity, metal handling, oxidant/antioxidant 
balance and protease/antiprotease balance, alongside their respective % contributions to 
the total protein pool. Data is representative of n=5 for both subject groups. 
 
 Approximately two thirds of proteins common to young and aged RTLFs were 
extracellularly derived, either secreted into the RTLFs, or derived from the plasma. 
Proteins secreted within the airways, i.e. pneumoproteins, contributed only 10% to the 
identified proteome in both groups; with the proportion of intracellular proteins also 
similar; 32 and 26% in the young and aged RTLFs respectively. 
 Proteins uniquely identified in the aged RTLFs included CD166 antigen, a cell 
adhesion molecule implicated in the priming of T and B cells  (Degen et al., 1998) and 
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ferritin, a large (450 kDa) intracellular Fe storage protein, which has often, been used to 
signify cellular damage. Further by examining those proteins ‘missing’ in the aged RTLF 
(i.e. those unique to ‘young’ RTLFs), we identified proteins contributing to the 
antioxidant defence, including SOD (Cu-Zn) and the peroxiredoxins, indicative of a 
compromised antioxidant network at the air-lung interface. The low molecular weight 
innate immune peptide defensins were also found absent in aged RTLFs. Proteins 
responsible for the protease-antiprotease balance of the airways also appeared to be 
affected by age, with both leucocyte elastase inhibitor and plasma protease C1 inhibitor 
absent. Cathepsin D an intracellular secreted protease was also absent in aged RTLFs. 
Interestingly this lysosomal protein is believed to be involved in the induction of 
autophagy and has previously been implicated in the pathogenesis of age-related diseases 
(Papassotiropoulos et al., 2000; Steinfeld et al., 2006). Napsin A secreted locally by type 
II alveolar cells, which has been shown to be important in the processing of surfactant 
precursors (Woischnik et al., 2008; Chuman et al., 1999), was also absent in the aged 
RTLF proteome.  
 Proteins were classified according to their gene ontological definitions. As 
highlighted in Figure 4.1, the largest functional grouping was for proteins involved in 
inflammation and the immune response at the surface of the lung: 62 and 51 proteins in 
young and aged RTLFs respectively. This was followed by those with roles in the 
protease/antiprotease balance (25 (young) and 16 (aged) proteins) and metal handling (25 
and 22 proteins respectively). Only 9 and 5 proteins were identified as contributing to the 
oxidant-antioxidant balance within young and aged RTLFs (see Appendix B for full 
protein lists grouped by ontological definition). 
Based on a semi-quantitative comparison of the three most intense precursor ion 
peaks for the proteins identified, it was clear that the majority of common alveolar 
proteins decreased with age. Table 4.4 highlights the fifteen most abundant of the 124 
communal proteins (the full list is provided in Appendix B), further annotated by their 
source of origin, ontological definition and the relative fold difference between young and 
aged RTLFs. All, with the exception of uncharacterized protein C3orf38, a protein of 






Table 4.4: The most abundant alveolar proteins identified in RTLF samples from young and aged subjects. The 15 most abundant proteins 
common to both young and aged subjects identified (out of 125) are listed alongside their source of origin, ontological classification and relative 
fold differences. In all cases the proteins listed were identidied in all five of the concentrated BAL fluid samples. 
      
Protein Source Ontology Young (n=5) Aged (n=5) 
Fold difference 
(Aged v Young) 
Serotransferrin Extracellular, Secreted Metal Handling and Transport 1.28E+10 7.62E+09 0.6  ↓ with age 
Ig gamma-1 chain C region Extracellular, Secreted Immunity and Inflammation 1.23E+10 8.92E+09 0.7  ↓ with age 
Ig gamma-3 chain C region Extracellular, Secreted Immunity and Inflammation 9.36E+09 6.71E+09 0.7  ↓ with age 
Ig gamma-2 chain C region Extracellular, Secreted Immunity and Inflammation 9.10E+09 5.60E+09 0.6  ↓ with age 
Ig gamma-4 chain C region Extracellular, Secreted Immunity and Inflammation 9.10E+09 5.60E+09 0.6  ↓ with age 
Ig kappa chain C region Extracellular, Secreted Immunity and Inflammation 5.90E+09 3.47E+09 0.6  ↓ with age 
Uncharacterized protein 
C3orf38 
Unknown Unknown 4.10E+09 2.73E+09 0.7  ↓ with age 
Serum albumin Extracellular, Secreted Metal Handling and Transport 3.97E+09 2.77E+09 0.7  ↓ with age 
Ig lambda-2 chain C regions Extracellular, Secreted Immunity and Inflammation 3.07E+09 2.31E+09 0.8  ↓ with age 
Ig alpha-1 chain C region Extracellular, Secreted Immunity and Inflammation 2.81E+09 2.42E+09 0.9  ↓ with age 
Alpha-1-antitrypsin Extracellular, Secreted Protease/antiprotease   2.69E+09 3.20E+09 0.8  ↑ with age 
Ig alpha-2 chain C region Extracellular, Secreted Immunity and Inflammation 2.05E+09 1.79E+09 0.9 ↓ with age 
Immunoglobulin lambda-like 
polypeptide 5 
Extracellular, Secreted Immunity and Inflammation 1.96E+09 1.44E+09 0.7 ↓ with age 
Ig heavy chain V-III region HIL Extracellular, Secreted Immunity and Inflammation 1.66E+09 1.47E+09 0.9 ↓ with age 
Ig heavy chain V-III region 
CAM 
Extracellular, Secreted Immunity and Inflammation 1.22E+09 1.05E+09 0.9 ↓ with age 
       
121 
 
Table 4.5: Alveolar proteins demonstrating the largest relative fold decreases with increasing age. The proteins of the common 125 identified 
showing the greatest fold decreae with age are listed alongside their source of origin, ontological classification and relative fold differences. Data 
shown reflects the mean intensity of the three most abundant ion peaks of each protein identified, with an arbitrary fold change cut off threshold of 2.5 
used. The number of samples, out of five, in which the proteins were identified, is illustrated.  
 
Protein Source Ontology Young Aged 
Fold difference 
(Aged v Young) 
Annexin A5 Intracellular Blood coagulation, signalling 
6.60E+07 1.36E+06 
48.4 ↓ with age (n=3/5) (n=3/5) 
Pulmonary surfactant-associated protein B  Extracellular, Secreted Surfactant, Immunity 
2.54E+07 3.26E+06 
7.8 ↓ with age (n=4/5) (n=5/5) 
14-3-3 protein beta/alpha Intracellular Signalling, Apoptosis 
1.07E+08 1.46E+07 
7.3 ↓ with age (n=5/5) (n=3/5) 
Coactosin-like protein Intracellular Cell morphology / interaction 
3.46E+07 5.15E+06 
6.7 ↓ with age (n=3/5) (n=3/5) 
Carbonic anhydrase 1 Intracellular Metabolic process 
2.36E+07 3.91E+06 
6.1 ↓ with age (n=5/5) (n=5/5) 
Pulmonary surfactant-associated protein A2 Extracellular, Secreted Surfactant, Immunity 
1.95E+08 3.74E+07 
5.2 ↓ with age (n=4/5) (n=5/5) 
Glutathione S-transferase P  Intracellular Antioxidant/oxidant balance 
3.42E+07 8.51E+06 
4.0 ↓ with age (n=3/5) (n=3/5) 
Epididymal secretory protein E1 Secreted and Lysosomal Lipid transport 
5.26E+07 1.37E+07 
3.8 ↓ with age (n=5/5) (n=5/5) 
CC16  Extracellular, Secreted Immunity and Inflammation 
6.27E+08 1.74E+08 
3.6 ↓ with age (n=5/5) (n=5/5) 
Glutathione peroxidase 3  Extracellular Antioxidant/oxidant balance 
1.13E+07 3.66E+06 
3.1 ↓ with age (n=5/5) (n=3/5) 
Haptoglobin Extracellular, Secreted Immunity and Inflammation 
3.82E+08 1.26E+08 




Table 4.6: Alveolar proteins demonstrating the largest relative fold increases with age. The proteins of the common 125 identified showing the 
greatest fold increases with asthma are listed alongside their source of origin, ontological classification and  relative fold differences. The number of 
samples, out of five, in which the proteins were identified, is illustrated.   
 
Protein Source Ontology Young Aged 
Fold difference 
(Aged v Young) 
Dipeptidyl peptidase 4 Extracellular, Secreted Protease/antiprotease , signalling, apoptosis 
1.64E+07 6.17E+07 
3.8 ↑ with age 
(n=3/5) (n=3/5) 
Alpha-2-macroglobulin Extracellular, Secreted Protease/antiprotease 
6.75E+07 1.66E+08 

















Focusing on age-related differences across the entire proteome, the greatest fold 
differences were noted for intracellular signalling proteins annexin a5 and 14-3-3 protein 
beta/alpha, decreasing 48 and 7 fold in the aged population, Table 4.5. A similar pattern 
was observed with coactosin like protein, an F-actin binding intracellular protein 
predominantly expressed in the lungs. Glutathione-S-Transferase and glutathione 
peroxidase 3, two key proteins involved in the phase II xenobiotic metabolism (Ketterer, 
1982) and antioxidant defense (Erzurum et al., 1993; Cross et al., 1994)) exhibited a 4 
and 3 fold decrease respectively; with haptoglobin concentrations, a protein with both 
antioxidant and antimicrobial properties (Yang et al., 1995; Verrills et al., 1994), also 
observed to decrease with age, Table 4.5.  Proteins unique to the airways, including SP-
A, SP-B, secreted by type II pneumocytes and CC16, secreted by bronchial Clara cells 
(Hermans and Bernard, 1999) were also reduced within the aged RTLFs (8, 5 and 4-fold 
respectively), Table 4.5. Only two proteins were found to be elevated within the aged 
RTLFs: dipetidyl peptidase 4 and alpha 2 Macrogobulin (Table 4.6). 
 Using the proteomic data as a guide, a more quantitative analysis of the most 
abundant proteins was performed across all samples in each group. Again, as with the 
previous analysis in Chapter 3 the objective was to account for in excess of 70% of the 
total RTLF protein pool, which was the arbitrary cut off we employed for simulant 
design. Total alveolar protein concentrations were significantly elevated in the aged 
alveolar RTLFs: 35.3 (21.0-52.1) versus 13.8 (11.6-24.0) mg/mL, P=0.001. 
Correspondingly concentrations of albumin were also significantly elevated within the 
aged airways, approximately 3.5 fold greater than within young alveolar RTLFs: 28.1 
(23.1-35.9 and 7.8 (5.9-9.0) mg/mL P=0.0001, Figure 4.3. In contrast, although total 
bronchial protein concentrations were increased in the aged population, the approximate 
2-fold increase failed to attain statistical significance: 0.07 (0.04-0.1) and 0.035 (0.03-
0.05) mg/mL, with equivalent albumin concentration in the two groups: 23.6 (19.9-32.7) 
and 24.1 (16.0-30.0) mg/mL, Figure 4.4.  
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 Alveolar transferrin concentrations were equivalent in the aged and young groups: 
1.2 (0.5-1.6)  [aged] and 0.9 (0.6-1.7) mg/mL [young] (Figure 4.2), but were significantly 
lower in the bronchial RTLFs in the aged group: 0.89 (0.5-1.2) mg/mL versus 1.91 (1.3-
2.8) mg/mL, P=0.01, Figure 4.4. In contrast, alpha-2 macroglobulin was significantly 
elevated in the alveolar RTLF within the aged group only: 0.07 (0.04-0.23) versus 0.01 
(0.005-0.02) mg/mL, P= 0.008, Figure 4.5. Both alveolar and bronchial RTLF alpha-1 
antitrypsin concentrations were equivalent in the aged and young groups, Figure 4.5 and 
4.6.  
 
Figure 4.3: Transport and metal handling proteins of the alveolar RTLFs. Alveolar 
protein concentrations as determined by ELISA, with values corrected for lavage dilution 
using the urea method.  (A) Albumin and (B) Transferrin. Data are illustrated as box 
plots, with the central line indicating the median concentration, the lower and upper 
boundaries of the box, the 25th and 75 percentiles, respectively, and the whiskers the 95% 
confidence interval. Healthy young non-smoker n=16, healthy aged non-smoker n=14, * 
denotes a statistical difference where p<0.05. 
 
Of the RTLF innate immunity proteins only IgA was significantly higher in the 
aged alveolar proteome: 1.5 (0.9-2.1) versus (0.7(0.5-0.9) mg/mL, P= 0.0001, with 
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equivalent concentrations of IgG: 2.2 (1.0-3.6) and 1.5 (0.9-2.5) mg/mL and haptoglobin; 
0.05 (0.02-0.07) and (0.08 (0.07-0.1) mg/mL, Figure 4.7. In contrast within the bronchial 
RTLFs, no aged related differences were noted in either IgA or IgG, but a significant age-
related decrease in haptoglobin was noted: 2.2 (1.0-3.6) and 1.5 (0.9-2.5), P=0.003 
(Figure 4.8).  
Surfactant proteins A and B were both observed to decrease significantly in 
alveolar RTLFs of the aged group: 0.3 (0.2-0.5) versus 1.04 (0.5-1.3) mg/mL and 0.0045 
(0.003-0.006) versus 0.009 (0.008-0.01) mg/mL, P=0.0001 and 0.021 in the aged and 
young respectively, Figure 4.9, with the age related decline in SP-A also evident in the 
bronchial RTLFs: 0.17 (0.13-0.45) and 1.15 (0.86-1.5) mg/mL, P=0.0001, Figure 4.10. A 
similar trend for an age-related decrease in SP-B was also observed in the bronchial 
RTLFs, but this failed to attain statistical significance: 0.007(0.004-0.01) and 0.61 (0. 4-
1.1) mg/mL. CC16 revealed no such significant declines with age in either the alveolar: 
0.07 (0.04-0.1) and 0.035 (0.03-0.05) mg/mL; or bronchial RTLFs: 0.003 (0.002-0.005) 



















Figure 4.4: Transport and metal handling proteins of the Bronchial RTLF. Details as 





Figure 4.5: Airway antiproteases in the alveolar RTLFs. Panel (A) alpha-1 Antitrypsin 
and (B) alpha-2 Macroglobulin. All other details as outlined in the legend to Figure 4.3. 
 
 
  Considering the relative contributions of the individual proteins to the total 
protein pool, only albumin was noted to increase markedly within aged alveolar RTLFs: 
85 (82–90) versus 48 (33–62) %, see Figure 4.11. With the exception of IgA: 5.6 (1.4–
7.7) versus 4.8 (3.3–5.6)%, and alpha-2 macroglobulin: 0.1 (0.09–0.15) versus 0.09 
(0.04–0.13)%, which represented similar proportions in both the aged and young 
proteomes, the remaining proteins contributed markedly lower proportions in the alveolar 
RTLF.  Considering the bronchial RTLFs, again the proportion of albumin: 65 (40-77) 
and 55 (47-89) %, alongside alpha 2-macroglobulin: 0.27 (0.0-0.65) and 0.08 (0.07-
0.1)%, were increased within the aged proteome, with lower % contributions from the 























Figure 4.6: Airway antiproteases in the bronchial RTLFs. Panel (A) alpha-1 Antitrypsin 
and (B) alpha-2 Macroglobulin. All other details as outlined in the legend to Figure 4.3. 
 
 
To fully explore the impact of a potential imbalance of the oxidant-antioxidant 
handling within the ageing RTLFs, aged and young bronchoalveolar lavage samples were 
analysed for a panel of low molecular weight antioxidants (ascorbate, urate, and 
glutathione), together with markers of oxidative injury: protein carbonyls, 4-
hydroxynonenal protein adducts and glutathione disulphide. Insufficent material was 
available to perform these analyses in the bronchial compartment. Individual lavage urea 
corrections factors were determined (Section 2.5, Tables 2.2a and 2.2b) and applied to 
the antioxidant concentrations measured in the lavage samples, to derive undiluted RTLF 




























Figure 4.8: Innate immunity proteins of the bronchial RTLFs. Panel (A) IgA, (B) IgG and (C) haptoglobin. All other details as outlined in the legend 










Figure 4.9: Alveolar RTLF pneumoproteins. Panel (A) surfactant protein-A, (B) surfcatant protein-B and (C) CC16. All other details as outlined in the 












Figure 4.10: Bronchial RTLF pneumoproteins. Panel (A) surfactant protein-A, (B) surfcatant protein-B and (C) CC16. All other details as outlined in 







Figure 4.11: Percentage contributions of individual alveolar protein components relative 




Figure 4.12: Percentage contributions of individual bronchial protein components 






Table 4.7. Low molecular weight antioxidants in alveolar RTLFs fron young and aged 
subjects.  
 
  Young  Aged  
Vitamin C  141.5 (110.7-198) 80.4(46.0-119.3) 
Ascorbate  122.1 (97.7-154.3) 0.00 (0.00-2.54)** 
Dehydroascorbate  1.22 (1.12-1.30) 66.7 (35.5-94.3) 
Urate  95.5 (59.0-107.7) 86.2 (64.1-184.8) 
GSx  161.6 (128.0-243.9) 141.1 (128.9-190.1) 
GSH ) 137.2 (114.3-184.7) 118.9 (82.8-154.5) 
GSSG  3.4 (0-25.9) 11.1 (0-39.5) 
GSSG:GSH 0.15 (0.09-0.22) 2.75 (2.26-3.31)** 
 
Data represents median values and the interquartile range, where n=16 for healthy young subjects, 
n=13 for healthy aged subjects. * denotes a statistical difference where p<0.05, ** denotes a statistical 
difference where p<0.001. 
 
 
4.3.3: The oxidant-antioxidant imbalance in ageing RTLFs 
Vitamin C concentrations were lower within the aged alveolar RTLFs: 80.4 (46.0-119.3) 
versus 141.5 (110.7-198) Table 4.7. This difference was highly significant when 
ascorbate concentrations were considered (P=0.001) with non-detectable levels observed 
in the majority of the aged subjects. This was associated with a corresponding increase in 
the concentration of dehydroascorbate, though this failed to attain statisitical significance 
due to the large inter-individual variation in concentration. No other statistically 
significant differences in the antioxidants measured were observed, though the 
concentrations of glutathione disulphide were increased within the aged RTLFs (non-
significantly), and the ratio of the oxidised to reduced form of glutathione was 
significantly increased with age: 2.75 (2.26-3.31) versus 0.15 (0.09-0.22) respectively, 
P=0.0001, consistent with oxidative stress within the aged RTLF, Table 4.7. 
 These changes in ascorbate concentration and glutathione disulphide/glutathione 
ratio occurred parallel to an increase in the total protein carbonyl concentration in the 
aged group: 69.8 (66.0-89.7) nmol (aged) versus 26.3 (18.7-33.5) nmol (young). However 
when the data was expressed per unit of concentration of RTLF protein, this increase in 
carbonyl protein adduct was no longer significant: 367.5(280.3-471.4) versus 267.5 
(169.3-355.9) nmol/mg protein, Figure 4.13. Within the ageing bronchial RTLFs no 
significant change in carbonyl adduct formation was observed: 859.1(192.33-2492.9) and 
1346.8 (1065.6-1759.7) nmol/mg RTLF protein, between young and aged RTLFs 
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respectively, Figure 4.14. It was notable however that when protein carbonyl 
concentrations in the bronchial RTLFs were compared against those in the alveolar 
compartment there was a significant elevation in concentration in the former 
compartment, Figures 4.13 and 4.14, consistent with a more oxidizing environment in the 
upper airways, though this regional difference was most marked in the young group. 
Consistent with evidence of oxidative stress in the aged group, concentrations of 4-HNE 
protein adducts were significantly elevated, 4.5 fold, in the aged alveolar RTLFs: 425.0 
(384.0-489.0) versus 94.2 (54.9-116.4)  Unfortunately 
insufficient bronchial wash was available for 4-HNE measurements to be made in this 
compartment. 
 Finally, based on the results obtained in Chapter 3, I decided to examine age 
dependent changes in transition metals concentrations within the RTLF. This analysis was 
restricted to the determination of BAL fluid Cu, Zn and Fe concentrations. Whilst no 
statistical difference was noted in Cu or Zn concentrations with age, total Fe 
concentrations appeared significantly elevated in the aged alveolar RTLFs:  5.14 (4.8-5.4) 
- Figure 4.15. No statistically significant correlations were 
observed between transition metals with markers of protein oxidation (protein carbonyl or 

















Figure 4.13: Total alveolar RTLF protein (A) , protein carbonyl (per mg protein) (B) and 4-HNE adduct (per mg protein) concentrations (C) in young 
















Figure 4.14: Total bronchial RTLF protein (A) , protein carbonyl (per mg protein) (B) and 4-HNE adduct (per mg protein) concentrations (C) in 






Figure 4.15: The concentrations of metals: Cu, Zn and Fe, in aged and young bronchoalveolar lavage samples. Healthy young non-Smoker n=16, 








 The primary aim of this analysis was to characterize the composition of the 
RTLFs in healthy aged individuals, reflective of the normal ageing process, independent 
of disease. In light of the previous literature demonstrating both deterioration of 
antioxidant and innate immune defences with age in other organs (Mahbub et al., 
2011;Vida et al., 2011; Fernandez-Real and Pickup, 2012; Solana et al., 2012; Shaw et 
al., 2013; Vitale et al., 2013) I hypothesised that similar changes would occur in the lung, 
altering the composition of the RTLFs and increasingly pulmonary susceptibility to 
various extrinsic and intrinsic factors.  
 The ageing lung is characterized by a well defined decline in lung function 
(Anthonisen et al., 1986), associated with low grade chronic inflammation (Ito and 
Barnes, 2009; Okamoto et al., 2012), and the imposition of oxidative stress, reflecting 
increased ROS generation against a background of deteriorating antioxidant defences.  
Together these progressive changes result in the formation of the ‘senile lung’, increasing 
the lungs susceptability to respiratory infections and other inhaled xenobiotics. Despite 
the importance of respiratory infections in the aged population surprising little is known 
concerning age-related changes to the composition of the RTLFs during normal 
physiological ageing, with the majority of studies focusing on respiratory disease. In this 
study I attempted to fill this data gap by performing a detailed compositional analysis in 
healthy and aged adults. The key observations were as follows: 
 
1. There were no differences in the ontological classes of proteins identified across 
age groups, or their source of origin.  
2. A general dysregulation of the immune and inflammatory processes within the 
ageing RTLFs was evident. 
3. An age-related dysregulation of protease-antiprotease was not seen. 
4. A pro-oxidant shift in the RTLF redox balance was seen in the aged population. 
  
 While numerous previous studies have employed MS based proteomics to assess 
the nature of the airways under disease conditions, only two such studies have 
investigated healthy ageing in the airways (Merkel et al., 2005 and Ohlmeier et al., 2008). 
As with this investigation, Merkel utilized BAL fluid samples, though without pre-
concentration, combining a nano LC MS/MS method with Surface-Enhanced Laser 
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Desorption/Ionization (SELDI) MS for identification. In contrast to the present study 
where individual samples within each group were analysed separately, in their analysis 
the 5 samples investigated were pooled to provide a single representative sample, with 
only 60 individual proteins identified, across all of the investigated groups; COPD 
smokers and healthy smoking subjects were also included. Ohlmeier et al (2008) focused 
their analysis on lung tissue and induced sputum retrieved from subjects, preventing 
simple comparisons with our investigation, in addition, in this study they limited 
themselves to a 2-D approach, quantifying and comparing specific proteins identified by 
western blot anlaysis 
In this context, the current investigation is unique in that it directly addresses the 
impact of normal physiological ageing, without the presence of concomitant age-related 
disease.  It employs a more stringent analytical approach, with panels of individual 
samples (n=5 per group) analysed after pre-concentration, to both encompass normal 
inter-individual variability and optimize the detection of relatively low abundance 
proteins, that would otherwise not be detectable within dilute lavage samples. The 
majority of early investigations into the RTLF proteome utilized a 2-DE approach, 
however the nanoLC MS/MS methodology employed in this investigation not only allows 
for the identification of a larger number of proteins, with a higher degree of certainty, it 
also permits a semiquantitative comparison of relative changes in MS signal intensities. 
Here, in line with good analytical practice the semiquantitive MS based approach was 
employed as an exploratory tool, alongside an antibody based approach, to validate any 
changes oberved (Bodarenko et al., 2002; Chelius et al., 2003; Wang et al., 2003; Liao et 
al, 2004; Wu et al., 2005). 
As with Chapter 3 we focused our attention on the high abundance proteins of 
the RTLFs to guide the design of lung lining fluid simulants. Using this approach I was 
again able to account for in excess of 70% of the total alveolar and bronchial RTLF 
protein pool. My investigation also demonstrated significantly elevated total protein and 
albumin concentrations within the alveolar RTLFs of the aged group. To date only a 
single investigation has examined RTLF albumin concentrations during ageing, 
demonstrating significantly elevated albumin concentration across both bronchial and 
distal airway lavage samples, consistent with the present result (Thompson et al., 1992).  
Intriguingly this major plasma protein has previously been reported to decline in serum 
with age and has been used as a predictor of subclinical disease in otherwise healthy 
elderly patients (Campion et al., 1988; Salive et al., 1992). However a more recent study 
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has ruled this out, revealing no age related changes in the synthesis or concentration of 
this protein, associated with declining health status (Schalk et al., 2004). 
Proteins related to immunity and inflammatory responses represented the greatest 
proportion of the proteome by number, in both groups. IgA, a key component of mucosal 
immunity, often regarded as a bridge between innate and adaptive responses was 
observed to increase in the alveolar RTLF with age, with a similar trend evident in the 
bronchial RTLFs. IgA, within the upper respiratory tract, is produced locally by B cells 
within the mucosa, the airway epithelium plays a vital role in maintaining concentrations 
of the secreted form within the RTLF, through expression of the polymeric 
immunoglobulin receptor (PigR). The pIgR is considered an essential part of airway 
antibody immunity, restricted to mucosal and glandular epithelia, where it is responsible 
for binding polymeric IgA at the basolateral surface of the lung epithelium, transporting 
the secreted complex to the airway lumen and thus into the RTLFs (Kuhn and 
Kraehenbuhl, 1981; Jaffar et al., 2009). In the present study despite PIgR’s significant 
role in the transycotis of secretory IgA, it was actually found to decrease three fold, based 
upon our semiquantitative proteomic analysis, with age. 
During the transcytosis of dimeric IgA onto the apical surface by pIgR, a cleavage 
occurs separating what is known as the extracellular secretory component from the 
transmembrane receptor segment as part of the secretory form of IgA. Unfortunately the 
antibody based ELISA used in this study is unable to distinguish the form (serum or 
secretory) of IgA within the RTLFs sampled. Interestingly however the J chain, 
responsible for linking IgA dimers of the secretory phenotype, was absent in the 
proteomic investigation of aged RTLFs. IgG, the most abundant plasma derived 
immunoglobulin, demonstrated no such difference in either the bronchial or alveolar 
regions of the airways with age. 
In line with our observations, previous studies have also demonstrated the 
production of immunoglobulins by bronchial lymph nodes to be more efficient within the 
airways of aged individuals. The BAL cooperative study (1990), a multicenter study 
involving 198 volunteers, demonstrated increased IgA and IgG in the aged airways, 
however the subjects recruited included both smokers and non-smokers making 
interpretation of the findings difficult. Meyer et al. (1996) similarly reported significantly 
increased concentrations of IgA in RTLFs from non-smoking aged individuals (in 
addition to IgM), in the absence of a similar increase in IgG. A study by Thompson et al 
(1992) however was unable to demonstrate consistent differences for IgA, in aged 
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bronchial and alveolar RTLFs, and in contrast to our study reported significantly 
increased IgG concentrations with age. 
 
Whilst lysozyme was also elevated within the aged alveolar RTLFs, beta2 
microglobulin, lactotransferrin, galectin-3 and complement c3 and complement factor B 
were all diminished within the aged airways, according to the proteomic analysis.  These 
proteins also form an important component of immune defences of the mucosal airways. 
Further, the major family of antimicrobial peptides, defensins, associated with mucosal 
immunity undetected in aged RTLFs using MS/MS methodology, yet consistently present 
across all healthy young control samples analyzed. Thus the overall picture that emerges 
is one of innate immune dysregulation with age, rather than a simple global 
downregulation of innate immunity proteins. This may reflect a general drift towards 
cellular senescence in the aged airway. As the number of senescent cells increases with 
age, there is evidence of a senescence associated secretory phenotype that promotes the 
secretion of a series of proinflammatory cytokines, chemokines, growth factors and 
remodeling factors, which together may contribute to the presence of a low level chronic 
inflammation in age, furthermore altering local tissue structure and function (Campisi, 
2003; Campisi, 2005; Ohtani and Hara, 2013; Kuilman et al., 2010; Rodier and Campisi, 
2011). The presence of chronic BAL inflammation in the ageing airways may however 
also be beneficial, by permitting a natural, non-injurious and efficient exit of pro-
inflammatory cells through apoptotic and phagocytic pathways (Persson and Uller, 2010). 
 
The reduced concentrations of haptoglobin within the aged alveolar RTLF 
identified by the semi-quantitative proteomic analysis were confirmed in the full panel of 
subjects using ELISA in both the bronchial and alveolar samples. This plasma protein 
synthesized predominately by hepatocytes, but also by lung epithelial cells and in alveolar 
macrophages (Yang et al., 1995; Sung-Min Kang et al., 2011), possesses antimicrobial, 
antibacterial and antioxidant properties by sequestering haem iron. Whilst no previous 
studies have reported changes in the expression of this protein with age, the presence of 
chronic inflammation within the ageing lungs may play a role in modifying the 
expression of this protein. Haptoglobin is part of the acute phase response, during acute 
inflammation and infection, with its expression regulated by several cytokines associated 
with the response (IL1, IL-6, TNF alpha). It is therefore tempting to speculate that the 
decreased concentrations in the aged RTLF may imply the altered expression of these 
regulatory inflammatory cytokines under chronic inflammation of the ageing airways 
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(Okamoto et al., 2012), though it should be noted that in the present study no evidence of 
chronic inflammation was observed in our aged population.   
This investigation also revealed that SP-A, a member of the collectin family of 
glycoproteins, secreted by alveolar type II cells and non ciliated bronchial cells was 
significantly decreased in the bronchial and alveolar RTLF of aged individuals. An 
investigation by Betsuyaku et al. (2004) also reported bronchial concentrations of 
surfactant protein A to be decreased in older (non-smoking) subjects, however the 
bronchoalveolar concentrations in their investigation demonstrated no such age-
dependence. While SP-A plays an important role in surfactant stabilization, it also confers 
innate immunity to the distal airspaces (Wright, 1997; Crouch, 1998; Eggleton and Reid, 
1999; Lawson and Reid, 2000), facilitating the clearance of microorganisms by the 
opsonization and agglutination of a broad range of pathogens and particles, enhancing 
phagocytosis (Tenner et al., 1989; Van Iwaarden et al., 1990). No previous studies have 
examined altered surfactant protein expression as a result of normal physiological ageing, 
unassociated with extrinsic factors such as smoking or COPD. A decline in the function 
of alveolar type II pneumocytes has however been reported, associated with the 
remodeling of the lung parenchyma with age, this may contribute to the decrease in SP-A 
secretion observed in this study (Janssens et al., 1999). It has also been suggested SP-A 
may serve as an indicator of epithelial integrity, with the decrease in RTLF SP-A 
concentrations possibly reflecting its retrograde diffusion from the surface of the lung 
into the plasma pool (Betsuyaku et al., 2004). To date however no such changes in 
alveolar epithelial permeability have been shown to occur with age. 
SP-B was also observed to decline in the ageing alveolar RTLFs. This surfactant 
protein is also secreted by type II pneumocytes, but has no function in immunity, with its 
predominant role being the maintenance of alveolar stability by lowering surface tension 
at the air-liquid interface (Revak et al., 1988; Suzuki et al., 1989; Williams et al., 1991). 
Given the similar response to SP-A, it seems likely that the reduced concentrations of 
both of these proteins may reflect a similar underlying mechanism and suggests an age 
related impairement in the function of type II cells. 
The final pneumoprotein investigated in detail was CC16; a major secretory 
protein within the airways. The precise function of this protein remains unknown, 
however its role in inflammatory processes within the airways has long been 
hypothesized (Evans et al. 1978, Plopper et al. 1992). Secreted by the nonciliated 
bronchiolar Clara cells, it is perhaps unsurprising that CC16 was significantly elevated in 
the conducting young bronchial RTLFs. Concentrations of CC16 were not altered 
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between the aged and young groups in either the upper or lower airway. As CC16 has 
been used extensively as a marker of lung epithelial/endothelial barrier permeability 
(Hermans and Bernard, 1996; Blomberg et al, 2003), the fact that it did not behave in the 
same manner as SP-A or SP-B further supports the contention that the decreased 
concentrations of these two proteins reflect defective production by type II pneumocytes.  
 
The protease/antiprotease balance of the aged airway is particularly important in 
the understanding of the structural changes occurring within the aging airway. 
Interestingly the present data failed to show any age-related change in the major 
antiprotease of the airways, alpha-1 antitrypsin (α1AT). Whilst inherited deficiencies of 
this antiprotease are associated with the development of early onset emphysema 
(Eriksson, 1965; Kueppers and Black, 1974), Meyer et al. (1998) previously reported 
increased levels of α1AT /neutrophil elastase complex in older subjects, in contrast to our 
observations. This was related to the presence of infiltrating neutrophils, routinely 
observed in older airways, though not in our present study. Our MS/MS proteomic 
analysis was unable to detect neutrophil elastase or other degradative enzymes including 
the Cathepsin family of lysosomal proteases, implicated in diseases of the aged airways 
such as emphysema (Papassotiropoulos et al., 2000; Steinfeld et al., 2006). Our results 
suggest the protease-antiprotease balance of the airways does not appear to be 
dysregulated in healthy ageing in the absence of overt inflammation. 
In contrast to α1AT, our study demonstrated significantly elevated concentrations 
of alpha 2 Macroglobulin (A2M), another major antiprotease in both the bronchial and 
alveolar RTLFs in aged subjects (based upon both MS/MS and antibody quantification). 
A2M has been heavily linked to diseases of ageing: genetically with Alzheimers disease, 
as a result of its role in the clearance and degradation of amyloid beta (Blacker et al., 
1998) and with diabetes, where it has been observed to be found significantly elevated 
with age (James, 1990). A2M has the capacity to recognize and bind a broad spectrum of 
proteinases, forming complexes that are subsequently recognized and cleared by alveolar 
macrophages (Marchandise et al., 1988; Starkey et al., 1977; Strauss et al., 1999; 
Armstrong and Quigley, 2001). It also has a key immunoregulatory role, with the A2M 
receptors of the alveolar macrophage presenting an important clearance mechanism for 
the pro-inflammatory cytokine IL-8, and with A2M having also been demonstrated to 
modulate inflammatory T cell responses (Kurdowska et al., 2000). A2M has also been 
implicated as a marker of airway plasma exudation (Cucullo et al., 2003; Hye et al., 
2006), as it increases rapidly following acute lung injury (Jorens, 1995; Out, 1987). In the 
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absence of significant increases in the permeability of the epithelial/endothelial barrier as 
a consequence of ageing in the present study (based on the equivalent urea ratios), the 
increases in A2M observed cannot be explained by this phenomenon.  
 
As stated previously the RTLF possesses a robust antioxidant network under 
normal conditions that protects the underlying epithelium from oxidant injury from 
inhaled xenobiotics and acute inflammatory episodes. Ascorbate concentrations within 
the alveolar RTLFs were significantly reduced, often to non-detectable levels in the aged 
subjects, with a corresponding increase in its oxidation product dehydroascorbate. Whilst 
such deficiencies at the air lung interface have been reported previously, associated with 
asthma (Kelly et al., 1999), the inhalation of oxidants (Kelly et al., 1996; Mudway et al., 
2001) and inflammation (McGrath et al., 1999), the presence of active neutrophilia is 
usually a cardinal feacture of these conditions. In the current study, in the absence of clear 
inflammation in the aged subjects, the deficiency may simply reflect low vitamin C 
intakes in the elderly (Kelly and Mudway, 2003), though the fact that this was seen in 
parallel to increased GSSG/GSH ratios and evidence of protein oxidation (4-HNE 
adducts) suggests an increased oxidative burden in the lung, independent of neutrophilic 
inflammation. Investigations using the Senescence-accelerated mouse model of ageing 
have also reported similar changes in GSSG/GSH ratio, in both BAL fluid and lung tissue 
with age (Teramoto et al., 1994).  
The increase in 4-HNE adducts, together with the increased total protein and 
albumin observed in the aged RTLF, suggest the accumulation of oxidatively modified 
proteins within the normal aged airway, which may therefore impair normal clearance 
mechanisms. A study by Umstead et al. (2009) investigating proteins associated with 
healthy ageing in rat airways, has demonstrated that in addition to changes in protein 
concentration, specific proteins possess a higher potential to from adducts during periods 
of oxidative stress. The importance of these oxidative post-translational modifications 
depends on whether they cause functional consequences. For example, oxidation of a 
critical Met residue in alpha-1 antirtypsin, results in its loss of function (Taggart et al., 
2000), actin carbonylation results in functional impairment of filament formation (Conrad 
et al., 2001) and albumin oxidation reduces its binding capacity (Iwao et al., 2006; Oettl 
and, Stauber, 2007). Unfortunately due to experimental limitations, this investigation was 
unable to determine which proteins, if any, were more sensitive to adduct formation and 
the role this may play within the ageing process still requires clarification. 
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 I also examined the concentration of transition metals within the RTLFs as a 
potential cause for the observed oxidative imbalance within the aged airways. The 
maintenance of metal ions within strict physiological limits as a result of their great 
catalytic and redox potential is essential, and thus proteins directly involved in the 
‘handling’ (storage, transport and sequestration) of metals possess crucial antioxidant 
roles (Bertini and Cavallaro, 2008; Jomova and Valko, 2011). In this study we observed 
significantly elevated total Fe concentrations within the aged RTLFs.  This is consistent 
with previous reports demonstrating increased free non-haem bound iron in infection, 
fibrosis and neoplasms (Munro and Linder, 1978; Worwood, 1982; Erbaycu et al., 2007). 
Similarly studies in the ageing non-smoking airways of both humans and animals have 
also demonstrated elevated free iron, with extrinsic factors, such as smoking, only serving 
to further elevate these concentrations (Ghio et al.,1997). 
The majority of biological Fe is not however ‘free’, with approximately two 
thirds bound to hemoglobin, 10% reserved for cellular processes through myoglobin, 
cytochromes, and iron-containing enzymes, with the remainder found in iron storage 
proteins such as ferritin (Cheng and Li, 2007). Iron concentrations are maintained in the 
RTLFs by their high affinity for Transferrin and Lactoferrin (Young and Woodside, 
2001), and MS/MS proteomic analysis revealed both these proteins to be significantly 
diminished in the ageing alveolar RTLFs, with transferrin additionally decreased in the 
bronchial compartment, as determined by the antibody based approach.  MS/MS results 
further revealed both heavy and light chains of Ferritin, were completely absent in young 
healthy RTLFs, their presence thus unique to the ageing RTLFs. Elevated concentrations 
of ferritin are typically associated with tissue necrosis, with high alveolar concentrations 
most likely the result of cell death. Ferritin concentrations have been reported to increase 
in the lower respiratory tracts of smokers, sufferers of chronic bronchitis, cystic fibrosis, 
pneumonia and lung transplant patients, with its synthesis potentially regulated by factors 
including hypoxia, NO, oxidative stress and various cytokines, all extrinsic factors the 
ageing lungs are likely to be exposed to (Mateos et al., 1998; Brewer et al., 2007; 
Erbaycu et al., 2008). 
  Altered iron homeostasis is well established as a consequence of ageing, with 
total iron content (both free and protein bound) shown to increase with age in various 
species (Cook and Yu, 1998). Such an age related disturbance in iron homeostasis is 
particularly important because of the capacity of iron to catalyze the production of 
damaging ROS, including the toxic hydroxyl radical (Brewer, 2007). In addition 
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increased iron has been associated with various diseases of ageing, including 
atherosclerosis and Alzheimers Disease (Ong and Haliwell, 2004; Brewer, 2007). 
 
 
Summary and conclusions 
 
 This is the first study to investigate changes in the RTLF proteome associated 
with healthy ageing, combining a stringent semi-quantitative MS analytical approach with 
validation using antibody based methods. It is also the first study to examine age-related 
changes in the bronchial airways. My data revealed clear differences between the healthy 
young and aged RTLFs, with increased alveolar total protein, albumin and alpha-2-
macroglobulin, consistent with an age-related increase in the permeability of the 
endothelial/epithelial barrier. Despite this, in the absence of differing blood to lavage urea 
ratios, it appeared more likely that the accumulation of vascular proteins in aged RTLFs, 
was attributable to a failure of clearance mechanisms. I also observed a general 
dysregulation of innate immunity proteins within the aged RTLFs, characterized by 
elevated IgA, alongside significant declines in the concentrations of transferrin, SP-A and 
haptoglobin. This occurred in parallel to a more oxidizing environment present within the 
RTLFs, as demonstrated by the significant decline in ascorbate and the corresponding 
increase in oxidized protein adducts. The increased concentration of Fe within the 
alveolar RTLF, associated with the reduced transferrin concentrations also suggests 
defective metal handling at the air-lung interface, the first time this has been observed in 
the aged lung. This would not only potentially contribute to the more oxidizing 
environment within aged RTLFs by catalyzing reactive oxygen species generation, but 
also promote bacterial growth. In general, the changes observed within the aged RTLFs 
are consistent with the increasing sensitivity of the aged lung to the detrimental effects of 










Chronic Obstructive Pulmonary Disease changes in 





Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating 
disease of the airway, estimated to affect over 65 million people worldwide (although it 
should be noted that physician based diagnosis has been suggested to underestimate true 
COPD prevalence), and to rank as the 3rd leading cause of death by 2030 (WHO). 
However the Global initiative for chronic obstructive lung disease (GOLD) defines 
COPD as a health challenge that is both preventable and treatable, but with no treatments 
currently able to prevent disease progression and at best able to reduce symptoms of 
breathlessness, or exacerbations of this disease, new insights into the pathogenesis of 
COPD are urgently required (Macnee, 2000; Alexandre and Penque, 2012).  
The GOLD classification system, describes COPD as a disease ‘characterized by 
airflow limitation that is not fully reversible’, assessing the severity of the disease by lung 
function, FEV1 (forced expiratory volume in 1 second). With airflow limitation (reduction 
in FEV1) usually progressive in COPD, the disease can be further categorized into rapid 
and slow declining subjects.  Rapid decliners are defined by a FEV1 loss of more than 63 
ml per year while slow decliners display losses in FEV1 of approximately 31 ml per year 
(Vestbo et al., 2011; Nishimura et al., 2012).  It should be noted however that age itself is 
an important factor in this decline and even in the absence of disease, the decline in FEV1 
in healthy non-smokers is approximately 20-30 ml per year (Tager et al., 1988); therefore 
the use of lung function alone appears inappropriate in classifying COPD (Burgel et al., 
2010). COPD has further been described as a disease of accelerated ageing, with markers 
of cell senescence observed in lung cells and circulating leukocytes in COPD and marked 
reductions in anti-ageing molecules (SIRT1), potentially providing compelling evidence 
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that underlying ageing processes are accelerated in the pathogenesis of this disease (Ito 
and Barnes, 2009; Macnee, 2009). 
Epidemiological studies have firmly established that cigarette smoking is the 
major risk factor for the development of COPD, with as many as 20–30% of smokers 
going on to develop this disease  (Fletcher and Peto, 1977; Snider, 1989; Doll et al., 
2004).  Further, the cessation of smoking has been demonstrated to prevent disease 
progression (Anthonisen et al., 1994). Age is another leading factor determining the 
incidence of COPD, with life expectancy further increasing in the western world, the 
incidence of COPD is thus likely to continue to remain a leading cause of death (Lokke et 
al., 2006). The morbidity, mortality and social impact is expected to increase as both 
smoking frequencies rise and the population ages  (Mannino and Buist, 2007; Macnee, 
2009). Whilst cigarette smoking remains the leading environmental risk factor for this 
disease, other risk factors include occupational and environmental exposures to dusts, 
fumes and biomass burning (Blanc et al., 2009). Furthermore an inherited Alpha-1 
antitrypsin deficiency is present in 1-2% of people with COPD (Tuder et al., 2010). 
It is the interaction of these various environmental and host factors that contribute 
to the highly variable histopathology of COPD, which ultimately result in the main 
pathophysiological features of this disease: the progressive destruction of the small 
airways and lung parenchyma and the chronic inflammation present in the central and 
peripheral airways, as inferred by its two major clinical manifestations: emphysema and 
chronic bronchitis (Ito and Barnes, 2009). 
Several underlying and interactive processes have been implicated in disease progression: 
 Oxidative stress 
 Protease-antiprotease imbalance  
 Chronic inflammation 
These interactions have previously been described as the ‘pathogenic triad’ of COPD, 
not separate independent entities on their own but integrally related with one another 
(Fischer et al., 2011). The resulting changing environment of the diseased airways, from 
hyperplasia of seromucousal and goblet cells, mucous hypersecretion, fibrosis and 
parenchymal destruction, correspondingly reflected in the composition of the RTLFs  




Figure 5.1: The interactivity of the classical ‘pathogenic triad’ of COPD 
 
 
COPD is a complex chronic inflammatory disease resulting in the airway 
remodeling and obstruction of the peripheral airways, as well as the destruction of the 
lung parenchyma. COPD patients also demonstrate further extra-pulmonary 
complications as a result of the ‘overspill’ of inflammatory mediators from the lung into 
the systemic circulation (Agusti et al., 2003; Barnes, 2004). Mediators that have been 
shown to play a critical role in the airflow obstruction observed in COPD, include 
leukotriene (LT) B4, interleukins (IL)-1, 6 and 8 and tumour necrosis factor alpha (TNFa) 
(Keatings et al., 1996; Chung, 2005; Profita et al., 2005; Sinden and Stockley, 2010), with 
multiple inflammatory and structural cells involved in the chronic inflammation of the 
airway, with characteristic infiltration of neutrophils, macrophages and T cells (Keatings 
et al., 1996; Di Stefano et al., 1998; Pesci et al., 1998; Saetta et al., 1998; Barnes et al., 
2003; Retamales et al., 2001). 
Neutrophils, have historically been the most investigated inflammatory cell in 
COPD, on account of their ability to cause deleterious tissue injury through secretion of a 
range of serine proteases including: neutrophil elastase, cathepsin G, and proteinase-3, as 
well as matrix metalloproteinase (MMP)-8 and MMP-9, highly implicated in the tissue 
destruction observed as COPD progresses. The increased presence of primed neutrophils 
in the COPD airway has been inferred from the increased concentrations of granule 
proteins myeloperoxidase and human neutrophil lipocalin, enhanced chemotaxis and 
increased extracellular proteolysis (Burnett et al., 1987; Keatings and Barnes, 1997; 




The presence of activated neutrophils has been observed in sputum and BAL 
retrieved from COPD airways, (Thompson et al., 1989; Lacoste et al., 1993; Linden et al., 
1993; Keatings et al., 1996; O’Shaughnessy et al., 1996; Di Stefano et al., 1998), with a 
correlation between the number of circulating neutrophils and airway obstruction, as 
measured by a fall in FEV1 (Sparrow et al., 1984). Smoking has been shown to directly 
stimulate the subsequent production of granulocytes such as neutrophils from the bone 
marrow  (Terashima et al., 1997), and may further increase the retention of neutrophils 
within the airways (MacNee et al., 1989). 
Macrophages are also markedly increased within the COPD airways (Shapiro, 
1999; Retamales et al., 2001; Barnes, 2004). Emphysematous patients have been shown 
to have a twenty-five-fold increase in the number of macrophages in both alveolar tissue 
and BAL fluid, with a clear correlation between the number of airway macrophages and 
the severity of COPD (Di Stefano et al., 1998). The increased alveolar macrophage 
populations seen in COPD have been associated with increased elastolytic activity, 
alongside augmented secretions of inflammatory proteins, which are only further 
exacerbated by smoking (Lim et al., 2000; Russell et al., 2002). 
An increase in total T cell numbers across the airways, from the conducting 
airways to the alveolar region, as well as within the pulmonary arteries has been reported 
(Finkelstein et al., 1995; O’Shaughnessy et al., 1997; Saetta et al., 1999; Majo et al., 
2001; Retamales et al., 2001). This predominately reflects an expansion in cytotoxic 
CD8+ T cells (de Jong et al., 1997; Kim et al., 2002).  
The changing nature of the inflammatory cell profile in COPD RTLFs is likely 
part of an overall increase in the innate and adaptive immune response associated with the 
progression of the disease (Hogg et al., 2004; Curtis et al., 2007). These altered responses 
are all also likely to have an important role in regulating the frequency, severity and 
duration of acute exacerbations, which further contribute to the decline in lung function. 
Cigarette smoke in particular has been shown to exacerbate immune and inflammatory 
mechanisms, reported to activate both innate and adaptive immune responses, influencing 
anti-microbial defense mechanisms (Nikota and Stampfli, 2012). 
The presence of chronic inflammation, and recurrent episodes of acute 
inflammation during exacerbations, is associated with evidence of pulmonary and 
systemic oxidative stress (Repine et al., 1997; MacNee, 2001), with increased 
concentrations of H2O2, 8-isoprostane, and ethane, measured in exhaled breath 
concentrate, correlated with disease severity (Dekhuijzen et al., 1996; Nowak et al., 1999; 
Paredi et al., 2000; Montuschi et al., 2000). Increased 4-HNE protein adducts have also 
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been observed in the alveolar epithelium of COPD subjects, with malondialdehyde 
(MDA), another end product of lipid peroxidation observed to increase in the plasma of 
COPD subjects (Rahman et al., 2002; Demedts et al., 2006; Wright et al., 2008). 
Consistent with oxidative damage degraded antioxidant defences have also been reported 
in COPD. Rahman et al., (1996) observed a significant decrease in the total antioxidant 
capacity and thus a shift in the oxidant-antioxidant balance, in smokers and subjects with 
acute exacerbations of COPD. Superoxide dismutase is also reportedly lower in COPD 
patients (Kirkil et al., 2008), with antioxidant proteins responsible for iron homeostasis 
such as caeruloplasmin, reported to decline in COPD, correlating positively with airway 
obstruction (Ito and Barnes, 2009).  
The imposition of oxidative stress in the airway, also acts to amplify the ongoing 
chronic inflammatory responses in COPD through the activation of pro-inflammatory 
2002). Oxidative stress and inflammation have also both been implicated in shifting the 
protease antiprotease balance of the COPD airways. Reactive oxygen species released 
from activated phagocytes promote the release of proteases from activated inflammatory 
cells, including cathepsins, MMPs, and neutrophil elastase, thus contributing to the 
airway tissue destruction observed in COPD (Shapiro, 2002; Churg and Wright, 2003).  
Additionally oxidative modifications act to impair the anti-protease activity of crucial 
enzymes found in RTLFs responsible for normal airway homeostasis, the most heavily 
implicated of which is alpha-1 antitrypsin (Taggart et al., 2000). Patients with an 
inherited alpha-1 antitrypsin deficiency have been shown to develop early-onset 
emphysema, and an increase in complexes of this enzyme with neutrophil elastase have 
been observed in BAL retrieved from COPD patients, correlating positively with the rate 
of FEV1 decline (Yoshioka et al., 1995; Betsuyaku et al., 2000).  
With several underlying mechanisms believed to contribute to disease 
pathogenesis: oxidative stress, chronic inflammation of the airways, an imbalance 
between proteolytic and anti-proteolytic activity, as well as alpha-1-antitrypsin deficiency 
(Demedts et al., 2006), it becomes interesting to note that the interaction of these self 
propagating processes have also been proposed to increase ageing associated events, 
including apoptosis, autophagy, and senescence, all of which have been reported in the 
progression of COPD (Fischer et al., 2009; Hogg and Timens, 2009). Ultimately it is the 
great heterogeneity of this disease, which has complicated our understanding into the 






With the mechanisms that govern COPD initiation and progression still poorly 
understood, the primary aim of the work described in this chapter was to characterize the 
changing composition of the RTLFs across the COPD airway, investigating this 
important extracellular compartment in both the smoking and non-smoking COPD 
airways using appropriate smoking and non-smoking aged matched controls. Secondly, 
with this disease affecting >10% of the world population over the age of 40 years, and 
with large clinical trials of current therapies showing limited effects on reducing 
morbidity and mortality, this data will be used to inform the development of 
physiologically relevant simulants representative of COPD airways, to aid future drug 





5.2.1: Subject demographics 
Subjects for all groups were invited to participate in the present study through 
advertisements in the local media. COPD patients (aged 50-75 years) had moderate to 
severe disease according to the GOLD criteria (FEV1 30-80% of predicted, FEV1/FVC 
less than 0.7) with a smoking history of at least ten pack-years and no evidence of other 
concomitant disease. All patients were required to be non-atopic and clinically stable, i.e. 
without any respiratory tract infection within a six-week period prior to and during the 
study, along with no history of frequent exacerbations during a period of at least 3 months 
prior to inclusion. The only medication permitted were short-acting β2-agonists and/or 
anti-cholinergic drugs. Neither long-acting bronchodilators nor inhaled corticosteroids 
were allowed. All subjects were also required to undergo a detailed medical consultation 
with an ECG and chest X-rays prior to inclusion. Healthy never-smoking volunteers were 
age-matched (50-75 years), had normal lung function (>80 FEV1 % of predicted) and 
were all non-atopic. Similarly, aged ‘healthy’ smokers were required to have normal lung 
function, as previously defined, were age-matched (50-75 years) and had a smoking 
history of more than ten pack-years. All subjects were non-atopic and clinically stable. A 
total of 62 subjects were recruited; 19 healthy aged controls (all ex-, or never smokers); 
11 aged smokers (with no evidence of chronic respiratory disease); 18 COPD patients 
(ex-smokers) and 14 patients who had continued to smoke following their diagnosis of 
COPD. All subjects participated following submission of formal consent with study 
approval awarded by the local Ethics Committee of the University of Umeå, in 
accordance with the declaration of Helsinki. A summary of the subject demographics is 
provided in Table 5.1.  
 
5.2.2: Pulmonary function test 
Dynamic spirometry variables (Vital capacity (VC), FVC and FEV1) were 
measured pre and 15-20 minutes post-bronchodilation with 1mg of terbutalin (Bricanyl® 
Turbuhaler® AstraZeneca, Södertälje, Sweden) using a Vitalograph spirometer 
(Buckingham, UK) and reversibility calculated. At least three satisfactorily performed 
and well-cooperated measurements of each variable were carried out according to the 




5.2.3: Bronchoscopy-based lavage  
Bronchoscopy with bronchial wash and bronchoalveolar lavage was performed as 
described in Section 3.2.3. Nasal lavage was not performed on the aged subjects. Details 
of the total and differential cell counts have been described previously (Section 3.2.3). 
 
 
5.2.4: Antioxidant, total protein and urea determinations 
Vitamin C, (ascorbate and dehydroascorbate), urate, total glutathione (GSx), 
glutathione (GSH), and glutathione disulphide (GSSG) concentrations were determined in 
BW and BAL as previously described, (Mudway et al., 2001; Behndig et al., 2009); 
further details are provided in Chapter 2 (Section 2.4). Total protein determinations were 
made using the BCA assay (Smith et al., 1985), with paired plasma and lavage urea 
concentrations assessed using the high sensitivity QuantiChrom urea assay kit (BioAssay 
Systems, Hayward). Protein carbonyl formation was measured spectrophotometrically 
using OxiSelect protein carbonyl spectrophotometric kit (Cell Biolabs, Inc., USA), with 
4-HNE protein adducts determined using the OxiSelect HNE Adduct ELISA Kit (Cell 
Biolabs, San Diego, CA, USA).  
 
 
5.2.5: Proteomic analysis 
 The strategy employed was identical to that outlined in the previous chapter 
(Section 3.2.5), with analysis performed on a subset of 5 individual’s drawn from the 
each of the four groups. For the healthy aged group, (n=5), 67±6 years, 3 male/ 2 female; 
aged smokers (n=5), 61±6 years 1M/4F; COPD ex-smokers, 66±7 years, 6M/4F; and for 
the current COPD smokers, 64±7 years, 2M/3F. A larger number of COPD ex-smokers 






Table 5.1: Subject demographics for the subject groups employed in the current investigation. 
 














      
Age (mean + range) 67.8 (57-77) 61.7 (50-76)a 67.7 (53-77) 63.1 (55-75) P = 0.014 
Gender (m/f) 11/8 4/7 13/5 9/5  
Pack years (mean + range) 0 36.9 (18-95)a 33.5 (5-68)c 35.2 (13-80) P < 0.001 
FVC (median, IQR, L) 4.1 (3.6-4.7) 4.0 (3.1-4.9) 2.9 (2.3-3.0)c 2.4 (2.2-2.6)b P < 0.001 
FVC % of predicted (%) 104.0 (95.0-116.0) 114.5 (107.0-122.3) 73.0 (66.0-77.5)c 85.0 (67.5-91.0)b P < 0.001 
FEV1 (median, IQR, L) 3.0 (2.2-3.4) 3.2 (2.6-3.8) 1.4 (1.0-1.9)c 1.3 (1.1-1.6)b P < 0.001 
FEV1 % of predicted (%) 100.0 (91.0-118.0) 113.0 (104.0-115.8) 51.0 (42.0-64.0)c 60.0 (39.0-69.0)b P < 0.001 
Reversibility (%) 1.0 (-0.5-4.4) 2.7 (1.2-4.9) 17.1 (12.0-24.4)c 6.2 (1.9-15.1)d P < 0.001 
TLC (median, IQR, L) nd 6.8 (5.4-8.1) 7.0 (6.1-7.6) 6.0 (5.3-6.5) NS 
IC (median, IQR, L) nd 3.1 (2.7-3.6) 2.6 (2.2-3.0) 2.0 (1.7-2.5)b P = 0.006 
MEF50 (median, IQR, L s
-1) nd 2.76 (2.15-3.64) 0.37 (0.28-0.70) 0.72 (0.40-0.79)b P < 0.001 
TLCO
SB (median, IQR, mmol min-1 kPa-1) nd 7.4 (6.1-7.8) 5.7 (3.9-6.3) 5.2 (4.8-5.7)b P < 0.001 
BAL recovery (%) 50.0 (44.0-56.0) 53.0 (48.8-63.8) 36.0 (29.0-48.0)c  39.0 (29.0-48.0) P = 0.025 
      
 
All data are expressed as medians with either the inter-quartile or full range, as indicated. Significant differences across groups were assumed at the 5% level using the 
Kruskal–Wallis one-way analysis of variance by ranks (significance illustrated in the far right hand column), with post-hoc testing between specified groups performed using 
the Mann Whitney U Test. Comparison of individual groups were restricted to healthy smokers versus never smokers (a, P < 0.05), healthy smokers and COPD current 
smokers (b, P < 0.05), never smokers versus COPD ex-smokers (c, P < 0.05) and COPD current and ex-smokers (d, P < 0.05). Lung function measurements are based on post 
bronchodilator values, with evidence of % airway reversibility indicated. Pack years were calculated by multiplying the number of packs of cigarettes smoked per day by the 
number of years the person had smoked. FVC = Forced Vital Capacity; FEV1 = Forced Expiratory Volume in 1 second; TLC = Total Lung Capacity; IC = Inspiratory 
Capacity; MEF50 = Maximum Expiratory Flow when 50% of the FVC has been exhaled; TLCOSB, lung carbon monoxide diffusing capacity in a Single Breath; % BAL 
recovery, based on a total instilled saline volume of 180 mLs. 
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5.2.6: Statistics  
Data were not normally distributed (Shapiro-Wilks test) and are therefore expressed 
throughout as medians with the 25th and 75th percentiles. Comparison of inflammatory 
cell numbers, antioxidant and oxidative damage markers and protein concentrations 
across the various subject groups were performed using the Kruskal–Wallis one-way 
analysis of variance by ranks, with post-hoc testing between specific groups performed 
using the Mann-Whitney U test. In all cases significant differences were assumed at the 
5% level. Correlation analysis for each individual group, plus compiled groups of COPD 
patients (current and ex-smokers) and smokers (both aged ‘healthy’ smokers and COPD 
smokers) were performed using the Spearman Rank Order Correlation. Statistical 
analyses were performed using the IBM SPSS software, version 20 (SPSS, Armonk, NY, 
























5.3.1: Baseline characteristics 
BAL was tolerated well by all subjects, with recovery being significantly lower 
(36%) in the COPD ex-smoking group relative to the aged never-smokers (50%, p<0.05) 
– Table 5.2.  Increased leukocyte numbers were seen in smokers versus never-smokers, 
reflecting a 2.6 and 2.1-fold expansion in BAL macrophages in aged healthy and COPD 
smokers compared with their corresponding never-smoking or ex-smoking controls 
(p<0.001 in both cases – Table 5.2). No increase in macrophage numbers were observed 
in the COPD patients, current or ex-smokers, compared with their relevant control 
groups. Further there was no evidence of increased neutrophil numbers in the COPD 
smokers and non-smokers compared with their respective controls (Table 5.2). Increases 
in BAL mast cell numbers were observed in the aged smoking group (0.06 (0.03-0.10) 
cell/mL*104) relative to the aged non-smokers (0.01 (0.01-0.02) cell/mL*104, p=0.002), 
with a similar increase also apparent in the more proximal BW sample (p=0.017). 
Equivalent increases were not observed in the COPD smokers. 
 
5.3.2: The RTLF proteome in COPD: 1D PAGE and nano LC MS/MS  
 As previously described, the 1D PAGE and nano LC MS/MS proteomic analysis 
examined individual concentrated BAL samples, with protein concentrations 
approximated, based on the mean of the three most intense precursor ions, back corrected 
for the total protein concentration in the samples and the lavage dilution using the urea 
ratio method.  Furthermore proteins identified were limited to those present within at least 
3 out of 5 subjects investigated, except in the case of COPD ex-smokers where 10 
subjects underwent proteomic analysis (on account of the low number of protein 
identifications made in this group, and the repeat analysis performed to confirm this 
unexpected result), in which case proteins identified had to be present within at least 7 out 




Table 5.2: Differential white blood cell counts in BW and BAL fluids from COPD patients and aged and smoking matched controls. Cell numbers are 
presented as cell/mL*104. 

















Total Cells 7.0 (5.6-11.2) 9.7 (7.9-19.9) 3.8 (2.1-10.2) 9.7 (3.4-14.5) NS 
Macrophages 6.2 (3.4-9.3) 8.7 (6.5-17.0) 2.0 (1.6-6.6)c 8.9 (3.2-13.0) P = 0.031 
Neutrophils 1.2 (0.3-1.4) 0.4 (0.2-0.7) 0.6 (0.2-1.4) 0.5 (0.2-0.6) NS 
Lymphocytes 0.6 (0.3-0.8) 0.7 (0.4-0.9) 0.3 (0.1-0.5)c 0.2 (0.1-0.4)b P = 0.016 
Eosinophils 0.0 (0.0-0.1) 0.1 (0.0-0.1) 0.0 (0.0-0.1) 0.0 (0.0-0.2) NS 
Mast cells 0.00 (0.00-0.01) 0.03 (0.01-0.04)a 0.00 (0.00-0.01) 0.00 (0.00-0.01) P = 0.027 
 
Bronchoalveolar lavage fluid 
 
Total Cells 17.1 (11.1-26.9) 39.7 (34.0-48.3)a 17.7 (14.7-23.8) 29.7 (27.4-45.6)d P < 0.001 
Macrophages 14.1 (9.8-16.6) 36.6 (30.7-45.5)a 14.0 (11.3-20.7) 29.0 (26.1-39.3)d P < 0.001 
Neutrophils 0.1 (0.1-0.2) 0.5 (0.3-0.8)a 0.3 (0.1-0.4) 0.1 (0.1-0.6) NS 
Lymphocytes 1.7 (0.9-3.9) 2.3 (1.5-3.2) 2.3 (1.1-3.2) 1.3 (0.6-1.5) NS 
Eosinophils 0.0 (0.0-0.1) 0.1 (0.0-0.1) 0.1 (0.0-0.2) 0.2 (0.1-0.3) NS 
Mast cells 0.01 (0.01-0.02) 0.06 (0.03-0.10)a 0.01 (0.00-0.02) 0.03 (0.03-0.07) 
 
P = 0.013 
 
All data are expressed as medians with either the inter-quartile or full range, as indicated. Significant differences across groups were assumed at the 5% level using 
the Kruskal–Wallis one-way analysis of variance by ranks (significance illustrated in the far right hand column), with post-hoc testing between specified groups 
performed using the Mann Whitney U Test. Comparison of individual groups were restricted to healthy smokers versus never smokers (a, P < 0.05), healthy smokers 
and COPD current smokers (b, P < 0.05), never smokers versus COPD ex-smokers (c, P < 0.05) and COPD current and ex-smokers (d, P < 0.05). Subject numbers 





Figure 5.2: Venn diagrams illustrating the proteins common and unique to (A) aged non-smoking and aged smoking alveolar RTLFs; (B) aged smoking and COPD ex-
smoking alveolar RTLFs (C) COPD ex-smoking and COPD smoking alveolar RTLFs; and  (D) aged smoking and COPD smoking alveolar RTLFs, as organized by the most 
common ontological classifications. Classifications include: inflammation and immunity, metal handling, oxidant/antioxidant balance, protease/antiprotease balance, 




Table 5.3 highlights the fifteen most abundant communal proteins across all four 
subject groups (The full list is provided in Appendix C), further annotated by their source 
of origin, ontological definition. All, with the exception of uncharacterized protein 
C3orf38, a protein of unknown function and origin, and actin, an intracellular protein 
integral to cell motility, are derived from extracellular sources. 
Thirty-two proteins were identified as being common to all four proteomes 
investigated: healthy aged non-smokers, healthy aged smokers, COPD smokers and 
COPD ex-smokers (see Appendix C for full list of all proteins identified across and 
between groups).   A total of 163 proteins were identified in healthy aged controls, with a 
similar number, 145 proteins identified in healthy smoking proteomes. The COPD 
smoking proteome had the highest number of protein identifications, 234, in contrast to 
the COPD ex-smoking proteome that had only 58 identifiable proteins. The non-smoking 
proteomes demonstrated a higher percentage of proteins of extracellular origin 72 and 74 
% in healthy aged and COPD ex-smoking RTLFs respectively. Only 61% of the smoking 
proteomes (healthy and COPD) were classified as extra-cellular or secretory, indicative of 
a greater contribution from intra-cellular sources, potentially inferring cell injury. 
If we first compare the healthy aged RTLF with that of the healthy smokers, the 
majority of the identified proteins (105), were common to both proteomes.  Of these, only 
the calgranulin proteins A and B were found upregulated within the aged smoking 
RTLFs, 47 and 24 fold respectively (see Table 5.4). Of the 40 proteins uniquely 
identified in the smoking RTLFs, intracellular proteins contributing to the oxidant- 
antioxidant balance at the air-lung interface: SOD (Cu-Zn), peroxiredoxin and 
glutathione-S transferase, were identified. Further intracellular proteins involved in 
protease-antiprotease balance within the airways were identified, including the protease 
inhibitors serpin B4, cystatin, leucocyte elastase inhibitor and cathepsin S. Absent from 
the smoking proteome were a variety of proteins involved in innate immunity, from 
secreted proteins of the upper airways, such as mucin-1 and galectin-3, to proteins 
involved in innate immune responses such as CD59, which has a role in signaling for T-




Table 5.3: Abundant alveolar proteins common across the four subject groups. The 15 most abundant common proteins (out of 32) listed with their 
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Table 5.4: Alveolar proteins demonstrating the largest relative fold increases between healthy aged controls and healthy smokers. The proteins 
of the common 105 identified showing the greatest fold increase are listed alongside their source of origin, their ontological classification and 
their relative fold differences. The number of samples in which the protein was identified in each group is indicated. 
 






(Healthy Smoker v 
Healthy Aged Control) 




Calgranulin A Extracellular, Secreted Immunity and Inflammation 
3.59E+07 8.57E+08 











Comparing the healthy aged RTLF proteome to that of COPD ex-smokers 
provided an insight into the effect of COPD on the nature of this extra-cellular 
compartment, in the absence of smoking. Forty-five proteins were common to both 
RTLFs, with only 13 unique to the RTLF of COPD ex-smokers: mucin and SP-D, the 
immunoglobulin chains, kappa chain C and gamma-3 chain C, as well as the highly 
abundant plasma proteins: A2M, alpha-1-antichymotrypsin and haemoglobin were all 
absent. Of the communal RTLF proteins, large fold differences were noted, with a 
decreased expression of caeruloplasmin (134.6-fold), A1AT (82.9-fold), haptoglobin 
(13.3-fold) and SP-A (20.2-fold), see Table 5.5.  Proteins demonstrating large fold 
increases in the COPD ex-smokers included, PIGR and lysozyme with 12.3 and 754-fold 
increases respectively, with CC16 secreted by bronchial Clara cells also demonstrating a 
25.8 fold increase. Furthermore the intracellular proteins ferritin and actin were increased 
in COPD ex-smokers (31.9 and 5.9-fold) as highlighted in Table 5.6. 
Focusing down on the COPD RTLFs, 45 proteins were identified as common 
between smokers and ex-smokers. Mucin and SP-D were once more absent in the ex-
smokers, as was SP-B, immunoglobulin kappa C and gamma- 3 chains, A2M and alpha-
1-antichymotrypsin. Various proteins contributing to the protease-antiprotease balance of 
the airway; including serpins B6 and B12, pro-cathepsin H, cathepsins B, D, S and Z, 
were absent from the RTLF of COPD ex-smokers. Of the communal proteins, 
concentrations of SP-A and calgranulin A were depressed (15.6 and 10.5-fold 
respectively) in the COPD ex-smokers, as were the plasma proteins, caeruloplasmin, 
haptoglobin (87.2 and 27.8-fold), with the intracellular protein ferritin also decreased 
(2.6-fold), see Table 5.7. Of the proteins demonstrating the largest fold increases in the 
RTLF of COPD ex-smokers both PIGR and Lysozyme demonstrated an increase (8.4 and 
78.8 fold respectively), with this also the case for CC16 (22.6 fold). Finally once more, 
the intracellular protein actin was found elevated (7.6 fold) in the ex-smoking COPD 




Table 5.5: Alveolar proteins demonstrating the largest relative fold decrease between healthy aged controls and COPD ex-smokers. All detail as in the 
legend to Table 5.4. 
 






(COPD Ex-Smoker v 
Healthy Aged Control) 








Ig gamma-3 chain C region Extracellular, Secreted Immunity and Inflammation 
6.71E+09 5.64E+07 
 50.9 ↓ 
(n=5/5) (n=7/10) 
Caeruloplasmin Extracellular, Secreted Metal Handling and Transport 
3.67E+08 2.73E+06 
134.6 ↓  
(n=5/5) (n=7/10) 
Alpha-1-antitrypsin Extracellular, Secreted Protease/antiprotease   
3.20E+09 3.86E+07 
82.9 ↓  
(n=5/5) (n=7/10) 
Leucine-rich alpha-2-glycoprotein Extracellular, Secreted Cell morphology / interaction 
4.46E+07 7.23E+05 
61.7 ↓  
(n=5/5) (n=7/10) 









Table 5.6: Alveolar proteins demonstrating the largest relative fold increases between healthy aged controls and COPD ex-smokers.  






(COPD Ex-Smoker v 
Healthy Aged Control) 
Thioredoxin Intracellular Oxidant/antioxidant balance,  
8.21E+06 1.54E+08 
18.7 ↑  
(n=4/5) (n=7/10) 




Hemoglobin subunit beta Plasma Metal Handling and Transport 
1.28E+08 1.66E+09 
13.0 ↑  
(n=5/5) (n=10/10) 












CC16 Extracellular, Secreted Unknown 
1.74E+08 4.49E+09 










Intracellular Immunity and Inflammation 
6.43E+06 7.51E+07 
11.7 ↑  
(n=5/5) (n=9/10) 










Finally by comparing the RTLF proteomes of smokers, with and without COPD, 
we were able to explore the impact of current smoking, superimposed on the underlying 
disease. Of the 155 proteins unique to the COPD smokers airways, proteins involved in 
the protease-antiprotease balance were identified: cathepsin D, serpin B6 and B12; with 
glutathione synthetase and transferases also uniquely within this proteome, together with 
the innate immune proteins HLA class II histocompatibility antigen, CD59, CAM2, and 
complement C2 and C3. Interestingly, fewer (119) of the identified proteins were 
common to both proteomes. Of these proteins, lysozyme was elevated; as was locally 
secreted protein SP-D (2.6 and 5- fold respectively) in the COPD smokers. Abundant 
plasma proteins: A2M, A1AT and haptoglobin (2.7, 5.9 and 2.5 fold) were also elevated 
in the smoking COPD patents, but the greatest fold differences were for both chains of 
the intracellular protein ferritin (19.4 and 27.7-fold increase), Figure 5.9. In contrast the 
secretory protein calgranulin A was significantly depressed in the COPD smokers, 386-
fold compared with the healthy smoking group, as was the case for intracellular protein 
actin (2.6-fold), Table 5.10.  
All proteins identified with the alveolar RTLFs were classified based on their 
gene ontological definitions, with the largest classification being proteins involved in 
inflammation and immune responses, representing 57% of the identified COPD ex-
smoking proteome, but only 24% in the COPD smoker RTLF. Proteins annotated as 
being involved in metal handling represented the second greatest grouping within the 
healthy smoker, COPD smoker, and COPD ex-smoker  (22, 26 and 9 proteins 
respectively) proteomes. The second largest grouping in the healthy aged population was 
those proteins involved in the protease-antiprotease balance (16 proteins).  Only 5, 6, 3 
and 7 proteins were identified to contribute to the oxidant-antioxidant balance within 
healthy aged controls, healthy smokers, COPD ex-smokers and COPD smokers, 










Table 5.7: Alveolar proteins demonstrating the largest relative fold decreases between COPD smokers and ex-smokers.  
 
Protein Source Ontology COPD Smoker COPD Ex-Smoker 
Fold difference 
(COPD Ex-Smoker v 
COPD Smoker) 
Ig kappa chain C region  
Extracellular, 
Secreted 




Ig gamma-3 chain C region  
Extracellular, 
Secreted 





















































Table 5.8: Alveolar proteins demonstrating the largest relative fold increases between COPD smokers and ex-smokers.  
 
Protein Source Ontology COPD Smoker COPD Ex-Smoker 
Fold difference 
(COPD Ex-Smoker v 
COPD Smoker) 

























































Table 5.9: Alveolar proteins demonstrating the largest relative fold decreases between COPD smokers and healthy smokers  
 
Protein Source Ontology Healthy Smoker COPD Smoker 
Fold difference  
(COPD Smoker v Healthy 
Smoker) 
Beta-2-microglobulin Extracellular, Secreted Immunity and Inflammation 
1.03E+07 3.80E+07 
3.69 ↑  
(n=5/5) (n=5/5) 
Angiotensinogen Extracellular, Secreted Blood coagulation, signaling 
1.41E+06 5.39E+07 
38.23 ↑  
(n=5/5) (n=5/5) 
Hemoglobin subunit beta Plasma Metal Handling and Transport 
2.04E+07 7.32E+07 
3.59 ↑  
(n=5/5) (n=5/5) 
Ferritin light chain Intracellular Metal Handling and Transport 
2.03E+07 3.93E+08 
19.36 ↑  
(n=5/5) (n=5/5) 
Ferritin heavy chain Intracellular Metal Handling and Transport 
5.09E+06 1.41E+08 
27.70 ↑  
(n=5/5) (n=5/5) 
Lysozyme Extracellular, Secreted Immunity and Inflammation 
2.61E+06 6.74E+06 
2.58 ↑  
(n=5/5) (n=5/5) 
Cathepsin S Intracellular Protease/antiprotease 
3.74E+06 3.07E+07 
8.21 ↑  
(n=5/5) (n=5/5) 
Calmodulin Intracellular Signaling 
2.84E+06 2.48E+07 
8.73 ↑  
(n=4/5) (n=4/5) 
Apolipoprotein A-I Plasma Lipid Metabolism 
7.56E+06 5.68E+07 
7.51 ↑  
(n=4/5) (n=4/5) 
Dipeptidyl peptidase 4 Secreted, plasma 
Protease/antiprotease   , signaling, 
apoptosis 
3.08E+06 1.99E+07 
6.46 ↑  
(n=4/5) (n=3/5) 
Proactivator polypeptide Intracellular Not known 
1.35E+06 6.97E+06 
5.16 ↑  
(n=4/5) (n=4/5) 
Coactosin-like protein Intracellular Cell morphology / interaction 
6.78E+06 3.50E+07 




Secreted Immunity and Inflammation 
5.11E+06 2.63E+07 
5.15 ↑  
(n=5/5) (n=5/5) 
Ig kappa chain C region Extracellular, Secreted Immunity and Inflammation 
1.07E+09 2.92E+09 
2.73 ↑  
(n=5/5) (n=5/5) 
Alpha-1-antitrypsin Extracellular, Secreted Protease/antiprotease   
2.75E+08 1.61E+09 
5.85 ↑  
(n=5/5) (n=5/5) 
Haptoglobin Extracellular, Secreted Immunity and Inflammation 
1.04E+08 2.64E+08 
2.54 ↑  
(n=5/5) (n=5/5) 
Alpha-2-macroglobulin Extracellular, Secreted Protease/antiprotease   
4.14E+06 1.01E+07 





Table 5.10: Alveolar proteins demonstrating the largest relative fold decreases between 
COPD smokers and healthy smokers.  
















Actin, cytoplasmic 1 Intracellular 






Dilution factors for the lavage samples were calculated based on the urea method. 
These were similar across all four groups for the alveolar compartment: healthy aged, 
191.56 (166.1-300.1); healthy smokers, 172.4 (131.7-248.5); COPD ex smokers, 128.6 
(112.1-172.3) and COPD smokers 138.0 (89.3- 162.5). The urea-based lavage correction 
factors for the bronchial samples, although higher with respect to alveolar values, were 
also similar across the groups: 322.1 (221.3-466.2), 288.4 (254.3-330.4), 359.6 (265.6-
437.4) and 338.5 (164.5-439.5), respectively. It should be noted that these differences in 
Bronchial and Alveolar urea levels and thus the corresponding basal correction factors 
determined will directly influence all subsequently lavage corrected values. Whilst 
previous investigations have expressed specific proteins allowing for the numbers of cells 
determined, particularly those of an inflammatory nature, for the purpose of this study 
this was not performed in this investigation (Hatch, 1992). 
Based on the quantitative analysis of all the lavage samples, the total alveolar 
RTLF protein concentrations across the 4 groups were equivalent: 38.6 (21.7-56.0) and 
23.6 (16.7-35.9) mg/mL in healthy aged and smoking subjects, and 22.2 (14.2-59.2) and 
14.3 (8.5-22.7) mg/mL in COPD ex smokers and smokers. Focusing first on the selected 
proteins involved in transport and metal handling, ferritin was found to be significantly 
elevated in healthy smokers versus non-smoking controls (Figure 5.3). This was also the 
case for COPD smokers compared with the non-smoking controls, supporting the results 
of the semi-quantitative proteomic analysis. No other significant differences were noted 
in the concentration of the remaining proteins in this grouping: caeruloplasmin, 




Figure 5.3: Transport and metal handling proteins of the alveolar RTLFs. Alveolar protein 
concentrations as determined by ELISA; values corrected for lavage dilution using the urea method. 
(A) Ferritin, (B) Caeruloplasmin , (C) Transferrin and (D) Albumin. Healthy Aged Non-Smoker n=19, 
Healthy Aged Smoker n=11, COPD Ex-Smoker n = 18, COPD Smoker n = 14, * denotes a statistical 
difference where p<0.05. 
 
Examining the selected proteins involved in inflammation and immunity within 
the airways, IgA was found to be significantly decreased in COPD smokers (0.34 (0.2-
0.6mg/mL) compared to healthy smokers (2.1 (0.1-4.0), P=0.02 and healthy aged controls 
(1.4 (0.8-1.9) mg/mL), P=0.01, Figure 5.4. IgG appeared to follow a similar pattern, 
although no significant differences were observed. Haptoglobin concentrations were 
equivalent across the four subject groups, Figure 5.4. 
 
Figure 5.4:  Immunity and inflammatory process proteins of the alveolar RTLFs. All other 




Proteins involved in protease-antiprotease balance in the airways are summarised 
in Figure 5.5. The acute phase protein A2M, was significantly decreased in COPD ex-
smokers (0.00008 (0.00002-0.0001) mg/mL) versus healthy aged (0.12 (0.08-0.2) 
mg/mL), p=0.001, and healthy smoking (0.23 (0.17-0.67) mg/mL) controls, P=0.001. 
A2M was also decreased in the RTLFs of COPD smokers (0.017 (0.004-0.06) mg/mL) 
versus both healthy smokers, P=0.025, and healthy aged controls, P=0.005. No significant 
differences were observed in A1AT in the quantitative analysis, contrasting with the 
results of the semi-quantitative analysis, which suggested 82.0-fold decreases between 
COPD ex-smokers and healthy aged control, and a 5.9-fold increase between COPD 
smokers and healthy smokers. 
 
Figure 5.5:.Airway antiprotease-protease balance proteins of the alveolar RTLFs. All 
other details as outlined in the legend to Figure 5.3. 
 
Focusing on those proteins uniquely secreted by the airway epithelium itself (see 
Figure 5.6), Surfactant protein A, was observed to decline significantly in both COPD ex 
smokers (0.09 (0.01-0.14) mg/mL), P=0.003, and COPD smokers (0.09 (0.05-0.19) 
mg/mL), P=0.01 compared to the healthy aged controls (0.32 (0.2-0.5) mg/mL).  This 
concurred with the results of the more limited semi-quantitative analysis, which inferred a 
20-fold decrease in SP-A in COPD ex-smokers versus healthy aged controls. Surfactant 
protein B was signicantly elevated in smoking, without disease; healthy aged smokers 
(0.0076 (0.005-0.01) mg/mL) versus their non smoking counterparts (0.0038 (0.003-0.05) 
mg/mL), P=0.004, Figure 5.6. In the RTLFs of patients with COPD surfactant protein B 
was found to decline significantly: COPD ex-smokers (0.002 (0.001-0.003) mg/mL) 
compared to healthy smoking controls (0.0076 (0.005-0.01) mg/mL), P=0.002. 
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Furthermore, SP-B was observed to decrease in the RTLFs of COPD smokers (0.0018 
(0.0016-0.004) mg/mL) relative to the concentrations within the RTLFs of the healthy 
smoker, P=0.002.  Similar differences were not apparent from the semi-quantitative 
proteomic analysis. No significant differences were observed for CC16 in the alveolar 
RTLFs, again contrasting the semi-quantitative proteomic analysis, which inferred a 25.8-
fold increase in COPD ex-smokers versus healthy aged controls, and a 22.6-fold increase 
between the COPD ex-smokers and the COPD smokers, in the subgroup analysis. 
 
 
Figure 5.6: Lung specific proteins of the alveolar RTLFs. All other details as outlined in 
the legend to Figure 5.3. 
 
Within the bronchial RTLFs only transferrin, of the proteins involved in metal 
handling and transport, displayed significant differences in COPD, being lower in the 
COPD smokers (0.45(0.3-0.8) mg/mL) versus healthy smokers (1.21(1.1-2.1) mg/mL), 
P=0.004, and the healthy aged controls (0.87(0.5-1.2) mg/mL), P=0.02. Ferritin no longer 
demonstrated a smoking dependent effect in bronchial RTLFs, with caeruloplasmin and 
albumin equivalent across all groups, see Figure 5.7. 
Considering the bronchial RTLFs proteins, classified within the immune and 
inflammatory grouping (see Figure 5.8), the concentration of IgA was again found to be 
significantly lower in COPD smokers (0.68 (0.5-1.2) mg/mL), versus both the healthy 
smokers (3.6 (2.6-4.6) mg/mL), P=0.01, and the healthy aged controls (2.2 (1.5-3.8) 
mg/mL), P=0.02. IgG in the bronchial RTLF reflected this pattern, with reduced 
concentrations in COPD smokers (0.62 (0.45-0.89) mg/mL), versus both healthy smoking 
(2.4 (1.1-3.9) mg/mL), P=0.008, and non-smoking controls (1.05 (0.47-1.7) mg/mL), 




Figure 5.7:  Transport and metal handling proteins of the bronchial RTLF. All other 
details as outlined in the legend to Figure 5.3. 
 
 
Figure 5.8: Immunity and inflammatory process proteins of the bronchial RTLF. All 
other details as outlined in the legend to Figure 5.3. 
 
No significant differences in either A2M or A1AT concentrations were observed 
within the bronchial RTLFs (Figure 5.9). Of the pneumoproteins, bronchial SP-A 
concentrations, as observed in the alveolar compartment, were significantly lower in the 
patients with COPD: In COPD smokers (0.05 (0.02-0.07) mg/mL), compared with both 
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healthy smokers (0.40 (0.30-0.54) mg/mL), P=0.003, and healthy non-smokers (0.17 
(0.13-0.46) mg/mL), P=0.002; and significantly lower in COPD ex-smokers (0.06 (0.04-
0.19) mg/mL) versus the healthy smokers, P=0.016. SP-A was also found to be 
significantly elevated in the bronchial RTLFs of healthy smokers compared to their non-
smoking healthy counterparts, P=0.04. SP-B in contrast no longer demonstrated any 
differences across subject groups in bronchial RTLFs, and CC16 concentrations were 
equivalent across all 4 groups (see Figure 5.10). 
 
Figure 5.9: Airway antiprotease-protease balance proteins of the Bronchial RTLFs. All 
other details as outlined in the legend to Figure 5.3. 
 
Figure 5.10: Lung specific proteins of the bronchial RTLFs. All other details as outlined 
in the legend to Figure 5.3. 
 
Considering the relative contributions of individual proteins to the total alveolar 
protein pool, Smoking was observed to have a profound effect on RTLF protein 
composition (see Figure 5.11 panels A and B). Comparing healthy aged smoking and 
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healthy aged non-smoking RTLFs, albumin, was observed to increase markedly with 
smoking (from 56.1 (32.8-83.2) to 82.0 (79.9-86.2)% respectively). This was also the 
case for other plasma proteins; including haptoglobin, A2M, and caeruloplasmin, the 
latter demonstrating a ~40 fold increase (0.005 (0.002-0.01) to 0.5 (0.008-1.1)%). Of the 
locally secreted proteins, CC16, displayed a similar ~ 40 fold increase (0.16(0.04-0.2) to 
12.7(2.2-47.3)%) and SP-B a ~100 fold increase (0.07(0.004-0.014) to 1.3(0.4-3.3)%) in 
the smoking RTLFs. The most significant increase in % contribution (~400 fold) was 
however noted for ferritin, increasing from 0.0013 (0.007-0.003)% of total protein in 
healthy aged controls, to 9.5 (0.07-12.5)% in the healthy smokers.  
Within the bronchial airways (see Figure 5.12, panels A and B), the contribution 
of albumin was again observed to increase with smoking in the non-COPD population:  
from 68.8 (55.7-84.9) in the non-smokers to 81.7 (74.4-88.8)% in the healthy smokers. A 
similar smoking related increase was also noted in haptoglobin (0.15 (0.03-0.2) to 17.0 
(0.1-30.1)%) and A2M (.13 (0.001-0.5) to 19.7 (1.1-49.8)%, ~100 fold) concentrations. 
Of the locally secreted proteins SP-B contributions increased from 0.006 (0.002-0.008)% 
of total protein to 1.1 (0.01-4.1)% with smoking, 130 fold; with a similar increase in 
CC16: 0.33 (0.04-0.6) to 7.0 (0.1-17.2)%, 40 fold, As with the alveolar RTLFs smoking 
in the healthy population was associated with a significant increase in the proportion of 
ferrtitin within the bronchial RTLF proteome: 0.005 (0.001-0.008) to 0.87 (0.07-6.2)%, 
~170 fold).  
Focusing on the alveolar RTLF composition in COPD in ex-smokers (Figure 
5.11, panels A and C) I found the % contributions of albumin to the total proteome to 
decrease relative to aged non-smoking controls: 31.4 (27.4-39.5) compared with 56.1 
(32.8-83.2)%, with a similar decrease in A2M (0.0002 (0.0001-0.0007) versus 0.14 (0.1-
0.5%). Haptoglobin proved an exception, with its proportion increasing 2.5 fold in the 
COPD ex-smokers relative to the aged controls: 0.3 (0.15-0.42) and 0.12 (0.08-0.16)%. 
The proportion of CC16 was also observed to decrease, 2 fold, in COPD ex-smokers, 
with a similar 3-fold decrease in SP-A. Of the remaining panel of proteins investigated 
only ferritin was shown to differ markedly in the COPD ex-smokers relative to the aged 
controls, increasing 10 fold: 0.02 (0.003-0.06) versus 0.0013 (0.0007-0.003)%). A similar 
reduction of the contribution of albumin to bronchial RTLFs was seen in the COPD ex-
smokers, but the proportions of haptoglobin, a2M and SP-B were equivalent in the COPD 
ex and control non-smoking groups.  The contribution of SP-A was however once again 
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decreased in COPD: 0.12 (0.06-0.13) versus 0.56 (0.3-1.3)%), Figure 5.12, panels A and 
C.  
A comparison of the impact of current smoking on the proportion of major 
proteins within the COPD alveolar proteome is illustrated in Figure 15.11, panels C and 
D. A large proportion of the alveolar RTLF proteome in the COPD ex-smoking smoking 
alveolar protein pool appears unaccounted for (~60%). Consequently the relative 
proportions of these major proteins were significantly increased with current smoking in 
COPD; with marked increases in albumin (75.7 (73.7-81.6) versus 31.4 (27.4-39.5)%), 
A1AT (0.74 (0.3-1.0) versus 0.4 (0.2-0.6)%) and IgG (3.1 (1.5-7.8) versus 1.9 (1.2-
2.8)%).  Transferrin was also observed to increase in COPD smokers versus ex-smokers 
(4.5 (1.2-7.3) versus 1.2 (0.6-1.6)), as did caeruloplasmin (0.009 (0.005-0.01) versus 
0.004 (0.003-0.01)%), and A2M (0.1 (0.03-0.2) versus 0.0002 (0.0001-0.007)%).  The 
proportion of ferritin was also increased in COPD smoking RTLFs (0.15 (0.06-0.2) 
versus 0.02 (0.003-0.06)%), as was SP-A, (0.63(0.6-0.7) versus 0.14 (0.1-0.2)%). In 
contrast, few changes were evident in the protein proportions within the bronchial COPD 
RTLF, with only albumin shown to have increased in the smoking COPD patients:  85.8 




























Figure 5.11: Percentage contributions of individual alveolar protein components relative 



























Figure 5.12: Percentage contributions of individual bronchial protein components 








5.3.3: The RTLF oxidant-antioxidant imbalance in COPD 
To explore the impact of a potential oxidant-antioxidant imbalance, 
bronchoalveolar lavage samples were analysed for the low molecular weight antioxidants: 
vitamin C (ascorbate and dehydroascorbate), urate, and glutathione (total, reduced and 
glutathione disulphide). Individual lavage urea correction factors determined were 
applied to the antioxidant concentrations measured in order to yield alveolar RTLF 
concentrations, as illustrated in Table 5.11. Ascorbate was significantly increased in the 
RTLFs of COPD smokers (28.7 (7.5-48.9) μM) versus the healthy aged controls (0.00 
(0.0-11.0) μM). Within the COPD RTLFs, significantly elevated RTLF ascorbate was 
also observed in the COPD smokers versus the ex-smoking subjects (2.66 (0.0-11.9) μM). 
No significant differences were however noted in dehydroascorbate concentrations, or 
total vitamin C concentrations across subject groups. Conversely, glutathione was 
significantly decreased in the RTLFs of COPD smokers (29.7 (89.2-296.5) μM) versus, 
healthy smoking controls (400.5 (257.5-499.6) μM). However, the RTLF glutathione of 
COPD smokers was found to be significantly elevated versus that observed in ex-smokers 
(96.0 (45.0-123.2) μM). Healthy aged smokers displayed significantly elevated 
concentrations of GSH compared with both healthy non-smokers (118.9 (82.8-154.5) 
μM) and COPD ex-smokers (96.0 (45.0-123.2) μM). No significant differences in total 
glutathione or glutathione disulphide were observed across groups investigated. Despite 
the significant changes in RTLF antioxidant concentrations, no evidence of protein 
oxidation was apparent; either in terms of protein carbonyl (Figure 5.13) or 4-HNE 
adduct (Figure 5.14) concentrations across the four groups.  
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Data represents urea corrected values for all subjects: Healthy aged non-smoker (n=19), healthy aged smoker (n=11), COPD ex-smoker (n = 18), COPD smoker (n = 14). 
Concentrations are expressed median values with interquartile range. Statistical differences where p<0.05, are represented by the following symbols: * CS vs HS,  ♯ CS vs 





Healthy Aged Smoker COPD Ex-Smoker COPD Smoker 
Vitamin C (  82.5(67.6-123.4) 116.7 (68.7-141.7) 45.7 (35.0-66.1) 74.57(46.13-98.5) 
 0.00 (0.0-11.0) ♯ 19.2 (1.5-40.4) 2.66 (0.0-11.9) § 28.7 (7.5-48.9) § ♯ 
Dehydroascorbic acid 
 
73.6 (35.5-101.3) 58.6 (42.5-111.4) 34.3 (26.6-59.7) 58.1(34.0-65.9 
 86.6 (84.4-190.4) 81.1 (50.7-119.8) 70.8 (61.4-99.4) 72.3 (42.3-96.0) 
 141.1 (128.9-190.4) 473.8 (312.7-658.3) 110.3 (67.5-307.6) 286.4 (237.3-404.1) 
 118.9 (82.8-154.5) £ 400.5 (257.5-499.6) £ 96.0 (45.0-123.2) §** 229.7 (89.2-296.5) §* 
 11.14 (0.0-39.5) 43.1 (13.3-72.3) 4.0 (0.0-102.0) 29.0 (20.7-41.3) 




Figure 5.13: Protein carbonyl (per mg protein) in  (A) alveolar and (B) bronchial RTLFs of aged 
smoking, non-smoking healthy and smoking, non-smoking COPD airways. All other details as 












Figure 5.14: Protein HNE adducts (per mg protein) in alveolar RTLFs of aged smoking, 
non-smoking healthy and smoking, non-smoking COPD airways. All other details as 










The principal aim of this chapter was to characterize the composition of the 
RTLFs across the bronchial and alveolar compartments of the COPD airway. To achieve 
this I employed age and smoking history matched controls, including a group of aged 
healthy smokers, i.e. with normal lung function and no evidence of respiratory or 
cardiovascular disease, to fully isolate the effects of COPD itself from those of smoking. I 
hypothesized that the changes observed would be reflective not only of the key 
pathological changes occurring within the airway of COPD patients: oxidative stress, 
chronic inflammation and protease/anti-protease imbalance, but also features typical of 
the normal ageing processes of the airways (as outlined in Chapter 4). The investigation 
focused on the RTLF proteome, with identified proteins classified according to their role 
in the underlying pathology of the disease: grouped by the immune/inflammatory 
response, proteolytic/anti-proteolytic balance, and those with antioxidant properties. 
Furthermore, I identified that a large proportion of the proteins identified were related to 
metal handling processes; the second largest grouping in three of the four groups 
examined. This grouping was therefore included in my classification of alveolar proteins. 
Examining the existing literature regarding proteomic investigations into COPD, 
using a PubMed search for COPD and proteomics identified 84 papers. The majority of 
these previous investigations in COPD focused on the identification of biomarkers for 
diagnostic purposes, and thus plasma samples were routinely used to assess the 
systematic effects of this disease (Rana et al., 2010; York et al., 2010; Verrills et al., 
2011; Merali et al., 2014). Other proteomic investigations have employed induced sputum 
as a means of non-invasively sampling the central airways (Ohlmeier et al., 2012), with 
further studies examining lung tissue (Ohlmeier et al., 2008; Ishikawa et al., 2010; 
Ohlmeier et al., 2010; Barreiro et al., 2014) or the proteome associated with exhaled 
breath condensate (Chhabra and Gupta, 2012). Only four have specifically investigated 
the RTLF composition of the diseased airway itself (Merkel et al., 2005; Franciosi et al., 
2013; Pastor et al., 2013; Tu et al., 2013); these studies are summarized in Table 5.11, 
which summarizes the cited papers major findings, analysis platform and the manner of 
protein quantification performed. 
In this study I have utilized the same stringent analytical approach adopted in 
Chapters 3 and 4; analyzing five representative samples individually from each of the 4 
groups analysed, as opposed to pooling. In all cases lavage samples were analysed after 
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pre-concentration and the final data adjusted, both for the total protein concentration in 
the original sample, but also the lavage dilution. Of the 4 proteomic studies performed 
specifically addressing the RTLF, Merkel et al., (2005) concentrated samples, but did not 
attempt to quantify their results, whilst Tu et al., (2013) employed an ion-current-area-
based label-free quantification method, based on samples that had undergone a soft 
precipitation.  The present investigation is therefore the first proteomic study that has 
attempted to go one step further and derive semi-quantitative estimates of RTLF protein 
concentrations, based on the MS data after adjustment for the lavage dilution.  It is also 
important to state that the MS data has been employed only as an indicative guide for the 
identification of the major common proteins across the 4 proteomes and for the 
generation of novel hypotheses, and as with previous proteomic investigations I have 
used conventional antibody based techniques to follow-up and validate interesting results 
(Bondarenko et al., 2002; Chelius et al., 2003; Wang et al., 2003; Liao et al, 2004; Wu et 
al., 2005). 
Finally, this investigation arises out of a wider program of work aimed at 
characterizing RTLFs to permit the informed design of disease specific simulants for the 
improvement in the delivery of inhaled medicines. With COPD now believed to affect 
>10% of the world population over 40, COPD patients are clearly a key patient group and 
market for inhaled medicines.  Whilst it could be argued that the use of a COPD patient 
population not taking medication, such as inhaled corticosteroids, cannot be wholly 
considered a ‘real world’ population, however the focus of this investigation was to 
characterise changes in the RTLF attributed to COPD and not the likely significant 
influence of corticosteroids on disease progression. In choosing to focus on the most 
abundant proteins of the RTLF in this analysis, we were able to determine over ~65% of 
the total RTLF protein pool across all subject groups to inform the development of 
physiologically representative simulant lung lining fluids. It should be noted that within 
the COPD ex-smoking groups only 40% of the proteome was accounted for, with only 58 
proteins identified in the MS proteomic analysis. 
The key observations arising out of these investigations can be defined as those 
informing our understanding of the impact of cigarette smoking on the composition of the 
RTLF in the healthy (non and current smokers) and COPD lung (ex and current smokers); 
as well as changes related to the presence of COPD, either basally, i.e. through 
comparison of healthy aged non-smokers with COPD ex-smokers; or in relation to the 
response of the COPD airway to oxidative stress, related to cigarette smoke inhalation; 
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comparing healthy aged smokers to COPD active smokers. With this in mind the key 
observations arising out of this study were as follows:  
(1) Equivalent total protein concentrations were seen in the bronchial and alveolar 
RTLF across all four groups, though the concentrations were higher in the bronchial 
compartment. Despite this, the relative proportions of the most abundant proteins 
identified in the proteomic pre-screen varied markedly between groups. Significantly, 
within both RTLF compartments a significant proportion of the total protein was not 
accounted for, with the exception of the healthy aged smokers. 
(2) The proteomic analysis highlighted the importance of metal handling proteins 
at the air-lung interface, particularly iron related proteins, representing the second largest 
functional classification in three of the four groups. 
(3) The proteome in COPD ex-smokers lacked the complexity of that in healthy 
non smokers and smokers. This result was confirmed in two separate sub groups of 
COPD ex-smokers. The complexity of the COPD RTLF proteome was increased in the 
COPD current smokers, though there was a larger contribution of protein of intra-cellular 
origin.  
(4) Smoking induced a significant increase in alveolar RTLF ferritin, indicative of 
cellular injury and the release of this intra-cellular protein in healthy aged subjects and 
COPD patients, a similar response was not evident in the bronchial compartment.  
(5) Smoking was associated with an increase of SP-B in alveolar RTLFs, but this 
response was restricted to the healthy aged population. A similar increase in SP-B was 
also seen in the bronchial compartment of healthy smokers, through this failed to attain 
statistical significance. In contrast SP-A was increased with smoking in the aged healthy 
population, with the response again absent in the COPD patients.  
(6) Patients with COPD had significant reductions in alveolar RTLF innate 
immunity proteins (IgA, A2M and SP-A) compared with their age-matched controls, 
irrespective of smoking status. Similar deficiencies were observed within the bronchial 
RTLFs, with reduced concentrations of IgA, IgG, transferrin and SP-A.  
(7) Smoking was associated with an increase in transferrin concentrations in the 
bronchial RTLFs of healthy subjects. This response was absent in the COPD smokers.  
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(8) These changes in RTLF composition were seen within the context of an 
expansion of macrophages numbers in the distal lung of healthy and COPD smokers, 
relative to their non-smoking control groups. This was seen in the absence of 
neutrophilia, either related to smoking or disease status, suggesting that the COPD 
patients were well controlled. There was also an absence of overt oxidative stress in the 
COPD airway, with GSH concentrations significantly increased with smoking in both 
healthy control and COPD patients.  
The smoking related increase in macrophage number in the distal lung of both 
healthy subjects and COPD patients in the present study accord with other published 
studies showing an increase in total leukocytes in the airways of smokers with normal 
lung function (Wallace et al. 1992; Barcelo et al. 2008); with a similar expansion in 
airway macrophage numbers reported in the lungs of young smokers (Ohnishi et al. 
1998). No increase in macrophage numbers was observed in the COPD patients, current 
or ex-smokers compared with their relevant control groups. This result is somewhat at 
odds with the literature reports of increased macrophage numbers in the bronchial sub-
mucosa (Saetta et al. 1993; Di Stefano et al. 1996; Rutgers et al. 2000), bronchial glands 
(Saetta et al. 1997) and airway epithelium (Turato et al. 2002) of COPD patients. 
Furthermore, there is some evidence supporting a positive association between alveolar 
macrophage numbers and the severity of COPD (Finkelstein et al. 1995; Gorska et al. 
2008).  
In addition I observed no evidence of neutrophilia in COPD smokers and non-
smokers relative to their control groups. This observation differs markedly from the 
published literature where increased BAL neutrophils have been reported in both smoking 
and ex-smoking COPD patients (Babusyte et al. 2007). Moreover, this increase in 
neutrophil numbers has been reported to persist even after smoking cessation 
(Louhelainen et al. 2009). The basis for this cellular recruitment to the airways has been 
associated with the increased release of chemotactic factors such as interleukin 8 (IL-8) 
and leukotriene B4 (LTB4), which have been shown to be elevated in the airways of 
patients with COPD (Corhay et al. 2009). It is important to state that the COPD patients 
in the current study were all clinically stable, with no airway infection for a period of 3 
months prior to the bronchoscopy, no recent exacerbations and were not taking anti-
inflammatory medications. These tight recruitment criteria were adopted to minimise the 
influence of recent exacerbations and medication usage. Other studies examining airway 
inflammation in COPD have often provided limited information on the patient’s recent 
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history of infection, medication usage or smoking history, which makes a simple 
comparison of observations between studies difficult. 
The observation of an increase in respiratory tract lining fluid GSH 
concentrations in the smoker groups, accords with previous observations (Cantin et al 
1987; MacNee, 2000). Whether this reflects an adaptive response to oxidative stress or 
the consequence of the release of intra-cellular GSH into the extra-cellular spaces from 
dying cells is not clear. Notably this increase occurred in parallel to increased alveolar 
RTLF ascorbate and ferritin concentration. As ascorbate is exclusively derived from the 
diet in humans and ferritin is a large intra-cellular protein, these parallel increases are 
supportive of GSH leakage from injured or dying cells. It is long established that cells 
induced to undergo apoptosis demonstrate a rapid and specific efflux of GSH (van den 
Dobbelsteen et al. 1996). Beyond these smoking related impacts on the RTLF antioxidant 
network, no affect of COPD itself was seen. Further, no increases in markers of protein 
oxidation, or indeed, increased concentrations of either dehydroascorbate or glutathione 
disulphide were observed in the distal lung in relation to either smoking status, or the 
presence of COPD. Thus in contrast to previous studies (Nowak et al., 1999; Montuschi 
et al. 2000; Beeh et al. 2004; Di Stefano et al. 2002; Rahman et al. 2002; Ricciardolo et 
al. 2005), we saw no overt evidence of oxidative stress in our COPD subjects.  
Despite the absence of active neutrophilia, or oxidative stress within the alveolar 
or bronchial RTLF proteomes clear smoking related responses were observed. Ferritin 
concentrations were increased in the alveolar RTLFs of both healthy and COPD smokers, 
in the absence of a similar response in the bronchial compartment. Elevated 
concentrations of ferritin have previously been associated with necrosis in the RTLFs of 
smokers (Mateos et al, 1998; Erbaycu et al., 2007). Dying alveolar macrophages have 
also been shown to release ferritin, with a significant association observed between 
ferritin and LDH concentrations, which is significant given the increase in alveolar 
macrophage numbers associated with smoking (McGowan and Henley, 1988; Wesselius 
et al., 1994). Evidence was also observed for smoking related increases in surfactant 
proteins in bronchial and alveolar compartments, though the responses were restricted to 
the healthy aged controls. The presence of surfactant proteins within the bronchial 
compartment indicates a certain degree of admixture between the proximal and distal 
airway lavages. Consequently here I will discuss the smoking related increases in SP-A 
and SP-B in general across the airway, rather than focus on a given compartment. With 
regard to the smoking related increase in SP-A seen in the healthy aged subjects in the 
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present study the existing literature presents conflicting evidence, with some in line with 
our findings  (Behera et al., 2005; Ohlmeier et al., 2008; Mazur et al., 2011), whilst others 
reported decreased concentrations (Honda et al., 1996; Hermans et al., 1999; Betsuyaku 
et al., 2004). Vlachaki et al, (2010) suggested that SP-A may play a protective effect role 
against effects of smoking, due to its anti-inflammatory properties. SP-B was similarly 
increased with smoking in the healthy aged subjects, though the effect was most marked 
in the alveolar RTLFs. No previous reports have identified a similar cigarette smoke 
induced increase in this protein in the lung. Significantly no such response was seen in 
the COPD smokers, despite previous evidence of increased concentrations of SP-A in the 
sputum of COPD smokers (Ishikawa et al., 2011). In contrast Betsuyaku et al., (2004) 
observed a reduction in both SP-A and SP-D, in aged smokers with emphysema.  
Under the chronic inflammatory conditions such as those observed within the 
COPD airway, phenotypic changes in resident alveolar cells, from type II pneumocytes 
into the non surfactant secreting type I pneumocytes has been observed (Wirtz and 
Schmidt, 1996; Subramaniam et al., 1996; Barnes et al.,  2003; Bernhard et al., 2004; 
Milic-Emili, 2004). It is therefore plausible that the absence of a smoking related increase 
in surfactant proteins in COPD patients may reflect an underlying remodelling of the 
alveolar epithelium. 
One of the key observations of the current study was the decrease in a number of 
key innate immunity proteins within the RTLFs of COPD patients, which was observed 
irrespective of the patients smoking status (IgA, IgG, SP-A and A2M). The lower 
concentrations of SP-A in both lower and upper airway COPD RTLFs likely reflected a 
reduction in the number of type II pneumocytes in COPD due to squamous cell 
metaplasia, as described above. The reduced concentration of IgA may reflect isotype 
switching of immunoglobulin secreting plasma cells of the airways (from IgA to IgG) in 
COPD patients, which has been proposed to occur in response to bacterial or viral 
infections, and as a specific response induced by long term smoking (Soutar, 1977; Bell, 
1981; Stockley, 1980; Brandsma et al., 2012).  However the fact that IgG was also 
depressed suggests a more fundamental dysregulation of antibody production within the 
COPD airway (Pauwels, 2001). Similarly, in the absence of a clear signal indicative or 
altered airway permeability, the decreased concentrations of both A2M and haptoglobin 
suggest a reduction in the local production within the lung, from epithelial cells and 
alveolar macrophages (Yang et al., 1995). Smoking was associated with increased 
transferrin concentrations in the healthy bronchial RTLF, which was absent in the COPD 
smokers. The available literature on airway transferrin concentrations in relation to 
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smoking is varied and restricted to healthy controls, with evidence of both decreased 
concentrations (Stites et al., 1995; Ghio et al., 2008), or no overall change (Mateos et al., 
1998). Transferrin however is also secreted locally within the airways and thus the 
remodelling of the airway epithelium in COPD might impact on basal rate of production, 
explaining the current result (Bell et al., 1981; Wesselius et al., 1992; Stites et al., 1995; 
Mateos et al., 1998). 
Conclusions 
 
 In the present study I sought to investigate the composition of the RTLFs in 
COPD patients, an important group for the development of inhaled medications. In order 
to isolate disease specific signatures it was necessary to include both age and cigarette 
smoking matched controls groups. Consequently, the subsequent analysis revealed 
information not only on COPD itself, but also on the impact of smoking on the RTLF 
proteome. Using the approaches adopted in the previous two chapters I first identified the 
most abundant proteins common across the four groups in subsets of subjects, before 
analyzing these within the full groups. Whereas previously using this approach I had been 
able to account for the majority of the total protein within both the bronchial and alveolar 
RTLFs (>70%), in the current investigation, a significant proportion of the total protein 
pool remained unaccounted for, in all groups, with the exception of the COPD smokers. 
Also, whilst total protein concentrations were equivalent across the 4 groups, the relative 
proportion of individual proteins varied considerably, suggesting that COPD RTLF 
simulants would need to differ significantly from the base model identified in Chapter 3.  
 The relative paucity of the RTLF proteome in the COPD ex-smokers was an 
unexpected result. When it was initially observed in the first subset of subjects, the 
decision was made to repeat the analysis in a further 5 COPD ex-smokers, which 
confirmed the original result. At this time there is no simple explanation for this finding 
and further work will be required to assess whether this is a function of decreased basal 
secretion from airways cells, attributable to increased levels of senescence, or increased 
proteolysis. The result is further complicated by the observation that the COPD smokers 
had the most abundant proteome, though many of the identified protein were of intra-
cellular origin and may therefore reflect augmented injury, rather than an enhanced 
secretory response. Finally, perhaps the most significant ancillary observation arising 
from this study was clear evidence of reduced innate immunity protein concentrations 
within the airway of COPD subjects, which was apparent throughout the respiratory tract, 
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irrespective of the subjects smoking status. Such an underlying change would confer an 
increased sensitivity to the COPD airway to both infection and other inhaled irritants, in 
line with the formal definition of the disease. A key question going forward will be 
whether this reflects a remodeling of the airways, or precedes it, and hence contributes to 











The overall aim of this thesis was to develop a series of standardised lung lining 
fluid simulants reflective of the different regions of the airways and compositional 
alterations characteristic of asthmatic and chronic obstructive pulmonary disease. Lung 
lining fluid stimulants, designed to represent different lung regions and disease 
conditions, will be used for the in vitro biopharmaceutical screening of inhaled particulate 
drugs, and therefore must not only be physiologically representative of RTLF 
composition, but also optimised for cost, convenience and reproducibility, as well as 
stability upon storage.  
 
The approach was first to design a ‘base’ model simulant based on the major 
protein, lipid and low molecular weight constituents, referencing this against human 
RTLF composition. As described in detail throughout Chapters 3, 4 and 5, the 
composition of the RTLF varied significantly across the proximal conducting bronchial 
airways down to the distal alveolar regions, reflective of the physiological requirements 
of these airway compartments. Table 6.1 highlights the variations in concentrations 
determined in healthy RTLFs compared to those previously reported within the literature. 
Furthermore, significant compositional changes within this crucial extracellular 
compartment were established in relationship to age, airway disease and smoking status, 
presumably reflective of ongoing processes. The focus on these subgroups is believed to 
be a necessary consideration in the design of simulated epithelial lining fluids, with the 
majority of the key demographic user groups of inhaled medicines consisting of 
individuals in both the disease and age groups. 
190 
 









Bronchial RTLF Concentrations 
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Catalase  U/mL   410     
Glutathione Peroxidase  U/mL   0.051     
Superoxide dismutase  U/mL   4010     
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Transferrin mg/mL 1.5 0.4 2.3 0.2
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IgM mg/mL 0.1 0.03 0.1   









Alpha 1-antitrypsin mg/mL 2.0   1.2   





















     
Phosphatidylglycerol mg/mL   0.002 ± 0.0003
8
     
Neutral lipids mg/mL 0.1 0.02 ± 0.006
14
     









1.5   
SP-B mg/mL   0.0007 ± 0.00009
15
     
SP-C mg/mL   0.0006 ± 0.00005
16
     
SP-D mg/mL   0.5±0.07
11
, 0.00007 ± 0.000003
12
     
1. Van der Vliet et al., (1999); 2. Hatch (1992); 3..  Slade  et al.,(1993); 4. Cantin et al.,(1987);  5. Cross et al., (1994); 6.  Rennard et al., (1990); 7.  Sutinen et al., (1995); 8.  Meyer et al., (2000); 9.  Thompson et al., 
(1990); 10.  Sun et al., (2001); 11. Cheng  et al., (2000); 12. Honda et al., (1996); 13 Hamm et al., (1994); 14  Ito et al., (2006); 15 Kramer et al., (1995); 16 Schmidt et al., (2002).
191 
 
First, it must be recognized why the design and development of physiologically 
representative simulants is necessary. As discussed in detail (see Chapter 1) RTLFs form 
the first physical interface inhaled particles encounter following their delivery into the 
airways. In the fields of geochemistry and environmental studies simulated extracellular 
lung fluids are an integral part of in vitro investigations, despite their relative simplicity they 
nevertheless illustrate the importance of biorelevant models in the analysis of inhaled 
materials (de Meringo et al., 1994; Herting et al., 2006; Sdraulig et al., 2008). In contrast 
however, fluids representative of this extracellular compartment have not been incorporated 
into the majority of in vitro studies investigating the fate of inhaled medicines (Eixarch et 
al., 2010; Agu and Ugwoke, 2011). 
 
The advantages of delivering drugs through the inhalatory route are extensive: the 
large surface area for drug absorption alongside the extensive alveolar capillary network 
result in both rapid clearance and rapid onset of drug action, suitable for small molecules to 
large molecular weight proteins. Furthermore, low extracellular and intracellular enzymatic 
activity and the absence of first pass metabolism have made inhalation an attractive and 
established route for both local and systemic drug delivery (Dolovich, 1989; Newman et al., 
1991; Liu et al., 1993).  Nevertheless gaps remain in our understanding of the fate of inhaled 
medicines, and with emerging developments in pulmonary medicine (particularly in the 
development of nanoparticulate formulations) the need for physiologically representative in 
vitro methods to evaluate the behaviour and thus ultimately bioavailability of inhaled drugs 
is apparent (Forbes and Ehrhardt, 2005; Sadler et al., 2011). 
 
In the case of orally delivered compounds the use of bio relevant media, FASSIF 
and FESSIF, have demonstrated clear improvements in establishing in vitro- in vivo 
correlations of drug behaviour (versus that of compendial media) (Sunesen et al., 2005; Wei 
and Lobenberg et al., 2006; Lue et al., 2008; Okumu et al., 2008; Jantratid et al., 2009; 
Shono et al., 2009). However the complexity in modeling the various unique features of the 
respiratory system in vitro, i.e. the large surface area (human alveolar surface area alone is  
~100 m2), anatomical diversity, the relatively low volume and the static nature of the 
RTLFs, have limited the use of physiologically relevant media in in vitro models of inhaled 
drugs, in contrast to use of biorelevant media to represent the fluid in the gastro-intestinal 




Preliminary studies incorporating RTLF components, into simulated fluids, although 
mainly limited to DPPC, have already demonstrated significant effects in the relative 
solubilization of drug compounds, particularly those hydrophobic in nature, by increasing 
both wettability and preventing aggregation of drug particles (Wiedmann et al., 2000; 
Sinswat et al., 2008). Similarly with investigations into the dissolution of inhaled drug 
particulates, buffer systems incorporating varying concentrations of DPPC have been 
investigated in attempts to mimic the in vivo situation. The addition of DPPC has been 
demonstrated to enhance the dissolution profiles of poorly soluble compounds, predictably 
following the trend observed in solubility studies (Wiedmann et al., 2000; Pham and 
Wiedmann, 2001; Davies and Feddah, 2003; Son and McConville, 2009). Obtaining 
accurate in vitro dissolution profiles of drugs is a necessary parameter in estimating the 
bioavailability of drugs in vivo (and thus establishing in vitro-in vivo correlation), however, 
no pharmacopoeial standard for the dissolution media or apparatus required for the testing of 
inhaled drugs is available (Davies and Feddah, 2003).  
 
The use of in vitro cell-culture techniques (A549, Calu-3, 16HBE14o-, hAEpC 
primary cell cultures) are also employed in investigations to screen the behaviour of inhaled 
medicines. Cell culture studies are typically useful for examining aspects of drug delivery 
such as absorption, permeability, transport, metabolism and toxicity, crucial factors in 
evolving our understanding of the underlying mechanisms at the cellular level (Forbes, 
2000; Forbes et al., 2003; Cooney et al., 2004; Rothen-Rutishauser et al., 2005; Sporty et al., 
2008; Agu and Ugwoke, 2011). These techniques have undergone significant developments, 
incorporating particle deposition, dissolution and absorption in immortalized cell culture 
models (Tee et al., 2001; Fiegel et al., 2003; Forbes et al., 2003; Cooney et al., 2004; Buttini 
et al., 2008; Bur et al., 2009; Grainger et al., 2009; Hein et al., 2011). Also, fully 
differentiated models of primary nasal, bronchial and trachea cells cultured at the air liquid 
interface are commercially available (PneumaCult™-ALI  and MucilAir™) and have been 
reported to be capable of mimicking aspects of airway epithelium from ion transport, 
metabolic activity, chemokine and cytokine release to mucus production and ciliary beating. 
However, these models are less robust and less economically viable compared to 
immortalized cell lines and thus have not become a routine part of biopharmaceutical 
screening of inhaled drugs (Forbes and Ehrhardt, 2005).  
 
An international workshop held by the Academy of Pharmaceutical Sciences Great 
Britain in 2010, was convened to discuss the challenges in the development of inhaled 
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medicines, one of the main summary objectives reached describes the necessity for the 
development of physiologically relevant simulated fluids based upon the characterization of 
RTLFs to improve these current in vitro methods for assessing inhaled drug behaviour 
(Forbes et al., 2010). The incorporation of simulated RTLFs in such models would be of 
great significance in guiding the formulation, development and design of inhaled drugs 
particularly from a biopharmaceutical perspective, improving prediction of the in vivo 
behaviour of inhaled medicines. 
However, not all inhaled particles dissolve within the RTLFs. Mucociliary clearance 
mechanisms dominate the larger ciliated airways whilst phagocytic and endocytic clearance 
mechanisms are crucial in the clearance of slowly dissolving and insoluble particles in the 
distal alveolar regions (Sibille and Reynolds., 1990; Yang et al., 2008). Nanoparticles 
deposit optimally within the distal alveolar RTLFS and make use of non-absorptive 
clearance mechanisms, with the ability to translocate across the respiratory epithelium 
(approximately only 0.2 μm thick in the alveoli) to the systemic circulation (Weibel, 1973; 
Borm et al., 2006). Nanoparticles have exceptional and unique properties on account of their 
size and increased particle surface-to-volume ratio. It is these properties that have thus been 
exploited for drug delivery purposes (Shargel and Yu, 1999; Oberdorster et al., 2005; Jones 
and Grainger, 2009; Nel et al., 2006; Sung et al., 2007). 
 
For the inhaled drug delivery of nanomedicines (it should be noted that 1 to 1000 
nm diameter sized particles are encompassed by this term for drug delivery purposes) 
formulations have been developed using polymeric or liposomal materials (Sun et al., 2004; 
Yokoyama, 2005; Medina et al., 2007; Braeckmans, 2010). Once deposited within the 
RTLFs the physiochemical properties of nanoparticles (size, composition material, surface 
charge, hydrophobicity) determine their degree of interaction with protein and lipid 
components of RTLF and thus the nature of the dynamic ‘corona’ that forms on their surface 
(Vranic et al., 2013). The formation of these protein-lipid complexes on the surface of 
nanoparticles has the capability of modifying particle behaviour, from influencing the rate of 
particle aggregation to cellular interactions including macrophage phagocytosis and 
endocytosis, or increasing their recognition by surface receptors and uptake into cells 
(Oberdorster et al., 2005; Borm et al., 2006; Nel et al., 2006; Yang et al., 2008). Therefore it 
comes as a surprise that physiologically relevant RTLF simulants have not become an 





Whilst particles can be characterized in simple media at the time of preparation to 
provide useful information regarding the physiochemical properties of nanoparticles, these 
do not take into account constituents of the RTLFs, and it is the characterization of 
nanoparticles in biologically relevant media that is essential in providing the basis for 
understanding the properties of nanoparticles that go on to determine their biological fate 
and effects (Powers et al., 2006).  
 
The commercially available, surfactant preparations for treatment of respiratory 
distress syndrome of neonates are the only physiologically relevant epithelial lung lining 
fluid simulants in use both clinically and additionally in the in vitro investigations of inhaled 
particle behaviour. These commercial preparations consist of natural, modified or synthetic 
surfactants, with six out of the nine surfactant replacements available today being natural 
surfactants (Wrobel, 2004; Lopez et al., 2013; Polin et al., 2014). The animal derived 
surfactants, isolated from porcine or bovine lungs (lavage or minced) by organic solvent 
extraction, with saturated phospholipids particularly DPPC and the hydrophobic surfactant 
proteins B and C form the major active components of these clinical formulations (Sun et 
al., 1997; Lal and Sinha, 2008). Commonly used animal surfactants include, Curosurf®  (a 
porcine surfactant extract) purified after extraction from porcine lungs by liquid-gel 
chromatography, Infasurf® (a bovine surfactant) an unmodified suspension obtained from 
bovine lung lavage and Survanta®, also a bovine surfactant extract, fortified with additional 
synthetic lipids (Bloom et al., 1997; Soll and Fermin, 2001; Nguyen et al., 2003; 
Ramanathan et al., 2004; Bloom and Clark, 2005; Kim and Shim, 2013; Do et al., 2014). 
However individual natural surfactant preparations demonstrate significant variation ‘batch 
to batch’ in the concentrations of phospholipid and protein components (Lal and Sinha, 
2008). Synthetic surfactant preparations such as Exosurf® (which lacks protein) have also 
been developed (Jobe et al., 1993; Corcoran et al., 1994), and Surfaxin®, a synthetic 
formulation containing a novel synthetic peptide, KL4, designed to mimic surfactant protein 
B. Clinical trials have demonstrated the safety and efficacy of this preparation (Curstedt and 
Johansson, 2006).  
These commercially available preparations have been used in investigations 
assessing the influence surfactant has on the dispersion, toxicity and bioavailability of 
particles in vitro. Those investigations included carbon walled nanotubes in Survanta® and 
SiO2 and TiO2 nanoparticles in Curosurf
® (Keane et al., 1991; Kendall et al., 2004; Foucaud 
et al., 2007; Schleh et al., 2009; Wang et al., 2010; Vranic et al., 2013). Whilst the majority 
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of these studies come from an environmental and occupational exposure perspective, they 
nevertheless demonstrate the necessity to mimic a more physiologically representative 
media representative of the RTLFs. The commercially available preparations are limited to 
representing the surfactant component of distal RTLFs, the highly abundant proteins 
composing the aqueous component of this fluid is absent. Thus, in the development of a ‘fit 
for purpose’ simulant, an ideal model would possess physiological relevance and 
biocompatibility, but must also be able to be manufactured in a standardised, cost effective 
manner. 
Aims and objectives 
A physiologically-relevant simulated lung fluid ‘base model’ representative of the 
alveolar RTLFs will be developed and optimized incorporating the objectives summarized 
below, and evaluated in preliminary investigations for the assessment of its suitability for 
the biopharmaceutical screening  of inhaled particles. 
 
1. Physiologically relevant: unlike generic ionic solutions, which are supplemented 
with arbitrarily chosen protein and/or DPPC concentrations, the base model must 
incorporate the major protein, lipid and low molecular weight components at 
concentrations determined to be representative of the RTLF. Whilst compositional 
differences attributed to region, disease and age have all been characterised, as a 
‘first step’ a base model will be designed to represent the  healthy alveolar RTLF. 
2. Cost: It must be appreciated that the components chosen for the base model should 
be readily and commercially available. 
3. Ease of manufacture: The stimulant preparation procedure must be reproducible, and 
the time to manufacture simulant must be realistic. 
4. Stability: Both optimal temperature upon storage, the length of time that the 
simulant remains viable, and remains within acceptable limits of microbial growth 
must be considered and assessed. 
5. Incorporation into existing in vitro investigations: This base model will be used in 
the physiochemical characterisation of reference drug delivery particles. 
6. Biocompatibility - How readily can simulants be incorporated into currently 
employed in vitro cell models used to investigate the behaviour of inhaled drug 






6.2.1: Simulant development and preparation 
The formulation of simulant was based upon measured RTLF concentrations of 
protein, lipid and antioxidant components of healthy human lavage samples, corrected for 
dilution by the urea method, as detailed in Chapter 3, referencing data obtained from the 
literature. Table 6.2 outlines the concentrations of the major protein, lipid and antioxidant 
constituents of the base model of stimulant. 
 
Table 6.2: Components of  ‘base’ simulated lung epithelial lining fluid  
Base model components Concentration 
Albumin 8.8 mg/mL 
IgG 2.6 mg/mL 
Transferrin 1.5 mg/mL 
DPPC 4.8 mg/mL 
DPPG 0.5 mg/mL 
Cholesterol 0.1 mg/mL 
Ascorbate 140 µM 
Urate 95  µM 
Glutathione 170  µM 
 
6.2.2: Protocol for preparation of 10 mL of base alveolar simulant 
First liposome variants were manufactured by the two methods described below: 
1. DPPC only  
a. 0.048 g DPPC weighed into small glass round bottomed flask containing 1 
mL chloroform which was evaporated under nitrogen in waterbath at 55 oC 
for ~15 mins 
b. 2 mL resuspending solution (HBSS) pre-warmed to 55 oC was added 
c. This was then mixed vigorously on a vortex for 15-30 min 






2. DPPC with PG and cholesterol  
a. 0.048 g DPPC, 0.005 g PG, 0.001 g cholesterol weighed into small glass 
round bottomed flask containing 1 mL chloroform and evaporated under 
nitrogen in waterbath at 55 oC for ~15 min 
b. 2 mL resuspending solution (HBSS) pre-warmed to 55 oC was added 
c. This was then mixed vigorously on a vortex for 15-30 min 
d. Finally sonicated for ~ 1 h in waterbath at 55 oC 
 
To this mixture of lipids, a solution of proteins was added slowly (0.0816 g of albumin, 
0.0158 g IgG, 0.01904 g transferrin, to make up to 3 mL with buffer) Finally, UA, AA and 
GSH were added from concentrated 100mL stock solutions for AA, GSH and UA. For AA 
81.43 µl were added, for GSH 85.87 µl added and finally 85.39 µl of UA was added. HBSS 
was added to a final volume of 10mL. The pH of simulant was checked to be between 7.2 
and 7.4 and stored at 4oC. 
 
6.2.3: Dynamic Viscosity 
The viscosity of simulants, RTLF, BAL and cell culture medium (supplemented 
with 2% fetal bovine serum (FBS)) was measured at 37°C using an AMVn Automated 
Micro Viscometer (Anton Parr). Briefly the samples were loaded onto the microcapillary 
and the viscosity was determined in triplicate according to Höpplers falling ball principle. 
The following viscosity values were obtained, CCM FBS2%= 0.734x10-3 Pa s, simulant 
(DPPC)= 0.738x10-3 Pa s and simulant (DPPC, PG, cholesterol)= = 0.789x10-3 Pa s. 
 
6.2.4: DLS measurements 
All DLS sizing was performed using a Zetasizer Nano ZS (Malvern, Worcestershire, 
UK). Size was measured at 37 °C and measurements were taken at a scattering angle of 
173° and a refractive index of 1.337 (176). Viscosity values were adjusted for each medium: 
CCM FBS2%= 0.734x10-3 Pa s, simulant (DPPC)= 0.738x10-3 Pa s and simulant (DPPC, 
PG, Cholesterol)= = 0.789x10-3 Pa s.  Three batches of each simulant formulation were 





6.2.5: Particle sizing in simulant and concentrated BAL 
50 nm (2.62% w/v) and 200 nm (2.5% w/v) non-functionalized polystyrene 
microsphere aqueous suspensions and 50 nm (2.5% w/v) 
carboxylated polystyrene microsphere aqueous suspensions were used (Duke Scientific, 
Palo Alto, CA). For particle size analysis, particles were prepared at a concentration of 2.5 
mg/mL in the respective medium. Three batches of each nanoparticle investigated were 
analysed for size in triplicate for 4 h periods, measurements were made every 15 min. 
 
6.2.6: Culture of A549 cells 
Human alveolar epithelial cells (A549, ATCC, USA) were cultured in cell culture 
medium supplemented with 10% FBS (CCMFBS10%) in a humidified incubator at 37°C 
and 95% air and 5% CO2. All experiments were performed on cells seeded at a density of 
10,000 cells/cm2 in cell culture medium supplemented with 2% fetal bovine serum 
(CCMFBS2%), unless stated otherwise. 
 
6.2.7: Cell viability assay using MTT  
The MTT assay is a colorimetric assay used to measure the metabolic activity of 
cells. The mitochondrial reductase enzyme reduces the yellow tetrazole, MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), to a formazan dye, which has a 
purple colour, thus allowing the investigator to assess the viability and/or death of cells. 
Sodium dodecyl sulphate (SDS), a solubilising agent, is then used to dissolve the insoluble 
purple formazan, which yields a coloured solution. A spectrophotometer is then used to 
measure the absorbance of this coloured solution at 570 nm. 
 
Cell viability as assessed by the MTT assay, was used as a proxy to determine the 
bicompatibilty of simulants with cells in vitro, by assessing the effects of the exogenously 
applied simulants on cell layer metabolism. Cells were seeded in a 96-well plate (see Figure 
6.1 below) and, after 24 h, were treated with 100 μL concentrations of simulant species 
(Protein and DPPC and Protein DPPC, PG and Cholesterol) (at concentrations of 1.1, 2.2, 
4.3, 6.5, 8.7, 10.8 mg/mL protein respectively) CCM FBS2% alone (negative control) and 
incubated at for 1, 2, 4 and 12 h. After the exposure period, the particle suspensions were 
aspirated and replaced by 200 μL fresh CCMFBS2%. 50 μL MTT (5 mg/mL) was then 
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added to the wells and the plate was incubated for a further 4 h. The medium was then 
removed and the resulting intracellular formazan crystals were dissolved over 24 h in 100 
μL of 10% SDS prepared in 1:1 water:DMF, after which the absorbance from the 
solubilized formazan was measured spectrophotometrically (SpectraMax UK) at an 
absorbance wavelength of 560 nm.  
 
The relative viability of cells was calculated as follows: 
 
Where A is the absorbance obtained for each concentration of the simulant, S is the 
absorbance obtained for positive control (1% v/v Triton-X) and CM is the absorbance 
obtained for untreated cells (incubated with CCM FBS2% alone). The latter reading is 
defined as 100% cell proliferation (fully viable cells). 
 
Figure 6.1: Template of the 96-well plate used in MTT investigation assessing the 
biocompatibility of A549 cell lines with simulant. Dilutions and negative controls are 
highlighted on the left. 
6.2.8: Transmission Electron Microscopy  
Morphological examination of simulant and of NPs in simulant were conducted by 
transmission electron microscopy (TEM). The samples were negatively stained with 2% 
(w/v) phosphotungstic acid pH 6.5 and 0.1% trehalose and placed on 150 mesh Formvar 
copper grids prior to TEM observation. Samples were examined on a FEI Tecnai 12 
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transmission microscope operated at 120 kV. Images were acquired with an AMT 16000M 
camera, with a minimum of 10 images per condition acquired. 
 
A549 cells were grown to confluence inside a 6 well plate and treated with or 
without simulated epithelial lining fluids suspended in cell culture medium (2% FBS) for 4 
hs. After treatment with simulant for TEM, cells were fixed by removing the medium and 
replacing it immediately with 2.5% (v/v) glutaraldehyde in 0.15 M cacodylate (pH 7.3). The 
cells were fixed for 1 h at room temperature. The cells were then scraped from wells using a 
cell scraper (BD Falcon), transferred into ependorff tubes and spun for 5 minutes at 3,000 
rpm in a microcentrifuge. Cells were then resuspended in fresh 2.5% (v/v) glutaraldehyde in 
0.15 M cacodylate buffer and further fixed overnight at 4°C. After fixation, cells were 
washed with 0.15M cacodylate buffer and post-fixed in 1% (w/v) osmium tetroxide in 
0.15M cacodylate buffer (pH 7.3) for 1 h at 4°C. Samples were then dehydrated through a 
graded ethanol series, equilibrated with propylene oxide before infiltration with TAAB 
epoxy resin and polymerised at 70°C for 24 hs. Ultrathin sections (50-70 nm) were prepared 
using a Reichert-Jung Ultracut E ultramicrotome, mounted on 150 mesh Formvar copper 
grids and contrasted using uranyl acetate and lead citrate. Samples were examined on a FEI 
Tecnai 12 transmission microscope operated at 120 kV. Images were acquired with an AMT 
16000M camera.  At least 10 images from each condition were acquired, cellular changes 
were assessed by visual inspection of the representative TEM images, and quantitative 
estimates of cell morphology made. using ImageJ 1.47 software (http://rsb.info.nih.gov/ij).  
 
6.2.9: Statistical analysis 
All statistical analysis was performed using the student’s t-test. All analyses were 






6.3.1: Base model development 
Table 6.3: Protein, lipid and antioxidant concentrations in RTLF, Simulant and CCM 






Simulant CCM 2% FBS  
Ionic constituent Concentration (mg/mL) 
Inorganic salts       
Calcium Chloride  
(CaCl2) anhydrous   
0.14 0.2 
Magnesium Chloride 
 (MgCl2-6H2O)   
0.1   
Magnesium Sulfate  
(MgSO4-7H2O)   
0.1 0.098 
Potassium Chloride  




(KH2PO4)   
0.06   
Sodium Bicarbonate  
(NaHCO3)   
0.35 0.85 
Sodium Chloride  
(NaCl)   
8 6.8 
Sodium Phosphate dibasic 
(Na2HPO4) anhydrous   
0.048 0.12 
Other 
Glucose   1 1 
Amino acids       
L-glutamine     0.292 
Proteins 
Albumin 8.8±3.6 8.8 0.4 
IgG 2.6±2.4 2.6   
IgA 0.79±0.4     
Transferrin 1.50±1.2 1.5   
alpha globulins 1.03±0.5   0.3 
beta globulins 1.99±1.9   0.1 
Lipids 
PL 6.55 ± 3.9 6.6 - 
PC 4.84±2.22 4.8 - 
Cholesterol 0.11±0.04 0.1 - 
Antioxidants (μM) 
Ascorbate 137.1±75.5 140   
Urate 92.6±39.4 95   
GSH 171.4±111.7 170   
pH   7.2-7.4 7.4 
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The formulation of simulants, whilst different to BAL, were based upon measured 
RTLF concentrations, as detailed in Chapter 3, additionally referencing data obtained from 
the literature. Urea corrected total protein concentrations were determined to be 17.9±8.6 
mg/mL however only 12.9 mg/mL total protein could be used within the developed 
simulants (due to commercial unavailability of RTLF human protein components: SP-A, 
IgA, A1AT), approximately 15-fold greater than frequently used cell culture media 
supplemented with FBS (0.8 mg/mL total protein). The major protein, lipid and antioxidant 
constituents of the base model of simulant relative to RTLF and CCM 2%FBS are described 
in Table 6.3 above. 
 
Due to the inherent limitations of DLS sizing techniques in media with high protein 
content, significant background scattering occurs as a result of the formation of bimolecular 
protein agglomerates (Felipe et al., 2010). It should therefore be noted that the Z-average 
size is calculated using the intensity weighted distribution, and thus is shifted in the 
presence of light scattering non uniform solutions such as concentrated BAL and simulant. 
It can be more informative to focus on the intensity distribution graphs as opposed to the 
calculated Z-average values alone. Consequently as part of the characterization of the 
developed base models, intensity distribution profiles obtained using DLS were used also in 
conjunction with TEM imaging, to provide more accurate insights regarding the size and 
behaviour of simulant protein and lipid components. 
 
It should be noted that two “buffers” were used in simulant development, Hanks 
balanced salt solution) HBSS and 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethane sulfonic acid 
(HEPES).  HBSS, a commercially available chemically defined, balanced salt solution (see 
Appendix D for formulation and product no.) was chosen for physiologically relevance, 
however high salt concentrations interfered with TEM imaging and thus simulant prepared 
in both HBSS and the zwitterionic chemical buffer HEPES. DLS measurements shown 
below are representative of n=3 at t=0 h, however each sample was measured for 4 h with 
measurements taken automatically every 15 min. 
Despite the limitations in DLS, size based on intensity was able to provide a clear 
picture of the protein and lipid particle agglomeration in the fluids investigated. Interesting 
differences in the relative intensity profiles were observed across fluids investigated, 
concentrated BAL samples demonstrate a single highly intense peak at ~5000 nm (see 
Figure 6.2 E), representative of large protein and lipid aggregates, as confirmed by TEM 
(see Figure 6.2 F, see Appendix D for more images). In simulant containing proteins and 
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liposomes made of DPPC only, DLS measurements obtained revealed a predominant peak 
(according to both volume and intensity) between ~150-250 nm, representative of liposomes 
of corresponding size, as confirmed by TEM (see Figure 6.2 A and B). The DPPC 
liposomes manufactured appear to be broadly uniform across images obtained from simulant 
in HEPES (see Appendix D). A low intensity peak at ~30nm was indicative of the presence 
of non-agglomerated simulant-protein, with a second intensity peak observed at ~5000 nm 
representative of low levels of simulant protein agglomeration (see Figure 6.2 E and F). 
Within simulant in HBSS the high salt concentration appears to influence the formation of 
protein agglomerates, with the large peaks of ~5000nm at an almost 10X greater intensity 
compared to simulant manufactured in HEPES (see Appendix D). 
Previous investigations have focused solely upon DPPC as the representative 
surfactant component in simulated lung lining fluids, with DPPC responsible for 40-70% of 
phosphatidlycholines present in surfactant, in turn contributing to 80% of surfactant 
phospholipids. The analysis previously performed in this investigation (see Chapter 3) 
determined the RTLF concentration of PC. With physiological relevance a key objective in 
the design and development of simulants however, the other major lipid species of 
surfactant were also incorporated in base model simulant development. Of the lipids 
included in this second variation of simulant, Phosphatidylglycerol (PG) was chosen, the 
second most abundant component of surfactant after DPPC, reported to represent 
approximately 10% of total phospholipids and observed to increase the dynamic properties 
of surfactant alongside DPPC in vitro and cholesterol a neutral lipid, reported to account for 
up to 5-10% of surfactant (Yu et al., 1992; Holm et al., 1996; Karagiorga, 2006; Perez-gil et 
al., 1998; Perez-gil, 2006). Furthermore, cholesterol, known to have a stabilizing role in 
bilayer structures (such as the plasma membrane),  ‘filling in the gaps’, often included to 
increase the rigidity of bilayers improving liposome stability (Tseng, 2007), was 
incorporated into the developed simulants. Cholesterol concentrations used in the simulant 
were based upon measurements outlined in Chapter 3 and representative of 2.8 mol% 
phospholipid. 
Within this ‘second’ simulant developed using liposomes made of DPPC, PG with 
cholesterol in HEPES, DLS intensity profiles revealed low intensity peaks representative of 
lipid formations at ~2000-8000 nm (see Figure 6.2 C and D).  Peaks observed at ~10 nm 
and ~100 nm (of the greatest intensity) were attributed to the presence of non-agglomerated 
and agglomerated protein respectively. In HBSS the high salt concentration once again 
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influences the formation of protein agglomerates, with intensity peaks only observed 
at~100-200 nm (see Appendix D). 
 
 
Figure 6.2: Intensity distribution measurements and corresponding TEM images acquired for  
simulant variants and concentrated BAL fluids investigated. Representative DLS and TEM 
images of (A) and (B) simulant: Protein and DPPC in HEPES; (B) and (C) simulant: Protein 
and DPPC, PG, Cholesterol in HEPES; (D) and (E) Concentrated BAL, respectively. Individual 
distribution curves as measured by DLS are representative of at n = 3 at 37 °C at t=0 h, TEM 
images were acquired with an AMT 16000M camera using a FEI Tecnai 12 transmission 
microscope operated at 120 kV, Negative staining of liposomes with 2% PTA  pH 6.5 and  0.1%  
trehalosewas employed. 
 
6.3.2: Simulant- Particle interactions 
Commercially available polystyrene particles are well-defined with regards to their 
shape, size and chemical composition and have been investigated in a variety of studies 
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(Brown et al., 2001; Kato et al., 2003; Xia et al., 2007; Monopoli et al., 2011; Jones et al., 
2014). For these reasons, they were chosen as the reference nanoparticles to investigate the 
interaction of drug delivery like particles within simulant fluid, as part of a series of 
fundamental investigations into the applications of simulant. With the physicochemical 
properties particularly hydrophobicity, size and surface chemistry implicated to play a 
crucial role in both the behaviour and biocompatibility of nanoparticles (McNeil, 2009; Nel 
et al., 2009), the three model polystyrene nanoparticles chosen for this investigation into 
particle sizing in simulant were: unmodified 50 nm, 200 nm and carboxyl surface modified 
50 nm polystyrene particles. 
 The size of PS 50 nm increased two and five-fold to 90.9±1.4 nm and 250.5±157.0 
nm in HEPES and HBSS respectively, remaining stable over the 4 h time course 
investigated. Sizes based on intensity distribution as opposed to the hydrodynamic diameter 
calculated, have been used in the following discussion into particle behaviour in simulant 
and BAL solutions. In simulant (DPPC HEPES), peaks observed at 379.8±6.81 nm were the 
result of the formation of PS50 nm particle plus liposome interactions, see Figure 6.3.A 
and B. Low intensity peaks between 60-100 nm were confirmed by TEM to be the result of 
non aggregated particles and/or non agglomerated simulant protein. Within simulant (DPPC, 
PG, cholesterol in HEPES) investigated, TEM analysis (see Figure 6.3 C and D) similarly 
confirmed the presence of particle plus lipid interactions, responsible for peaks observed at 
151.27±31.41 nm. The presence of few but large particle, protein and lipid aggregate 
formations were also observed, with the presence of low intensity peaks between ~3000-
5000 nm. In concentrated BAL however, PS50 nm particles demonstrated a large degree of 
aggregation, the presence of particle plus protein and lipid aggregates, were seen between 
1056±87 nm and 4752±1840.1 nm. Particle aggregates however remained stable at sizes 
measured over the time course investigated. 
In contrast to PS50 nm particles, ps200nm particles investigated demonstrated only minor 
increases in diameter to 305.6±66.3 nm and 315.3±95.39 nm in HEPES and HBSS respectively, 
again remaining stable over the 4 h time course investigated. In simulant (DPPC HEPES), the 
intensity profiles obtained revealed few PS200 nm particles remained unassociated with simulant 
components- the lowest intensity peak was observed ~200 nm, see Figure 6.3 A and B. It should 
be noted that the DPPC liposomes themselves however were also of this size (150-200 nm) (Figure 
6.2 A and B). The most intense peak observed at 2104±1856.05 nm represents the formation of 
large agglomerates, the result of interactions between particles and lipid or protein, with few but 
larger aggregates observed around ~4000 nm (see Figure 6.4 A and B).  In contrast, the majority 
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of PS200 nm in simulant (DPPC, PG, Cholesterol HEPES) did not aggregate to the extent observed 
in simulant (DPPC), with the most intense peak observed at 363.55±62.5 nm, the result of low- 
 
 
Figure 6.3: The average intensity distribution measurements and  respective TEM images acquired 
for  50nm polystyrene particles in simulant variants and concentrated BAL fluids investigated. (A) 
and (B) simulant: Protein and DPPC in HEPES; (B) and (C) simulant: Protein and DPPC, PG, 
Cholesterol in HEPES; (D) and (E) Concentrated BAL, respectively. Individual distribution curves 
as measured by DLS are representative of at n = 3 at 37 °C at t=0 h, TEM images wereacquired 
with an AMT 16000M camera using a FEI Tecnai 12 transmission microscope operated at 120 kV, 
Negative staining of liposomes with 2% PTA  pH 6.5 and  0.1%  trehalosewas employed. 
 
levels of protein interaction on the surface of particles. Low intensity 4862±894 nm peaks observed 
were the result of the larger lipid formations within the simulant (DPPC, PG, cholesterol) 
formulation (see Figure 6.2 C and D). In concentrated BAL, TEM work confirms the presence of 
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particle plus protein and lipid aggregates, in accordance with peaks observed at 446.6±89 nm and 
988.35±395.48 nm. The third peak observed at 3022.0±387 nm was attributed to the protein lipid 
aggregates within BAL samples themselves. In general, PS200 nm particles demonstrated a much 






Figure 6.4: The average intensity distribution measurements and  respective TEM images 
acquired for  200nm polystyrene particles in simulant variants and concentrated BAL fluids 
investigated. (A) and (B) simulant: Protein and DPPC in HEPES; (B) and (C) simulant: Protein 
and DPPC, PG, Cholesterol in HEPES; (D) and (E) Concentrated BAL, respectively. Individual 
distribution curves as measured by DLS are representative of at n = 3 at 37 °C at t=0 h, TEM 
images wereacquired with an AMT 16000M camera using a FEI Tecnai 12 transmission 








PS50 nm carboxyl-modified particles demonstrated an increase in size to 73.28±6.97 
nm and 90.6±27.9 nm in HEPES and HBSS respectively. With respect to unmodified 50 nm 
particles, the carboxylate anion appeared to have an immediate stabilizing effect, preventing 
the aggregation observed in the non-functionalized particles which remained stable over the 
4 h time course investigated. In simulant (DPPC HEPES), peaks observed at 96.3±69.9 nm 
were the result of visible particle surface interactions with both proteins and lipids of 
simulant, see Figure 6.5 A and B. TEM and DLS analysis together also confirmed the 
presence of a peak of similar intensity at 2104±129 nm, due to the formation of larger such 
aggregates (see Appendix D). 
 
In the DPPC, PG, Cholesterol in HEPES simulant broad intensity peaks were 
observed between 84.4±14.0 and 282.15±96.8 nm. TEM images revealed the presence of 
fairly well dispersed particles, with minimal particle aggregation, see Figure 6.5 B and C. 
The negatively charged particles appear to interact with both protein and lipids in solution, 
resulting in the broad peak size measured. The lower intensity peaks observed at ~5000 nm 
were the result of few but large particle protein aggregates, as confirmed by TEM. In 
concentrated BAL, the carboxylated PS50 nm particles continued to demonstrate a relatively 
greater degree of interaction with protein and lipid components (compared to unmodified 
particles), TEM work confirmed the presence of particle plus protein and lipid aggregates of 
1043±218.8 nm. Aggregates appear well dispersed and remained stable over the time course 
investigated.  
Ultimately it appeared the carboxylated surface of PS50 nm particles limited the 
formation of larger particle-only aggregates in simulant versus non surface modified  
particles. The formation of the ‘dynamic’ corona at the surface interface of particles with 
biomolecules, such as proteins and lipids that are found within physiologically relevant 
systems, such as the simulants developed for this investigation, have been described in the 
literature for over ten years (Kendall et al., 2004; Nel et al., 2009; Braeckmans et al., 2010; 
Monopoli et al., 2011). The modification of particle surface, in this case through 
functionalization of carboxyl groups, appears to have altered the nature of these 
biomolecular surface interactions. Increased particle size (PS200 nm) has also resulted in 
clear changes in particle stability and behaviour within the physiologically relevant simulant 
solutions. DLS measurements were performed over a four h period to monitor any changes 
in these ‘dynamic interactions’ and thus the behaviour of nanoparticles over an extended 
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period of time. However particles either demonstrated immediate aggregation (in the case of 
PS50 nm particles) or stayed at the same or similar sizes for the four h period investigated 




Figure 6.5: The average intensity distribution measurements and respective TEM images acquired for  
50 nm carboxylated polystyrene particles in simulant variants and concentrated BAL fluids 
investigated. (A) and (B) simulant: Protein and DPPC in HEPES; (B) and (C) simulant: Protein and 
DPPC, PG, Cholesterol in HEPES; (D) and (E) Concentrated BAL, respectively. Individual 
distribution curves as measured by DLS are representative of at n = 3 at 37 °C at t=0 h, TEM images 
were acquired with an AMT 16000M camera using a FEI Tecnai 12 transmission microscope operated 





6.3.3: Simulant - Cell interactions 
The biocompatibility of the alveolar base simulant (HBSS) model developed was 
investigated using the A549 alveolar epithelial cell line in vitro, the MTT assay was used to 
assess mitochondrial activity and thus the proliferation of cells following simulant 
incubation over 2, 4 and 12 h periods respectively.  
For simulant (DPPC only), no significant differences in A549 cell proliferation were 
observed. The lowest % cell proliferation (compared to CCM FBS 2% only controls, in 
which cells were observed to proliferate ‘normally’) was calculated after the longest, 12 h, 
incubation with simulant DPPC. In which cell proliferation was observed to decrease by 
~30%, see Figure 6.7. However, no significant differences in cell proliferation were 
observed for either 4 and 12 h incubations (see Figure 6.7 A) At the shortest incubation 
time of 2 h, cell proliferation demonstrated no measurable difference in proliferation versus 
control cells incubated in CCM FBS 2%. 
Similarly for A549 cells incubated in the presence of simulant (DPPC, PG, 
cholesterol), the lowest % cell proliferation was determined after 12 h. Interestingly a 
concentration dependent trend was observed for cells incubated for this time point, with cell 
proliferation found to increase alongside increasing concentrations of the lipid and protein 
simulant components, see Figure 6.3. B. 
The biocompatibility of concentrated BAL samples with A549 cells monolayers was 
also assessed to complement simulant-investigations, with a statistically significant time 
dependent effect in % proliferation observed. Significantly lower mitochondrial viability 
was determined after 12 h versus both 2 and 4 h incubation periods (p=0.02).  Furthermore, 
a protein concentration dependent effect was observed across all time points, with % 
proliferation increasing alongside increasing protein and lipid concentration of BAL. 
After the 4 h incubation time point, cell proliferation was significantly decreased 
(p=0.02) versus the 2 h simulant incubation period, with no demonstrable change in 
mitochondrial viability calculated for 2 h long incubations 
No measurable detrimental effects on mitochondrial viability (as assessed by MTT) 
were determined for A549 cells incubated with base simulant models.  The data suggests 
that simulant and thus the physiologically relevant protein and liposome concentrations 
within simulant are compatible with A549 cell monolayers in vitro. In order to fully 
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Figure 6.6: The effect of concentrated BAL on the proliferation of A549 cell monolayers. 
The influence of BAL on cell proliferation was calculated as a percentage of the control 
(CCM FBS2%). The effect of simulant (at protein concentrations of 0.04, 0.07, 0.3, 0.4 
mg/mL protein respectively) was assessed over 2, 4 and 12 h periods of incubation with 
cells respectively. Cellular metabolic activity was measured spectrophotometrically at 570 




Morphometric analysis following a 4-h incubation of simulant (simulant DPPC) 
with A549 cells revealed no major differences versus controls (CCM FBS 2% treated), see 
Figure 6.5. The average cellular, nuclear and mitochondrial areas of A549 cells incubated 
with simulant versus control cells, demonstrated no significant differences, see Figure 6.9. 
212 
 
Figure 6.7: The effect of (A) simulant (Protein and DPPC) and (B) simulant (Protein and DPPC, PG, cholesterol) on the proliferation of A549 cell 
monolayers. The influence of simulant on cell proliferation was calculated as a percentage of the control (CCM FBS2%). The effect of simulant (at 
different protein concentrations of 1.1, 2.2, 4.3, 6.5, 8.7, 10.8 mg/mL respectively) was assessed over 2, 4 and 12 h periods of incubation with cells 
respectively. Cellular metabolic activity was measured spectrophotometrically at 570nm, data represents the mean±SD, , n = 3 experiments, four 








Figure 6.8: Morphology of A549 epithelial cells treated with or without simulated 
epithelial lining fluids  (simulant). TEM images are representative of (A), (C) and (E) 
A549 control cells incubated with CCM 2%, (B), (D) and (F) A549 cells incubated with 
simulant for 4 hs. Interactions of simulant with A549 cells are indicated with arrows, 
cellular organelles are also indicated: mitochondria (Mt), Lamellar bodies (LB), epithelial 
projections (Ep), Nuclei (Nu) and rough endoplasmic reticulum (RER), no differences in 
cellular morphology were observed between groups. Samples were examined on a FEI 
Tecnai 12 transmission microscope operated at 120 kV. Images were acquired with an 






Figure 6.9: Morphometric analysis of A549 epithelial ells following 4 h incubation with 
simulated epithelial lining fluids versus control. The overall morphologies of control 
versus simulant incubated cells were equivalent, the average cellular, nuclear and 
mitochondrial areas of A549 cells demonstrated no significant differences. Data 
calculated represent the mean ± sd of n=10 images.  
 
Furthermore, no differences in the presence of other morphological cell features 
(lamellar bodies, and epithelial projections) characteristic of A549 cells were observed 
between treated and non-treated cells see Figure 6.8. No signs of cellular distress (nuclear 
condensation or evidence of crescent shaped condensed chromatin) were noted upon visual 
inspection either. However TEM analysis of simulant treated cells revealed what appeared 
to be the internalization of DPPC liposomes in the majority of cells examined. Figure 6.10 
highlights the presence of these inclusions following simulant incubation. Membrane 
bound liposome containing vacuoles were particularly prominent at the apical surface of 
the plasma membrane. Additionally, the epithelial microvilli like projections characteristic 
of A549 cells, appear to have interacted with lipid or protein components following 
simulant incubation, see Figure 6.10 It should be noted however that these may also be 
potential artefacts attributed to the fixing process prior to TEM imaging (note: cell area 





Figure 6.10: Morphology of A549 epithelial cells treated with simulated epithelial lining 
fluids (simulant).TEM images are representative of A549 cells incubated with simulant for 
4 hs, the presence of phospholipid inclusions and lipid interactions on the cell surface are 
indicated with arrows. Samples were examined on a FEI Tecnai 12 transmission 





The first steps in the design of a simulated epithelial lining fluid as a 
physiologically relevant base model for the investigation of inhaled materials in vitro were 
performed in this investigation.  
In the objectives outlined for the development of the base model, the major 
protein, lipid and low molecular weight components representative of healthy alveolar 
RTLFs were incorporated into the simulant. Components within the base model were 
commercially available: Synthetic antioxidants (Sigma Chemical Company Ltd. Poole, 
U.K.) and phospholipids were purchased from Avanti lipids, lyophilized human proteins: 
albumin, transferrin and Immunoglobulin G were all obtained from Sigma Aldrich, and 
sourced from human serum. The inclusion of other RTLF human protein components such 
as SP-A however proved impractical, their inclusion in previous studies either the result of 
extraction and isolation from human alveolar proteinosis patients (Ruge et al., 2012) or 
recombinant forms, expressed in SF21 cells, the cDNA of SP-A contained in the plasmids 
pMTE HS10/5 and pMTE HS10/4 subcloned into the EcoRI site of the baculovirus 
expression vector pVL1393Th (Sanchez-Barbero et al., 2007). Furthermore the 
biocompatibility requirements and need to incorporate simulants into existing in vitro 
studies has resulted in the use of two buffering systems: HBSS and HEPES, one a 
physiologically balanced salt solution, microbiologically tested, containing glucose was 
deemed necessary for in vitro cell culture investigations, whereas the zwitterionic chemical 
buffer, HEPES was considered most suitable for TEM and DLS analysis. 
 
Using the successfully developed base alveolar model in a series of preliminary 
investigations it’s suitability for the biopharmaceutical screening of inhaled particles in the 
fundamental applications of particle and cellular interactions were assessed for the first 
time. 
6.4.1: Particle behaviour in simulant 
Dynamic light scattering has become the most established method to obtain 
particle sizing data as part of the physiocochemical characterisation of particles in solution. 
DLS determines the Z-average by calculating the intensity weighted distribution or the 
intensity weighted harmonic mean size (by the method of cumulants), and has become the 
standard way in which to present DLS sizing data. However the suitability of this 
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technique in obtaining sizing data from particles within biological fluids has been 
questioned. Biologically relevant solutions generally already consist of particles, in the 
case of simulant, in the form of its protein and lipid components. It is the presence of such 
particles in solution which results in background light scattering that influence the 
calculation of the Z-average value (Braeckmans et al., 2010; van Gaal et al., 2010). The 
difficulty in assigning peak intensity profiles obtained from DLS in non ‘simple’ media as 
the developed simulants, necessitated the use of TEM methodology in conjunction with 
this sizing technique. Whilst TEM provides limited statistical power, and the preparation 
and fixation of cells for microscopy has the potential to result in morphological changes, 
the use of TEM provided a clearer insight into the previously unreported behaviour of 
particles within physiologically relevant lung simulants. 
 
A study by van Gaal et al (2010) attempted to resolve the significant background 
scattering observed in particle sizing within biological solutions (CCM supplemented with 
FBS) by labelling and subsequently measuring particle fluorescence intensity, in an 
attempt to subtract ‘background noise’, distinguishing the particles of interest from 
background signals of equivalent intensity. Whilst this has the additional complication of 
changing the nature of the particles surface, it may also simply not be relevant for use in 
biological solutions including the developed simulants, where as observed in this 
investigation the interaction of particles with protein and lipid components of simulant did 
not result in the formation of a simple corona at the particle surface, but in its place, large 
agglomerates of particle, protein and lipid composition.  
The formation of the biomolecular corona at the surface of particles in biological 
fluids has been heavily investigated in the literature, with particle-plasma interactions in 
particular the focus of recent work (Kobzik et al., 1990; Bihari et al., 2008; Nel et al., 
2009; Braeckmans et al., 2010; Doshi and Mitragotri, 2010; Monopoli et al., 2011).  
However, whilst the influence of inhaled particle opsonisation on the receptor mediated 
endocytosis of particles in cells has been demonstrated in vivo and in vitro, no previous 
studies have investigated this in physiologically-relevant lung lining fluids until now. The 
significant levels of particle agglomeration and the high degree of interaction observed 
between simulant components are likely to have a greater impact than simple protein 
opsinization on the final particle size ‘seen’ by cells, and thus ultimately the bioavailability 
and potential toxicity of these particles (Brown et al., 1997; Furumoto et al., 2001; 
Oberdorster et al., 2005; Chithrani et al., 2006; Kanno et al., 2007; Powers et al., 2007; 
Muhlfeld et al., 2008; Doshi and Mitragotri, 2010). 
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Nanoparticle uptake mechanisms exhibit clear size dependence (Doshi and 
Mitragotri, 2010). For particles less than 200 nm clathrin-dependent and caveolae-
mediated modes of endocytosis are thought to dominate, clathrin-dependent endocytosis 
have a reported maximum uptake size of 200 nm, attributed to the size limit of endocytotic 
compartments within cells (Zauner et al., 2001; Rejman et al., 2004). Pinocytotic 
mechanisms are believed to play an important role in the uptake of smaller nanoparticles, 
limited to less than 100 nm since this cellular mechanism is responsible for the uptake of 
soluble material (Rejman et al., 2004; Nel et al., 2009).  Phagocytic mediated uptake by 
macrophages has also demonstrated size dependence, preferentially internalizing particle 
sizes greater that 500 nm (Nel et al., 2009). 
The physicochemical aspects of size and surface charge were targeted in this study, 
with both properties highly implicated in influencing the formation of the macromolecular 
corona at the surface of particles (Braeckmans et al., 2010; Monopoli et al., 2011). It is 
well established that particle size determines the surface area of particles and thus the area 
available for interaction with proteins or lipids in solution, the reduced uptake of 200 nm 
polystyrene versus 50 nm polystyrene particles by the human hepatocyte cell lines (C3A 
and HepG2) has been reported and attributed to the reduced surface area available for 
adsorption of biological components (Renwick et al. 2001; Borm et al. 2006; Choi et al. 
2007; Nel et al., 2009; Johnston et al., 2010). The surface charge of particles is also 
believed to play a significant role in determining the degree of surface interactions with the 
components of biological solutions and cells, particularly charged phospholipid heads or 
protein domains. For example changing the surface charge of gold nanorods was shown to 
dramatically modify the nature of the biomolecular surface of gold nanorods decreasing 
their uptake into cells (Gratton et al., 2008; Nel et al., 2009). In contrast the carboxylated 
negatively charged surface of polystyrene particles, has previously been reported to 
enhance cellular uptake as a consequence of improved dispersion of negative charged 
particles, a lower extent of aggregation and thus smaller size for uptake (Johnston et al., 
2010) 
The interaction between protein and lipid components of simulant and the 
formation of large agglomerates across all particle sizes investigated, and whilst 
differences attributed to surface charge in particular were apparent, future work must focus 
on the impact of particle incubation within the physiologically-relevant simulant solutions 
in order to establish how these interactions may then influence underlying cellular uptake 
mechanisms which ultimately determine the fate of these inhaled particles. 
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Whilst simulants and reference RTLFs (concentrated BAL solutions) revealed 
similar levels of particle agglomeration and protein/lipid interactivity (particularly evident 
when compared to sizing perfomed in HBSS, HEPES and CCM FBS 2%), differences 
were observed in sizing perfomed within concentrated BAL, with larger agglomerates of 
<5000 nm observed. This could be attributed to the presence of surfactant proteins within 
BAL samples, absent within the developed simulants. The role of both hydrophilic 
surfactant proteins A and D in influencing the bimolecular nature at the surface of inhaled 
nanoparticulates, promoting the interaction of particles with macrophages and particle 
agglomeration has previously been reported (Wright, 2005; Ruge et al., 2012). Surfactant 
protein A, the most abundant of the surfactant proteins possesses a quaternary structure 
consisting of a ‘hexamer of trimers’, each of which possess a globular head containing a 
carbohydrate-recognition domain (CRD domain) (Casals, 2001; Hawgood and Poulain, 
2001; Haagsman, 2002; Heinrich et al., 2006). It is these CRD domains that enable the 
association of SP-A with pulmonary surfactant lipid membranes (Palaniyar et al., 1998; 
Palaniyar et al., 2001). SP-A has been observed to both promote and maintain the 
aggregation of surfactant (Ruano et al., 1996; Veldhuizen et al., 1996; Worthman et al., 
2000; Sanchez-Barbero et al., 2005), in vitro investigations have revealed SP-A induced 
aggregation of lipids occurs in a Ca2+ dependent manner and is observed at physiological 
Ca2+ concentrations (Ruano et al., 1996; Ruano et al., 2000; Casals, 2001). This SP-A 
dependent phospholipid aggregation is dependent on the intact CRD domain, it has been 
proposed that through these domains SP-A is able to recognise ordered lipid patterns, in 
both a hydrophobic and polar manner (Casals, 2001; Palaniyar et al., 2001), which may in 
turn be responsible for the lattice architecture of TM in vivo.  
 
6.4.2: Biocompatibility of simulant 
The A549 cells used as part of the vitro assessment of the biocompatibility of the 
healthy alveolar base model are representative of type II alveolar epithelial cells, 
originating from a lung carcinoma (PubMed 4357758), they have been used extensively 
since their initiation by D.J. Giard et al (1972). The A549 cell line has most often been 
used to assess the toxicity of inhaled materials alongside standard cellular metabolic assays 
including the MTT assay as performed in this study (Wilson et al., 2000; Kawasaki et al., 
2001; Laan et al., 2004; Forbes and Ehrhardt, 2005).  
This investigation revealed no adverse impact of the physiologically relevant 
protein and liposome concentrations within simulant on the proliferation of A549 cell 
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monolayers. The observations obtained were somewhat unexpected with in vitro models 
described to possess a higher susceptibility to toxicity than in vivo, for example the 
toxicity of plasma on vascular endothelial cells in vitro is well established despite this 
being the physiologically occurring interface in vivo, the toxicity observed has been 
attributed to various physiological limitations including the absence of innate defence 
mechanisms (Kleberg et al., 2010). The compatibility of simulated intestinal fluid (SIF) 
with in vitro cell models have similarly been investigated, both fasted, FaSSIF and fed, 
FeSSIF, formulations have been assessed on the apical surface of the intestinal Caco-2 cell 
line in vitro (Kataoka et al., 2006; Patel et al., 2006). With the Caco-2 cell line widely used 
in studies of oral drug permeability, the incorporation and tissue compatibility of 
biorelevant SIFs with cellular models, as with this investigation, were viewed as a step 
forward in improving the predictability of these in vitro assays, to avoid the over or under 
estimation of drug solubility or permeability (Kleberg et al., 2010; Marques et al., 2011). 
Ingels et al (2002) reported the high toxicity of FeSSiF on Caco-2 cells, the conversion of 
MTT was even reduced in the mitochondria of cells and the absorbance of the purple 
formazan extremely low following FeSSIF incubation. The high toxicity of this SIF 
formulation has also been observed to result in the collapse of transepithelial resistance in 
monolayers (Patel, et al. 2006). However, Caco-2 cells demonstrated increased viability 
following incubation with a modified formulation of this simulant, with the observed 
toxicity of FeSSIF determined to be the combination of high concentrations of sodium 
tacrocholate (15 mM), low pH of 5.0 and high osmalilty (Ingels et al., 2002; Lind et al., 
2007). Furthermore, cells treated with FASSIF, have demonstrated normal cell viability 
using the MTT assay, with no significant differences observed for this formulation, in fact 
incorporating FASSIF into the Caco-2 model was used to successfully determine the in 
vitro-in vivo correlation (IVIVC) of six oral solid drug formulations (Buch et al., 2009; 
Kleberg, 2010). The modification of simulants to enable tissue compatibility whilst 
remaining biorelevant is necessary, accordingly this investigation tried to ensure the 
compatibility of developed simulants, and achieved it by incorporating HBSS with 
physiologically relevant pH and electrolytes and glucose concentrations. 
Although previous investigations with SIFs, suggest the relative concentrations and 
interactions of individual components within the simulant may influence biocompatibility, 
the different lipid compositions investigated revealed no quantifiable differences in 
biocompatibility versus CCM controls. It was only the concentrated BAL preparations, 
which lack glucose, prepared in 150 mM saline solution that proved incapable of 
maintaining A549 cell viability. Whilst the vacuolisation of phospholipid liposomes was 
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observed within A549 cells, this did not appear to influence cell viability. Type II cells 
possess well characterized endocytic properties with the endocytosis of various particles; 
nanoparticles (50 nm TiO2) cationic liposomes, previously reported (Ito et al., 1992; Ryan 
et al., 1994; Friend et al., 1996; Foster et al., 1998; Stearns et al 2001). Type II cells 
additionally play a role in the ‘recycling’ of surfactant components, which may in turn 
explain the endocytosis of liposomes observed following simulant incubation. It has been 
proposed that the cleared surfactant lipids either end up in lamellar bodies or are degraded 
to then be reused in the synthesis of new surfactant lipids (Wright et al., 1984; Wright, 
1990). 
As has already been achieved with SIF formulations, the incorporation of 
physiologically relevant yet biocompatible media, such as the simulant developed in this 
investigation, must be the gold standard reached for the in vitro cellular studies 
investigating the behaviour of inhaled drugs and particles. Ultimately this must be attained 
if we are to develop a better understanding of the interaction of inhaled materials and will 




In conclusion, this thesis describes the first steps in the development of a 
standardised epithelial lining fluid simulant from which the following conclusions were 
reached : 
 
1. Particle sizing with DLS alongside TEM revealed the interaction of particles 
investigated with both the protein and lipid components of developed simulants. The 
large agglomerates observed may provide a more realistic reflection of the in vivo 
situation following particle deposition, and thus may be significant in evolving our 
interpretation and understanding of inhaled particle bioavailability and toxicity. 
 
2. Broad biocompatibility of the base alveolar simulant was established across 
commonly used in vitro cell line representative of the alveolar airways, at time points 






Future and ongoing studies 
 
The extensive characterization of healthy human RTLFs as described in Chapter 
3, was the foundation behind the design of the base simulant model, representing the major 
protein, lipid and antioxidant components of this extracellular compartment, the results 
described here in Chapter 6 detailing the first few steps undertaken in assessing the 
applicability of the base model, as illustrated in Figure 6.11 below. 
Figure 6.11: Requirements for the development of a validated, disease and region specific 
lung lining fluid simulant. 
 
However whilst one of the strengths of the developed model is its physiological 
relevance, the implementation of a primary base model also created several practical 
limitations, these were resolved by the decision to focus the design of simulant, in this 
initial phase of its development, on the alveolar RTLFs alone.  The assessment of the 
biocompatibility of this model was thus focused on the human alveolar epithelial A549 
cell line, however future work must incorporate the characterization of different regions of 
the airways, the composition of which has already been examined and outlined within this 
thesis (Chapters 3, 4 and 5). Not only is the development of ‘bespoke’ regionally specific 
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models: bronchial or nasal RTLF simulants, an important next step, these regionally 
specific simulants must also be evaluated for their compatibility with the most relevant cell 
lines employed in vitro. This is a crucial step in fully integrating simulants with models 
used in screens for drug dissolution-absorption, biocompatibility and particle uptake. In 
addition to investigations determining cell proliferation (such as the MTT assay employed 
within this thesis) more refined markers of cellular dysfunction from cytokine and 
chemokine release, cell metabolism to tight junction formation must be employed in the 
assessment of simulant compatibility.  It must be highlighted that one of the critical 
limitations of the A549 cell line is it’s unsuitability for use in drug absorption and 
permeability assays, on account of the lack of tight junction formation and their inherent 
leakiness (Elbert et al., 1999; Kim et al., 2001). Thus more relevant barrier forming cell 
lines including the Calu-3, 16HBE14o- or primary cells may be more relevant in 
determining simulant integration into commonly used in vitro models for drug 
development. Future work must also refine models in order to effectively reflect diseased 
(asthma and COPD) and aged RTLFs, with the current base model only representative of 
the healthy young airways, not only are these key user groups of inhaled medicines, but as 
established throughout Chapters 3, 4 and 5 the composition of this extracellular 
compartment is significantly altered in these conditions. Whether suitable in vitro cell lines 
are currently available for which modified simulants can then be incorporated may 
however be an important limitation in exploring this next step.  
Whilst in vitro cell culture models have proven useful in the study of drug 
absorption and transport, the integration of region and disease specific simulants with the 
currently available in vitro cell models would ultimately provide the greatest relevance to 
the in vivo situation. If integrated cell culture models are developed in the future they 
would not only permit for the rapid screening, establishing the pharmacokinetics and 
pharmacodynamic effects of inhaled particulates, but become an essential part of 
mechanistic investigations concerning drug permeability and metabolism. The 
incorporation of simulants in in vitro dissolution tests which are are often used to guide the 
early development of drugs and their formulation, as well as to ensure quality assurance 
(QA) and IVIVC of drugs (Davies, 2003; Agu, 2011), as well as to predict the 
solubilization process of inhaled formulations  (Wiedmann, 2000; Pham and Wiedmann, 
2001) is another key point for future studies to address, with no current standardized 
method available for the evaluation of dissolution of inhaled drugs. 
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In addition to these future pharmaceutical challenges that must be explored 
throughout the continued development of lung lining fluid simulants, the integration of 
physiologically relevant simulants within the various toxicity screening methods used for 
inhaled environmental particulates will also be an important next step. Ultimately the 
impact the pre-incubation of particulate formulations within the developed simulant 
models and their subsequent uptake into pulmonary cells, i.e.  ‘the particle –cell 
interaction’ must be established. Studies evaluating the incubation of nanoparticles within 
the developed base models (and concentrated human BAL samples as a reference) are 
currently underway. The aim of these experiments is to explore the nature of the 
macromolecular ‘corona’ that forms on the surface of nanoparticles following their 
deposition in the RTLFs. Since it is this corona that ultimately represents the biological 
identity of particles, only by understanding the nature of this interaction can we begin to 
elucidate just how this biomolecular interface influences the cellular interactions of 
particles in vitro and in vivo. 200nm SiO2 and polyvinyl acetate (PVA) particles (particles 
of varying degrees of hydrophobicity) have been chosen for this investigation. Focusing 
on, the proteomic identity and thus the nature of the ‘protein corona’ formed, the number 
and classification of proteins bound to the surface of particles is being evaluated using a 
semi-quantitive nanoLC-MS/MS approach, as previously explored in this thesis. No 
previous studies have investigated the nature of this interaction using a physiologically 
relevant model, however as highlighted earlier in this chapter, TEM imaging obtained 
following particle incubation within the base model has already demonstrated the 
interaction between protein and lipid components of simulant. The data obtained will be 
the first to elucidate the protein corona profile of particles within RTLF models. 
Whatever the next steps are in the continuing development of the lung lining fluid 
simulant, more detailed and informative measures regarding the compatibility of simulated 
lung lining fluids with the many various assays in use must be considered. Whether it is 
the incorporation of components such as growth factors, which may become necessary if 
primary cells are in use, or if lipid analysis is an important component of the assay in 
question, surfactant proteins may be a necessary addition. What exact refinements are 
necessary will ultimately depend on the experimental objective in question. 
However future studies must ultimately provide greater insight into the ‘real 
world’ applicability of the developed simulants in order for them become successfully and 
easily incorporated into in vitro investigations guiding and improving the drug 
development process of inhaled medicines.  The development of a standardised simulant 
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model must consider the requirements of pharmacopoeial or ISO standards, information 
regarding appearance, sterility and endotoxin content, purity, buffer capacity, ionic 
strength, osmolality and viscosity must be accounted for, with defined limits and 
acceptance criteria based on an observed range of variation. However in physiological 
solutions such as simulant practical considerations must also include colloidal stability and 
aggregation, criteria must account for the acceptable limits for liposome size distribution 
and a validated sizing method (DLS, TEM), to assure a consistent particle distribution. 
This study investigated both the reproducibility of manufactured simulants and the 
stability of formulations with TEM and DLS techniques in order to fulfill the criteria 
described above. Simulants were stored at 4° C, and stability assessed over 3 and 6 month 
periods. How this influences the physicochemical interactions of simulants with particles 
or cells must however be established in more detail if they are to incorporated in 
standardised in vitro testing of inhaled drugs in future studies. Furthermore, volume, 
temperature and pH requirements for individual assay purposes must also be tailored to 
physiological features of the airways as well as the practical limits of the test apparatus. As 
of yet the preliminary investigations performed have utilised the physiological temperature 
of 37OC at volumes suited to cell culture and particle sizing requirements. But with a wide 
range of inhaled and nasal pharmaceutical products, flexibility in testing methodology will 
be required. These criteria must be an important component of future work in the 

















Figure A.1: The bronchial versus alveolar airway RTLF protein components in healthy 
controls: Transferrin, Lysozyme, Alpha-1 Antitrypsin, SP-A, IgG, IgM, IgA and Albumin. 






Figure A.2: The bronchial versus alveolar airway RTLF protein components in mild 
asthmatics: Transferrin, Lysozyme, Alpha-1 Antitrypsin, SP-A, IgG, IgM, IgA and 
Albumin, in mild asthmatic. Mild asthmatics n=16, 26.7±6.2 years, 5M/11F. * denotes a 


























































































































Figure A.3: Correlation of proteins of innate immunity ( IgA, Alpha-1 Antitrypsin, 
Transferrin) and LTA concentrations in asthmatic Bronchial Wash . Mild asthmatics 
n=16, 26.7±6.2 years, 5M/11F. * denotes a statistical difference where p<0.05. 
 
Table A.1: All alveolar proteins identified by 1D PAGE and nano LC MS/MS in healthy 
control RTLFs. The 199 proteins identified in healthy control subjects investigated, (n=5), 
alongside the mean of the three most abundant ion peaks of each respective protein 
identified. Accession numbers included according to entries in UniProtKB/Swiss-Prot.  
 
Healthy Control 
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 1.28E+10 
Ig gamma-1 chain C region; [Homo sapiens (Human)] - [IGHG1_HUMAN] 1.23E+10 
Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=1 SV=2 9.36E+09 
Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2 9.10E+09 
Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 9.10E+09 
Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 5.90E+09 
Uncharacterized protein C3orf38; [Homo sapiens (Human)] - 
[CC038_HUMAN] 
4.10E+09 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 3.97E+09 
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Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 SV=1 3.07E+09 
Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 2.81E+09 
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 2.69E+09 
Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 2.05E+09 
Immunoglobulin lambda-like polypeptide 5; AltName: Full=G lambda-1; 
AltName: Full=Germline immunoglobulin lambda 1; Flags: Precursor; [Homo 
sapiens (Human)] - [IGLL5_HUMAN] 
1.96E+09 
Ig heavy chain V-III region HIL; [Homo sapiens (Human)] - 
[HV310_HUMAN] 
1.66E+09 
Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 1.38E+09 
Rho GDP-dissociation inhibitor 2 OS=Homo sapiens GN=ARHGDIB PE=1 
SV=3 
1.36E+09 
Ig heavy chain V-III region VH26 OS=Homo sapiens PE=1 SV=1 1.25E+09 
Ig heavy chain V-III region CAM OS=Homo sapiens PE=1 SV=1 1.22E+09 
Ig heavy chain V-III region BRO; [Homo sapiens (Human)] - 
[HV305_HUMAN] 
1.19E+09 
Ig heavy chain V-III region TUR; [Homo sapiens (Human)] - 
[HV318_HUMAN] 
1.18E+09 
Ig heavy chain V-III region GAL OS=Homo sapiens PE=1 SV=1 1.17E+09 
Ig heavy chain V-III region BUT OS=Homo sapiens PE=1 SV=1 1.16E+09 
Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 1.10E+09 
Probable E3 ubiquitin-protein ligase HERC6; EC=6.3.2.-; AltName: 
Full=HECT domain and RCC1-like domain-containing protein 6; [Homo 
sapiens (Human)] - [HERC6_HUMAN] 
8.68E+08 
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 7.70E+08 
Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=1 SV=1 6.27E+08 
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 5.37E+08 
Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 
SV=4 
5.24E+08 
Ig kappa chain V-I region Wes; [Homo sapiens (Human)] - 
[KV119_HUMAN] 
5.03E+08 
Ig kappa chain V-I region DEE OS=Homo sapiens PE=1 SV=1 4.84E+08 





Ig lambda chain V-IV region Bau; [Homo sapiens (Human)] - 
[LV401_HUMAN] 
4.40E+08 
Ig kappa chain V-I region EU OS=Homo sapiens PE=1 SV=1 4.22E+08 
Xin actin-binding repeat-containing protein 2 OS=Homo sapiens GN=XIRP2 
PE=1 SV=2 
4.22E+08 
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 3.82E+08 
Ig kappa chain V-III region VG; Flags: Precursor; Fragment; [Homo sapiens 
(Human)] - [KV309_HUMAN] 
3.81E+08 
Ig kappa chain V-III region SIE OS=Homo sapiens PE=1 SV=1 3.17E+08 
Ig kappa chain V-III region POM OS=Homo sapiens PE=1 SV=1 3.13E+08 
Ig kappa chain V-II region GM607; Flags: Precursor; Fragment; [Homo 
sapiens (Human)] - [KV205_HUMAN] 
2.91E+08 
Ig lambda chain V-IV region Hil; [Homo sapiens (Human)] - 
[LV403_HUMAN] 
2.91E+08 
Ig heavy chain V-III region GAR; [Homo sapiens (Human)] - 
[HV322_HUMAN] 
2.84E+08 
Ig lambda chain V-III region LOI OS=Homo sapiens PE=1 SV=1 2.61E+08 
Ig kappa chain V-I region Scw; [Homo sapiens (Human)] - 
[KV117_HUMAN] 
2.48E+08 
Caspase recruitment domain-containing protein 6; [Homo sapiens (Human)] - 
[CARD6_HUMAN] 
2.40E+08 
Ig kappa chain V-III region Ti; [Homo sapiens (Human)] - [KV304_HUMAN] 2.35E+08 
Putative V-set and immunoglobulin domain-containing protein 6 OS=Homo 
sapiens GN=VSIG6 PE=5 SV=2 
2.22E+08 
FAS-associated factor 1; Short=hFAF1; AltName: Full=UBX domain-
containing protein 12; AltName: Full=UBX domain-containing protein 3A; 
[Homo sapiens (Human)] - [FAF1_HUMAN] 
2.21E+08 
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 2.19E+08 
Ig lambda chain V-I region HA OS=Homo sapiens PE=1 SV=1 2.17E+08 
Ig heavy chain V-I region HG3; Flags: Precursor; [Homo sapiens (Human)] - 
[HV102_HUMAN] 
2.14E+08 
Hemoglobin subunit alpha; AltName: Full=Alpha-globin; AltName: 
Full=Hemoglobin alpha chain; [Homo sapiens (Human)] - [HBA_HUMAN] 
2.06E+08 
Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 2.06E+08 
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 2.04E+08 
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Ig kappa chain V-I region Roy; [Homo sapiens (Human)] - 
[KV116_HUMAN] 
1.96E+08 
Pulmonary surfactant-associated protein A2 OS=Homo sapiens GN=SFTPA2 
PE=1 SV=1 
1.95E+08 
Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2 1.81E+08 
Ig kappa chain V-III region NG9; Flags: Precursor; Fragment; [Homo sapiens 
(Human)] - [KV303_HUMAN] 
1.74E+08 
Hemoglobin subunit delta OS=Homo sapiens GN=HBD PE=1 SV=2 1.66E+08 
Ig kappa chain V-IV region Len OS=Homo sapiens PE=1 SV=2 1.66E+08 
Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 1.60E+08 
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 1.49E+08 
Ribonuclease P protein subunit p40; Short=RNaseP protein p40; EC=3.1.26.5; 
AltName: Full=RNase P subunit 1; [Homo sapiens (Human)] - 
[RPP40_HUMAN] 
1.42E+08 
Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein; 
Short=P-Rex1; Short=PtdIns(3,4,5)-dependent Rac exchanger 1; [Homo 
sapiens (Human)] - [PREX1_HUMAN] 
1.41E+08 
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 1.36E+08 
Ig lambda chain V-I region WAH OS=Homo sapiens PE=1 SV=1 1.26E+08 
cGMP-specific 3',5'-cyclic phosphodiesterase; EC=3.1.4.35; AltName: 
Full=cGMP-binding cGMP-specific phosphodiesterase; Short=CGB-PDE; 
[Homo sapiens (Human)] - [PDE5A_HUMAN] 
1.22E+08 
Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 1.20E+08 
Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 1.16E+08 
Ig kappa chain V-I region Ni; [Homo sapiens (Human)] - [KV121_HUMAN] 1.15E+08 
Ig heavy chain V-II region NEWM; [Homo sapiens (Human)] - 
[HV207_HUMAN] 
1.14E+08 
LIM domain only protein 7; Short=LMO-7; AltName: Full=F-box only 
protein 20; AltName: Full=LOMP; [Homo sapiens (Human)] - 
[LMO7_HUMAN] 
1.14E+08 
Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 1.12E+08 
14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 1.07E+08 
14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 1.07E+08 
14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 1.07E+08 
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Ig lambda chain V region 4A OS=Homo sapiens PE=4 SV=1 1.06E+08 
Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 9.61E+07 
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 9.59E+07 
Protein S100-A6 OS=Homo sapiens GN=S100A6 PE=1 SV=1 9.49E+07 
Ig kappa chain V-IV region JI; Flags: Precursor; [Homo sapiens (Human)] - 
[KV403_HUMAN] 
9.06E+07 
14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 9.02E+07 
Protein Shroom3; AltName: Full=Shroom-related protein; Short=hShrmL; 
[Homo sapiens (Human)] - [SHRM3_HUMAN] 
8.34E+07 
Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 8.29E+07 
Histone-lysine N-methyltransferase MLL3 OS=Homo sapiens GN=MLL3 
PE=1 SV=3 
7.98E+07 
Pre-mRNA cleavage complex 2 protein Pcf11; AltName: Full=Pre-mRNA 
cleavage complex II protein Pcf11; [Homo sapiens (Human)] - 
[PCF11_HUMAN] 
7.88E+07 
CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=3 7.78E+07 
Ig heavy chain V-II region ARH-77 OS=Homo sapiens PE=4 SV=1 7.57E+07 
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 7.52E+07 
Ig lambda chain V-I region NIG-64 OS=Homo sapiens PE=1 SV=1 6.96E+07 
ATP-binding cassette sub-family C member 8; AltName: Full=Sulfonylurea 
receptor 1; [Homo sapiens (Human)] - [ABCC8_HUMAN] 
6.85E+07 
Coiled-coil domain-containing protein 37; [Homo sapiens (Human)] - 
[CCD37_HUMAN] 
6.84E+07 
Ig heavy chain V-II region OU; [Homo sapiens (Human)] - 
[HV201_HUMAN] 
6.80E+07 
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 6.75E+07 
Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 6.60E+07 
Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 6.47E+07 
Ig heavy chain V-I region V35 OS=Homo sapiens PE=1 SV=1 6.05E+07 
Glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 2; 
EC=2.6.1.16; AltName: Full=D-fructose-6-phosphate amidotransferase 2; 
AltName: Full=Glutamine:fructose 6 phosphate amidotransferase 2; 
Short=GFAT 2; Short=GFAT2; AltName: Full=Hexosephosphate 




Glutathione S-transferase A2 OS=Homo sapiens GN=GSTA2 PE=1 SV=4 5.83E+07 
Beta-microseminoprotein; AltName: Full=Immunoglobulin-binding factor; 
Short=IGBF; AltName: Full=PN44; AltName: Full=Prostate secreted seminal 
plasma protein; AltName: Full=Prostate secretory protein of 94 amino acids; 
Short=PSP-94; Short=PSP94; AltName: Full=Seminal plasma beta-inhibin; 
Flags: Precursor; [Homo sapiens (Human)] - [MSMB_HUMAN] 
5.82E+07 
Deleted in malignant brain tumors 1 protein OS=Homo sapiens GN=DMBT1 
PE=1 SV=2 
5.59E+07 
Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 5.55E+07 
Epididymal secretory protein E1 OS=Homo sapiens GN=NPC2 PE=1 SV=1 5.26E+07 
Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 PE=1 
SV=1 
5.17E+07 
28S ribosomal protein S26, mitochondrial; Short=MRP-S26; Short=S26mt; 
AltName: Full=28S ribosomal protein S13, mitochondrial; Short=MRP-S13; 
Short=S13mt; Flags: Precursor; [Homo sapiens (Human)] - [RT26_HUMAN] 
4.89E+07 
Transmembrane protein 198; [Homo sapiens (Human)] - [TM198_HUMAN] 4.77E+07 
Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 4.75E+07 
Pulmonary surfactant-associated protein D OS=Homo sapiens GN=SFTPD 
PE=1 SV=3 
4.71E+07 
G antigen family D member 2; AltName: Full=Cancer/testis antigen 12.1; 
Short=CT12.1; AltName: Full=Protein XAGE-1; [Homo sapiens (Human)] - 
[GAGD2_HUMAN] 
4.41E+07 
Intercellular adhesion molecule 1 OS=Homo sapiens GN=ICAM1 PE=1 SV=2 4.01E+07 
Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 3.98E+07 
Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 3.83E+07 
Calmodulin OS=Homo sapiens GN=CALM1 PE=1 SV=2 3.58E+07 
Coactosin-like protein OS=Homo sapiens GN=COTL1 PE=1 SV=3 3.46E+07 
Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 3.42E+07 
Serpin B3 OS=Homo sapiens GN=SERPINB3 PE=1 SV=2 3.01E+07 
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 2.92E+07 
Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1 2.86E+07 
Ig lambda chain V-III region SH; [Homo sapiens (Human)] - 
[LV301_HUMAN] 
2.83E+07 
Pro-cathepsin H OS=Homo sapiens GN=CTSH PE=1 SV=4 2.79E+07 
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Apolipoprotein A-II OS=Homo sapiens GN=APOA2 PE=1 SV=1 2.59E+07 
Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 2.55E+07 
Pulmonary surfactant-associated protein B OS=Homo sapiens GN=SFTPB 
PE=1 SV=3 
2.54E+07 
Annexin A4 OS=Homo sapiens GN=ANXA4 PE=1 SV=4 2.52E+07 
Selenium-binding protein 1 OS=Homo sapiens GN=SELENBP1 PE=1 SV=2 2.43E+07 
Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 2.36E+07 
Transaldolase OS=Homo sapiens GN=TALDO1 PE=1 SV=2 2.33E+07 
Scavenger receptor cysteine-rich type 1 protein M130 OS=Homo sapiens 
GN=CD163 PE=1 SV=2 
2.29E+07 
CD9 antigen OS=Homo sapiens GN=CD9 PE=1 SV=4 2.20E+07 
Complement C4-A; AltName: Full=Acidic complement C4; AltName: 
Full=C3 and PZP-like alpha-2-macroglobulin domain-containing protein 2; 
Contains: RecName: Full=Complement C4 beta chain; Contains: RecName: 
Full=Complement C4-A alpha chain; Contains: RecName: Full=C4a 
anaphylatoxin; Contains: RecName: Full=C4b-A; Contains: RecName: 
Full=C4d-A; Contains: RecName: Full=Complement C4 gamma chain; Flags: 
Precursor; [Homo sapiens (Human)] - [CO4A_HUMAN] 
1.80E+07 
Delta-like protein 4; AltName: Full=Drosophila Delta homolog 4; 
Short=Delta4; Flags: Precursor; [Homo sapiens (Human)] - [DLL4_HUMAN] 
1.80E+07 
Mesothelin OS=Homo sapiens GN=MSLN PE=1 SV=2 1.78E+07 
Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2 1.64E+07 
Actin-related protein 2; AltName: Full=Actin-like protein 2; [Homo sapiens 
(Human)] - [ARP2_HUMAN] 
1.56E+07 
Uncharacterized protein KIAA0947; [Homo sapiens (Human)] - 
[K0947_HUMAN] 
1.56E+07 
Thyroxine-binding globulin OS=Homo sapiens GN=SERPINA7 PE=1 SV=2 1.56E+07 
Complement decay-accelerating factor OS=Homo sapiens GN=CD55 PE=1 
SV=4 
1.49E+07 
Aldo-keto reductase family 1 member C3; EC=1.-.-.-; AltName: Full=17-beta-
hydroxysteroid dehydrogenase type 5; Short=17-beta-HSD 5; AltName: 
Full=3-alpha-HSD type II, brain; AltName: Full=3-alpha-hydroxysteroid 
dehydrogenase type 2; Short=3-alpha-HSD type 2; EC=1.1.1.213; AltName: 
Full=Chlordecone reductase homolog HAKRb; AltName: Full=Dihydrodiol 
dehydrogenase 3; Short=DD-3; Short=DD3; AltName: Full=Dihydrodiol 
dehydrogenase type I; AltName: Full=HA1753; AltName: Full=Indanol 
dehydrogenase; EC=1.1.1.112; AltName: Full=Prostaglandin F synthase; 
Short=PGFS; EC=1.1.1.188; AltName: Full=Testosterone 17-beta-




dihydrobenzene-1,2-diol dehydrogenase; EC=1.3.1.20; [Homo sapiens 
(Human)] - [AK1C3_HUMAN] 
Protein kinase-like protein SgK196; AltName: Full=Sugen kinase 196; [Homo 
sapiens (Human)] - [SG196_HUMAN] 
1.39E+07 
Mucin-1 OS=Homo sapiens GN=MUC1 PE=1 SV=3 1.31E+07 
Thioredoxin; Short=Trx; AltName: Full=ATL-derived factor; Short=ADF; 
AltName: Full=Surface-associated sulphydryl protein; Short=SASP; [Homo 
sapiens (Human)] - [THIO_HUMAN] 
1.30E+07 
Retinoic acid-induced protein 3 OS=Homo sapiens GN=GPRC5A PE=1 SV=2 1.29E+07 
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 1.25E+07 
Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 
SV=2 
1.19E+07 
Biotinidase OS=Homo sapiens GN=BTD PE=1 SV=2 1.19E+07 
Xaa-Pro dipeptidase; Short=X-Pro dipeptidase; EC=3.4.13.9; AltName: 
Full=Imidodipeptidase; AltName: Full=Peptidase D; AltName: Full=Proline 
dipeptidase; Short=Prolidase; [Homo sapiens (Human)] - [PEPD_HUMAN] 
1.18E+07 
Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1 1.14E+07 
Puromycin-sensitive aminopeptidase; Short=PSA; EC=3.4.11.14; AltName: 
Full=Cytosol alanyl aminopeptidase; Short=AAP-S; [Homo sapiens (Human)] 
- [PSA_HUMAN] 
1.13E+07 
SH3 domain-binding glutamic acid-rich-like protein 3; AltName: Full=SH3 
domain-binding protein 1; Short=SH3BP-1; [Homo sapiens (Human)] - 
[SH3L3_HUMAN] 
1.13E+07 
Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2 1.13E+07 
Histone H3.3C; [Homo sapiens (Human)] - [H3C_HUMAN] 1.08E+07 
Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 SV=3 1.04E+07 
Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 9.95E+06 
Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 9.83E+06 
Fatty acid-binding protein, adipocyte OS=Homo sapiens GN=FABP4 PE=1 
SV=3 
9.73E+06 
Ig lambda chain V-V region DEL; [Homo sapiens (Human)] - 
[LV501_HUMAN] 
9.50E+06 
Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2 9.50E+06 
Superoxide dismutase [Cu-Zn] OS=Homo sapiens GN=SOD1 PE=1 SV=2 9.13E+06 
Transcriptional adapter 2-beta; AltName: Full=ADA2-like protein beta; 8.54E+06 
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Short=ADA2-beta; [Homo sapiens (Human)] - [TAD2B_HUMAN] 
Leukocyte elastase inhibitor OS=Homo sapiens GN=SERPINB1 PE=1 SV=1 8.21E+06 
V-set and immunoglobulin domain-containing protein 4; AltName: 
Full=Protein Z39Ig; Flags: Precursor; [Homo sapiens (Human)] - 
[VSIG4_HUMAN] 
8.17E+06 
Protein S100-A11 OS=Homo sapiens GN=S100A11 PE=1 SV=2 7.59E+06 
Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 7.58E+06 
Cell adhesion molecule 1; AltName: Full=Immunoglobulin superfamily 
member 4; Short=IgSF4; AltName: Full=Nectin-like protein 2; Short=NECL-
2; AltName: Full=Spermatogenic immunoglobulin superfamily; 
Short=SgIgSF; AltName: Full=Synaptic cell adhesion molecule; 
Short=SynCAM; AltName: Full=Tumor suppressor in lung cancer 1; 
Short=TSLC-1; Flags: Precursor; [Homo sapiens (Human)] - 
[CADM1_HUMAN] 
7.37E+06 
Long palate, lung and nasal epithelium carcinoma-associated protein 1; 
AltName: Full=Von Ebner minor salivary gland protein; Short=VEMSGP; 
Flags: Precursor; [Homo sapiens (Human)] - [LPLC1_HUMAN] 
7.16E+06 
Glutathione S-transferase omega-1 OS=Homo sapiens GN=GSTO1 PE=1 
SV=2 
6.98E+06 
Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2 6.82E+06 
Ig delta chain C region; [Homo sapiens (Human)] - [IGHD_HUMAN] 6.39E+06 
Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 6.20E+06 
Peroxiredoxin-5, mitochondrial OS=Homo sapiens GN=PRDX5 PE=1 SV=4 6.12E+06 
Vitamin K-dependent protein S; Flags: Precursor; [Homo sapiens (Human)] - 
[PROS_HUMAN] 
6.05E+06 
Junctional adhesion molecule A OS=Homo sapiens GN=F11R PE=1 SV=1 5.60E+06 
Heme-binding protein 2; AltName: Full=Placental protein 23; Short=PP23; 
AltName: Full=Protein SOUL; [Homo sapiens (Human)] - 
[HEBP2_HUMAN] 
5.28E+06 
Glyoxalase domain-containing protein 4 OS=Homo sapiens GN=GLOD4 
PE=1 SV=1 
5.28E+06 
Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 5.17E+06 
Prostaglandin-H2 D-isomerase; EC=5.3.99.2; AltName: Full=Beta-trace 
protein; AltName: Full=Cerebrin-28; AltName: Full=Glutathione-independent 
PGD synthase; AltName: Full=Lipocalin-type prostaglandin-D synthase; 
AltName: Full=Prostaglandin-D2 synthase; Short=PGD2 synthase; 





Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 4.56E+06 
Myoglobin; [Homo sapiens (Human)] - [MYG_HUMAN] 4.44E+06 
Putative inactive carboxylesterase 4; AltName: Full=Inactive carboxylesterase 
1 pseudogene 1; AltName: Full=Placental carboxylesterase 3; Short=PCE-3; 
Flags: Precursor; [Homo sapiens (Human)] - [CES1P_HUMAN] 
4.34E+06 
Neutrophil gelatinase-associated lipocalin; Short=NGAL; AltName: Full=25 
kDa alpha-2-microglobulin-related subunit of MMP-9; AltName: 
Full=Lipocalin-2; AltName: Full=Oncogene 24p3; AltName: Full=p25; Flags: 
Precursor; [Homo sapiens (Human)] - [NGAL_HUMAN] 
4.22E+06 
Glutathione peroxidase 3 OS=Homo sapiens GN=GPX3 PE=1 SV=2 4.07E+06 
CD59 glycoprotein OS=Homo sapiens GN=CD59 PE=1 SV=1 4.04E+06 
Phosphatidylethanolamine-binding protein 1; Short=PEBP-1; AltName: 
Full=HCNPpp; AltName: Full=Neuropolypeptide h3; AltName: 
Full=Prostatic-binding protein; AltName: Full=Raf kinase inhibitor protein; 
Short=RKIP; Contains: RecName: Full=Hippocampal cholinergic 
neurostimulating peptide; Short=HCNP; [Homo sapiens (Human)] - 
[PEBP1_HUMAN] 
4.01E+06 
Phosphoglycerate mutase 1 OS=Homo sapiens GN=PGAM1 PE=1 SV=2 3.87E+06 
Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2 3.79E+06 
Thioredoxin domain-containing protein 17; AltName: Full=14 kDa 
thioredoxin-related protein; Short=TRP14; AltName: Full=Protein 42-9-9; 
AltName: Full=Thioredoxin-like protein 5; [Homo sapiens (Human)] - 
[TXD17_HUMAN] 
3.64E+06 
Serpin B6; AltName: Full=Cytoplasmic antiproteinase; Short=CAP; AltName: 
Full=Peptidase inhibitor 6; Short=PI-6; AltName: Full=Placental thrombin 
inhibitor; [Homo sapiens (Human)] - [SPB6_HUMAN] 
3.30E+06 
Eosinophil lysophospholipase; EC=3.1.1.5; AltName: Full=Charcot-Leyden 
crystal protein; Short=CLC; AltName: Full=Galectin-10; Short=Gal-10; 
AltName: Full=Lysolecithin acylhydrolase; [Homo sapiens (Human)] - 
[LPPL_HUMAN] 
3.22E+06 
Folate receptor alpha OS=Homo sapiens GN=FOLR1 PE=1 SV=3 3.11E+06 
Transmembrane protein 200C; AltName: Full=Transmembrane protein 
TTMA; AltName: Full=Two transmembrane domain-containing family 
member A; [Homo sapiens (Human)] - [T200C_HUMAN] 
2.87E+06 
SH3 domain-binding glutamic acid-rich-like protein OS=Homo sapiens 
GN=SH3BGRL PE=1 SV=1 
2.80E+06 
Aldose 1-epimerase OS=Homo sapiens GN=GALM PE=1 SV=1 2.77E+06 
Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 2.75E+06 
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Matrix metalloproteinase-23; Short=MMP-23; EC=3.4.24.-; AltName: 
Full=Femalysin; AltName: Full=MIFR-1; AltName: Full=Matrix 
metalloproteinase-21; Short=MMP-21; AltName: Full=Matrix 
metalloproteinase-22; Short=MMP-22; Contains: RecName: Full=Matrix 
metalloproteinase-23, soluble form; Flags: Precursor; [Homo sapiens 
(Human)] - [MMP23_HUMAN] 
2.66E+06 
Napsin-A OS=Homo sapiens GN=NAPSA PE=1 SV=1 2.37E+06 
Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 2.13E+06 
Protein S100-P; AltName: Full=Protein S100-E; AltName: Full=S100 
calcium-binding protein P; [Homo sapiens (Human)] - [S100P_HUMAN] 
2.12E+06 
Neutrophil defensin 1 OS=Homo sapiens GN=DEFA1 PE=1 SV=1 1.79E+06 
Gamma-glutamylcyclotransferase; EC=2.3.2.4; AltName: Full=Cytochrome c-
releasing factor 21; [Homo sapiens (Human)] - [GGCT_HUMAN] 
1.29E+06 
Sodium-dependent phosphate transport protein 2B; Short=Sodium-phosphate 
transport protein 2B; AltName: Full=Na(+)-dependent phosphate cotransporter 
2B; AltName: Full=NaPi3b; AltName: Full=Sodium/phosphate cotransporter 
2B; Short=Na(+)/Pi cotransporter 2B; Short=NaPi-2b; AltName: Full=Solute 




Table A.2: All alveolar proteins identified by 1D PAGE and nano LC MS/MS in mild 
asthmatic RTLFs. The 217 proteins identified in mild asthmatic subjects investigated, 
(n=5), alongside the mean of the three most abundant ion peaks of each respective protein 
identified. Accession numbers included according to entries in UniProtKB/Swiss-Prot.  
 
Mild asthmatic 
14-3-3 protein beta/alpha; AltName: Full=Protein 1054; AltName: Full=Protein 
kinase C inhibitor protein 1; Short=KCIP-1; Contains: RecName: Full=14-3-3 protein 
beta/alpha, N-terminally processed; [Homo sapiens (Human)] - [1433B_HUMAN] 
1.82E+07 
14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 1.49E+07 
14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 1.82E+07 
28S ribosomal protein S26, mitochondrial; Short=MRP-S26; Short=S26mt; 
AltName: Full=28S ribosomal protein S13, mitochondrial; Short=MRP-S13; 
Short=S13mt; Flags: Precursor; [Homo sapiens (Human)] - [RT26_HUMAN] 
2.80E+07 
Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 3.03E+07 
ADP-ribosyl cyclase 2 OS=Homo sapiens GN=BST1 PE=1 SV=2 1.38E+06 
Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 7.98E+06 
Aldo-keto reductase family 1 member C2; EC=1.-.-.-; AltName: Full=3-alpha-
HSD3; AltName: Full=Chlordecone reductase homolog HAKRD; AltName: 
Full=Dihydrodiol dehydrogenase 2; Short=DD-2; Short=DD2; AltName: 
Full=Dihydrodiol dehydrogenase/bile acid-binding protein; Short=DD/BABP; 
AltName: Full=Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase; EC=1.3.1.20; 
AltName: Full=Type III 3-alpha-hydroxysteroid dehydrogenase; EC=1.1.1.213; 
[Homo sapiens (Human)] - [AK1C2_HUMAN] 
2.09E+06 
Aldose 1-epimerase OS=Homo sapiens GN=GALM PE=1 SV=1 3.53E+06 
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 2.89E+08 
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Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2 2.60E+08 
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 3.86E+07 
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 7.42E+08 
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 3.46E+07 
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 1.13E+08 
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 6.40E+07 
Alpha-N-acetylglucosaminidase OS=Homo sapiens GN=NAGLU PE=1 SV=2 1.61E+06 
Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 1.95E+07 
Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2 7.67E+06 
Annexin A3 OS=Homo sapiens GN=ANXA3 PE=1 SV=3 1.29E+07 
Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 1.83E+07 
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 7.80E+06 
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 1.55E+08 
Apolipoprotein A-II OS=Homo sapiens GN=APOA2 PE=1 SV=1 1.84E+07 
Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 SV=3 7.77E+06 
Aspartate aminotransferase, cytoplasmic OS=Homo sapiens GN=GOT1 PE=1 SV=3 3.43E+06 
ATP-binding cassette sub-family C member 8; AltName: Full=Sulfonylurea receptor 
1; [Homo sapiens (Human)] - [ABCC8_HUMAN] 
2.80E+07 
ATP-sensitive inward rectifier potassium channel 10; AltName: Full=ATP-
dependent inwardly rectifying potassium channel Kir4.1; AltName: Full=Inward 
rectifier K(+) channel Kir1.2; AltName: Full=Potassium channel, inwardly rectifying 
subfamily J member 10; [Homo sapiens (Human)] - [IRK10_HUMAN] 
2.14E+06 
Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2 9.79E+06 
Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 6.95E+07 
Biotinidase OS=Homo sapiens GN=BTD PE=1 SV=2 6.35E+06 
BTB/POZ domain-containing protein 8; [Homo sapiens (Human)] - 
[BTBD8_HUMAN] 
4.21E+05 
C-type natriuretic peptide; Contains: RecName: Full=CNP-22; Contains: RecName: 
Full=CNP-29; Contains: RecName: Full=CNP-53; Flags: Precursor; [Homo sapiens 
(Human)] - [ANFC_HUMAN] 
2.75E+08 
Calcyphosin OS=Homo sapiens GN=CAPS PE=1 SV=1 2.67E+06 
Calmodulin OS=Homo sapiens GN=CALM1 PE=1 SV=2 1.93E+07 
Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 2.40E+07 
Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2 6.78E+06 
CASP8-associated protein 2; AltName: Full=FLICE-associated huge protein; [Homo 
sapiens (Human)] - [C8AP2_HUMAN] 
2.44E+07 
Caspase recruitment domain-containing protein 6; [Homo sapiens (Human)] - 
[CARD6_HUMAN] 
1.40E+08 
Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 4.60E+08 
Caveolin-1; [Homo sapiens (Human)] - [CAV1_HUMAN] 2.23E+06 
CD151 antigen; AltName: Full=GP27; AltName: Full=Membrane glycoprotein SFA-
1; AltName: Full=Platelet-endothelial tetraspan antigen 3; Short=PETA-3; AltName: 
Full=Tetraspanin-24; Short=Tspan-24; AltName: CD_antigen=CD151; [Homo 
sapiens (Human)] - [CD151_HUMAN] 
1.17E+06 
CD166 antigen OS=Homo sapiens GN=ALCAM PE=1 SV=2 3.45E+06 
CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=3 5.58E+07 
CD63 antigen; AltName: Full=Granulophysin; AltName: Full=Lysosomal-associated 
membrane protein 3; Short=LAMP-3; AltName: Full=Melanoma-associated antigen 
ME491; AltName: Full=OMA81H; AltName: Full=Ocular melanoma-associated 
antigen; AltName: Full=Tetraspanin-30; Short=Tspan-30; AltName: 




CD9 antigen OS=Homo sapiens GN=CD9 PE=1 SV=4 1.45E+07 
Cell adhesion molecule 1 OS=Homo sapiens GN=CADM1 PE=1 SV=2 3.41E+06 
Cell adhesion molecule 2; AltName: Full=Immunoglobulin superfamily member 4D; 
Short=IgSF4D; AltName: Full=Nectin-like protein 3; Short=NECL-3; Flags: 
Precursor; [Homo sapiens (Human)] - [CADM2_HUMAN] 
4.06E+06 
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 1.23E+08 
cGMP-specific 3',5'-cyclic phosphodiesterase; EC=3.1.4.35; AltName: Full=cGMP-
binding cGMP-specific phosphodiesterase; Short=CGB-PDE; [Homo sapiens 
(Human)] - [PDE5A_HUMAN] 
5.00E+07 
Choline transporter-like protein 2 OS=Homo sapiens GN=SLC44A2 PE=1 SV=3 1.09E+06 
Choline transporter-like protein 4; AltName: Full=Solute carrier family 44 member 
4; [Homo sapiens (Human)] - [CTL4_HUMAN] 
9.70E+05 
Coactosin-like protein OS=Homo sapiens GN=COTL1 PE=1 SV=3 1.15E+07 
Coiled-coil and C2 domain-containing protein 1B; [Homo sapiens (Human)] - 
[C2D1B_HUMAN] 
2.00E+07 
Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2 6.38E+06 
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 2.94E+07 
Complement decay-accelerating factor OS=Homo sapiens GN=CD55 PE=1 SV=4 1.63E+07 
COP9 signalosome complex subunit 1; Short=SGN1; Short=Signalosome subunit 1; 
AltName: Full=G protein pathway suppressor 1; Short=GPS-1; AltName: 
Full=JAB1-containing signalosome subunit 1; AltName: Full=Protein MFH; [Homo 
sapiens (Human)] - [CSN1_HUMAN] 
7.47E+08 
Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 PE=1 SV=1 1.39E+07 
Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 6.67E+06 
Deleted in malignant brain tumors 1 protein OS=Homo sapiens GN=DMBT1 PE=1 
SV=2 
3.56E+07 
Delta-like protein 4; AltName: Full=Drosophila Delta homolog 4; Short=Delta4; 
Flags: Precursor; [Homo sapiens (Human)] - [DLL4_HUMAN] 
1.73E+07 
Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 3.67E+06 
Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 6.95E+06 
Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 2.67E+07 
Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2 1.11E+07 
DNA mismatch repair protein Msh3; Short=hMSH3; AltName: Full=Divergent 
upstream protein; Short=DUP; AltName: Full=Mismatch repair protein 1; 
Short=MRP1; [Homo sapiens (Human)] - [MSH3_HUMAN] 
5.91E+06 
Dynein heavy chain 10, axonemal; AltName: Full=Axonemal beta dynein heavy 
chain 10; AltName: Full=Ciliary dynein heavy chain 10; [Homo sapiens (Human)] - 
[DYH10_HUMAN] 
1.80E+08 
Ecto-ADP-ribosyltransferase 4; EC=2.4.2.31; AltName: Full=Dombrock blood 
group carrier molecule; AltName: Full=Mono(ADP-ribosyl)transferase 4; AltName: 
Full=NAD(P)(+)--arginine ADP-ribosyltransferase 4; AltName: 
CD_antigen=CD297; Flags: Precursor; [Homo sapiens (Human)] - 
[NAR4_HUMAN] 
5.37E+07 
Epididymal secretory protein E1 OS=Homo sapiens GN=NPC2 PE=1 SV=1 1.26E+08 
Erythrocyte band 7 integral membrane protein OS=Homo sapiens GN=STOM PE=1 
SV=3 
1.60E+08 
Ezrin OS=Homo sapiens GN=EZR PE=1 SV=4 3.09E+06 
FAS-associated factor 1; Short=hFAF1; AltName: Full=UBX domain-containing 
protein 12; AltName: Full=UBX domain-containing protein 3A; [Homo sapiens 
(Human)] - [FAF1_HUMAN] 
1.03E+08 
Fatty acid-binding protein, adipocyte; AltName: Full=Adipocyte lipid-binding 1.31E+07 
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protein; Short=ALBP; AltName: Full=Adipocyte-type fatty acid-binding protein; 
Short=A-FABP; Short=AFABP; AltName: Full=Fatty acid-binding protein 4; [Homo 
sapiens (Human)] - [FABP4_HUMAN] 
Ferritin heavy chain; Short=Ferritin H subunit; EC=1.16.3.1; AltName: Full=Cell 
proliferation-inducing gene 15 protein; [Homo sapiens (Human)] - [FRIH_HUMAN] 
2.76E+06 
Fibrocystin-L; AltName: Full=Polycystic kidney and hepatic disease 1-like protein 1; 
Short=PKHD1-like protein 1; Flags: Precursor; [Homo sapiens (Human)] - 
[PKHL1_HUMAN] 
2.62E+06 
Folate receptor alpha OS=Homo sapiens GN=FOLR1 PE=1 SV=3 2.79E+06 
Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1 3.89E+06 
Ganglioside GM2 activator; AltName: Full=Cerebroside sulfate activator protein; 
AltName: Full=GM2-AP; AltName: Full=Shingolipid activator protein 3; 
Short=SAP-3; Contains: RecName: Full=Ganglioside GM2 activator isoform short; 
Flags: Precursor; [Homo sapiens (Human)] - [SAP3_HUMAN] 
3.20E+06 
Gastricsin OS=Homo sapiens GN=PGC PE=1 SV=1 1.71E+07 
Glutathione S-transferase A1 OS=Homo sapiens GN=GSTA1 PE=1 SV=3 1.83E+07 
Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 9.57E+06 
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 1.13E+09 
HEAT repeat-containing protein 1; AltName: Full=Protein BAP28; [Homo sapiens 
(Human)] - [HEAT1_HUMAN] 
9.00E+06 
Heme-binding protein 2; AltName: Full=Placental protein 23; Short=PP23; 
AltName: Full=Protein SOUL; [Homo sapiens (Human)] - [HEBP2_HUMAN] 
2.71E+06 
Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 6.04E+08 
Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 4.82E+08 
Hemoglobin subunit delta OS=Homo sapiens GN=HBD PE=1 SV=2 3.78E+08 
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 4.44E+08 
Histone-lysine N-methyltransferase MLL3; EC=2.1.1.43; AltName: 
Full=Homologous to ALR protein; AltName: Full=Lysine N-methyltransferase 2C; 
Short=KMT2C; AltName: Full=Myeloid/lymphoid or mixed-lineage leukemia 
protein 3; [Homo sapiens (Human)] - [MLL3_HUMAN] 
8.05E+07 
HLA class II histocompatibility antigen, DP beta 1 chain; AltName: Full=HLA class 
II histocompatibility antigen, DP(W4) beta chain; AltName: Full=MHC class II 
antigen DPB1; Flags: Precursor; [Homo sapiens (Human)] - [DPB1_HUMAN] 
1.03E+07 
HLA class II histocompatibility antigen, DR alpha chain OS=Homo sapiens 
GN=HLA-DRA PE=1 SV=1 
3.67E+06 
HLA class II histocompatibility antigen, DRB1-15 beta chain OS=Homo sapiens 
GN=HLA-DRB1 PE=1 SV=2 
9.93E+06 
HLA class II histocompatibility antigen, DRB1-4 beta chain; AltName: Full=MHC 
class II antigen DRB1*4; Short=DR-4; Short=DR4; Flags: Precursor; [Homo sapiens 
(Human)] - [2B14_HUMAN] 
4.70E+06 
Homeobox protein Nkx-3.2; AltName: Full=Bagpipe homeobox protein homolog 1; 
AltName: Full=Homeobox protein NK-3 homolog B; [Homo sapiens (Human)] - 
[NKX32_HUMAN] 
5.43E+06 
Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 1.24E+09 
Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 8.46E+08 
Ig delta chain C region; [Homo sapiens (Human)] - [IGHD_HUMAN] 8.04E+06 
Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 3.04E+09 
Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2 2.20E+09 
Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=1 SV=2 2.52E+09 
Ig heavy chain V-I region HG3 OS=Homo sapiens PE=4 SV=1 5.87E+07 




Ig heavy chain V-II region ARH-77 OS=Homo sapiens PE=4 SV=1 1.73E+08 
Ig heavy chain V-II region NEWM; [Homo sapiens (Human)] - [HV207_HUMAN] 6.76E+07 
Ig heavy chain V-II region OU; [Homo sapiens (Human)] - [HV201_HUMAN] 2.46E+07 
Ig heavy chain V-III region BUR; [Homo sapiens (Human)] - [HV312_HUMAN] 6.85E+08 
Ig heavy chain V-III region BUT; [Homo sapiens (Human)] - [HV306_HUMAN] 5.55E+08 
Ig heavy chain V-III region CAM OS=Homo sapiens PE=1 SV=1 5.71E+08 
Ig heavy chain V-III region GAL OS=Homo sapiens PE=1 SV=1 4.86E+08 
Ig heavy chain V-III region GAR; [Homo sapiens (Human)] - [HV322_HUMAN] 7.31E+07 
Ig heavy chain V-III region HIL; [Homo sapiens (Human)] - [HV310_HUMAN] 6.93E+08 
Ig heavy chain V-III region TUR OS=Homo sapiens PE=1 SV=1 4.62E+08 
Ig heavy chain V-III region VH26 OS=Homo sapiens PE=1 SV=1 5.29E+08 
Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 1.00E+09 
Ig kappa chain V-I region DEE; [Homo sapiens (Human)] - [KV105_HUMAN] 3.48E+08 
Ig kappa chain V-I region EU OS=Homo sapiens PE=1 SV=1 1.95E+08 
Ig kappa chain V-I region Kue; [Homo sapiens (Human)] - [KV112_HUMAN] 1.92E+08 
Ig kappa chain V-I region Roy; [Homo sapiens (Human)] - [KV116_HUMAN] 1.45E+08 
Ig kappa chain V-I region Wes; [Homo sapiens (Human)] - [KV119_HUMAN] 2.28E+08 
Ig kappa chain V-II region TEW OS=Homo sapiens PE=1 SV=1 1.29E+08 
Ig kappa chain V-III region NG9 (Fragment) OS=Homo sapiens PE=1 SV=1 1.00E+08 
Ig kappa chain V-III region POM OS=Homo sapiens PE=1 SV=1 1.01E+08 
Ig kappa chain V-III region SIE OS=Homo sapiens PE=1 SV=1 1.59E+08 
Ig kappa chain V-III region VG; Flags: Precursor; Fragment; [Homo sapiens 
(Human)] - [KV309_HUMAN] 
1.06E+08 
Ig kappa chain V-IV region JI OS=Homo sapiens PE=4 SV=1 6.13E+07 
Ig lambda chain V region 4A; Flags: Precursor; [Homo sapiens (Human)] - 
[LV001_HUMAN] 
6.04E+07 
Ig lambda chain V-I region HA OS=Homo sapiens PE=1 SV=1 3.45E+07 
Ig lambda chain V-I region NIG-64 OS=Homo sapiens PE=1 SV=1 2.39E+07 
Ig lambda chain V-II region NEI; [Homo sapiens (Human)] - [LV202_HUMAN] 2.39E+07 
Ig lambda chain V-III region LOI OS=Homo sapiens PE=1 SV=1 3.54E+07 
Ig lambda chain V-III region SH; [Homo sapiens (Human)] - [LV301_HUMAN] 1.90E+07 
Ig lambda chain V-III region SH; [Homo sapiens (Human)] - [LV301_HUMAN] 3.54E+07 
Ig lambda chain V-IV region Bau; [Homo sapiens (Human)] - [LV401_HUMAN] 4.15E+07 
Ig lambda chain V-IV region Hil; [Homo sapiens (Human)] - [LV403_HUMAN] 3.39E+07 
Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 SV=1 7.00E+08 
Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 7.42E+07 
Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 8.35E+07 
Immunoglobulin lambda-like polypeptide 5 OS=Homo sapiens GN=IGLL5 PE=2 
SV=2 
4.17E+08 
Intercellular adhesion molecule 1 OS=Homo sapiens GN=ICAM1 PE=1 SV=2 1.77E+07 
Junctional adhesion molecule A OS=Homo sapiens GN=F11R PE=1 SV=1 9.69E+06 
Lactotransferrin; Short=Lactoferrin; EC=3.4.21.-; AltName: Full=Talalactoferrin; 
Contains: RecName: Full=Kaliocin-1; Contains: RecName: Full=Lactoferroxin-A; 
Contains: RecName: Full=Lactoferroxin-B; Contains: RecName: 
Full=Lactoferroxin-C; Flags: Precursor; [Homo sapiens (Human)] - 
[TRFL_HUMAN] 
7.34E+08 
Latexin; AltName: Full=Endogenous carboxypeptidase inhibitor; Short=ECI; 
AltName: Full=Protein MUM; AltName: Full=Tissue carboxypeptidase inhibitor; 
Short=TCI; [Homo sapiens (Human)] - [LXN_HUMAN] 
2.49E+08 
Lethal(3)malignant brain tumor-like protein 4; Short=H-l(3)mbt-like protein 4; 9.09E+06 
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Short=L(3)mbt-like protein 4; [Homo sapiens (Human)] - [LMBL4_HUMAN] 
Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2 2.36E+07 
Leukocyte elastase inhibitor OS=Homo sapiens GN=SERPINB1 PE=1 SV=1 9.09E+06 
Liprin-beta-2; AltName: Full=Protein tyrosine phosphatase receptor type f 
polypeptide-interacting protein-binding protein 2; Short=PTPRF-interacting protein-
binding protein 2; [Homo sapiens (Human)] - [LIPB2_HUMAN] 
8.52E+06 
Lysozyme C; EC=3.2.1.17; AltName: Full=1,4-beta-N-acetylmuramidase C; Flags: 
Precursor; [Homo sapiens (Human)] - [LYSC_HUMAN] 
4.75E+05 
Mesothelin OS=Homo sapiens GN=MSLN PE=1 SV=2 1.74E+07 
Mucin-1 OS=Homo sapiens GN=MUC1 PE=1 SV=3 8.52E+06 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial; 
AltName: Full=Complex I-AGGG; Short=CI-AGGG; AltName: Full=NADH-
ubiquinone oxidoreductase AGGG subunit; Flags: Precursor; [Homo sapiens 
(Human)] - [NDUB2_HUMAN] 
1.75E+07 
Napsin-A; EC=3.4.23.-; AltName: Full=Aspartyl protease 4; Short=ASP4; 
Short=Asp 4; AltName: Full=Napsin-1; AltName: Full=TA01/TA02; Flags: 
Precursor; [Homo sapiens (Human)] - [NAPSA_HUMAN] 
1.75E+07 
Neuron navigator 1; AltName: Full=Pore membrane and/or filament-interacting-like 
protein 3; AltName: Full=Steerin-1; AltName: Full=Unc-53 homolog 1; 
Short=unc53H1; [Homo sapiens (Human)] - [NAV1_HUMAN] 
9.10E+06 
Neutrophil defensin 1; AltName: Full=Defensin, alpha 1; AltName: Full=HNP-1; 
Short=HP-1; Short=HP1; Contains: RecName: Full=HP 1-56; Contains: RecName: 
Full=Neutrophil defensin 2; AltName: Full=HNP-2; Short=HP-2; Short=HP2; Flags: 
Precursor; [Homo sapiens (Human)] - [DEF1_HUMAN] 
3.60E+06 
Olfactory receptor 4K5 OS=Homo sapiens GN=OR4K5 PE=2 SV=1 3.84E+08 
Pancreatic alpha-amylase; Short=PA; EC=3.2.1.1; AltName: Full=1,4-alpha-D-
glucan glucanohydrolase; Flags: Precursor; [Homo sapiens (Human)] - 
[AMYP_HUMAN] 
7.36E+06 
Peroxiredoxin-5, mitochondrial OS=Homo sapiens GN=PRDX5 PE=1 SV=4 3.31E+06 
Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 4.96E+06 
Phosphatidylethanolamine-binding protein 1; Short=PEBP-1; AltName: 
Full=HCNPpp; AltName: Full=Neuropolypeptide h3; AltName: Full=Prostatic-
binding protein; AltName: Full=Raf kinase inhibitor protein; Short=RKIP; Contains: 
RecName: Full=Hippocampal cholinergic neurostimulating peptide; Short=HCNP; 
[Homo sapiens (Human)] - [PEBP1_HUMAN] 
8.97E+05 
Phosphoglycerate mutase 1 OS=Homo sapiens GN=PGAM1 PE=1 SV=2 1.88E+06 
Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 6.56E+06 
Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 SV=4 3.32E+08 
Pro-cathepsin H OS=Homo sapiens GN=CTSH PE=1 SV=4 2.12E+07 
Proactivator polypeptide OS=Homo sapiens GN=PSAP PE=1 SV=2 4.34E+06 
Probable G-protein coupled receptor 116; Flags: Precursor; [Homo sapiens (Human)] 
- [GP116_HUMAN] 
2.77E+07 
Prostasin; EC=3.4.21.-; AltName: Full=Serine protease 8; Contains: RecName: 
Full=Prostasin light chain; Contains: RecName: Full=Prostasin heavy chain; Flags: 
Precursor; [Homo sapiens (Human)] - [PRSS8_HUMAN] 
2.35E+06 
Proteasome subunit alpha type-1; EC=3.4.25.1; AltName: Full=30 kDa prosomal 
protein; Short=PROS-30; AltName: Full=Macropain subunit C2; AltName: 
Full=Multicatalytic endopeptidase complex subunit C2; AltName: Full=Proteasome 
component C2; AltName: Full=Proteasome nu chain; [Homo sapiens (Human)] - 
[PSA1_HUMAN] 
3.32E+07 
Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1 2.31E+06 
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Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 1.75E+07 
Protein S100-A11 OS=Homo sapiens GN=S100A11 PE=1 SV=2 4.68E+06 
Protein S100-A6 OS=Homo sapiens GN=S100A6 PE=1 SV=1 8.46E+07 
Protein Shroom3; AltName: Full=Shroom-related protein; Short=hShrmL; [Homo 
sapiens (Human)] - [SHRM3_HUMAN] 
7.90E+07 
Pulmonary surfactant-associated protein A2 OS=Homo sapiens GN=SFTPA2 PE=1 
SV=1 
5.87E+07 
Pulmonary surfactant-associated protein B OS=Homo sapiens GN=SFTPB PE=1 
SV=3 
2.53E+07 
Pulmonary surfactant-associated protein D OS=Homo sapiens GN=SFTPD PE=1 
SV=3 
2.06E+07 
Puromycin-sensitive aminopeptidase; Short=PSA; EC=3.4.11.14; AltName: 
Full=Cytosol alanyl aminopeptidase; Short=AAP-S; [Homo sapiens (Human)] - 
[PSA_HUMAN] 
1.43E+07 
Putative inactive carboxylesterase 4; AltName: Full=Inactive carboxylesterase 1 
pseudogene 1; AltName: Full=Placental carboxylesterase 3; Short=PCE-3; Flags: 
Precursor; [Homo sapiens (Human)] - [CES1P_HUMAN] 
3.62E+06 
Putative uncharacterized protein HUG-1; AltName: Full=HOX11 upstream gene 1 
protein; [Homo sapiens (Human)] - [HUG1_HUMAN] 
3.05E+06 
Putative V-set and immunoglobulin domain-containing protein 6 OS=Homo sapiens 
GN=VSIG6 PE=5 SV=2 
7.72E+07 
Retinoic acid-induced protein 3 OS=Homo sapiens GN=GPRC5A PE=1 SV=2 3.24E+07 
Retinol-binding protein 4; AltName: Full=Plasma retinol-binding protein; 
Short=PRBP; Short=RBP; Contains: RecName: Full=Plasma retinol-binding 
protein(1-182); Contains: RecName: Full=Plasma retinol-binding protein(1-181); 
Contains: RecName: Full=Plasma retinol-binding protein(1-179); Contains: 
RecName: Full=Plasma retinol-binding protein(1-176); Flags: Precursor; [Homo 
sapiens (Human)] - [RET4_HUMAN] 
3.11E+07 
Rho GDP-dissociation inhibitor 2 OS=Homo sapiens GN=ARHGDIB PE=1 SV=3 6.99E+06 
Rho guanine nucleotide exchange factor 17; AltName: Full=164 kDa Rho-specific 
guanine-nucleotide exchange factor; Short=p164-RhoGEF; Short=p164RhoGEF; 
AltName: Full=Tumor endothelial marker 4; [Homo sapiens (Human)] - 
[ARHGH_HUMAN] 
1.03E+08 
Ribonuclease P protein subunit p40; Short=RNaseP protein p40; EC=3.1.26.5; 
AltName: Full=RNase P subunit 1; [Homo sapiens (Human)] - [RPP40_HUMAN] 
9.04E+07 
RNA-binding protein MEX3A; AltName: Full=RING finger and KH domain-
containing protein 4; [Homo sapiens (Human)] - [MEX3A_HUMAN] 
5.43E+08 
Scavenger receptor cysteine-rich type 1 protein M130 OS=Homo sapiens 
GN=CD163 PE=1 SV=2 
1.28E+07 
Selenium-binding protein 1 OS=Homo sapiens GN=SELENBP1 PE=1 SV=2 2.55E+07 
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A; 
Short=PP6-ARS-A; Short=Serine/threonine-protein phosphatase 6 regulatory subunit 
ARS-A; AltName: Full=Ankyrin repeat domain-containing protein 28; AltName: 
Full=Phosphatase interactor targeting protein hnRNP K; Short=PITK; [Homo 
sapiens (Human)] - [ANR28_HUMAN] 
3.40E+06 
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 4.55E+09 
Serpin B3 OS=Homo sapiens GN=SERPINB3 PE=1 SV=2 7.74E+06 
Serpin B6; AltName: Full=Cytoplasmic antiproteinase; Short=CAP; AltName: 
Full=Peptidase inhibitor 6; Short=PI-6; AltName: Full=Placental thrombin inhibitor; 
[Homo sapiens (Human)] - [SPB6_HUMAN] 
1.37E+06 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 3.32E+09 
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Sodium-dependent phosphate transport protein 2B; Short=Sodium-phosphate 
transport protein 2B; AltName: Full=Na(+)-dependent phosphate cotransporter 2B; 
AltName: Full=NaPi3b; AltName: Full=Sodium/phosphate cotransporter 2B; 
Short=Na(+)/Pi cotransporter 2B; Short=NaPi-2b; AltName: Full=Solute carrier 
family 34 member 2; [Homo sapiens (Human)] - [NPT2B_HUMAN] 
2.12E+06 
Spectrin beta chain, brain 2; AltName: Full=Beta-III spectrin; AltName: 
Full=Spectrin, non-erythroid beta chain 2; [Homo sapiens (Human)] - 
[SPTN2_HUMAN] 
2.24E+07 
Superoxide dismutase [Cu-Zn] OS=Homo sapiens GN=SOD1 PE=1 SV=2 6.94E+06 
Sushi domain-containing protein 2 OS=Homo sapiens GN=SUSD2 PE=1 SV=1 9.38E+06 
Tetraspanin-1; Short=Tspan-1; AltName: Full=Tetraspan NET-1; AltName: 
Full=Tetraspanin TM4-C; [Homo sapiens (Human)] - [TSN1_HUMAN] 
2.59E+06 
Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 1.15E+07 
Thyroxine-binding globulin OS=Homo sapiens GN=SERPINA7 PE=1 SV=2 8.96E+06 
Transaldolase OS=Homo sapiens GN=TALDO1 PE=1 SV=2 2.30E+07 
Transcriptional adapter 2-beta; AltName: Full=ADA2-like protein beta; 
Short=ADA2-beta; [Homo sapiens (Human)] - [TAD2B_HUMAN] 
3.36E+06 
Transmembrane protease serine 13; EC=3.4.21.-; AltName: Full=Membrane-type 
mosaic serine protease; Short=Mosaic serine protease; [Homo sapiens (Human)] - 
[TMPSD_HUMAN] 
2.98E+07 
Transmembrane protein 198; [Homo sapiens (Human)] - [TM198_HUMAN] 1.29E+07 
Transmembrane protein 200C; AltName: Full=Transmembrane protein TTMA; 
AltName: Full=Two transmembrane domain-containing family member A; [Homo 
sapiens (Human)] - [T200C_HUMAN] 
2.80E+06 
Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 2.05E+07 
Trypsin-3; EC=3.4.21.4; AltName: Full=Brain trypsinogen; AltName: 
Full=Mesotrypsinogen; AltName: Full=Serine protease 3; AltName: Full=Serine 
protease 4; AltName: Full=Trypsin III; AltName: Full=Trypsin IV; Flags: Precursor; 
[Homo sapiens (Human)] - [TRY3_HUMAN] 
2.49E+06 
Uncharacterized protein C19orf68; [Homo sapiens (Human)] - [CS068_HUMAN] 1.26E+07 
Uncharacterized protein C3orf38; [Homo sapiens (Human)] - [CC038_HUMAN] 2.18E+09 
UPF0556 protein C19orf10; AltName: Full=Interleukin-25; Short=IL-25; AltName: 
Full=Stromal cell-derived growth factor SF20; Flags: Precursor; [Homo sapiens 
(Human)] - [CS010_HUMAN] 
3.69E+06 
Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=1 SV=1 4.14E+08 
V-set and immunoglobulin domain-containing protein 4; AltName: Full=Protein 
Z39Ig; Flags: Precursor; [Homo sapiens (Human)] - [VSIG4_HUMAN] 
1.67E+06 
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 2.16E+08 
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 2.16E+08 
Voltage-gated potassium channel subunit beta-1; AltName: Full=K(+) channel 
subunit beta-1; AltName: Full=Kv-beta-1; [Homo sapiens (Human)] - 
[KCAB1_HUMAN] 
9.03E+07 
Xin actin-binding repeat-containing protein 2; AltName: Full=Beta-xin; AltName: 
Full=Cardiomyopathy-associated protein 3; AltName: Full=Xeplin; [Homo sapiens 
(Human)] - [XIRP2_HUMAN] 
1.92E+08 
Zinc finger protein 784; [Homo sapiens (Human)] - [ZN784_HUMAN] 9.62E+05 







Table A.3: Alveolar proteins identified by 1D PAGE and nano LC MS/MS in healthy and 
mild asthmatic RTLFs. The 140 proteins common to both healthy and mild asthmatic 
subjects investigated, n=5 for both subject groups, alongside the mean of the three most 
abundant ion peaks of each respective protein identified,.Accession numbers included are 
according to entries in UniProtKB/Swiss-Prot.  
 
Healthy Control Mild asthmatic 
14-3-3 protein beta/alpha 
OS=Homo sapiens GN=YWHAB 
PE=1 SV=3 
1.07E+08 
14-3-3 protein beta/alpha; AltName: 
Full=Protein 1054; AltName: 
Full=Protein kinase C inhibitor 
protein 1; Short=KCIP-1; Contains: 
RecName: Full=14-3-3 protein 
beta/alpha, N-terminally processed; 




14-3-3 protein epsilon OS=Homo 
sapiens GN=YWHAE PE=1 SV=1 
9.02E+07 
14-3-3 protein epsilon OS=Homo 
sapiens GN=YWHAE PE=1 SV=1 
1.49E+0
7 
14-3-3 protein zeta/delta OS=Homo 
sapiens GN=YWHAZ PE=1 SV=1 
1.07E+08 
14-3-3 protein zeta/delta OS=Homo 
sapiens GN=YWHAZ PE=1 SV=1 
1.82E+0
7 
28S ribosomal protein S26, 
mitochondrial; Short=MRP-S26; 
Short=S26mt; AltName: Full=28S 
ribosomal protein S13, 
mitochondrial; Short=MRP-S13; 
Short=S13mt; Flags: Precursor; 
[Homo sapiens (Human)] - 
[RT26_HUMAN] 
4.89E+07 
28S ribosomal protein S26, 
mitochondrial; Short=MRP-S26; 
Short=S26mt; AltName: Full=28S 
ribosomal protein S13, 
mitochondrial; Short=MRP-S13; 
Short=S13mt; Flags: Precursor; 




Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 
5.55E+07 
Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 
3.03E+0
7 
Afamin OS=Homo sapiens 
GN=AFM PE=1 SV=1 
2.55E+07 
Afamin OS=Homo sapiens 
GN=AFM PE=1 SV=1 
7.98E+0
6 
Aldose 1-epimerase OS=Homo 
sapiens GN=GALM PE=1 SV=1 
2.77E+06 
Aldose 1-epimerase OS=Homo 
sapiens GN=GALM PE=1 SV=1 
3.53E+0
6 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 
2.04E+08 
Alpha-1-acid glycoprotein 1 




Alpha-1-acid glycoprotein 2 
OS=Homo sapiens GN=ORM2 
PE=1 SV=2 
1.81E+08 
Alpha-1-acid glycoprotein 2 






















sapiens GN=A1BG PE=1 SV=4 
1.36E+08 
Alpha-1B-glycoprotein OS=Homo 












sapiens GN=A2M PE=1 SV=3 
6.75E+07 
Alpha-2-macroglobulin OS=Homo 






sapiens GN=AGT PE=1 SV=1 
9.61E+07 
Angiotensinogen OS=Homo sapiens 
GN=AGT PE=1 SV=1 
1.95E+0
7 
Annexin A5 OS=Homo sapiens 
GN=ANXA5 PE=1 SV=2 
6.60E+07 
Annexin A5 OS=Homo sapiens 




sapiens GN=SERPINC1 PE=1 
SV=1 
2.92E+07 
Antithrombin-III OS=Homo sapiens 
GN=SERPINC1 PE=1 SV=1 
7.80E+0
6 
Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 SV=1 
9.59E+07 
Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 SV=1 
1.55E+0
8 
Apolipoprotein A-II OS=Homo 
sapiens GN=APOA2 PE=1 SV=1 
2.59E+07 
Apolipoprotein A-II OS=Homo 
sapiens GN=APOA2 PE=1 SV=1 
1.84E+0
7 
Apolipoprotein A-IV OS=Homo 
sapiens GN=APOA4 PE=1 SV=3 
1.04E+07 
Apolipoprotein A-IV OS=Homo 
sapiens GN=APOA4 PE=1 SV=3 
7.77E+0
6 
ATP-binding cassette sub-family C 
member 8; AltName: 
Full=Sulfonylurea receptor 1; 
[Homo sapiens (Human)] - 
[ABCC8_HUMAN] 
6.85E+07 
ATP-binding cassette sub-family C 
member 8; AltName: 
Full=Sulfonylurea receptor 1; [Homo 




Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 
1.13E+07 
Attractin OS=Homo sapiens 




sapiens GN=B2M PE=1 SV=1 
1.20E+08 
Beta-2-microglobulin OS=Homo 
sapiens GN=B2M PE=1 SV=1 
6.95E+0
7 
Biotinidase OS=Homo sapiens 
GN=BTD PE=1 SV=2 
1.19E+07 
Biotinidase OS=Homo sapiens 
GN=BTD PE=1 SV=2 
6.35E+0
6 
Calmodulin OS=Homo sapiens 
GN=CALM1 PE=1 SV=2 
3.58E+07 
Calmodulin OS=Homo sapiens 
GN=CALM1 PE=1 SV=2 
1.93E+0
7 
Carbonic anhydrase 1 OS=Homo 
sapiens GN=CA1 PE=1 SV=2 
2.36E+07 
Carbonic anhydrase 1 OS=Homo 
sapiens GN=CA1 PE=1 SV=2 
2.40E+0
7 
Carbonic anhydrase 2 OS=Homo 
sapiens GN=CA2 PE=1 SV=2 
9.50E+06 
Carbonic anhydrase 2 OS=Homo 




containing protein 6; [Homo 




containing protein 6; [Homo sapiens 
(Human)] - [CARD6_HUMAN] 
1.40E+0
8 
Cathepsin D OS=Homo sapiens 
GN=CTSD PE=1 SV=1 
1.10E+09 
Cathepsin D OS=Homo sapiens 
GN=CTSD PE=1 SV=1 
4.60E+0
8 
CD44 antigen OS=Homo sapiens 
GN=CD44 PE=1 SV=3 
7.78E+07 
CD44 antigen OS=Homo sapiens 
GN=CD44 PE=1 SV=3 
5.58E+0
7 
CD9 antigen OS=Homo sapiens 
GN=CD9 PE=1 SV=4 
2.20E+07 
CD9 antigen OS=Homo sapiens 
GN=CD9 PE=1 SV=4 
1.45E+0
7 
Cell adhesion molecule 1; 
AltName: Full=Immunoglobulin 
superfamily member 4; 
Short=IgSF4; AltName: 





Full=Synaptic cell adhesion 
molecule; Short=SynCAM; 
AltName: Full=Tumor suppressor 
7.37E+06 
Cell adhesion molecule 1 OS=Homo 





in lung cancer 1; Short=TSLC-1; 
Flags: Precursor; [Homo sapiens 
(Human)] - [CADM1_HUMAN] 
Ceruloplasmin OS=Homo sapiens 
GN=CP PE=1 SV=1 
5.37E+08 
Ceruloplasmin OS=Homo sapiens 







Short=CGB-PDE; [Homo sapiens 






Short=CGB-PDE; [Homo sapiens 
(Human)] - [PDE5A_HUMAN] 
5.00E+0
7 
Coactosin-like protein OS=Homo 
sapiens GN=COTL1 PE=1 SV=3 
3.46E+07 
Coactosin-like protein OS=Homo 
sapiens GN=COTL1 PE=1 SV=3 
1.15E+0
7 
Complement C2 OS=Homo sapiens 
GN=C2 PE=1 SV=2 
6.82E+06 
Complement C2 OS=Homo sapiens 
GN=C2 PE=1 SV=2 
6.38E+0
6 
Complement C3 OS=Homo sapiens 
GN=C3 PE=1 SV=2 
1.25E+07 
Complement C3 OS=Homo sapiens 




factor OS=Homo sapiens 
GN=CD55 PE=1 SV=4 
1.49E+07 
Complement decay-accelerating 













Cystatin-B OS=Homo sapiens 
GN=CSTB PE=1 SV=2 
7.58E+06 
Cystatin-B OS=Homo sapiens 
GN=CSTB PE=1 SV=2 
6.67E+0
6 
Deleted in malignant brain tumors 1 
protein OS=Homo sapiens 
GN=DMBT1 PE=1 SV=2 
5.59E+07 
Deleted in malignant brain tumors 1 
protein OS=Homo sapiens 
GN=DMBT1 PE=1 SV=2 
3.56E+0
7 
Delta-like protein 4; AltName: 
Full=Drosophila Delta homolog 4; 
Short=Delta4; Flags: Precursor; 
[Homo sapiens (Human)] - 
[DLL4_HUMAN] 
1.80E+07 
Delta-like protein 4; AltName: 
Full=Drosophila Delta homolog 4; 
Short=Delta4; Flags: Precursor; 




Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 
6.20E+06 
Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 
3.67E+0
6 
Desmoplakin OS=Homo sapiens 
GN=DSP PE=1 SV=3 
1.60E+08 
Desmoplakin OS=Homo sapiens 
GN=DSP PE=1 SV=3 
2.67E+0
7 
Dipeptidyl peptidase 4 OS=Homo 
sapiens GN=DPP4 PE=1 SV=2 
1.64E+07 
Dipeptidyl peptidase 4 OS=Homo 
sapiens GN=DPP4 PE=1 SV=2 
1.11E+0
7 
Epididymal secretory protein E1 
OS=Homo sapiens GN=NPC2 
PE=1 SV=1 
5.26E+07 
Epididymal secretory protein E1 




FAS-associated factor 1; 
Short=hFAF1; AltName: 
Full=UBX domain-containing 
protein 12; AltName: Full=UBX 
domain-containing protein 3A; 
[Homo sapiens (Human)] - 
[FAF1_HUMAN] 
2.21E+08 
FAS-associated factor 1; 
Short=hFAF1; AltName: Full=UBX 
domain-containing protein 12; 
AltName: Full=UBX domain-
containing protein 3A; [Homo 




Fatty acid-binding protein, 
adipocyte OS=Homo sapiens 
GN=FABP4 PE=1 SV=3 
9.73E+06 
Fatty acid-binding protein, 
adipocyte; AltName: Full=Adipocyte 





AltName: Full=Adipocyte-type fatty 
acid-binding protein; Short=A-
FABP; Short=AFABP; AltName: 
Full=Fatty acid-binding protein 4; 
[Homo sapiens (Human)] - 
[FABP4_HUMAN] 
Folate receptor alpha OS=Homo 
sapiens GN=FOLR1 PE=1 SV=3 
3.11E+06 
Folate receptor alpha OS=Homo 





GN=LGALS3BP PE=1 SV=1 
1.14E+07 
Galectin-3-binding protein 




Glutathione S-transferase P 
OS=Homo sapiens GN=GSTP1 
PE=1 SV=2 
3.42E+07 
Glutathione S-transferase P 




Haptoglobin OS=Homo sapiens 
GN=HP PE=1 SV=1 
3.82E+08 
Haptoglobin OS=Homo sapiens 
GN=HP PE=1 SV=1 
1.13E+0
9 
Heme-binding protein 2; AltName: 
Full=Placental protein 23; 
Short=PP23; AltName: 
Full=Protein SOUL; [Homo sapiens 
(Human)] - [HEBP2_HUMAN] 
5.28E+06 
Heme-binding protein 2; AltName: 
Full=Placental protein 23; 
Short=PP23; AltName: Full=Protein 




Hemoglobin subunit alpha; 
AltName: Full=Alpha-globin; 
AltName: Full=Hemoglobin alpha 
chain; [Homo sapiens (Human)] - 
[HBA_HUMAN] 
2.06E+08 
Hemoglobin subunit alpha 




Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB PE=1 
SV=2 
2.06E+08 
Hemoglobin subunit beta OS=Homo 
sapiens GN=HBB PE=1 SV=2 
4.82E+0
8 
Hemoglobin subunit delta 
OS=Homo sapiens GN=HBD PE=1 
SV=2 
1.66E+08 
Hemoglobin subunit delta OS=Homo 
sapiens GN=HBD PE=1 SV=2 
3.78E+0
8 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 
7.70E+08 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 
4.44E+0
8 
Ig alpha-1 chain C region 
OS=Homo sapiens GN=IGHA1 
PE=1 SV=2 
2.81E+09 
Ig alpha-1 chain C region OS=Homo 
sapiens GN=IGHA1 PE=1 SV=2 
1.24E+0
9 
Ig alpha-2 chain C region 
OS=Homo sapiens GN=IGHA2 
PE=1 SV=3 
2.05E+09 
Ig alpha-2 chain C region OS=Homo 
sapiens GN=IGHA2 PE=1 SV=3 
8.46E+0
8 
Ig delta chain C region; [Homo 
sapiens (Human)] - 
[IGHD_HUMAN] 
6.39E+06 
Ig delta chain C region; [Homo 




Ig gamma-1 chain C region; [Homo 
sapiens (Human)] - 
[IGHG1_HUMAN] 
1.23E+10 
Ig gamma-1 chain C region 




Ig gamma-2 chain C region 
OS=Homo sapiens GN=IGHG2 
PE=1 SV=2 
9.10E+09 
Ig gamma-2 chain C region 




Ig gamma-3 chain C region 
OS=Homo sapiens GN=IGHG3 
PE=1 SV=2 
9.36E+09 
Ig gamma-3 chain C region 






Ig heavy chain V-II region ARH-77 
OS=Homo sapiens PE=4 SV=1 
7.57E+07 
Ig heavy chain V-II region ARH-77 
OS=Homo sapiens PE=4 SV=1 
1.73E+0
8 
Ig heavy chain V-II region NEWM; 
[Homo sapiens (Human)] - 
[HV207_HUMAN] 
1.14E+08 
Ig heavy chain V-II region NEWM; 




Ig heavy chain V-II region OU; 
[Homo sapiens (Human)] - 
[HV201_HUMAN] 
6.80E+07 
Ig heavy chain V-II region OU; 




Ig heavy chain V-III region BUT 
OS=Homo sapiens PE=1 SV=1 
1.16E+09 
Ig heavy chain V-III region BUT; 




Ig heavy chain V-III region CAM 
OS=Homo sapiens PE=1 SV=1 
1.22E+09 
Ig heavy chain V-III region CAM 
OS=Homo sapiens PE=1 SV=1 
5.71E+0
8 
Ig heavy chain V-III region GAL 
OS=Homo sapiens PE=1 SV=1 
1.17E+09 
Ig heavy chain V-III region GAL 
OS=Homo sapiens PE=1 SV=1 
4.86E+0
8 
Ig heavy chain V-III region GAR; 
[Homo sapiens (Human)] - 
[HV322_HUMAN] 
2.84E+08 
Ig heavy chain V-III region GAR; 




Ig heavy chain V-III region HIL; 
[Homo sapiens (Human)] - 
[HV310_HUMAN] 
1.66E+09 
Ig heavy chain V-III region HIL; 




Ig heavy chain V-III region VH26 
OS=Homo sapiens PE=1 SV=1 
1.25E+09 
Ig heavy chain V-III region VH26 
OS=Homo sapiens PE=1 SV=1 
5.29E+0
8 
Ig kappa chain C region OS=Homo 
sapiens GN=IGKC PE=1 SV=1 
5.90E+09 
Ig kappa chain C region OS=Homo 
sapiens GN=IGKC PE=1 SV=1 
1.00E+0
9 
Ig kappa chain V-I region EU 
OS=Homo sapiens PE=1 SV=1 
4.22E+08 
Ig kappa chain V-I region EU 
OS=Homo sapiens PE=1 SV=1 
1.95E+0
8 
Ig kappa chain V-I region Roy; 
[Homo sapiens (Human)] - 
[KV116_HUMAN] 
1.96E+08 
Ig kappa chain V-I region Roy; 




Ig kappa chain V-I region Wes; 
[Homo sapiens (Human)] - 
[KV119_HUMAN] 
5.03E+08 
Ig kappa chain V-I region Wes; 




Ig kappa chain V-III region POM 
OS=Homo sapiens PE=1 SV=1 
3.13E+08 
Ig kappa chain V-III region POM 
OS=Homo sapiens PE=1 SV=1 
1.01E+0
8 
Ig kappa chain V-III region SIE 
OS=Homo sapiens PE=1 SV=1 
3.17E+08 
Ig kappa chain V-III region SIE 
OS=Homo sapiens PE=1 SV=1 
1.59E+0
8 
Ig kappa chain V-III region VG; 
Flags: Precursor; Fragment; [Homo 
sapiens (Human)] - 
[KV309_HUMAN] 
3.81E+08 
Ig kappa chain V-III region VG; 
Flags: Precursor; Fragment; [Homo 




Ig lambda chain V-I region HA 
OS=Homo sapiens PE=1 SV=1 
2.17E+08 
Ig lambda chain V-I region HA 
OS=Homo sapiens PE=1 SV=1 
3.45E+0
7 
Ig lambda chain V-I region NIG-64 
OS=Homo sapiens PE=1 SV=1 
6.96E+07 
Ig lambda chain V-I region NIG-64 
OS=Homo sapiens PE=1 SV=1 
2.39E+0
7 
Ig lambda chain V-III region LOI 
OS=Homo sapiens PE=1 SV=1 
2.61E+08 
Ig lambda chain V-III region LOI 
OS=Homo sapiens PE=1 SV=1 
3.54E+0
7 
Ig lambda chain V-III region SH; 
[Homo sapiens (Human)] - 
[LV301_HUMAN] 
2.83E+07 
Ig lambda chain V-III region SH; 




Ig lambda chain V-IV region Bau; 4.40E+08 Ig lambda chain V-IV region Bau; 4.15E+0
250 
 
[Homo sapiens (Human)] - 
[LV401_HUMAN] 
[Homo sapiens (Human)] - 
[LV401_HUMAN] 
7 
Ig lambda chain V-IV region Hil; 
[Homo sapiens (Human)] - 
[LV403_HUMAN] 
2.91E+08 
Ig lambda chain V-IV region Hil; 




Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 
3.07E+09 
Ig lambda-2 chain C regions 




Ig mu chain C region OS=Homo 
sapiens GN=IGHM PE=1 SV=3 
6.47E+07 
Ig mu chain C region OS=Homo 
sapiens GN=IGHM PE=1 SV=3 
7.42E+0
7 
Immunoglobulin J chain OS=Homo 
sapiens GN=IGJ PE=1 SV=4 
8.29E+07 
Immunoglobulin J chain OS=Homo 




polypeptide 5; AltName: Full=G 
lambda-1; AltName: Full=Germline 
immunoglobulin lambda 1; Flags: 
Precursor; [Homo sapiens 
(Human)] - [IGLL5_HUMAN] 
1.96E+09 
Immunoglobulin lambda-like 
polypeptide 5 OS=Homo sapiens 
GN=IGLL5 PE=2 SV=2 
4.17E+0
8 
Intercellular adhesion molecule 1 
OS=Homo sapiens GN=ICAM1 
PE=1 SV=2 
4.01E+07 
Intercellular adhesion molecule 1 




Junctional adhesion molecule A 
OS=Homo sapiens GN=F11R PE=1 
SV=1 
5.60E+06 
Junctional adhesion molecule A 




Lactotransferrin OS=Homo sapiens 
























Leukocyte elastase inhibitor 
OS=Homo sapiens GN=SERPINB1 
PE=1 SV=1 
8.21E+06 
Leukocyte elastase inhibitor 




Lysozyme C OS=Homo sapiens 
GN=LYZ PE=1 SV=1 
2.75E+06 
Lysozyme C; EC=3.2.1.17; 
AltName: Full=1,4-beta-N-
acetylmuramidase C; Flags: 




Mesothelin OS=Homo sapiens 
GN=MSLN PE=1 SV=2 
1.78E+07 
Mesothelin OS=Homo sapiens 
GN=MSLN PE=1 SV=2 
1.74E+0
7 
Mucin-1 OS=Homo sapiens 
GN=MUC1 PE=1 SV=3 
1.31E+07 
Mucin-1 OS=Homo sapiens 
GN=MUC1 PE=1 SV=3 
8.52E+0
6 
Napsin-A OS=Homo sapiens 
GN=NAPSA PE=1 SV=1 
2.37E+06 
Napsin-A; EC=3.4.23.-; AltName: 





Short=ASP4; Short=Asp 4; 
AltName: Full=Napsin-1; AltName: 
Full=TA01/TA02; Flags: Precursor; 
[Homo sapiens (Human)] - 
[NAPSA_HUMAN] 
Neutrophil defensin 1 OS=Homo 
sapiens GN=DEFA1 PE=1 SV=1 
1.79E+06 
Neutrophil defensin 1; AltName: 
Full=Defensin, alpha 1; AltName: 
Full=HNP-1; Short=HP-1; 
Short=HP1; Contains: RecName: 
Full=HP 1-56; Contains: RecName: 
Full=Neutrophil defensin 2; 
AltName: Full=HNP-2; Short=HP-2; 
Short=HP2; Flags: Precursor; [Homo 













Peroxiredoxin-6 OS=Homo sapiens 
GN=PRDX6 PE=1 SV=3 
2.13E+06 
Peroxiredoxin-6 OS=Homo sapiens 




protein 1; Short=PEBP-1; 
AltName: Full=HCNPpp; AltName: 
Full=Neuropolypeptide h3; 
AltName: Full=Prostatic-binding 
protein; AltName: Full=Raf kinase 




Short=HCNP; [Homo sapiens 
(Human)] - [PEBP1_HUMAN] 
4.01E+06 
Phosphatidylethanolamine-binding 




protein; AltName: Full=Raf kinase 




Short=HCNP; [Homo sapiens 
(Human)] - [PEBP1_HUMAN] 
8.97E+0
5 
Phosphoglycerate mutase 1 
OS=Homo sapiens GN=PGAM1 
PE=1 SV=2 
3.87E+06 
Phosphoglycerate mutase 1 




Plasma protease C1 inhibitor 
OS=Homo sapiens GN=SERPING1 
PE=1 SV=2 
9.83E+06 
Plasma protease C1 inhibitor 





receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
5.24E+08 
Polymeric immunoglobulin receptor 




Pro-cathepsin H OS=Homo sapiens 
GN=CTSH PE=1 SV=4 
2.79E+07 
Pro-cathepsin H OS=Homo sapiens 
GN=CTSH PE=1 SV=4 
2.12E+0
7 
Protein DJ-1 OS=Homo sapiens 
GN=PARK7 PE=1 SV=2 
3.98E+07 
Protein DJ-1 OS=Homo sapiens 
GN=PARK7 PE=1 SV=2 
1.75E+0
7 
Protein S100-A11 OS=Homo 
sapiens GN=S100A11 PE=1 SV=2 
7.59E+06 
Protein S100-A11 OS=Homo sapiens 
GN=S100A11 PE=1 SV=2 
4.68E+0
6 
Protein S100-A6 OS=Homo 
sapiens GN=S100A6 PE=1 SV=1 
9.49E+07 
Protein S100-A6 OS=Homo sapiens 
GN=S100A6 PE=1 SV=1 
8.46E+0
7 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 
Short=hShrmL; [Homo sapiens 
8.34E+07 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 





(Human)] - [SHRM3_HUMAN] (Human)] - [SHRM3_HUMAN] 
Pulmonary surfactant-associated 
protein A2 OS=Homo sapiens 
GN=SFTPA2 PE=1 SV=1 
1.95E+08 
Pulmonary surfactant-associated 
protein A2 OS=Homo sapiens 




protein B OS=Homo sapiens 
GN=SFTPB PE=1 SV=3 
2.54E+07 
Pulmonary surfactant-associated 
protein B OS=Homo sapiens 




protein D OS=Homo sapiens 
GN=SFTPD PE=1 SV=3 
4.71E+07 
Pulmonary surfactant-associated 
protein D OS=Homo sapiens 













AltName: Full=Cytosol alanyl 
aminopeptidase; Short=AAP-S; 




Putative inactive carboxylesterase 
4; AltName: Full=Inactive 
carboxylesterase 1 pseudogene 1; 
AltName: Full=Placental 
carboxylesterase 3; Short=PCE-3; 
Flags: Precursor; [Homo sapiens 
(Human)] - [CES1P_HUMAN] 
4.34E+06 
Putative inactive carboxylesterase 4; 
AltName: Full=Inactive 
carboxylesterase 1 pseudogene 1; 
AltName: Full=Placental 
carboxylesterase 3; Short=PCE-3; 
Flags: Precursor; [Homo sapiens 
(Human)] - [CES1P_HUMAN] 
3.62E+0
6 
Putative V-set and immunoglobulin 
domain-containing protein 6 
OS=Homo sapiens GN=VSIG6 
PE=5 SV=2 
2.22E+08 
Putative V-set and immunoglobulin 
domain-containing protein 6 




Retinoic acid-induced protein 3 
OS=Homo sapiens GN=GPRC5A 
PE=1 SV=2 
1.29E+07 
Retinoic acid-induced protein 3 




Rho GDP-dissociation inhibitor 2 
OS=Homo sapiens GN=ARHGDIB 
PE=1 SV=3 
1.36E+09 
Rho GDP-dissociation inhibitor 2 




Ribonuclease P protein subunit p40; 
Short=RNaseP protein p40; 
EC=3.1.26.5; AltName: 
Full=RNase P subunit 1; [Homo 
sapiens (Human)] - 
[RPP40_HUMAN] 
1.42E+08 
Ribonuclease P protein subunit p40; 
Short=RNaseP protein p40; 
EC=3.1.26.5; AltName: Full=RNase 
P subunit 1; [Homo sapiens 
(Human)] - [RPP40_HUMAN] 
9.04E+0
7 
Scavenger receptor cysteine-rich 
type 1 protein M130 OS=Homo 
sapiens GN=CD163 PE=1 SV=2 
2.29E+07 
Scavenger receptor cysteine-rich 
type 1 protein M130 OS=Homo 
sapiens GN=CD163 PE=1 SV=2 
1.28E+0
7 
Selenium-binding protein 1 
OS=Homo sapiens 
GN=SELENBP1 PE=1 SV=2 
2.43E+07 
Selenium-binding protein 1 




Serotransferrin OS=Homo sapiens 
GN=TF PE=1 SV=3 
1.28E+10 
Serotransferrin OS=Homo sapiens 
GN=TF PE=1 SV=3 
4.55E+0
9 
Serpin B3 OS=Homo sapiens 
GN=SERPINB3 PE=1 SV=2 
3.01E+07 
Serpin B3 OS=Homo sapiens 
GN=SERPINB3 PE=1 SV=2 
7.74E+0
6 
Serpin B6; AltName: 
Full=Cytoplasmic antiproteinase; 
3.30E+06 







Full=Peptidase inhibitor 6; 
Short=PI-6; AltName: 
Full=Placental thrombin inhibitor; 
[Homo sapiens (Human)] - 
[SPB6_HUMAN] 
Short=CAP; AltName: 
Full=Peptidase inhibitor 6; Short=PI-
6; AltName: Full=Placental thrombin 
inhibitor; [Homo sapiens (Human)] - 
[SPB6_HUMAN] 
Serum albumin OS=Homo sapiens 
GN=ALB PE=1 SV=2 
3.97E+09 
Serum albumin OS=Homo sapiens 




transport protein 2B; 
Short=Sodium-phosphate transport 
protein 2B; AltName: Full=Na(+)-
dependent phosphate cotransporter 
2B; AltName: Full=NaPi3b; 
AltName: Full=Sodium/phosphate 
cotransporter 2B; Short=Na(+)/Pi 
cotransporter 2B; Short=NaPi-2b; 
AltName: Full=Solute carrier 
family 34 member 2; [Homo 




transport protein 2B; Short=Sodium-
phosphate transport protein 2B; 
AltName: Full=Na(+)-dependent 
phosphate cotransporter 2B; 
AltName: Full=NaPi3b; AltName: 
Full=Sodium/phosphate 
cotransporter 2B; Short=Na(+)/Pi 
cotransporter 2B; Short=NaPi-2b; 
AltName: Full=Solute carrier family 
34 member 2; [Homo sapiens 
(Human)] - [NPT2B_HUMAN] 
2.12E+0
6 
Superoxide dismutase [Cu-Zn] 
OS=Homo sapiens GN=SOD1 
PE=1 SV=2 
9.13E+06 
Superoxide dismutase [Cu-Zn] 








protein; Short=SASP; [Homo 
sapiens (Human)] - 
[THIO_HUMAN] 
1.30E+07 
Thioredoxin OS=Homo sapiens 












Transaldolase OS=Homo sapiens 
GN=TALDO1 PE=1 SV=2 
2.33E+07 
Transaldolase OS=Homo sapiens 
GN=TALDO1 PE=1 SV=2 
2.30E+0
7 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like protein 
beta; Short=ADA2-beta; [Homo 
sapiens (Human)] - 
[TAD2B_HUMAN] 
8.54E+06 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like protein 
beta; Short=ADA2-beta; [Homo 




Transmembrane protein 198; 
[Homo sapiens (Human)] - 
[TM198_HUMAN] 
4.77E+07 
Transmembrane protein 198; [Homo 




Transmembrane protein 200C; 
AltName: Full=Transmembrane 
protein TTMA; AltName: 
Full=Two transmembrane domain-
containing family member A; 
[Homo sapiens (Human)] - 
[T200C_HUMAN] 
2.87E+06 
Transmembrane protein 200C; 
AltName: Full=Transmembrane 
protein TTMA; AltName: Full=Two 
transmembrane domain-containing 
family member A; [Homo sapiens 
(Human)] - [T200C_HUMAN] 
2.80E+0
6 
Triosephosphate isomerase 3.83E+07 Triosephosphate isomerase 2.05E+0
254 
 
OS=Homo sapiens GN=TPI1 PE=1 
SV=3 
OS=Homo sapiens GN=TPI1 PE=1 
SV=3 
7 
Uncharacterized protein C3orf38; 
[Homo sapiens (Human)] - 
[CC038_HUMAN] 
4.10E+09 
Uncharacterized protein C3orf38; 




Uteroglobin OS=Homo sapiens 
GN=SCGB1A1 PE=1 SV=1 
6.27E+08 
Uteroglobin OS=Homo sapiens 
GN=SCGB1A1 PE=1 SV=1 
4.14E+0
8 
V-set and immunoglobulin domain-
containing protein 4; AltName: 
Full=Protein Z39Ig; Flags: 
Precursor; [Homo sapiens 
(Human)] - [VSIG4_HUMAN] 
8.17E+06 
V-set and immunoglobulin domain-
containing protein 4; AltName: 
Full=Protein Z39Ig; Flags: 




Vitamin D-binding protein 
OS=Homo sapiens GN=GC PE=1 
SV=1 
2.19E+08 
Vitamin D-binding protein 




Xin actin-binding repeat-containing 
protein 2 OS=Homo sapiens 
GN=XIRP2 PE=1 SV=2 
4.22E+08 
Xin actin-binding repeat-containing 
protein 2; AltName: Full=Beta-xin; 
AltName: Full=Cardiomyopathy-
associated protein 3; AltName: 
Full=Xeplin; [Homo sapiens 













Table A.4: The biological process classification of Metal handling according to Gene 
Ontology annotation of proteins identified. Data shown is a comparison of the mean of the 
three most abundant ion peaks of each protein identified, in Healthy Controls and Mild 
Asthmatics respectively, n=5 for both subject groups. 
 
Metal handling  Healthy control Mild Asthmatic 
Annexin A2 X 7.67E+06 
Annexin A3 X 1.29E+07 
Annexin A4 2.52E+07 X 
Annexin A5 6.60E+07 1.83E+07 
Calcyphosin X 2.67E+06 
Calmodulin 3.58E+07 1.93E+07 
Carbonic anhydrase 1 2.36E+07 2.40E+07 
Carbonic anhydrase 2  9.50E+06 6.78E+06 
Ceruloplasmin 5.37E+08 1.23E+08 
Complement decay-accelerating factor 1.49E+07 1.63E+07 
Ferritin heavy chain X 2.76E+06 
Gelsolin 9.95E+06 X 
Glutathione peroxidase 3  4.07E+06 X 
Hemoglobin subunit alpha 2.06E+08 6.04E+08 
Hemoglobin subunit beta 2.09E+08 4.82E+08 
Hemoglobin subunit delta 1.66E+08 3.78E+08 
Hemopexin 7.70E+08 4.44E+08 
Hornerin 4.56E+06 X 
Kininogen-1 5.17E+06 X 
Lactotransferrin 1.38E+09 7.34E+08 
Neutrophil gelatinase-associated lipocalin 4.22E+06 X 
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Probable hydrolase PNKD 1.07E+07 X 
Protein S100-A11 7.59E+06 4.68E+06 
Protein S100-A3  1.22E+07 X 
Protein S100-A6 X 8.46E+07 
Retinoic acid-induced protein 3 X 3.24E+07 
Selenium-binding protein 1  2.43E+07 2.55E+07 
Serotransferrin  1.28E+10 4.55E+09 
Serum albumin  3.97E+09 3.32E+09 
Superoxide dismutase [Cu-Zn]  9.13E+06 6.94E+06 
Zinc-alpha-2-glycoprotein 1.16E+08 1.08E+08 
 
 
Table A.5: The biological process classification of Inflammation/immunity according to 
Gene Ontology annotation of proteins identified. Data shown is a comparison of the mean 
of the three most abundant ion peaks of each protein identified, in Healthy Controls and 
Mild Asthmatics respectively, n=5 for both subject groups. 
 
Inflammation/immunity  Healthy control Mild Asthmatic 
Alpha-1-acid glycoprotein 1 2.04E+08 2.89E+08 
Alpha-1-antichymotrypsin 1.49E+08 3.86E+07 
Alpha-1-antichymotrypsin 1.49E+08 3.86E+07 
Alpha-2-HS-glycoprotein (fetuin A) 7.52E+07 1.13E+08 
Annexin A3 X 1.29E+07 
Antithrombin-III 2.92E+07 7.80E+06 
Beta-2-microglobulin 1.20E+08 6.95E+07 
Beta-microseminoprotein 5.82E+07 X 
Cell adhesion molecule 1 7.37E+06 3.41E+06 
Cell adhesion molecule 2 X 4.06E+06 
Complement C2 6.82E+06 6.38E+06 
Complement C3 1.25E+07 2.94E+07 




Deleted in malignant brain tumors 1 
protein 
5.59E+07 3.56E+07 
Dipeptidyl peptidase 4 1.64E+07 1.11E+07 
Galectin-3 binding protein 1.14E+07 3.89E+06 
Haptoglobin 3.82E+08 1.13E+09 
HLA class II histocompatibility 
antigen, DR alpha chain 
X 3.67E+06 
HLA class II histocompatibility 
antigen, DRB1-15 beta chain 
7.37E+06 9.93E+06 
Ig alpha-1 chain C region  2.81E+09 1.24E+09 
Ig alpha-2 chain C region  2.05E+09 8.46E+08 
Ig delta chain C region  6.39E+06 8.04E+06 
Ig gamma-1 chain C region  1.23E+10 3.04E+09 
Ig gamma-2 chain C region  9.10E+09 2.20E+09 
Ig gamma-3 chain C region  9.36E+09 2.52E+09 
Ig gamma-4 chain C region 9.10E+09 X 
Ig heavy chain V-I region HG3 2.14E+08 5.87E+07 
Ig heavy chain V-I region V35 6.05E+07 1.96E+07 
Ig heavy chain V-II region ARH-77  7.57E+07 3.81E+07 
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Ig heavy chain V-III region CAM 1.22E+09 5.71E+08 
Ig heavy chain V-III region GAL  1.17E+09 4.86E+08 
Ig kappa chain C region  5.90E+09 1.00E+09 
Ig kappa chain V-I region DEE  4.84E+08 X 
Ig kappa chain V-I region Kue  X 1.92E+08 
Ig kappa chain V-II region TEW X 1.29E+08 
Ig kappa chain V-III region POM 3.13E+08 1.01E+08 
Ig kappa chain V-III region SIE  3.17E+08 1.59E+08 
Ig kappa chain V-IV region Len 1.66E+08 6.04E+07 
Ig lambda chain V region 4A 1.06E+08 9.96E+06 
Ig lambda chain V-I region HA 2.17E+08 3.45E+07 
Ig lambda chain V-I region NIG-64  6.96E+07 2.39E+07 
Ig lambda chain V-III region LOI  2.61E+08 3.54E+07 
Ig lambda chain V-III region SH  2.83E+07 1.90E+07 
Ig lambda chain V-VI region SUT  2.58E+07 X 
Ig lambda-2 chain C regions 3.07E+09 7.00E+08 
Ig mu chain C region 6.47E+07 7.42E+07 
IgBF 5.82E+07 X 
Immunoglobulin J chain 8.29E+07 8.35E+07 
Immunoglobulin lambda-like 
polypeptide 5  
1.96E+09 4.17E+08 
Intercellular adhesion molecule 1 4.01E+07 1.77E+07 
Junctional adhesion molecule A 5.60E+06 9.69E+06 
Lactotransferrin 1.38E+09 7.34E+08 
Leukocyte elastase inhibitor 8.21E+06 9.09E+06 
Lysozyme C 2.75E+06 4.75E+05 




Plasma protease C1 inhibitor 9.83E+06 6.56E+06 







Sushi domain-containing protein 2 X 9.38E+06 
V-set and immunoglobulin domain-
containing protein 6 
2.22E+08 
7.72E+07 
V-set and immunoglobulin domain-
containing protein 8 
3.05E+07 X 




Table A.6: The biological process classification of Oxidant/antioxidant balance  to Gene 
Ontology annotation of proteins identified. Data shown is a comparison of the mean of the 
three most abundant ion peaks of each protein identified, in Healthy Controls and Mild 




Table A7.: The biological process classification of Protease/antiprotease balance to Gene 
Ontology annotation of proteins identified. Data shown is a comparison of the mean of the 
three most abundant ion peaks of each protein identified, in Healthy Controls and Mild 
Asthmatics respectively, n=5 for both subject groups. 
Oxidant/antioxidant balance  Healthy control Mild Asthmatic 
Glutathione peroxidase 3  4.07E+06 X 
Glutathione S-transferase A1 X 1.83E+07 
Glutathione S-transferase A2 5.83E+07 X 
Glutathione S-transferase omega-1 6.98E+06 X 
Glutathione S-transferase P 3.42E+07 9.57E+06 
Peroxiredoxin-5, mitochondrial 6.12E+06 X 
Peroxiredoxin-6  2.13E+06 X 
Protein DJ-1  3.98E+07 1.75E+07 
Superoxide dismutase [Cu-Zn] 9.13E+06 6.94E+06 
Thioredoxin 1.30E+07 1.15E+07 
Protease/antiprotease balance   Healthy control Mild Asthmatic 
Alpha-1-antichymotrypsin 1.49E+08 3.86E+07 
Alpha-1-antitrypsin 2.69E+09 7.42E+08 
Alpha-2-macroglobulin 6.75E+07 6.40E+07 
Alpha-N-acetylglucosaminidase X 1.61E+06 
Angiotensin-converting enzyme; 
Dipeptidyl carboxypeptidase I 
2.86E+07 X 
Antithrombin-III 2.92E+07 7.80E+06 
Cathepsin D 1.10E+09 4.60E+08 
Cathepsin Z 4.01E+06 X 
Complement C2 6.82E+06 6.38E+06 
Cystatin-B 7.58E+06 6.67E+06 
Dermcidin 6.20E+06 3.67E+06 
Dipeptidyl peptidase 4 1.64E+07 1.11E+07 
Gastricsin 7.66E+06 1.71E+07 




Lactotransferrin 1.38E+09 7.34E+08 
Latexin X 2.49E+08 




Matrix metalloproteinase-23 2.66E+06 X 
Matrix metalloproteinase-28   x 
Napsin-A 2.37E+06 1.75E+07 
Pancreatic alpha-amylase X 7.36E+06 
Pro-cathepsin H 2.79E+07 2.12E+07 
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Probable hydrolase PNKD 1.07E+07 X 
Prostasin 2.41E+06 2.35E+06 
Proteasome subunit alpha type-1 X 3.32E+07 
Protein DJ-1 3.98E+07 1.75E+07 
Serpin B6 X 1.37E+06 
Transmembrane protease serine 13 X 2.98E+07 
Trypsin-3 X 2.49E+06 





Table. B.1: All alveolar proteins identified by 1D PAGE and nano LC MS/MS in healthy control 
RTLFs. The 199 proteins identified in healthy control subjects investigated, (n=5), alongside the 
mean of the three most abundant ion peaks of each respective protein identified. Accession 
numbers included according to entries in UniProtKB/Swiss-Prot 
Healthy Control 
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 1.28E+10 
Ig gamma-1 chain C region; [Homo sapiens (Human)] - [IGHG1_HUMAN] 1.23E+10 
Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=1 SV=2 9.36E+09 
Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2 9.10E+09 
Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 9.10E+09 
Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 5.90E+09 
Uncharacterized protein C3orf38; [Homo sapiens (Human)] - 
[CC038_HUMAN] 4.10E+09 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 3.97E+09 
Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 SV=1 3.07E+09 
Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 2.81E+09 
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 2.69E+09 
Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 2.05E+09 
Immunoglobulin lambda-like polypeptide 5; AltName: Full=G lambda-1; 
AltName: Full=Germline immunoglobulin lambda 1; Flags: Precursor; [Homo 
sapiens (Human)] - [IGLL5_HUMAN] 
1.96E+09 
Ig heavy chain V-III region HIL; [Homo sapiens (Human)] - 
[HV310_HUMAN] 1.66E+09 
Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 1.38E+09 
Rho GDP-dissociation inhibitor 2 OS=Homo sapiens GN=ARHGDIB PE=1 
SV=3 
1.36E+09 
Ig heavy chain V-III region VH26 OS=Homo sapiens PE=1 SV=1 1.25E+09 
Ig heavy chain V-III region CAM OS=Homo sapiens PE=1 SV=1 1.22E+09 
Ig heavy chain V-III region BRO; [Homo sapiens (Human)] - 
[HV305_HUMAN] 1.19E+09 
Ig heavy chain V-III region TUR; [Homo sapiens (Human)] - 
[HV318_HUMAN] 1.18E+09 
Ig heavy chain V-III region GAL OS=Homo sapiens PE=1 SV=1 1.17E+09 
Ig heavy chain V-III region BUT OS=Homo sapiens PE=1 SV=1 1.16E+09 
Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 1.10E+09 
Probable E3 ubiquitin-protein ligase HERC6; EC=6.3.2.-; AltName: 
Full=HECT domain and RCC1-like domain-containing protein 6; [Homo 
sapiens (Human)] - [HERC6_HUMAN] 8.68E+08 
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 7.70E+08 
Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=1 SV=1 6.27E+08 
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 5.37E+08 
Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 
SV=4 
5.24E+08 
Ig kappa chain V-I region Wes; [Homo sapiens (Human)] - 
[KV119_HUMAN] 5.03E+08 
Ig kappa chain V-I region DEE OS=Homo sapiens PE=1 SV=1 4.84E+08 
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Ig kappa chain V-I region WAT; [Homo sapiens (Human)] - 
[KV125_HUMAN] 4.74E+08 
Ig lambda chain V-IV region Bau; [Homo sapiens (Human)] - 
[LV401_HUMAN] 4.40E+08 
Ig kappa chain V-I region EU OS=Homo sapiens PE=1 SV=1 4.22E+08 
Xin actin-binding repeat-containing protein 2 OS=Homo sapiens GN=XIRP2 
PE=1 SV=2 
4.22E+08 
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 3.82E+08 
Ig kappa chain V-III region VG; Flags: Precursor; Fragment; [Homo sapiens 
(Human)] - [KV309_HUMAN] 3.81E+08 
Ig kappa chain V-III region SIE OS=Homo sapiens PE=1 SV=1 3.17E+08 
Ig kappa chain V-III region POM OS=Homo sapiens PE=1 SV=1 3.13E+08 
Ig kappa chain V-II region GM607; Flags: Precursor; Fragment; [Homo 
sapiens (Human)] - [KV205_HUMAN] 2.91E+08 
Ig lambda chain V-IV region Hil; [Homo sapiens (Human)] - 
[LV403_HUMAN] 2.91E+08 
Ig heavy chain V-III region GAR; [Homo sapiens (Human)] - 
[HV322_HUMAN] 2.84E+08 
Ig lambda chain V-III region LOI OS=Homo sapiens PE=1 SV=1 2.61E+08 
Ig kappa chain V-I region Scw; [Homo sapiens (Human)] - 
[KV117_HUMAN] 2.48E+08 
Caspase recruitment domain-containing protein 6; [Homo sapiens (Human)] - 
[CARD6_HUMAN] 2.40E+08 
Ig kappa chain V-III region Ti; [Homo sapiens (Human)] - [KV304_HUMAN] 2.35E+08 
Putative V-set and immunoglobulin domain-containing protein 6 OS=Homo 
sapiens GN=VSIG6 PE=5 SV=2 
2.22E+08 
FAS-associated factor 1; Short=hFAF1; AltName: Full=UBX domain-
containing protein 12; AltName: Full=UBX domain-containing protein 3A; 
[Homo sapiens (Human)] - [FAF1_HUMAN] 2.21E+08 
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 2.19E+08 
Ig lambda chain V-I region HA OS=Homo sapiens PE=1 SV=1 2.17E+08 
Ig heavy chain V-I region HG3; Flags: Precursor; [Homo sapiens (Human)] - 
[HV102_HUMAN] 2.14E+08 
Hemoglobin subunit alpha; AltName: Full=Alpha-globin; AltName: 
Full=Hemoglobin alpha chain; [Homo sapiens (Human)] - [HBA_HUMAN] 2.06E+08 
Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 2.06E+08 
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 2.04E+08 
Ig kappa chain V-I region Roy; [Homo sapiens (Human)] - [KV116_HUMAN] 1.96E+08 
Pulmonary surfactant-associated protein A2 OS=Homo sapiens GN=SFTPA2 
PE=1 SV=1 
1.95E+08 
Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2 1.81E+08 
Ig kappa chain V-III region NG9; Flags: Precursor; Fragment; [Homo sapiens 
(Human)] - [KV303_HUMAN] 1.74E+08 
Hemoglobin subunit delta OS=Homo sapiens GN=HBD PE=1 SV=2 1.66E+08 
Ig kappa chain V-IV region Len OS=Homo sapiens PE=1 SV=2 1.66E+08 
Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 1.60E+08 
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 1.49E+08 
Ribonuclease P protein subunit p40; Short=RNaseP protein p40; EC=3.1.26.5; 
AltName: Full=RNase P subunit 1; [Homo sapiens (Human)] - 
[RPP40_HUMAN] 1.42E+08 
Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein; 1.41E+08 
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Short=P-Rex1; Short=PtdIns(3,4,5)-dependent Rac exchanger 1; [Homo 
sapiens (Human)] - [PREX1_HUMAN] 
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 1.36E+08 
Ig lambda chain V-I region WAH OS=Homo sapiens PE=1 SV=1 1.26E+08 
cGMP-specific 3',5'-cyclic phosphodiesterase; EC=3.1.4.35; AltName: 
Full=cGMP-binding cGMP-specific phosphodiesterase; Short=CGB-PDE; 
[Homo sapiens (Human)] - [PDE5A_HUMAN] 1.22E+08 
Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 1.20E+08 
Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 1.16E+08 
Ig kappa chain V-I region Ni; [Homo sapiens (Human)] - [KV121_HUMAN] 1.15E+08 
Ig heavy chain V-II region NEWM; [Homo sapiens (Human)] - 
[HV207_HUMAN] 1.14E+08 
LIM domain only protein 7; Short=LMO-7; AltName: Full=F-box only protein 
20; AltName: Full=LOMP; [Homo sapiens (Human)] - [LMO7_HUMAN] 1.14E+08 
Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 1.12E+08 
14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 1.07E+08 
14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 1.07E+08 
14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 1.07E+08 
Ig lambda chain V region 4A OS=Homo sapiens PE=4 SV=1 1.06E+08 
Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 9.61E+07 
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 9.59E+07 
Protein S100-A6 OS=Homo sapiens GN=S100A6 PE=1 SV=1 9.49E+07 
Ig kappa chain V-IV region JI; Flags: Precursor; [Homo sapiens (Human)] - 
[KV403_HUMAN] 9.06E+07 
14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 9.02E+07 
Protein Shroom3; AltName: Full=Shroom-related protein; Short=hShrmL; 
[Homo sapiens (Human)] - [SHRM3_HUMAN] 8.34E+07 
Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 8.29E+07 
Histone-lysine N-methyltransferase MLL3 OS=Homo sapiens GN=MLL3 
PE=1 SV=3 
7.98E+07 
Pre-mRNA cleavage complex 2 protein Pcf11; AltName: Full=Pre-mRNA 
cleavage complex II protein Pcf11; [Homo sapiens (Human)] - 
[PCF11_HUMAN] 7.88E+07 
CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=3 7.78E+07 
Ig heavy chain V-II region ARH-77 OS=Homo sapiens PE=4 SV=1 7.57E+07 
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 7.52E+07 
Ig lambda chain V-I region NIG-64 OS=Homo sapiens PE=1 SV=1 6.96E+07 
ATP-binding cassette sub-family C member 8; AltName: Full=Sulfonylurea 
receptor 1; [Homo sapiens (Human)] - [ABCC8_HUMAN] 6.85E+07 
Coiled-coil domain-containing protein 37; [Homo sapiens (Human)] - 
[CCD37_HUMAN] 6.84E+07 
Ig heavy chain V-II region OU; [Homo sapiens (Human)] - 
[HV201_HUMAN] 6.80E+07 
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 6.75E+07 
Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 6.60E+07 
Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 6.47E+07 
Ig heavy chain V-I region V35 OS=Homo sapiens PE=1 SV=1 6.05E+07 
Glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 2; 
EC=2.6.1.16; AltName: Full=D-fructose-6-phosphate amidotransferase 2; 
AltName: Full=Glutamine:fructose 6 phosphate amidotransferase 2; 
Short=GFAT 2; Short=GFAT2; AltName: Full=Hexosephosphate 5.95E+07 
262 
 
aminotransferase 2; [Homo sapiens (Human)] - [GFPT2_HUMAN] 
Glutathione S-transferase A2 OS=Homo sapiens GN=GSTA2 PE=1 SV=4 5.83E+07 
Beta-microseminoprotein; AltName: Full=Immunoglobulin-binding factor; 
Short=IGBF; AltName: Full=PN44; AltName: Full=Prostate secreted seminal 
plasma protein; AltName: Full=Prostate secretory protein of 94 amino acids; 
Short=PSP-94; Short=PSP94; AltName: Full=Seminal plasma beta-inhibin; 
Flags: Precursor; [Homo sapiens (Human)] - [MSMB_HUMAN] 5.82E+07 
Deleted in malignant brain tumors 1 protein OS=Homo sapiens GN=DMBT1 
PE=1 SV=2 
5.59E+07 
Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 5.55E+07 
Epididymal secretory protein E1 OS=Homo sapiens GN=NPC2 PE=1 SV=1 5.26E+07 
Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 PE=1 
SV=1 
5.17E+07 
28S ribosomal protein S26, mitochondrial; Short=MRP-S26; Short=S26mt; 
AltName: Full=28S ribosomal protein S13, mitochondrial; Short=MRP-S13; 
Short=S13mt; Flags: Precursor; [Homo sapiens (Human)] - [RT26_HUMAN] 4.89E+07 
Transmembrane protein 198; [Homo sapiens (Human)] - [TM198_HUMAN] 4.77E+07 
Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 4.75E+07 
Pulmonary surfactant-associated protein D OS=Homo sapiens GN=SFTPD 
PE=1 SV=3 
4.71E+07 
G antigen family D member 2; AltName: Full=Cancer/testis antigen 12.1; 
Short=CT12.1; AltName: Full=Protein XAGE-1; [Homo sapiens (Human)] - 
[GAGD2_HUMAN] 4.41E+07 
Intercellular adhesion molecule 1 OS=Homo sapiens GN=ICAM1 PE=1 SV=2 4.01E+07 
Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 3.98E+07 
Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 3.83E+07 
Calmodulin OS=Homo sapiens GN=CALM1 PE=1 SV=2 3.58E+07 
Coactosin-like protein OS=Homo sapiens GN=COTL1 PE=1 SV=3 3.46E+07 
Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 3.42E+07 
Serpin B3 OS=Homo sapiens GN=SERPINB3 PE=1 SV=2 3.01E+07 
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 2.92E+07 
Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1 2.86E+07 
Ig lambda chain V-III region SH; [Homo sapiens (Human)] - 
[LV301_HUMAN] 
2.83E+07 
Pro-cathepsin H OS=Homo sapiens GN=CTSH PE=1 SV=4 2.79E+07 
Apolipoprotein A-II OS=Homo sapiens GN=APOA2 PE=1 SV=1 2.59E+07 
Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 2.55E+07 
Pulmonary surfactant-associated protein B OS=Homo sapiens GN=SFTPB 
PE=1 SV=3 
2.54E+07 
Annexin A4 OS=Homo sapiens GN=ANXA4 PE=1 SV=4 2.52E+07 
Selenium-binding protein 1 OS=Homo sapiens GN=SELENBP1 PE=1 SV=2 2.43E+07 
Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 2.36E+07 
Transaldolase OS=Homo sapiens GN=TALDO1 PE=1 SV=2 2.33E+07 
Scavenger receptor cysteine-rich type 1 protein M130 OS=Homo sapiens 
GN=CD163 PE=1 SV=2 
2.29E+07 
CD9 antigen OS=Homo sapiens GN=CD9 PE=1 SV=4 2.20E+07 
Complement C4-A; AltName: Full=Acidic complement C4; AltName: 
Full=C3 and PZP-like alpha-2-macroglobulin domain-containing protein 2; 
Contains: RecName: Full=Complement C4 beta chain; Contains: RecName: 
Full=Complement C4-A alpha chain; Contains: RecName: Full=C4a 
anaphylatoxin; Contains: RecName: Full=C4b-A; Contains: RecName: 1.80E+07 
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Full=C4d-A; Contains: RecName: Full=Complement C4 gamma chain; Flags: 
Precursor; [Homo sapiens (Human)] - [CO4A_HUMAN] 
Delta-like protein 4; AltName: Full=Drosophila Delta homolog 4; 
Short=Delta4; Flags: Precursor; [Homo sapiens (Human)] - [DLL4_HUMAN] 1.80E+07 
Mesothelin OS=Homo sapiens GN=MSLN PE=1 SV=2 1.78E+07 
Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2 1.64E+07 
Actin-related protein 2; AltName: Full=Actin-like protein 2; [Homo sapiens 
(Human)] - [ARP2_HUMAN] 1.56E+07 
Uncharacterized protein KIAA0947; [Homo sapiens (Human)] - 
[K0947_HUMAN] 1.56E+07 
Thyroxine-binding globulin OS=Homo sapiens GN=SERPINA7 PE=1 SV=2 1.56E+07 
Complement decay-accelerating factor OS=Homo sapiens GN=CD55 PE=1 
SV=4 
1.49E+07 
Aldo-keto reductase family 1 member C3; EC=1.-.-.-; AltName: Full=17-beta-
hydroxysteroid dehydrogenase type 5; Short=17-beta-HSD 5; AltName: 
Full=3-alpha-HSD type II, brain; AltName: Full=3-alpha-hydroxysteroid 
dehydrogenase type 2; Short=3-alpha-HSD type 2; EC=1.1.1.213; AltName: 
Full=Chlordecone reductase homolog HAKRb; AltName: Full=Dihydrodiol 
dehydrogenase 3; Short=DD-3; Short=DD3; AltName: Full=Dihydrodiol 
dehydrogenase type I; AltName: Full=HA1753; AltName: Full=Indanol 
dehydrogenase; EC=1.1.1.112; AltName: Full=Prostaglandin F synthase; 
Short=PGFS; EC=1.1.1.188; AltName: Full=Testosterone 17-beta-
dehydrogenase 5; EC=1.1.1.63; EC=1.1.1.64; AltName: Full=Trans-1,2-
dihydrobenzene-1,2-diol dehydrogenase; EC=1.3.1.20; [Homo sapiens 
(Human)] - [AK1C3_HUMAN] 1.46E+07 
Protein kinase-like protein SgK196; AltName: Full=Sugen kinase 196; [Homo 
sapiens (Human)] - [SG196_HUMAN] 1.39E+07 
Mucin-1 OS=Homo sapiens GN=MUC1 PE=1 SV=3 1.31E+07 
Thioredoxin; Short=Trx; AltName: Full=ATL-derived factor; Short=ADF; 
AltName: Full=Surface-associated sulphydryl protein; Short=SASP; [Homo 
sapiens (Human)] - [THIO_HUMAN] 1.30E+07 
Retinoic acid-induced protein 3 OS=Homo sapiens GN=GPRC5A PE=1 SV=2 1.29E+07 
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 1.25E+07 
Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 
SV=2 
1.19E+07 
Biotinidase OS=Homo sapiens GN=BTD PE=1 SV=2 1.19E+07 
Xaa-Pro dipeptidase; Short=X-Pro dipeptidase; EC=3.4.13.9; AltName: 
Full=Imidodipeptidase; AltName: Full=Peptidase D; AltName: Full=Proline 
dipeptidase; Short=Prolidase; [Homo sapiens (Human)] - [PEPD_HUMAN] 1.18E+07 
Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1 1.14E+07 
Puromycin-sensitive aminopeptidase; Short=PSA; EC=3.4.11.14; AltName: 
Full=Cytosol alanyl aminopeptidase; Short=AAP-S; [Homo sapiens (Human)] 
- [PSA_HUMAN] 1.13E+07 
SH3 domain-binding glutamic acid-rich-like protein 3; AltName: Full=SH3 
domain-binding protein 1; Short=SH3BP-1; [Homo sapiens (Human)] - 
[SH3L3_HUMAN] 1.13E+07 
Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2 1.13E+07 
Histone H3.3C; [Homo sapiens (Human)] - [H3C_HUMAN] 1.08E+07 
Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 SV=3 1.04E+07 
Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 9.95E+06 
Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 9.83E+06 
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Fatty acid-binding protein, adipocyte OS=Homo sapiens GN=FABP4 PE=1 
SV=3 
9.73E+06 
Ig lambda chain V-V region DEL; [Homo sapiens (Human)] - 
[LV501_HUMAN] 9.50E+06 
Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2 9.50E+06 
Superoxide dismutase [Cu-Zn] OS=Homo sapiens GN=SOD1 PE=1 SV=2 9.13E+06 
Transcriptional adapter 2-beta; AltName: Full=ADA2-like protein beta; 
Short=ADA2-beta; [Homo sapiens (Human)] - [TAD2B_HUMAN] 8.54E+06 
Leukocyte elastase inhibitor OS=Homo sapiens GN=SERPINB1 PE=1 SV=1 8.21E+06 
V-set and immunoglobulin domain-containing protein 4; AltName: 
Full=Protein Z39Ig; Flags: Precursor; [Homo sapiens (Human)] - 
[VSIG4_HUMAN] 8.17E+06 
Protein S100-A11 OS=Homo sapiens GN=S100A11 PE=1 SV=2 7.59E+06 
Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 7.58E+06 
Cell adhesion molecule 1; AltName: Full=Immunoglobulin superfamily 
member 4; Short=IgSF4; AltName: Full=Nectin-like protein 2; Short=NECL-
2; AltName: Full=Spermatogenic immunoglobulin superfamily; 
Short=SgIgSF; AltName: Full=Synaptic cell adhesion molecule; 
Short=SynCAM; AltName: Full=Tumor suppressor in lung cancer 1; 
Short=TSLC-1; Flags: Precursor; [Homo sapiens (Human)] - 
[CADM1_HUMAN] 7.37E+06 
Long palate, lung and nasal epithelium carcinoma-associated protein 1; 
AltName: Full=Von Ebner minor salivary gland protein; Short=VEMSGP; 
Flags: Precursor; [Homo sapiens (Human)] - [LPLC1_HUMAN] 7.16E+06 
Glutathione S-transferase omega-1 OS=Homo sapiens GN=GSTO1 PE=1 
SV=2 
6.98E+06 
Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2 6.82E+06 
Ig delta chain C region; [Homo sapiens (Human)] - [IGHD_HUMAN] 6.39E+06 
Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 6.20E+06 
Peroxiredoxin-5, mitochondrial OS=Homo sapiens GN=PRDX5 PE=1 SV=4 6.12E+06 
Vitamin K-dependent protein S; Flags: Precursor; [Homo sapiens (Human)] - 
[PROS_HUMAN] 6.05E+06 
Junctional adhesion molecule A OS=Homo sapiens GN=F11R PE=1 SV=1 5.60E+06 
Heme-binding protein 2; AltName: Full=Placental protein 23; Short=PP23; 
AltName: Full=Protein SOUL; [Homo sapiens (Human)] - [HEBP2_HUMAN] 5.28E+06 
Glyoxalase domain-containing protein 4 OS=Homo sapiens GN=GLOD4 
PE=1 SV=1 
5.28E+06 
Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 5.17E+06 
Prostaglandin-H2 D-isomerase; EC=5.3.99.2; AltName: Full=Beta-trace 
protein; AltName: Full=Cerebrin-28; AltName: Full=Glutathione-independent 
PGD synthase; AltName: Full=Lipocalin-type prostaglandin-D synthase; 
AltName: Full=Prostaglandin-D2 synthase; Short=PGD2 synthase; 
Short=PGDS; Short=PGDS2; Flags: Precursor; [Homo sapiens (Human)] - 
[PTGDS_HUMAN] 4.69E+06 
Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 4.56E+06 
Myoglobin; [Homo sapiens (Human)] - [MYG_HUMAN] 4.44E+06 
Putative inactive carboxylesterase 4; AltName: Full=Inactive carboxylesterase 
1 pseudogene 1; AltName: Full=Placental carboxylesterase 3; Short=PCE-3; 
Flags: Precursor; [Homo sapiens (Human)] - [CES1P_HUMAN] 4.34E+06 
Neutrophil gelatinase-associated lipocalin; Short=NGAL; AltName: Full=25 
kDa alpha-2-microglobulin-related subunit of MMP-9; AltName: 4.22E+06 
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Full=Lipocalin-2; AltName: Full=Oncogene 24p3; AltName: Full=p25; Flags: 
Precursor; [Homo sapiens (Human)] - [NGAL_HUMAN] 
Glutathione peroxidase 3 OS=Homo sapiens GN=GPX3 PE=1 SV=2 4.07E+06 
CD59 glycoprotein OS=Homo sapiens GN=CD59 PE=1 SV=1 4.04E+06 
Phosphatidylethanolamine-binding protein 1; Short=PEBP-1; AltName: 
Full=HCNPpp; AltName: Full=Neuropolypeptide h3; AltName: 
Full=Prostatic-binding protein; AltName: Full=Raf kinase inhibitor protein; 
Short=RKIP; Contains: RecName: Full=Hippocampal cholinergic 
neurostimulating peptide; Short=HCNP; [Homo sapiens (Human)] - 
[PEBP1_HUMAN] 4.01E+06 
Phosphoglycerate mutase 1 OS=Homo sapiens GN=PGAM1 PE=1 SV=2 3.87E+06 
Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2 3.79E+06 
Thioredoxin domain-containing protein 17; AltName: Full=14 kDa 
thioredoxin-related protein; Short=TRP14; AltName: Full=Protein 42-9-9; 
AltName: Full=Thioredoxin-like protein 5; [Homo sapiens (Human)] - 
[TXD17_HUMAN] 3.64E+06 
Serpin B6; AltName: Full=Cytoplasmic antiproteinase; Short=CAP; AltName: 
Full=Peptidase inhibitor 6; Short=PI-6; AltName: Full=Placental thrombin 
inhibitor; [Homo sapiens (Human)] - [SPB6_HUMAN] 3.30E+06 
Eosinophil lysophospholipase; EC=3.1.1.5; AltName: Full=Charcot-Leyden 
crystal protein; Short=CLC; AltName: Full=Galectin-10; Short=Gal-10; 
AltName: Full=Lysolecithin acylhydrolase; [Homo sapiens (Human)] - 
[LPPL_HUMAN] 3.22E+06 
Folate receptor alpha OS=Homo sapiens GN=FOLR1 PE=1 SV=3 3.11E+06 
Transmembrane protein 200C; AltName: Full=Transmembrane protein 
TTMA; AltName: Full=Two transmembrane domain-containing family 
member A; [Homo sapiens (Human)] - [T200C_HUMAN] 2.87E+06 
SH3 domain-binding glutamic acid-rich-like protein OS=Homo sapiens 
GN=SH3BGRL PE=1 SV=1 
2.80E+06 
Aldose 1-epimerase OS=Homo sapiens GN=GALM PE=1 SV=1 2.77E+06 
Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 2.75E+06 
Matrix metalloproteinase-23; Short=MMP-23; EC=3.4.24.-; AltName: 
Full=Femalysin; AltName: Full=MIFR-1; AltName: Full=Matrix 
metalloproteinase-21; Short=MMP-21; AltName: Full=Matrix 
metalloproteinase-22; Short=MMP-22; Contains: RecName: Full=Matrix 
metalloproteinase-23, soluble form; Flags: Precursor; [Homo sapiens 
(Human)] - [MMP23_HUMAN] 2.66E+06 
Napsin-A OS=Homo sapiens GN=NAPSA PE=1 SV=1 2.37E+06 
Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 2.13E+06 
Protein S100-P; AltName: Full=Protein S100-E; AltName: Full=S100 
calcium-binding protein P; [Homo sapiens (Human)] - [S100P_HUMAN] 2.12E+06 
Neutrophil defensin 1 OS=Homo sapiens GN=DEFA1 PE=1 SV=1 1.79E+06 
Gamma-glutamylcyclotransferase; EC=2.3.2.4; AltName: Full=Cytochrome c-
releasing factor 21; [Homo sapiens (Human)] - [GGCT_HUMAN] 1.29E+06 
Sodium-dependent phosphate transport protein 2B; Short=Sodium-phosphate 
transport protein 2B; AltName: Full=Na(+)-dependent phosphate cotransporter 
2B; AltName: Full=NaPi3b; AltName: Full=Sodium/phosphate cotransporter 
2B; Short=Na(+)/Pi cotransporter 2B; Short=NaPi-2b; AltName: Full=Solute 





Table B.2: All alveolar proteins identified by 1D PAGE and nano LC MS/MS in healthy aged 
RTLFs. The 163 proteins identified in healthy aged subjects investigated, (n=5), alongside the 
mean of the three most abundant ion peaks of each respective protein identified. Accession 
numbers included according to entries in UniProtKB/Swiss-Prot.  
 
Healthy Aged Control 
14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 1.46E+07 
14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 1.86E+07 
14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 1.57E+07 
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase; EC=1.14.13.95; 
AltName: Full=7-alpha-hydroxy-4-cholesten-3-one 12-alpha-hydroxylase; 
AltName: Full=CYPVIIIB1; AltName: Full=Cytochrome P450 8B1; AltName: 
Full=Sterol 12-alpha-hydroxylase; [Homo sapiens (Human)] - 
[CP8B1_HUMAN] 4.20E+07 
Actin-related protein 2; AltName: Full=Actin-like protein 2; [Homo sapiens 
(Human)] - [ARP2_HUMAN] 1.97E+07 
Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 6.89E+07 
Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 2.54E+07 
Aldo-keto reductase family 1 member C3; EC=1.-.-.-; AltName: Full=17-beta-
hydroxysteroid dehydrogenase type 5; Short=17-beta-HSD 5; AltName: 
Full=3-alpha-HSD type II, brain; AltName: Full=3-alpha-hydroxysteroid 
dehydrogenase type 2; Short=3-alpha-HSD type 2; EC=1.1.1.213; AltName: 
Full=Chlordecone reductase homolog HAKRb; AltName: Full=Dihydrodiol 
dehydrogenase 3; Short=DD-3; Short=DD3; AltName: Full=Dihydrodiol 
dehydrogenase type I; AltName: Full=HA1753; AltName: Full=Indanol 
dehydrogenase; EC=1.1.1.112; AltName: Full=Prostaglandin F synthase; 
Short=PGFS; EC=1.1.1.188; AltName: Full=Testosterone 17-beta-
dehydrogenase 5; EC=1.1.1.63; EC=1.1.1.64; AltName: Full=Trans-1,2-
dihydrobenzene-1,2-diol dehydrogenase; EC=1.3.1.20; [Homo sapiens 
(Human)] - [AK1C3_HUMAN] 3.18E+07 
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 3.39E+08 
Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2 2.40E+08 
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 8.21E+07 
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 3.20E+09 
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 1.33E+08 
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 1.16E+08 
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 1.66E+08 
Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 4.14E+06 
Angiotensin-converting enzyme; Short=ACE; EC=3.2.1.-; EC=3.4.15.1; 
AltName: Full=Dipeptidyl carboxypeptidase I; AltName: Full=Kininase II; 
AltName: CD_antigen=CD143; Contains: RecName: Full=Angiotensin-
converting enzyme, soluble form; Flags: Precursor; [Homo sapiens (Human)] - 
[ACE_HUMAN] 1.46E+07 
Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 4.94E+07 
Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 1.36E+06 
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 1.84E+07 
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 1.38E+08 
Apolipoprotein A-II OS=Homo sapiens GN=APOA2 PE=1 SV=1 7.40E+07 
Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 SV=3 2.74E+07 
ATP-binding cassette sub-family F member 1; AltName: Full=ATP-binding 
cassette 50; AltName: Full=TNF-alpha-stimulated ABC protein; [Homo 1.17E+07 
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sapiens (Human)] - [ABCF1_HUMAN] 
Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2 5.23E+06 
Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 2.59E+07 
Biotinidase OS=Homo sapiens GN=BTD PE=1 SV=2 2.84E+06 
C2 calcium-dependent domain-containing protein 4B; AltName: Full=Nuclear-
localized factor 2; AltName: Full=Protein FAM148B; [Homo sapiens 
(Human)] - [C2C4B_HUMAN] 8.25E+07 
Calmodulin OS=Homo sapiens GN=CALM1 PE=1 SV=2 2.68E+06 
Calmodulin-like protein 5; AltName: Full=Calmodulin-like skin protein; 
[Homo sapiens (Human)] - [CALL5_HUMAN] 2.82E+07 
Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 3.91E+06 
CD166 antigen; AltName: Full=Activated leukocyte cell adhesion molecule; 
AltName: CD_antigen=CD166; Flags: Precursor; [Homo sapiens (Human)] - 
[CD166_HUMAN] 1.35E+07 
CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=3 2.73E+07 
CD59 glycoprotein; AltName: Full=1F5 antigen; AltName: Full=20 kDa 
homologous restriction factor; Short=HRF-20; Short=HRF20; AltName: 
Full=MAC-inhibitory protein; Short=MAC-IP; AltName: Full=MEM43 
antigen; AltName: Full=Membrane attack complex inhibition factor; 
Short=MACIF; AltName: Full=Membrane inhibitor of reactive lysis; 
Short=MIRL; AltName: Full=Protectin; AltName: CD_antigen=CD59; Flags: 
Precursor; [Homo sapiens (Human)] - [CD59_HUMAN] 3.54E+06 
CD9 antigen; AltName: Full=5H9 antigen; AltName: Full=Cell growth-
inhibiting gene 2 protein; AltName: Full=Leukocyte antigen MIC3; AltName: 
Full=Motility-related protein; Short=MRP-1; AltName: Full=Tetraspanin-29; 
Short=Tspan-29; AltName: Full=p24; AltName: CD_antigen=CD9; [Homo 
sapiens (Human)] - [CD9_HUMAN] 9.50E+06 
Cell adhesion molecule 2; AltName: Full=Immunoglobulin superfamily 
member 4D; Short=IgSF4D; AltName: Full=Nectin-like protein 3; 
Short=NECL-3; Flags: Precursor; [Homo sapiens (Human)] - 
[CADM2_HUMAN] 2.00E+06 
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 3.67E+08 
Coactosin-like protein OS=Homo sapiens GN=COTL1 PE=1 SV=3 5.15E+06 
Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2 3.41E+07 
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 2.66E+06 
Complement decay-accelerating factor OS=Homo sapiens GN=CD55 PE=1 
SV=4 7.63E+06 
Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 PE=1 
SV=1 3.95E+07 
Deleted in malignant brain tumors 1 protein OS=Homo sapiens GN=DMBT1 
PE=1 SV=2 3.69E+07 
Delta-like protein 4; AltName: Full=Drosophila Delta homolog 4; 
Short=Delta4; Flags: Precursor; [Homo sapiens (Human)] - [DLL4_HUMAN] 1.23E+07 
Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 2.13E+06 
Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 1.40E+08 
Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2 6.17E+07 
Disintegrin and metalloproteinase domain-containing protein 2; Short=ADAM 
2; AltName: Full=Cancer/testis antigen 15; Short=CT15; AltName: 
Full=Fertilin subunit beta; AltName: Full=PH-30; Short=PH30; AltName: 




Ecto-ADP-ribosyltransferase 4; EC=2.4.2.31; AltName: Full=Dombrock blood 
group carrier molecule; AltName: Full=Mono(ADP-ribosyl)transferase 4; 
AltName: Full=NAD(P)(+)--arginine ADP-ribosyltransferase 4; AltName: 
CD_antigen=CD297; Flags: Precursor; [Homo sapiens (Human)] - 
[NAR4_HUMAN] 5.81E+07 
Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 2.16E+07 
Epididymal secretory protein E1 OS=Homo sapiens GN=NPC2 PE=1 SV=1 1.37E+07 
FAS-associated factor 1; Short=hFAF1; AltName: Full=UBX domain-
containing protein 12; AltName: Full=UBX domain-containing protein 3A; 
[Homo sapiens (Human)] - [FAF1_HUMAN] 4.89E+08 
Ferritin heavy chain; Short=Ferritin H subunit; EC=1.16.3.1; AltName: 
Full=Cell proliferation-inducing gene 15 protein; [Homo sapiens (Human)] - 
[FRIH_HUMAN] 2.34E+06 
Ferritin light chain; Short=Ferritin L subunit; [Homo sapiens (Human)] - 
[FRIL_HUMAN] 4.73E+06 
Galectin-3-binding protein; AltName: Full=Basement membrane autoantigen 
p105; AltName: Full=Lectin galactoside-binding soluble 3-binding protein; 
AltName: Full=Mac-2-binding protein; Short=MAC2BP; Short=Mac-2 BP; 
AltName: Full=Tumor-associated antigen 90K; Flags: Precursor; [Homo 
sapiens (Human)] - [LG3BP_HUMAN] 7.88E+06 
Galectin-3; Short=Gal-3; AltName: Full=35 kDa lectin; AltName: 
Full=Carbohydrate-binding protein 35; Short=CBP 35; AltName: 
Full=Galactose-specific lectin 3; AltName: Full=Galactoside-binding protein; 
Short=GALBP; AltName: Full=IgE-binding protein; AltName: Full=L-31; 
AltName: Full=Laminin-binding protein; AltName: Full=Lectin L-29; 
AltName: Full=Mac-2 antigen; [Homo sapiens (Human)] - [LEG3_HUMAN] 2.03E+06 
Glutathione peroxidase 3 OS=Homo sapiens GN=GPX3 PE=1 SV=2 1.19E+06 
Glutathione S-transferase A2 OS=Homo sapiens GN=GSTA2 PE=1 SV=4 4.18E+07 
Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 8.51E+06 
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 1.26E+08 
Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2 8.93E+06 
Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 1.49E+08 
Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 1.28E+08 
Hemoglobin subunit delta OS=Homo sapiens GN=HBD PE=1 SV=2 7.65E+07 
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 2.71E+08 
Histone H3.3C; [Homo sapiens (Human)] - [H3C_HUMAN] 1.79E+07 
Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 2.45E+07 
HLA class II histocompatibility antigen, DR alpha chain; AltName: 
Full=MHC class II antigen DRA; Flags: Precursor; [Homo sapiens (Human)] - 
[DRA_HUMAN] 1.69E+06 
HLA class II histocompatibility antigen, DRB1-1 beta chain OS=Homo 
sapiens GN=HLA-DRB1 PE=1 SV=2 6.88E+06 
Homeobox protein Nkx-3.2; AltName: Full=Bagpipe homeobox protein 
homolog 1; AltName: Full=Homeobox protein NK-3 homolog B; [Homo 
sapiens (Human)] - [NKX32_HUMAN] 1.75E+07 
Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 2.42E+09 
Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 1.79E+09 
Ig delta chain C region OS=Homo sapiens GN=IGHD PE=1 SV=2 1.10E+07 
Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 8,918,000,000 
Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2 5.60E+09 
Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=1 SV=2 6.71E+09 
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Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 5.60E+09 
Ig heavy chain V-I region Mot OS=Homo sapiens PE=1 SV=1 2.05E+08 
Ig heavy chain V-II region ARH-77; Flags: Precursor; [Homo sapiens 
(Human)] - [HV209_HUMAN] 4.86E+07 
Ig heavy chain V-II region NEWM OS=Homo sapiens PE=1 SV=1 1.47E+08 
Ig heavy chain V-II region OU; [Homo sapiens (Human)] - 
[HV201_HUMAN] 1.44E+08 
Ig heavy chain V-III region BRO; [Homo sapiens (Human)] - 
[HV305_HUMAN] 1.02E+09 
Ig heavy chain V-III region BUT; [Homo sapiens (Human)] - 
[HV306_HUMAN] 1.03E+09 
Ig heavy chain V-III region CAM OS=Homo sapiens PE=1 SV=1 1.05E+09 
Ig heavy chain V-III region GAL OS=Homo sapiens PE=1 SV=1 1.05E+09 
Ig heavy chain V-III region GAR; [Homo sapiens (Human)] - 
[HV322_HUMAN] 1.05E+08 
Ig heavy chain V-III region HIL; [Homo sapiens (Human)] - 
[HV310_HUMAN] 1.47E+09 
Ig heavy chain V-III region TIL OS=Homo sapiens PE=1 SV=1 1.06E+09 
Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 3.47E+09 
Ig kappa chain V-I region CAR; [Homo sapiens (Human)] - 
[KV104_HUMAN] 7.26E+07 
Ig kappa chain V-I region DEE; [Homo sapiens (Human)] - 
[KV105_HUMAN] 2.73E+08 
Ig kappa chain V-I region EU OS=Homo sapiens PE=1 SV=1 2.41E+08 
Ig kappa chain V-I region Kue OS=Homo sapiens PE=1 SV=1 1.89E+08 
Ig kappa chain V-I region Ni; [Homo sapiens (Human)] - [KV121_HUMAN] 1.45E+08 
Ig kappa chain V-I region OU; [Homo sapiens (Human)] - [KV114_HUMAN] 3.43E+08 
Ig kappa chain V-I region Wes; [Homo sapiens (Human)] - 
[KV119_HUMAN] 2.71E+08 
Ig kappa chain V-II region FR OS=Homo sapiens PE=1 SV=1 8.51E+07 
Ig kappa chain V-II region RPMI 6410 OS=Homo sapiens PE=4 SV=1 1.62E+08 
Ig kappa chain V-III region B6; [Homo sapiens (Human)] - 
[KV301_HUMAN] 2.39E+08 
Ig kappa chain V-III region POM OS=Homo sapiens PE=1 SV=1 9.77E+07 
Ig kappa chain V-III region SIE OS=Homo sapiens PE=1 SV=1 2.40E+08 
Ig kappa chain V-III region VG; Flags: Precursor; Fragment; [Homo sapiens 
(Human)] - [KV309_HUMAN] 1.46E+08 
Ig kappa chain V-IV region JI OS=Homo sapiens PE=4 SV=1 3.74E+07 
Ig kappa chain V-IV region Len OS=Homo sapiens PE=1 SV=2 9.86E+07 
Ig lambda chain V region 4A OS=Homo sapiens PE=4 SV=1 5.01E+07 
Ig lambda chain V-I region HA OS=Homo sapiens PE=1 SV=1 1.91E+08 
Ig lambda chain V-I region NIG-64 OS=Homo sapiens PE=1 SV=1 7.21E+07 
Ig lambda chain V-II region NEI; [Homo sapiens (Human)] - 
[LV202_HUMAN] 1.91E+07 
Ig lambda chain V-III region LOI OS=Homo sapiens PE=1 SV=1 1.57E+08 
Ig lambda chain V-III region SH; [Homo sapiens (Human)] - 
[LV301_HUMAN] 3.09E+07 
Ig lambda chain V-IV region Bau; [Homo sapiens (Human)] - 
[LV401_HUMAN] 1.58E+08 




Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 SV=1 2.31E+09 
Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 4.16E+07 
Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 4.76E+07 
Immunoglobulin lambda-like polypeptide 5 OS=Homo sapiens GN=IGLL5 
PE=2 SV=2 1.44E+09 
Intercellular adhesion molecule 1 OS=Homo sapiens GN=ICAM1 PE=1 SV=2 1.15E+07 
Lactotransferrin; Short=Lactoferrin; EC=3.4.21.-; AltName: 
Full=Talalactoferrin; Contains: RecName: Full=Kaliocin-1; Contains: 
RecName: Full=Lactoferroxin-A; Contains: RecName: Full=Lactoferroxin-B; 
Contains: RecName: Full=Lactoferroxin-C; Flags: Precursor; [Homo sapiens 
(Human)] - [TRFL_HUMAN] 9.47E+08 
Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2 4.46E+07 
LIM domain only protein 7; Short=LMO-7; AltName: Full=F-box only protein 
20; AltName: Full=LOMP; [Homo sapiens (Human)] - [LMO7_HUMAN] 1.36E+08 
Lysosomal alpha-glucosidase; EC=3.2.1.20; AltName: Full=Acid maltase; 
AltName: Full=Aglucosidase alfa; Contains: RecName: Full=76 kDa 
lysosomal alpha-glucosidase; Contains: RecName: Full=70 kDa lysosomal 
alpha-glucosidase; Flags: Precursor; [Homo sapiens (Human)] - 
[LYAG_HUMAN] 1.40E+06 
Lysozyme C; EC=3.2.1.17; AltName: Full=1,4-beta-N-acetylmuramidase C; 
Flags: Precursor; [Homo sapiens (Human)] - [LYSC_HUMAN] 1.48E+06 
Mucin-1 OS=Homo sapiens GN=MUC1 PE=1 SV=3 1.18E+07 
Myotubularin-related protein 14; EC=3.1.3.-; AltName: Full=HCV NS5A-
transactivated protein 4 splice variant A-binding protein 1; 
Short=NS5ATP4ABP1; AltName: Full=hJumpy; [Homo sapiens (Human)] - 
[MTMRE_HUMAN] 3.06E+06 
Pancreatic alpha-amylase; Short=PA; EC=3.2.1.1; AltName: Full=1,4-alpha-
D-glucan glucanohydrolase; Flags: Precursor; [Homo sapiens (Human)] - 
[AMYP_HUMAN] 1.35E+07 
Peptidyl-prolyl cis-trans isomerase A; Short=PPIase A; EC=5.2.1.8; AltName: 
Full=Cyclophilin A; AltName: Full=Cyclosporin A-binding protein; AltName: 
Full=Rotamase A; [Homo sapiens (Human)] - [PPIA_HUMAN] 6.43E+06 
Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 
SV=4 1.94E+08 
Pre-mRNA cleavage complex 2 protein Pcf11; AltName: Full=Pre-mRNA 
cleavage complex II protein Pcf11; [Homo sapiens (Human)] - 
[PCF11_HUMAN] 5.19E+07 
Pro-cathepsin H OS=Homo sapiens GN=CTSH PE=1 SV=4 1.06E+07 
Proactivator polypeptide OS=Homo sapiens GN=PSAP PE=1 SV=2 2.71E+06 
Prostasin; EC=3.4.21.-; AltName: Full=Serine protease 8; Contains: 
RecName: Full=Prostasin light chain; Contains: RecName: Full=Prostasin 
heavy chain; Flags: Precursor; [Homo sapiens (Human)] - [PRSS8_HUMAN] 1.22E+06 
Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 1.23E+07 
Protein S100-A6 OS=Homo sapiens GN=S100A6 PE=1 SV=1 2.38E+07 
Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 3.59E+07 
Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1 1.13E+07 
Protein Shroom3; AltName: Full=Shroom-related protein; Short=hShrmL; 
[Homo sapiens (Human)] - [SHRM3_HUMAN] 9.47E+07 
Protein-glutamine gamma-glutamyltransferase E; EC=2.3.2.13; AltName: 
Full=Transglutaminase E; Short=TG(E); Short=TGE; Short=TGase E; 
AltName: Full=Transglutaminase-3; Short=TGase-3; Contains: RecName: 3.65E+06 
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Full=Protein-glutamine gamma-glutamyltransferase E 50 kDa non-catalytic 
chain; Contains: RecName: Full=Protein-glutamine gamma-
glutamyltransferase E 27 kDa catalytic chain; Flags: Precursor; [Homo sapiens 
(Human)] - [TGM3_HUMAN] 
Pulmonary surfactant-associated protein A2 OS=Homo sapiens GN=SFTPA2 
PE=1 SV=1 3.74E+07 
Pulmonary surfactant-associated protein B; Short=SP-B; AltName: Full=18 
kDa pulmonary-surfactant protein; AltName: Full=6 kDa protein; AltName: 
Full=Pulmonary surfactant-associated proteolipid SPL(Phe); Flags: Precursor; 
[Homo sapiens (Human)] - [PSPB_HUMAN] 3.26E+06 
Pulmonary surfactant-associated protein D OS=Homo sapiens GN=SFTPD 
PE=1 SV=3 1.53E+07 
Putative V-set and immunoglobulin domain-containing protein 6 OS=Homo 
sapiens GN=VSIG6 PE=5 SV=2 2.00E+08 
Ribonuclease P protein subunit p40; Short=RNaseP protein p40; EC=3.1.26.5; 
AltName: Full=RNase P subunit 1; [Homo sapiens (Human)] - 
[RPP40_HUMAN] 5.47E+07 
Selenium-binding protein 1 OS=Homo sapiens GN=SELENBP1 PE=1 SV=2 1.67E+07 
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 7.62E+09 
Serpin B3 OS=Homo sapiens GN=SERPINB3 PE=1 SV=2 2.30E+07 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 2.77E+09 
SH3 domain-binding glutamic acid-rich-like protein 3; AltName: 
Full=SH3 domain-binding protein 1; Short=SH3BP-1; [Homo sapiens 
(Human)] - [SH3L3_HUMAN] 3.66E+06 
Sorting nexin-6; AltName: Full=TRAF4-associated factor 2; [Homo sapiens 
(Human)] - [SNX6_HUMAN] 2.15E+06 
Thioredoxin; Short=Trx; AltName: Full=ATL-derived factor; Short=ADF; 
AltName: Full=Surface-associated sulphydryl protein; Short=SASP; [Homo 
sapiens (Human)] - [THIO_HUMAN] 8.21E+06 
Thyroxine-binding globulin OS=Homo sapiens GN=SERPINA7 PE=1 SV=2 5.25E+06 
Transaldolase OS=Homo sapiens GN=TALDO1 PE=1 SV=2 4.47E+07 
Transcriptional adapter 2-beta; AltName: Full=ADA2-like protein beta; 
Short=ADA2-beta; [Homo sapiens (Human)] - [TAD2B_HUMAN] 2.22E+07 
Transmembrane protein 198; [Homo sapiens (Human)] - [TM198_HUMAN] 2.62E+07 
Transmembrane protein 200C; AltName: Full=Transmembrane protein 
TTMA; AltName: Full=Two transmembrane domain-containing family 
member A; [Homo sapiens (Human)] - [T200C_HUMAN] 3.59E+06 
Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 2.53E+08 
Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 4.37E+07 
Uncharacterized protein C3orf38; [Homo sapiens (Human)] - 
[CC038_HUMAN] 2.73E+09 
Uncharacterized protein KIAA0947; [Homo sapiens (Human)] - 
[K0947_HUMAN] 8.15E+06 
Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=1 SV=1 1.74E+08 
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 4.91E+08 
Vitamin K-dependent protein S; Flags: Precursor; [Homo sapiens (Human)] - 
[PROS_HUMAN] 3.31E+07 
Xin actin-binding repeat-containing protein 2 OS=Homo sapiens GN=XIRP2 
PE=1 SV=2 2.05E+08 




Table B.3: Alveolar proteins identified by 1D PAGE and nano LC MS/MS in healthy young 
and aged RTLFs. The 124 proteins common to both healthy young and aged subjects 
investigated n=5 for both subject groups, alongside the mean of the three most abundant ion 
peaks of each respective protein identified,.Accession numbers included are according to 
entries in UniProtKB/Swiss-Prot.  
 
Healthy Control Healthy Aged Control 
14-3-3 protein beta/alpha 
OS=Homo sapiens GN=YWHAB 
PE=1 SV=3 
1.07E+08 
14-3-3 protein beta/alpha 
OS=Homo sapiens GN=YWHAB 
PE=1 SV=3 
1.46E+07 
14-3-3 protein epsilon OS=Homo 
sapiens GN=YWHAE PE=1 
SV=1 
9.02E+07 
14-3-3 protein epsilon OS=Homo 
sapiens GN=YWHAE PE=1 
SV=1 
1.86E+07 
14-3-3 protein zeta/delta 
OS=Homo sapiens GN=YWHAZ 
PE=1 SV=1 
1.07E+08 
14-3-3 protein zeta/delta 
OS=Homo sapiens GN=YWHAZ 
PE=1 SV=1 
1.57E+07 
Actin-related protein 2; AltName: 
Full=Actin-like protein 2; [Homo 
sapiens (Human)] - 
[ARP2_HUMAN] 
1.56E+07 
Actin-related protein 2; AltName: 
Full=Actin-like protein 2; [Homo 
sapiens (Human)] - 
[ARP2_HUMAN] 
1.97E+07 
Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 
5.55E+07 
Actin, cytoplasmic 1 
OS=Homo sapiens 
GN=ACTB PE=1 SV=1 
6.89E+07 
Afamin OS=Homo sapiens 
GN=AFM PE=1 SV=1 
2.55E+07 
Afamin OS=Homo sapiens 
GN=AFM PE=1 SV=1 
2.54E+07 
Aldo-keto reductase family 1 
member C3; EC=1.-.-.-; AltName: 
Full=17-beta-hydroxysteroid 
dehydrogenase type 5; Short=17-
beta-HSD 5; AltName: Full=3-
alpha-HSD type II, brain; 
AltName: Full=3-alpha-
hydroxysteroid dehydrogenase 
type 2; Short=3-alpha-HSD type 
2; EC=1.1.1.213; AltName: 
Full=Chlordecone reductase 
homolog HAKRb; AltName: 
Full=Dihydrodiol dehydrogenase 
3; Short=DD-3; Short=DD3; 
AltName: Full=Dihydrodiol 













Aldo-keto reductase family 1 
member C3; EC=1.-.-.-; AltName: 
Full=17-beta-hydroxysteroid 
dehydrogenase type 5; Short=17-
beta-HSD 5; AltName: Full=3-
alpha-HSD type II, brain; 
AltName: Full=3-alpha-
hydroxysteroid dehydrogenase 
type 2; Short=3-alpha-HSD type 
2; EC=1.1.1.213; AltName: 
Full=Chlordecone reductase 
homolog HAKRb; AltName: 
Full=Dihydrodiol dehydrogenase 
3; Short=DD-3; Short=DD3; 
AltName: Full=Dihydrodiol 















[Homo sapiens (Human)] - 
[AK1C3_HUMAN] 
[Homo sapiens (Human)] - 
[AK1C3_HUMANsapiens 
(Human)] - [AK1C3_HUMAN] 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 
2.04E+08 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 
3.39E+08 
Alpha-1-acid glycoprotein 2 
OS=Homo sapiens GN=ORM2 
PE=1 SV=2 
1.81E+08 
Alpha-1-acid glycoprotein 2 









GN=SERPINA3 PE=1 SV=2 
8.21E+07 
Alpha-1-antitrypsin OS=Homo 











































enzyme, soluble form; Flags: 
Precursor; [Homo sapiens 
(Human)] - [ACE_HUMAN] 
1.46E+07 
Angiotensinogen OS=Homo 
sapiens GN=AGT PE=1 SV=1 
9.61E+07 
Angiotensinogen OS=Homo 
sapiens GN=AGT PE=1 SV=1 
4.94E+07 
Annexin A5 OS=Homo sapiens 
GN=ANXA5 PE=1 SV=2 
6.60E+07 
Annexin A5 OS=Homo sapiens 
GN=ANXA5 PE=1 SV=2 
1.36E+06 
Antithrombin-III OS=Homo 




sapiens GN=SERPINC1 PE=1 
SV=1 
1.84E+07 
Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 SV=1 
9.59E+07 
Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 SV=1 
1.38E+08 
Apolipoprotein A-II OS=Homo 
sapiens GN=APOA2 PE=1 SV=1 
2.59E+07 
Apolipoprotein A-II OS=Homo 
sapiens GN=APOA2 PE=1 SV=1 
7.40E+07 
Apolipoprotein A-IV OS=Homo 
sapiens GN=APOA4 PE=1 SV=3 
1.04E+07 
Apolipoprotein A-IV OS=Homo 
sapiens GN=APOA4 PE=1 SV=3 
2.74E+07 
Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 
1.13E+07 
Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 
5.23E+06 
Beta-2-microglobulin OS=Homo 
sapiens GN=B2M PE=1 SV=1 
1.20E+08 
Beta-2-microglobulin OS=Homo 




Biotinidase OS=Homo sapiens 
GN=BTD PE=1 SV=2 
1.19E+07 
Biotinidase OS=Homo sapiens 
GN=BTD PE=1 SV=2 
2.84E+06 
Calmodulin OS=Homo sapiens 
GN=CALM1 PE=1 SV=2 
3.58E+07 
Calmodulin OS=Homo sapiens 
GN=CALM1 PE=1 SV=2 
2.68E+06 
Carbonic anhydrase 1 OS=Homo 
sapiens GN=CA1 PE=1 SV=2 
2.36E+07 
Carbonic anhydrase 1 OS=Homo 
sapiens GN=CA1 PE=1 SV=2 
3.91E+06 
CD44 antigen OS=Homo sapiens 
GN=CD44 PE=1 SV=3 
7.78E+07 
CD44 antigen OS=Homo sapiens 
GN=CD44 PE=1 SV=3 
2.73E+07 
CD59 glycoprotein OS=Homo 
sapiens GN=CD59 PE=1 SV=1 
4.04E+06 
CD59 glycoprotein; AltName: 
Full=1F5 antigen; AltName: 
Full=20 kDa homologous 




Full=MEM43 antigen; AltName: 
Full=Membrane attack complex 
inhibition factor; Short=MACIF; 
AltName: Full=Membrane 




Precursor; [Homo sapiens 
(Human)] - [CD59_HUMAN] 
3.54E+06 
CD9 antigen OS=Homo sapiens 
GN=CD9 PE=1 SV=4 
2.20E+07 
CD9 antigen; AltName: Full=5H9 
antigen; AltName: Full=Cell 
growth-inhibiting gene 2 protein; 
AltName: Full=Leukocyte antigen 
MIC3; AltName: Full=Motility-




CD_antigen=CD9; [Homo sapiens 
(Human)] - [CD9_HUMAN] 
9.50E+06 
Ceruloplasmin OS=Homo sapiens 
GN=CP PE=1 SV=1 
5.37E+08 
Ceruloplasmin OS=Homo sapiens 
GN=CP PE=1 SV=1 
3.67E+08 
Coactosin-like protein OS=Homo 
sapiens GN=COTL1 PE=1 SV=3 
3.46E+07 
Coactosin-like protein OS=Homo 
sapiens GN=COTL1 PE=1 SV=3 
5.15E+06 
Complement C2 OS=Homo 
sapiens GN=C2 PE=1 SV=2 
6.82E+06 
Complement C2 OS=Homo 
sapiens GN=C2 PE=1 SV=2 
3.41E+07 
Complement C3 OS=Homo 
sapiens GN=C3 PE=1 SV=2 
1.25E+07 
Complement C3 OS=Homo 
sapiens GN=C3 PE=1 SV=2 
2.66E+06 
Complement decay-accelerating 
factor OS=Homo sapiens 
GN=CD55 PE=1 SV=4 
1.49E+07 
Complement decay-accelerating 
factor OS=Homo sapiens 








GN=SERPINA6 PE=1 SV=1 
3.95E+07 
Deleted in malignant brain tumors 
1 protein OS=Homo sapiens 
5.59E+07 
Deleted in malignant brain tumors 




GN=DMBT1 PE=1 SV=2 GN=DMBT1 PE=1 SV=2 
Delta-like protein 4; AltName: 
Full=Drosophila Delta homolog 4; 
Short=Delta4; Flags: Precursor; 
[Homo sapiens (Human)] - 
[DLL4_HUMAN] 
1.80E+07 
Delta-like protein 4; AltName: 
Full=Drosophila Delta homolog 4; 
Short=Delta4; Flags: Precursor; 
[Homo sapiens (Human)] - 
[DLL4_HUMAN] 
1.23E+07 
Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 
6.20E+06 
Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 
2.13E+06 
Desmoplakin OS=Homo sapiens 
GN=DSP PE=1 SV=3 
1.60E+08 
Desmoplakin OS=Homo sapiens 
GN=DSP PE=1 SV=3 
1.40E+08 
Dipeptidyl peptidase 4 OS=Homo 
sapiens GN=DPP4 PE=1 SV=2 
1.64E+07 
Dipeptidyl peptidase 4 OS=Homo 
sapiens GN=DPP4 PE=1 SV=2 
6.17E+07 
Epididymal secretory protein E1 
OS=Homo sapiens GN=NPC2 
PE=1 SV=1 
5.26E+07 
Epididymal secretory protein E1 
OS=Homo sapiens GN=NPC2 
PE=1 SV=1 
1.37E+07 
FAS-associated factor 1; 
Short=hFAF1; AltName: 
Full=UBX domain-containing 
protein 12; AltName: Full=UBX 
domain-containing protein 3A; 
[Homo sapiens (Human)] - 
[FAF1_HUMAN] 
2.21E+08 
FAS-associated factor 1; 
Short=hFAF1; AltName: 
Full=UBX domain-containing 
protein 12; AltName: Full=UBX 
domain-containing protein 3A; 









membrane autoantigen p105; 
AltName: Full=Lectin 
galactoside-binding soluble 3-




associated antigen 90K; Flags: 
Precursor; [Homo sapiens 
(Human)] - [LG3BP_HUMAN] 
7.88E+06 
Glutathione peroxidase 3 
OS=Homo sapiens GN=GPX3 
PE=1 SV=2 
4.07E+06 
Glutathione peroxidase 3 
OS=Homo sapiens GN=GPX3 
PE=1 SV=2 
1.19E+06 
Glutathione S-transferase A2 
OS=Homo sapiens GN=GSTA2 
PE=1 SV=4 
5.83E+07 
Glutathione S-transferase A2 
OS=Homo sapiens GN=GSTA2 
PE=1 SV=4 
4.18E+07 
Glutathione S-transferase P 
OS=Homo sapiens GN=GSTP1 
PE=1 SV=2 
3.42E+07 
Glutathione S-transferase P 
OS=Homo sapiens GN=GSTP1 
PE=1 SV=2 
8.51E+06 
Haptoglobin OS=Homo sapiens 
GN=HP PE=1 SV=1 
3.82E+08 
Haptoglobin OS=Homo sapiens 
GN=HP PE=1 SV=1 
1.26E+08 
Hemoglobin subunit alpha; 
AltName: Full=Alpha-globin; 
AltName: Full=Hemoglobin alpha 
chain; [Homo sapiens (Human)] - 
[HBA_HUMAN] 2.06E+08 
Hemoglobin subunit alpha 
OS=Homo sapiens GN=HBA1 
PE=1 SV=2 
1.49E+08 
Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB 
2.06E+08 
Hemoglobin subunit beta 




PE=1 SV=2 PE=1 SV=2 
Hemoglobin subunit delta 
OS=Homo sapiens GN=HBD 
PE=1 SV=2 
1.66E+08 
Hemoglobin subunit delta 
OS=Homo sapiens GN=HBD 
PE=1 SV=2 
7.65E+07 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 
7.70E+08 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 
2.71E+08 
Histone H3.3C; [Homo sapiens 
(Human)] - [H3C_HUMAN] 
1.08E+07 
Histone H3.3C; [Homo sapiens 
(Human)] - [H3C_HUMAN] 
1.79E+07 
Histone H4 OS=Homo sapiens 
GN=HIST1H4A PE=1 SV=2 
4.75E+07 
Histone H4 OS=Homo sapiens 
GN=HIST1H4A PE=1 SV=2 
2.45E+07 
Ig alpha-1 chain C region 
OS=Homo sapiens GN=IGHA1 
PE=1 SV=2 
2.81E+09 
Ig alpha-1 chain C region 
OS=Homo sapiens GN=IGHA1 
PE=1 SV=2 
2.42E+09 
Ig alpha-2 chain C region 
OS=Homo sapiens GN=IGHA2 
PE=1 SV=3 
2.05E+09 
Ig alpha-2 chain C region 
OS=Homo sapiens GN=IGHA2 
PE=1 SV=3 
1.79E+09 
Ig gamma-1 chain C region; 
[Homo sapiens (Human)] - 
[IGHG1_HUMAN] 
1.23E+10 
Ig gamma-1 chain C region 
OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 
8.92E+09 
Ig gamma-2 chain C region 
OS=Homo sapiens GN=IGHG2 
PE=1 SV=2 
9.10E+09 
Ig gamma-2 chain C region 
OS=Homo sapiens GN=IGHG2 
PE=1 SV=2 
5.60E+09 
Ig gamma-3 chain C region 
OS=Homo sapiens GN=IGHG3 
PE=1 SV=2 
9.36E+09 
Ig gamma-3 chain C region 
OS=Homo sapiens GN=IGHG3 
PE=1 SV=2 
6.71E+09 
Ig gamma-4 chain C region 
OS=Homo sapiens GN=IGHG4 
PE=1 SV=1 
9.10E+09 
Ig gamma-4 chain C region 
OS=Homo sapiens GN=IGHG4 
PE=1 SV=1 
5.60E+09 
Ig heavy chain V-II region ARH-
77 OS=Homo sapiens PE=4 SV=1 
7.57E+07 
Ig heavy chain V-II region ARH-
77; Flags: Precursor; [Homo 
sapiens (Human)] - 
[HV209_HUMAN] 
4.86E+07 
Ig heavy chain V-II region 
NEWM; [Homo sapiens (Human)] 
- [HV207_HUMAN] 
1.14E+08 
Ig heavy chain V-II region 
NEWM OS=Homo sapiens PE=1 
SV=1 
1.47E+08 
Ig heavy chain V-II region OU; 
[Homo sapiens (Human)] - 
[HV201_HUMAN] 
6.80E+07 
Ig heavy chain V-II region OU; 
[Homo sapiens (Human)] - 
[HV201_HUMAN] 
1.44E+08 
Ig heavy chain V-III region BRO; 
[Homo sapiens (Human)] - 
[HV305_HUMAN] 
1.19E+09 
Ig heavy chain V-III region BRO; 
[Homo sapiens (Human)] - 
[HV305_HUMAN] 
1.02E+09 
Ig heavy chain V-III region BUT 
OS=Homo sapiens PE=1 SV=1 
1.16E+09 
Ig heavy chain V-III region BUT; 
[Homo sapiens (Human)] - 
[HV306_HUMAN] 
1.03E+09 
Ig heavy chain V-III region CAM 
OS=Homo sapiens PE=1 SV=1 
1.22E+09 
Ig heavy chain V-III region CAM 
OS=Homo sapiens PE=1 SV=1 
1.05E+09 
Ig heavy chain V-III region GAL 
OS=Homo sapiens PE=1 SV=1 
1.17E+09 
Ig heavy chain V-III region GAL 
OS=Homo sapiens PE=1 SV=1 
1.05E+09 
Ig heavy chain V-III region GAR; 
[Homo sapiens (Human)] - 
[HV322_HUMAN] 
2.84E+08 
Ig heavy chain V-III region GAR; 
[Homo sapiens (Human)] - 
[HV322_HUMAN] 
1.05E+08 
Ig heavy chain V-III region HIL; 1.66E+09 Ig heavy chain V-III region HIL; 1.47E+09 
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[Homo sapiens (Human)] - 
[HV310_HUMAN] 
[Homo sapiens (Human)] - 
[HV310_HUMAN] 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 
5.90E+09 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 
3.47E+09 
Ig kappa chain V-I region DEE 
OS=Homo sapiens PE=1 SV=1 
4.84E+08 
Ig kappa chain V-I region DEE; 
[Homo sapiens (Human)] - 
[KV105_HUMAN] 
2.73E+08 
Ig kappa chain V-I region EU 
OS=Homo sapiens PE=1 SV=1 
4.22E+08 
Ig kappa chain V-I region EU 
OS=Homo sapiens PE=1 SV=1 
2.41E+08 
Ig kappa chain V-I region Ni; 
[Homo sapiens (Human)] - 
[KV121_HUMAN] 
1.15E+08 
Ig kappa chain V-I region Ni; 
[Homo sapiens (Human)] - 
[KV121_HUMAN] 
1.45E+08 
Ig kappa chain V-I region Wes; 
[Homo sapiens (Human)] - 
[KV119_HUMAN] 
5.03E+08 
Ig kappa chain V-I region Wes; 
[Homo sapiens (Human)] - 
[KV119_HUMAN] 
2.71E+08 
Ig kappa chain V-III region POM 
OS=Homo sapiens PE=1 SV=1 
3.13E+08 
Ig kappa chain V-III region POM 
OS=Homo sapiens PE=1 SV=1 
9.77E+07 
Ig kappa chain V-III region SIE 
OS=Homo sapiens PE=1 SV=1 
3.17E+08 
Ig kappa chain V-III region SIE 
OS=Homo sapiens PE=1 SV=1 
2.40E+08 
Ig kappa chain V-III region VG; 
Flags: Precursor; Fragment; 
[Homo sapiens (Human)] - 
[KV309_HUMAN] 
3.81E+08 
Ig kappa chain V-III region VG; 
Flags: Precursor; Fragment; 
[Homo sapiens (Human)] - 
[KV309_HUMAN] 
1.46E+08 
Ig kappa chain V-IV region Len 
OS=Homo sapiens PE=1 SV=2 
1.66E+08 
Ig kappa chain V-IV region Len 
OS=Homo sapiens PE=1 SV=2 
9.86E+07 
Ig lambda chain V region 4A 
OS=Homo sapiens PE=4 SV=1 
1.06E+08 
Ig lambda chain V region 4A 
OS=Homo sapiens PE=4 SV=1 
5.01E+07 
Ig lambda chain V-I region HA 
OS=Homo sapiens PE=1 SV=1 
2.17E+08 
Ig lambda chain V-I region HA 
OS=Homo sapiens PE=1 SV=1 
1.91E+08 
Ig lambda chain V-I region NIG-
64 OS=Homo sapiens PE=1 SV=1 
6.96E+07 
Ig lambda chain V-I region NIG-
64 OS=Homo sapiens PE=1 SV=1 
7.21E+07 
Ig lambda chain V-III region LOI; 
[Homo sapiens (Human)] - 
[LV302_HUMAN] 
2.61E+08 
Ig lambda chain V-III region LOI 
OS=Homo sapiens PE=1 SV=1 
1.57E+08 
Ig lambda chain V-IV region Bau; 
[Homo sapiens (Human)] - 
[LV401_HUMAN] 
4.40E+08 
Ig lambda chain V-IV region Bau; 
[Homo sapiens (Human)] - 
[LV401_HUMAN] 
1.58E+08 
Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 
3.07E+09 
Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 
2.31E+09 
Ig mu chain C region OS=Homo 
sapiens GN=IGHM PE=1 SV=3 
6.47E+07 
Ig mu chain C region OS=Homo 
sapiens GN=IGHM PE=1 SV=3 
4.16E+07 
Immunoglobulin J chain 
OS=Homo sapiens GN=IGJ PE=1 
SV=4 
8.29E+07 
Immunoglobulin J chain 







polypeptide 5 OS=Homo sapiens 
GN=IGLL5 PE=2 SV=2 
1.44E+09 
Intercellular adhesion molecule 1 
OS=Homo sapiens GN=ICAM1 
PE=1 SV=2 
4.01E+07 
Intercellular adhesion molecule 1 

















Flags: Precursor; [Homo sapiens 
(Human)] - [TRFL_HUMAN] 
9.47E+08 
Leucine-rich alpha-2-
glycoprotein; Short=LRG; Flags: 
Precursor; [Homo sapiens 
(Human)] - [A2GL_HUMAN] 
2.66E+07 
Leucine-rich alpha-2-glycoprotein 
OS=Homo sapiens GN=LRG1 
PE=1 SV=2 
4.46E+07 
LIM domain only protein 7; 
Short=LMO-7; AltName: Full=F-
box only protein 20; AltName: 
Full=LOMP; [Homo sapiens 
(Human)] - [LMO7_HUMAN] 
1.14E+08 
LIM domain only protein 7; 
Short=LMO-7; AltName: Full=F-
box only protein 20; AltName: 
Full=LOMP; [Homo sapiens 
(Human)] - [LMO7_HUMAN] 
1.36E+08 
Lysozyme C OS=Homo sapiens 
GN=LYZ PE=1 SV=1 
2.75E+06 
Lysozyme C; EC=3.2.1.17; 
AltName: Full=1,4-beta-N-
acetylmuramidase C; Flags: 
Precursor; [Homo sapiens 
(Human)] - [LYSC_HUMAN] 
1.48E+06 
Mucin-1 OS=Homo sapiens 
GN=MUC1 PE=1 SV=3 
1.31E+07 
Mucin-1 OS=Homo sapiens 
GN=MUC1 PE=1 SV=3 
1.18E+07 
Peptidyl-prolyl cis-trans 
isomerase A OS=Homo sapiens 
GN=PPIA PE=1 SV=2 
1.19E+07 
Peptidyl-prolyl cis-trans 
isomerase A; Short=PPIase A; 
EC=5.2.1.8; AltName: 
Full=Cyclophilin A; AltName: 
Full=Cyclosporin A-binding 
protein; AltName: Full=Rotamase 




receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
5.24E+08 
Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
1.94E+08 
Pre-mRNA cleavage complex 2 
protein Pcf11; AltName: 
Full=Pre-mRNA cleavage 
complex II protein Pcf11; [Homo 
sapiens (Human)] - 
[PCF11_HUMAN] 
7.88E+07 
Pre-mRNA cleavage complex 2 
protein Pcf11; AltName: 
Full=Pre-mRNA cleavage 
complex II protein Pcf11; [Homo 
sapiens (Human)] - 
[PCF11_HUMAN] 
5.19E+07 
Pro-cathepsin H OS=Homo 
sapiens GN=CTSH PE=1 SV=4 
2.79E+07 
Pro-cathepsin H OS=Homo 
sapiens GN=CTSH PE=1 SV=4 
1.06E+07 
Protein DJ-1 OS=Homo sapiens 
GN=PARK7 PE=1 SV=2 
3.98E+07 
Protein DJ-1 OS=Homo sapiens 
GN=PARK7 PE=1 SV=2 
1.23E+07 
Protein S100-A6 OS=Homo 
sapiens GN=S100A6 PE=1 SV=1 
9.49E+07 
Protein S100-A6 OS=Homo 
sapiens GN=S100A6 PE=1 SV=1 
2.38E+07 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 
8.34E+07 





Short=hShrmL; [Homo sapiens 
(Human)] - [SHRM3_HUMAN] 
Short=hShrmL; [Homo sapiens 
(Human)] - [SHRM3_HUMAN] 
Pulmonary surfactant-associated 
protein A2 OS=Homo sapiens 
GN=SFTPA2 PE=1 SV=1 
1.95E+08 
Pulmonary surfactant-associated 
protein A2 OS=Homo sapiens 
GN=SFTPA2 PE=1 SV=1 
3.74E+07 
Pulmonary surfactant-associated 
protein B OS=Homo sapiens 
GN=SFTPB PE=1 SV=3 
2.54E+07 
Pulmonary surfactant-associated 
protein B; Short=SP-B; AltName: 
Full=18 kDa pulmonary-
surfactant protein; AltName: 
Full=6 kDa protein; AltName: 
Full=Pulmonary surfactant-
associated proteolipid SPL(Phe); 
Flags: Precursor; [Homo sapiens 
(Human)] - [PSPB_HUMAN] 
3.26E+06 
Pulmonary surfactant-associated 
protein D OS=Homo sapiens 
GN=SFTPD PE=1 SV=3 
4.71E+07 
Pulmonary surfactant-associated 
protein D OS=Homo sapiens 
GN=SFTPD PE=1 SV=3 
1.53E+07 
Putative V-set and 
immunoglobulin domain-
containing protein 6 OS=Homo 
sapiens GN=VSIG6 PE=5 SV=2 
2.22E+08 
Putative V-set and 
immunoglobulin domain-
containing protein 6 OS=Homo 
sapiens GN=VSIG6 PE=5 SV=2 
2.00E+08 
Ribonuclease P protein subunit 
p40; Short=RNaseP protein p40; 
EC=3.1.26.5; AltName: 
Full=RNase P subunit 1; [Homo 
sapiens (Human)] - 
[RPP40_HUMAN] 
1.42E+08 
Ribonuclease P protein subunit 
p40; Short=RNaseP protein p40; 
EC=3.1.26.5; AltName: 
Full=RNase P subunit 1; [Homo 
sapiens (Human)] - 
[RPP40_HUMAN] 
5.47E+07 
Selenium-binding protein 1 
OS=Homo sapiens 
GN=SELENBP1 PE=1 SV=2 
2.43E+07 
Selenium-binding protein 1 
OS=Homo sapiens 
GN=SELENBP1 PE=1 SV=2 
1.67E+07 
Serotransferrin OS=Homo sapiens 
GN=TF PE=1 SV=3 
1.28E+10 
Serotransferrin OS=Homo sapiens 
GN=TF PE=1 SV=3 
7.62E+09 
Serpin B3 OS=Homo sapiens 
GN=SERPINB3 PE=1 SV=2 
3.01E+07 
Serpin B3 OS=Homo sapiens 
GN=SERPINB3 PE=1 SV=2 
2.30E+07 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
3.97E+09 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
2.77E+09 
SH3 domain-binding glutamic 
acid-rich-like protein 3; AltName: 
Full=SH3 domain-binding protein 
1; Short=SH3BP-1; [Homo 
sapiens (Human)] - 
[SH3L3_HUMAN] 
1.13E+07 
SH3 domain-binding glutamic 
acid-rich-like protein 3; AltName: 
Full=SH3 domain-binding protein 
1; Short=SH3BP-1; [Homo 





factor; Short=ADF; AltName: 
Full=Surface-associated 
sulphydryl protein; Short=SASP; 





factor; Short=ADF; AltName: 
Full=Surface-associated 
sulphydryl protein; Short=SASP; 













Transaldolase OS=Homo sapiens 
GN=TALDO1 PE=1 SV=2 
2.33E+07 
Transaldolase OS=Homo sapiens 
GN=TALDO1 PE=1 SV=2 
4.47E+07 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-beta; 
[Homo sapiens (Human)] - 
[TAD2B_HUMAN] 
8.54E+06 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-beta; 
[Homo sapiens (Human)] - 
[TAD2B_HUMAN] 
2.22E+07 
Transmembrane protein 198; 
[Homo sapiens (Human)] - 
[TM198_HUMAN] 
4.77E+07 
Transmembrane protein 198; 
[Homo sapiens (Human)] - 
[TM198_HUMAN] 
2.62E+07 
Transmembrane protein 200C; 
AltName: Full=Transmembrane 
protein TTMA; AltName: 
Full=Two transmembrane 
domain-containing family 
member A; [Homo sapiens 
(Human)] - [T200C_HUMAN] 
2.87E+06 
Transmembrane protein 200C; 
AltName: Full=Transmembrane 
protein TTMA; AltName: 
Full=Two transmembrane 
domain-containing family 
member A; [Homo sapiens 
(Human)] - [T200C_HUMAN] 
3.59E+06 
Transthyretin OS=Homo sapiens 
GN=TTR PE=1 SV=1 
1.12E+08 
Transthyretin OS=Homo sapiens 
GN=TTR PE=1 SV=1 
2.53E+08 
Triosephosphate isomerase 




OS=Homo sapiens GN=TPI1 
PE=1 SV=3 
4.37E+07 
Uncharacterized protein C3orf38; 
[Homo sapiens (Human)] - 
[CC038_HUMAN] 
4.10E+09 
Uncharacterized protein C3orf38; 




KIAA0947; [Homo sapiens 
(Human)] - [K0947_HUMAN] 
1.56E+07 
Uncharacterized protein 
KIAA0947; [Homo sapiens 
(Human)] - [K0947_HUMAN] 
8.15E+06 
Uteroglobin OS=Homo sapiens 
GN=SCGB1A1 PE=1 SV=1 
6.27E+08 
Uteroglobin OS=Homo sapiens 
GN=SCGB1A1 PE=1 SV=1 
1.74E+08 
Vitamin D-binding protein 
OS=Homo sapiens GN=GC PE=1 
SV=1 
2.19E+08 
Vitamin D-binding protein 
OS=Homo sapiens GN=GC PE=1 
SV=1 
4.91E+08 
Vitamin K-dependent protein S; 
Flags: Precursor; [Homo sapiens 
(Human)] - [PROS_HUMAN] 
6.05E+06 
Vitamin K-dependent protein S; 
Flags: Precursor; [Homo sapiens 
(Human)] - [PROS_HUMAN] 
3.31E+07 
Xin actin-binding repeat-
containing protein 2 OS=Homo 
sapiens GN=XIRP2 PE=1 SV=2 
4.22E+08 
Xin actin-binding repeat-
containing protein 2 OS=Homo 
sapiens GN=XIRP2 PE=1 SV=2 
2.05E+08 
Zinc-alpha-2-glycoprotein 















Table B.4: The biological process classification of Inflammation/immunity according to 
Gene Ontology annotation of proteins identified. Data shown is a comparison of the mean of 
the three most abundant ion peaks of each protein identified in Healthy Controls and 
Healthy Aged Controls respectively, n=5 for both subject groups. 
 
Inflammation/immunity  Healthy control Healthy aged control 
Alpha-1-acid glycoprotein 1 2.04E+08 3.39E+08 
Alpha-1-antichymotrypsin 1.49E+08 8.21E+07 
Alpha-1-antichymotrypsin 1.49E+08 8.21E+07 
Alpha-2-HS-glycoprotein (fetuin A) 7.52E+07 1.16E+08 
Antithrombin-III 2.92E+07 1.84E+07 
Beta-2-microglobulin 1.20E+08 2.59E+07 
Beta-microseminoprotein 5.82E+07 X 
Cell adhesion molecule 1 7.37E+06 X 
Complement C2 6.82E+06 3.41E+07 
Complement C3 1.25E+07 2.66E+06 




Complement factor B X 7.63E+06 
Deleted in malignant brain tumors 1 
protein 
5.59E+07 2.73E+07 
Dipeptidyl peptidase 4 1.64E+07 X 
Galectin-3 binding protein 1.14E+07 2.34E+06 
Haptoglobin 3.82E+08 X 
HLA class II histocompatibility 
antigen, DR alpha chain 
X 1.26E+08 
HLA class II histocompatibility 
antigen, DRB1-15 beta chain 
7.37E+06 1.69E+06 
Ig alpha-1 chain C region  2.81E+09 X 
Ig alpha-2 chain C region  2.05E+09 2.42E+09 
Ig delta chain C region  6.39E+06 1.79E+09 
Ig gamma-1 chain C region  1.23E+10 1.10E+07 
Ig gamma-2 chain C region  9.10E+09 8.92E+09 
Ig gamma-3 chain C region  9.36E+09 5.60E+09 
Ig gamma-4 chain C region 9.10E+09 6.71E+09 
Ig heavy chain V-I region HG3 2.14E+08 5.60E+09 
Ig heavy chain V-I region V35 6.05E+07 X 
Ig heavy chain V-II region ARH-77  7.57E+07 X 
Ig heavy chain V-III region CAM 1.22E+09 X 
Ig heavy chain V-III region GAL  1.17E+09 1.05E+09 
Ig heavy chain V-III region TIL X 1.05E+09 
Ig kappa chain C region  5.90E+09 X 
Ig kappa chain V-I region DEE  4.84E+08 3.47E+09 
Ig kappa chain V-I region Kue  X 2.73E+08 
Ig kappa chain V-II region RPMI 
6410 
X 1.89E+08 
Ig kappa chain V-II region TEW X 1.62E+08 
Ig kappa chain V-III region POM 3.13E+08 9.77E+07 
Ig kappa chain V-III region SIE  3.17E+08 2.40E+08 




Ig kappa chain V-IV region Len 1.66E+08 2.39E+08 
Ig lambda chain V region 4A 1.06E+08 9.86E+07 
Ig lambda chain V-I region HA 2.17E+08 5.01E+07 
Ig lambda chain V-I region NIG-64  6.96E+07 1.91E+08 
Ig lambda chain V-III region LOI  2.61E+08 7.21E+07 
Ig lambda chain V-III region SH  2.83E+07 1.57E+08 
Ig lambda chain V-VI region SUT  2.58E+07 X 
Ig lambda-2 chain C regions 3.07E+09 X 
Ig mu chain C region 6.47E+07 2.31E+09 
IgBF 5.82E+07 4.16E+07 
Immunoglobulin J chain 8.29E+07 X 
Immunoglobulin lambda-like 
polypeptide 5  
1.96E+09 4.76E+07 
Intercellular adhesion molecule 1 4.01E+07 1.44E+09 
Junctional adhesion molecule A 5.60E+06 1.15E+07 
Lactotransferrin 1.38E+09 9.06E+05 
Leukocyte elastase inhibitor 8.21E+06 9.47E+08 
Lysozyme C 2.75E+06 3.69E+07 
Macrophage Capping Protein X 1.48E+06 




Plasma protease C1 inhibitor 9.83E+06 X 







S100-A8 (Calgranulin A) X 3.59E+07 
Sushi domain-containing protein 2 X 1.63E+06 
V-set and immunoglobulin domain-
containing protein 6 
2.22E+08 X 
V-set and immunoglobulin domain-
containing protein 8 
3.05E+07 2.00E+08 
Zinc-alpha-2-glycoprotein 1.16E+08 1.24E+08 
 
Table B.5: The biological process classification of Protease/antiprotease balance to Gene 
Ontology annotation of proteins identified. Data shown is a comparison of the mean of the 
three most abundant ion peaks of each protein identified, in Healthy Controls and Healthy 
Aged Controls respectively, n=5 for both subject groups. 
 
Protease/antiprotease balance   Healthy control Healthy aged control 
Alpha-1-antichymotrypsin 1.49E+08 8.21E+07 
Alpha-1-antitrypsin 2.69E+09 3.20E+09 
Alpha-2-macroglobulin 6.75E+07 1.66E+08 
Alpha-N-acetylglucosaminidase X X 
Angiotensin-converting enzyme; 
Dipeptidyl carboxypeptidase I 
2.86E+07 
1.46E+07 
Antithrombin-III 2.92E+07 1.84E+07 
Cathepsin D 1.10E+09 X 
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Cathepsin Z 4.01E+06 X 
Complement C2 6.82E+06 3.41E+07 
Cystatin-B 7.58E+06 4.33E+06 
Dermcidin 6.20E+06 2.13E+06 
Dipeptidyl peptidase 4 1.64E+07 6.17E+07 




Latexin X X 





Matrix metalloproteinase-23 2.66E+06 X 
Matrix metalloproteinase-28   X 
Napsin-A 2.37E+06 X 
Pancreatic alpha-amylase X 1.35E+07 
Pro-cathepsin H 2.79E+07 1.06E+07 
Probable hydrolase PNKD 1.07E+07 X 
Prostasin 2.41E+06 1.22E+06 
Proteasome subunit alpha type-1 X X 
Protein DJ-1 3.98E+07 1.23E+07 
Serpin B6 X X 
Transmembrane protease serine 13 X X 
Trypsin-3 X X 
Xaa-Pro dipeptidase 1.18E+07 X 
 
Table B.6: The biological process classification of Oxidant/antioxidant balance to Gene 
Ontology annotation of proteins identified. Data shown is a comparison of the mean of the 
three most abundant ion peaks of each protein identified, in Healthy Controls and Healthy 







Oxidant/antioxidant balance  Healthy control Healthy aged control 
Glutathione peroxidase 3  4.07E+06 1.19E+06 
Glutathione S-transferase A2 5.83E+07 4.18E+07 
Glutathione S-transferase omega-1 6.98E+06 X 
Glutathione S-transferase P 3.42E+07 8.51E+06 
Peroxiredoxin-5, mitochondrial  6.12E+06 X 
Peroxiredoxin-6  2.13E+06 X 
Protein DJ-1  3.98E+07 1.23E+07 
Superoxide dismutase [Cu-Zn] 9.13E+06 X 
Thioredoxin 1.30E+07 8.21E+06 
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Table B.7: The biological process classification of Metal handling according to Gene 
Ontology annotation of proteins identified. Data shown is a comparison of the mean of the 
three most abundant ion peaks of each protein identified, in Healthy Controls and Healthy 
Aged Controls respectively, n=5 for both subject groups. 
 
Metal handling  Healthy control Healthy aged control 
Annexin A4  2.52E+07   
Annexin A5 6.60E+07 1.36E+06 
Calmodulin  3.58E+07 2.68E+06 
Carbonic anhydrase 1  2.36E+07 3.91E+06 
Carbonic anhydrase 2  9.50E+06 X 




Ferritin heavy chain  X 6.17E+07 
Ferritin light chain  X 4.73E+06 
Gelsolin  9.95E+06 X 
Glutathione peroxidase 3  4.07E+06 1.19E+06 
Hemoglobin subunit alpha 2.06E+08 1.49E+08 
Hemoglobin subunit beta  2.09E+08 1.28E+08 
Hemoglobin subunit delta  1.66E+08 7.65E+07 
Hemopexin 7.70E+08 2.71E+08 
Hornerin 4.56E+06 X 
Kininogen-1 5.17E+06 X 




Probable hydrolase PNKD 1.07E+07 X 
Protein S100-A11  7.59E+06 X 
Protein S100-A3  1.22E+07 X 
Protein S100-A7 X 1.37E+07 
Protein S100-A8  X 3.59E+07 
Protein S100-A9  X 1.13E+07 
Selenium-binding protein 1  2.43E+07 1.67E+07 
Serotransferrin  1.28E+10 7.62E+09 
Serum albumin  3.97E+09 2.77E+09 
Superoxide dismutase [Cu-Zn]  9.13E+06 X 












Figure C.1: The concentrations of metals: Cu, Zn and Fe, in bronchoalveolar lavage 
samples as determined by ICP-MS. Healthy Aged Non-Smoker n=12, Healthy Aged 
Smoker n=10, COPD Ex-Smoker n = 12, COPD Smoker n = 10 , * denotes a statistical 
difference where p<0.05. 
Table C.1: All alveolar proteins identified by 1D PAGE and nano LC MS/MS in healthy 
aged RTLFs. The 163 proteins identified in healthy aged subjects investigated, (n=5), 
alongside the mean of the three most abundant ion peaks of each respective protein 
identified. Accession numbers included according to entries in UniProtKB/Swiss-Prot.  
 
Healthy Aged Control 
14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 1.46E+07 
14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 1.86E+07 
14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 1.57E+07 
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase; EC=1.14.13.95; 
AltName: Full=7-alpha-hydroxy-4-cholesten-3-one 12-alpha-hydroxylase; 
AltName: Full=CYPVIIIB1; AltName: Full=Cytochrome P450 8B1; AltName: 
Full=Sterol 12-alpha-hydroxylase; [Homo sapiens (Human)] - [CP8B1_HUMAN] 
4.20E+07 
Actin-related protein 2; AltName: Full=Actin-like protein 2; [Homo sapiens 
(Human)] - [ARP2_HUMAN] 
1.97E+07 
Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 6.89E+07 
Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 2.54E+07 
Aldo-keto reductase family 1 member C3; EC=1.-.-.-; AltName: Full=17-beta-
hydroxysteroid dehydrogenase type 5; Short=17-beta-HSD 5; AltName: Full=3-
alpha-HSD type II, brain; AltName: Full=3-alpha-hydroxysteroid dehydrogenase 
type 2; Short=3-alpha-HSD type 2; EC=1.1.1.213; AltName: Full=Chlordecone 
reductase homolog HAKRb; AltName: Full=Dihydrodiol dehydrogenase 3; 
Short=DD-3; Short=DD3; AltName: Full=Dihydrodiol dehydrogenase type I; 
AltName: Full=HA1753; AltName: Full=Indanol dehydrogenase; EC=1.1.1.112; 
AltName: Full=Prostaglandin F synthase; Short=PGFS; EC=1.1.1.188; AltName: 
Full=Testosterone 17-beta-dehydrogenase 5; EC=1.1.1.63; EC=1.1.1.64; 
AltName: Full=Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase; EC=1.3.1.20; 
[Homo sapiens (Human)] - [AK1C3_HUMAN] 
3.18E+07 
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 3.39E+08 
Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2 2.40E+08 
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Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 8.21E+07 
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 3.20E+09 
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 1.33E+08 
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 1.16E+08 
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 1.66E+08 
Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 4.14E+06 
Angiotensin-converting enzyme; Short=ACE; EC=3.2.1.-; EC=3.4.15.1; 
AltName: Full=Dipeptidyl carboxypeptidase I; AltName: Full=Kininase II; 
AltName: CD_antigen=CD143; Contains: RecName: Full=Angiotensin-
converting enzyme, soluble form; Flags: Precursor; [Homo sapiens (Human)] - 
[ACE_HUMAN] 
1.46E+07 
Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 4.94E+07 
Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 1.36E+06 
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 1.84E+07 
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 1.38E+08 
Apolipoprotein A-II OS=Homo sapiens GN=APOA2 PE=1 SV=1 7.40E+07 
Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 SV=3 2.74E+07 
ATP-binding cassette sub-family F member 1; AltName: Full=ATP-binding 
cassette 50; AltName: Full=TNF-alpha-stimulated ABC protein; [Homo sapiens 
(Human)] - [ABCF1_HUMAN] 
1.17E+07 
Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2 5.23E+06 
Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 2.59E+07 
Biotinidase OS=Homo sapiens GN=BTD PE=1 SV=2 2.84E+06 
C2 calcium-dependent domain-containing protein 4B; AltName: Full=Nuclear-
localized factor 2; AltName: Full=Protein FAM148B; [Homo sapiens (Human)] - 
[C2C4B_HUMAN] 
8.25E+07 
Calmodulin OS=Homo sapiens GN=CALM1 PE=1 SV=2 2.68E+06 
Calmodulin-like protein 5; AltName: Full=Calmodulin-like skin protein; [Homo 
sapiens (Human)] - [CALL5_HUMAN] 
2.82E+07 
Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 3.91E+06 
CD166 antigen; AltName: Full=Activated leukocyte cell adhesion molecule; 
AltName: CD_antigen=CD166; Flags: Precursor; [Homo sapiens (Human)] - 
[CD166_HUMAN] 
1.35E+07 
CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=3 2.73E+07 
CD59 glycoprotein; AltName: Full=1F5 antigen; AltName: Full=20 kDa 
homologous restriction factor; Short=HRF-20; Short=HRF20; AltName: 
Full=MAC-inhibitory protein; Short=MAC-IP; AltName: Full=MEM43 antigen; 
AltName: Full=Membrane attack complex inhibition factor; Short=MACIF; 
AltName: Full=Membrane inhibitor of reactive lysis; Short=MIRL; AltName: 
Full=Protectin; AltName: CD_antigen=CD59; Flags: Precursor; [Homo sapiens 
(Human)] - [CD59_HUMAN] 
3.54E+06 
CD9 antigen; AltName: Full=5H9 antigen; AltName: Full=Cell growth-inhibiting 
gene 2 protein; AltName: Full=Leukocyte antigen MIC3; AltName: 
Full=Motility-related protein; Short=MRP-1; AltName: Full=Tetraspanin-29; 
Short=Tspan-29; AltName: Full=p24; AltName: CD_antigen=CD9; [Homo 
sapiens (Human)] - [CD9_HUMAN] 
9.50E+06 
Cell adhesion molecule 2; AltName: Full=Immunoglobulin superfamily member 
4D; Short=IgSF4D; AltName: Full=Nectin-like protein 3; Short=NECL-3; Flags: 
Precursor; [Homo sapiens (Human)] - [CADM2_HUMAN] 
2.00E+06 
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 3.67E+08 
Coactosin-like protein OS=Homo sapiens GN=COTL1 PE=1 SV=3 5.15E+06 
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Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2 3.41E+07 
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 2.66E+06 
Complement decay-accelerating factor OS=Homo sapiens GN=CD55 PE=1 SV=4 7.63E+06 
Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 PE=1 SV=1 3.95E+07 
Deleted in malignant brain tumors 1 protein OS=Homo sapiens GN=DMBT1 
PE=1 SV=2 
3.69E+07 
Delta-like protein 4; AltName: Full=Drosophila Delta homolog 4; Short=Delta4; 
Flags: Precursor; [Homo sapiens (Human)] - [DLL4_HUMAN] 
1.23E+07 
Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 2.13E+06 
Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 1.40E+08 
Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2 6.17E+07 
Disintegrin and metalloproteinase domain-containing protein 2; Short=ADAM 2; 
AltName: Full=Cancer/testis antigen 15; Short=CT15; AltName: Full=Fertilin 
subunit beta; AltName: Full=PH-30; Short=PH30; AltName: Full=PH30-beta; 
Flags: Precursor; [Homo sapiens (Human)] - [ADAM2_HUMAN] 
1.05E+08 
Ecto-ADP-ribosyltransferase 4; EC=2.4.2.31; AltName: Full=Dombrock blood 
group carrier molecule; AltName: Full=Mono(ADP-ribosyl)transferase 4; 
AltName: Full=NAD(P)(+)--arginine ADP-ribosyltransferase 4; AltName: 
CD_antigen=CD297; Flags: Precursor; [Homo sapiens (Human)] - 
[NAR4_HUMAN] 
5.81E+07 
Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 2.16E+07 
Epididymal secretory protein E1 OS=Homo sapiens GN=NPC2 PE=1 SV=1 1.37E+07 
FAS-associated factor 1; Short=hFAF1; AltName: Full=UBX domain-containing 
protein 12; AltName: Full=UBX domain-containing protein 3A; [Homo sapiens 
(Human)] - [FAF1_HUMAN] 
4.89E+08 
Ferritin heavy chain; Short=Ferritin H subunit; EC=1.16.3.1; AltName: Full=Cell 
proliferation-inducing gene 15 protein; [Homo sapiens (Human)] - 
[FRIH_HUMAN] 
2.34E+06 
Ferritin light chain; Short=Ferritin L subunit; [Homo sapiens (Human)] - 
[FRIL_HUMAN] 
4.73E+06 
Galectin-3-binding protein; AltName: Full=Basement membrane autoantigen 
p105; AltName: Full=Lectin galactoside-binding soluble 3-binding protein; 
AltName: Full=Mac-2-binding protein; Short=MAC2BP; Short=Mac-2 BP; 
AltName: Full=Tumor-associated antigen 90K; Flags: Precursor; [Homo sapiens 
(Human)] - [LG3BP_HUMAN] 
7.88E+06 
Galectin-3; Short=Gal-3; AltName: Full=35 kDa lectin; AltName: 
Full=Carbohydrate-binding protein 35; Short=CBP 35; AltName: Full=Galactose-
specific lectin 3; AltName: Full=Galactoside-binding protein; Short=GALBP; 
AltName: Full=IgE-binding protein; AltName: Full=L-31; AltName: 
Full=Laminin-binding protein; AltName: Full=Lectin L-29; AltName: Full=Mac-
2 antigen; [Homo sapiens (Human)] - [LEG3_HUMAN] 
2.03E+06 
Glutathione peroxidase 3 OS=Homo sapiens GN=GPX3 PE=1 SV=2 1.19E+06 
Glutathione S-transferase A2 OS=Homo sapiens GN=GSTA2 PE=1 SV=4 4.18E+07 
Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 8.51E+06 
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 1.26E+08 
Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2 8.93E+06 
Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 1.49E+08 
Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 1.28E+08 
Hemoglobin subunit delta OS=Homo sapiens GN=HBD PE=1 SV=2 7.65E+07 
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 2.71E+08 
Histone H3.3C; [Homo sapiens (Human)] - [H3C_HUMAN] 1.79E+07 
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Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 2.45E+07 
HLA class II histocompatibility antigen, DR alpha chain; AltName: Full=MHC 
class II antigen DRA; Flags: Precursor; [Homo sapiens (Human)] - 
[DRA_HUMAN] 
1.69E+06 
HLA class II histocompatibility antigen, DRB1-1 beta chain OS=Homo sapiens 
GN=HLA-DRB1 PE=1 SV=2 
6.88E+06 
Homeobox protein Nkx-3.2; AltName: Full=Bagpipe homeobox protein homolog 
1; AltName: Full=Homeobox protein NK-3 homolog B; [Homo sapiens (Human)] 
- [NKX32_HUMAN] 
1.75E+07 
Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 2.42E+09 
Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 1.79E+09 
Ig delta chain C region OS=Homo sapiens GN=IGHD PE=1 SV=2 1.10E+07 
Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 
8,918,00
0,000 
Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2 5.60E+09 
Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=1 SV=2 6.71E+09 
Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 5.60E+09 
Ig heavy chain V-I region Mot OS=Homo sapiens PE=1 SV=1 2.05E+08 
Ig heavy chain V-II region ARH-77; Flags: Precursor; [Homo sapiens (Human)] - 
[HV209_HUMAN] 
4.86E+07 
Ig heavy chain V-II region NEWM OS=Homo sapiens PE=1 SV=1 1.47E+08 
Ig heavy chain V-II region OU; [Homo sapiens (Human)] - [HV201_HUMAN] 1.44E+08 
Ig heavy chain V-III region BRO; [Homo sapiens (Human)] - [HV305_HUMAN] 1.02E+09 
Ig heavy chain V-III region BUT; [Homo sapiens (Human)] - [HV306_HUMAN] 1.03E+09 
Ig heavy chain V-III region CAM OS=Homo sapiens PE=1 SV=1 1.05E+09 
Ig heavy chain V-III region GAL OS=Homo sapiens PE=1 SV=1 1.05E+09 
Ig heavy chain V-III region GAR; [Homo sapiens (Human)] - [HV322_HUMAN] 1.05E+08 
Ig heavy chain V-III region HIL; [Homo sapiens (Human)] - [HV310_HUMAN] 1.47E+09 
Ig heavy chain V-III region TIL OS=Homo sapiens PE=1 SV=1 1.06E+09 
Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 3.47E+09 
Ig kappa chain V-I region CAR; [Homo sapiens (Human)] - [KV104_HUMAN] 7.26E+07 
Ig kappa chain V-I region DEE; [Homo sapiens (Human)] - [KV105_HUMAN] 2.73E+08 
Ig kappa chain V-I region EU OS=Homo sapiens PE=1 SV=1 2.41E+08 
Ig kappa chain V-I region Kue OS=Homo sapiens PE=1 SV=1 1.89E+08 
Ig kappa chain V-I region Ni; [Homo sapiens (Human)] - [KV121_HUMAN] 1.45E+08 
Ig kappa chain V-I region OU; [Homo sapiens (Human)] - [KV114_HUMAN] 3.43E+08 
Ig kappa chain V-I region Wes; [Homo sapiens (Human)] - [KV119_HUMAN] 2.71E+08 
Ig kappa chain V-II region FR OS=Homo sapiens PE=1 SV=1 8.51E+07 
Ig kappa chain V-II region RPMI 6410 OS=Homo sapiens PE=4 SV=1 1.62E+08 
Ig kappa chain V-III region B6; [Homo sapiens (Human)] - [KV301_HUMAN] 2.39E+08 
Ig kappa chain V-III region POM OS=Homo sapiens PE=1 SV=1 9.77E+07 
Ig kappa chain V-III region SIE OS=Homo sapiens PE=1 SV=1 2.40E+08 
Ig kappa chain V-III region VG; Flags: Precursor; Fragment; [Homo sapiens 
(Human)] - [KV309_HUMAN] 
1.46E+08 
Ig kappa chain V-IV region JI OS=Homo sapiens PE=4 SV=1 3.74E+07 
Ig kappa chain V-IV region Len OS=Homo sapiens PE=1 SV=2 9.86E+07 
Ig lambda chain V region 4A OS=Homo sapiens PE=4 SV=1 5.01E+07 
Ig lambda chain V-I region HA OS=Homo sapiens PE=1 SV=1 1.91E+08 
Ig lambda chain V-I region NIG-64 OS=Homo sapiens PE=1 SV=1 7.21E+07 
Ig lambda chain V-II region NEI; [Homo sapiens (Human)] - [LV202_HUMAN] 1.91E+07 
Ig lambda chain V-III region LOI OS=Homo sapiens PE=1 SV=1 1.57E+08 
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Ig lambda chain V-III region SH; [Homo sapiens (Human)] - [LV301_HUMAN] 3.09E+07 
Ig lambda chain V-IV region Bau; [Homo sapiens (Human)] - [LV401_HUMAN] 1.58E+08 
Ig lambda chain V-VI region SUT; [Homo sapiens (Human)] - 
[LV603_HUMAN] 
7.86E+06 
Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 SV=1 2.31E+09 
Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 4.16E+07 
Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 4.76E+07 
Immunoglobulin lambda-like polypeptide 5 OS=Homo sapiens GN=IGLL5 PE=2 
SV=2 
1.44E+09 
Intercellular adhesion molecule 1 OS=Homo sapiens GN=ICAM1 PE=1 SV=2 1.15E+07 
Lactotransferrin; Short=Lactoferrin; EC=3.4.21.-; AltName: Full=Talalactoferrin; 
Contains: RecName: Full=Kaliocin-1; Contains: RecName: Full=Lactoferroxin-
A; Contains: RecName: Full=Lactoferroxin-B; Contains: RecName: 
Full=Lactoferroxin-C; Flags: Precursor; [Homo sapiens (Human)] - 
[TRFL_HUMAN] 
9.47E+08 
Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2 4.46E+07 
LIM domain only protein 7; Short=LMO-7; AltName: Full=F-box only protein 
20; AltName: Full=LOMP; [Homo sapiens (Human)] - [LMO7_HUMAN] 
1.36E+08 
Lysosomal alpha-glucosidase; EC=3.2.1.20; AltName: Full=Acid maltase; 
AltName: Full=Aglucosidase alfa; Contains: RecName: Full=76 kDa lysosomal 
alpha-glucosidase; Contains: RecName: Full=70 kDa lysosomal alpha-
glucosidase; Flags: Precursor; [Homo sapiens (Human)] - [LYAG_HUMAN] 
1.40E+06 
Lysozyme C; EC=3.2.1.17; AltName: Full=1,4-beta-N-acetylmuramidase C; 
Flags: Precursor; [Homo sapiens (Human)] - [LYSC_HUMAN] 
1.48E+06 
Mucin-1 OS=Homo sapiens GN=MUC1 PE=1 SV=3 1.18E+07 
Myotubularin-related protein 14; EC=3.1.3.-; AltName: Full=HCV NS5A-
transactivated protein 4 splice variant A-binding protein 1; 
Short=NS5ATP4ABP1; AltName: Full=hJumpy; [Homo sapiens (Human)] - 
[MTMRE_HUMAN] 
3.06E+06 
Pancreatic alpha-amylase; Short=PA; EC=3.2.1.1; AltName: Full=1,4-alpha-D-
glucan glucanohydrolase; Flags: Precursor; [Homo sapiens (Human)] - 
[AMYP_HUMAN] 
1.35E+07 
Peptidyl-prolyl cis-trans isomerase A; Short=PPIase A; EC=5.2.1.8; AltName: 
Full=Cyclophilin A; AltName: Full=Cyclosporin A-binding protein; AltName: 
Full=Rotamase A; [Homo sapiens (Human)] - [PPIA_HUMAN] 
6.43E+06 
Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 SV=4 1.94E+08 
Pre-mRNA cleavage complex 2 protein Pcf11; AltName: Full=Pre-mRNA 
cleavage complex II protein Pcf11; [Homo sapiens (Human)] - 
[PCF11_HUMAN] 
5.19E+07 
Pro-cathepsin H OS=Homo sapiens GN=CTSH PE=1 SV=4 1.06E+07 
Proactivator polypeptide OS=Homo sapiens GN=PSAP PE=1 SV=2 2.71E+06 
Prostasin; EC=3.4.21.-; AltName: Full=Serine protease 8; Contains: RecName: 
Full=Prostasin light chain; Contains: RecName: Full=Prostasin heavy chain; 
Flags: Precursor; [Homo sapiens (Human)] - [PRSS8_HUMAN] 
1.22E+06 
Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 1.23E+07 
Protein S100-A6 OS=Homo sapiens GN=S100A6 PE=1 SV=1 2.38E+07 
Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 3.59E+07 
Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1 1.13E+07 
Protein Shroom3; AltName: Full=Shroom-related protein; Short=hShrmL; [Homo 
sapiens (Human)] - [SHRM3_HUMAN] 
9.47E+07 
Protein-glutamine gamma-glutamyltransferase E; EC=2.3.2.13; AltName: 3.65E+06 
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Full=Transglutaminase E; Short=TG(E); Short=TGE; Short=TGase E; AltName: 
Full=Transglutaminase-3; Short=TGase-3; Contains: RecName: Full=Protein-
glutamine gamma-glutamyltransferase E 50 kDa non-catalytic chain; Contains: 
RecName: Full=Protein-glutamine gamma-glutamyltransferase E 27 kDa catalytic 
chain; Flags: Precursor; [Homo sapiens (Human)] - [TGM3_HUMAN] 
Pulmonary surfactant-associated protein A2 OS=Homo sapiens GN=SFTPA2 
PE=1 SV=1 
3.74E+07 
Pulmonary surfactant-associated protein B; Short=SP-B; AltName: Full=18 kDa 
pulmonary-surfactant protein; AltName: Full=6 kDa protein; AltName: 
Full=Pulmonary surfactant-associated proteolipid SPL(Phe); Flags: Precursor; 
[Homo sapiens (Human)] - [PSPB_HUMAN] 
3.26E+06 
Pulmonary surfactant-associated protein D OS=Homo sapiens GN=SFTPD PE=1 
SV=3 
1.53E+07 
Putative V-set and immunoglobulin domain-containing protein 6 OS=Homo 
sapiens GN=VSIG6 PE=5 SV=2 
2.00E+08 
Ribonuclease P protein subunit p40; Short=RNaseP protein p40; EC=3.1.26.5; 
AltName: Full=RNase P subunit 1; [Homo sapiens (Human)] - 
[RPP40_HUMAN] 
5.47E+07 
Selenium-binding protein 1 OS=Homo sapiens GN=SELENBP1 PE=1 SV=2 1.67E+07 
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 7.62E+09 
Serpin B3 OS=Homo sapiens GN=SERPINB3 PE=1 SV=2 2.30E+07 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 2.77E+09 
SH3 domain-binding glutamic acid-rich-like protein 3; AltName: Full=SH3 
domain-binding protein 1; Short=SH3BP-1; [Homo sapiens (Human)] - 
[SH3L3_HUMAN] 
3.66E+06 
Sorting nexin-6; AltName: Full=TRAF4-associated factor 2; [Homo sapiens 
(Human)] - [SNX6_HUMAN] 
2.15E+06 
Thioredoxin; Short=Trx; AltName: Full=ATL-derived factor; Short=ADF; 
AltName: Full=Surface-associated sulphydryl protein; Short=SASP; [Homo 
sapiens (Human)] - [THIO_HUMAN] 
8.21E+06 
Thyroxine-binding globulin OS=Homo sapiens GN=SERPINA7 PE=1 SV=2 5.25E+06 
Transaldolase OS=Homo sapiens GN=TALDO1 PE=1 SV=2 4.47E+07 
Transcriptional adapter 2-beta; AltName: Full=ADA2-like protein beta; 
Short=ADA2-beta; [Homo sapiens (Human)] - [TAD2B_HUMAN] 
2.22E+07 
Transmembrane protein 198; [Homo sapiens (Human)] - [TM198_HUMAN] 2.62E+07 
Transmembrane protein 200C; AltName: Full=Transmembrane protein TTMA; 
AltName: Full=Two transmembrane domain-containing family member A; 
[Homo sapiens (Human)] - [T200C_HUMAN] 
3.59E+06 
Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 2.53E+08 
Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 4.37E+07 
Uncharacterized protein C3orf38; [Homo sapiens (Human)] - [CC038_HUMAN] 2.73E+09 
Uncharacterized protein KIAA0947; [Homo sapiens (Human)] - 
[K0947_HUMAN] 
8.15E+06 
Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=1 SV=1 1.74E+08 
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 4.91E+08 
Vitamin K-dependent protein S; Flags: Precursor; [Homo sapiens (Human)] - 
[PROS_HUMAN] 
3.31E+07 
Xin actin-binding repeat-containing protein 2 OS=Homo sapiens GN=XIRP2 
PE=1 SV=2 
2.05E+08 




Table C.2: All alveolar proteins identified by 1D PAGE and nano LC MS/MS in healthy 
smoker RTLFs. The 145 proteins identified in healthy smoker subjects investigated, 
(n=5), alongside the mean of the three most abundant ion peaks of each respective protein 
identified. Accession numbers included according to entries in UniProtKB/Swiss-Prot 
Healthy Smoker 
14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 6.47E+07 
14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 4.51E+07 
Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 1.38E+08 
Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 5.45E+06 
Aldo-keto reductase family 1 member B10; EC=1.1.1.-; AltName: Full=ARL-1; 
AltName: Full=Aldose reductase-like; AltName: Full=Aldose reductase-related 
protein; Short=ARP; Short=hARP; AltName: Full=Small intestine reductase; 
Short=SI reductase; [Homo sapiens (Human)] - [AK1BA_HUMAN] 5.19E+05 
Aldo-keto reductase family 1 member C1 OS=Homo sapiens GN=AKR1C1 
PE=1 SV=1 3.41E+06 
Aldose 1-epimerase; EC=5.1.3.3; AltName: Full=Galactose mutarotase; [Homo 
sapiens (Human)] - [GALM_HUMAN] 2.63E+06 
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 1.29E+08 
Alpha-1-acid glycoprotein 2; Short=AGP 2; AltName: Full=Orosomucoid-2; 
Short=OMD 2; Flags: Precursor; [Homo sapiens (Human)] - [A1AG2_HUMAN] 1.14E+08 
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 3.72E+07 
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 2.75E+08 
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 2.29E+07 
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 2.99E+07 
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 4.14E+06 
Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 3.19E+07 
Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 1.41E+06 
Annexin A3 OS=Homo sapiens GN=ANXA3 PE=1 SV=3 2.81E+06 
Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 5.18E+07 
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 7.56E+06 
Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2 4.53E+06 
Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 1.03E+07 
Beta-microseminoprotein; AltName: Full=Immunoglobulin-binding factor; 
Short=IGBF; AltName: Full=PN44; AltName: Full=Prostate secreted seminal 
plasma protein; AltName: Full=Prostate secretory protein of 94 amino acids; 
Short=PSP-94; Short=PSP94; AltName: Full=Seminal plasma beta-inhibin; 
Flags: Precursor; [Homo sapiens (Human)] - [MSMB_HUMAN] 1.50E+07 
C2 calcium-dependent domain-containing protein 4B; AltName: Full=Nuclear-
localized factor 2; AltName: Full=Protein FAM148B; [Homo sapiens (Human)] - 
[C2C4B_HUMAN] 7.49E+06 
Calcyphosin OS=Homo sapiens GN=CAPS PE=1 SV=1 1.44E+07 
Calmodulin OS=Homo sapiens GN=CALM1 PE=1 SV=2 2.84E+06 
Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2 3.84E+06 
Cathepsin B OS=Homo sapiens GN=CTSB PE=1 SV=3 2.14E+06 
Cathepsin S OS=Homo sapiens GN=CTSS PE=1 SV=3 3.74E+06 
Cathepsin Z OS=Homo sapiens GN=CTSZ PE=1 SV=1 4.21E+06 
CD166 antigen; AltName: Full=Activated leukocyte cell adhesion molecule; 
AltName: CD_antigen=CD166; Flags: Precursor; [Homo sapiens (Human)] - 
[CD166_HUMAN] 2.77E+06 
CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=3 3.34E+07 
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Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 1.15E+08 
Coactosin-like protein OS=Homo sapiens GN=COTL1 PE=1 SV=3 6.78E+06 
Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 PE=1 SV=1 5.20E+06 
Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 6.43E+06 
Deleted in malignant brain tumors 1 protein OS=Homo sapiens GN=DMBT1 
PE=1 SV=2 6.18E+06 
Delta-like protein 4; AltName: Full=Drosophila Delta homolog 4; Short=Delta4; 
Flags: Precursor; [Homo sapiens (Human)] - [DLL4_HUMAN] 1.12E+07 
Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 4.35E+06 
Desmoglein-1; AltName: Full=Cadherin family member 4; AltName: 
Full=Desmosomal glycoprotein 1; Short=DG1; Short=DGI; AltName: 
Full=Pemphigus foliaceus antigen; Flags: Precursor; [Homo sapiens (Human)] - 
[DSG1_HUMAN] 7.80E+06 
Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 9.94E+07 
Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2 3.08E+06 
Dynein heavy chain 10, axonemal; AltName: Full=Axonemal beta dynein heavy 
chain 10; AltName: Full=Ciliary dynein heavy chain 10; [Homo sapiens 
(Human)] - [DYH10_HUMAN] 1.25E+08 
Ecto-ADP-ribosyltransferase 4; EC=2.4.2.31; AltName: Full=Dombrock blood 
group carrier molecule; AltName: Full=Mono(ADP-ribosyl)transferase 4; 
AltName: Full=NAD(P)(+)--arginine ADP-ribosyltransferase 4; AltName: 
CD_antigen=CD297; Flags: Precursor; [Homo sapiens (Human)] - 
[NAR4_HUMAN] 2.69E+07 
Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1   
Epididymal secretory protein E1 OS=Homo sapiens GN=NPC2 PE=1 SV=1 1.32E+07 
FAS-associated factor 1; Short=hFAF1; AltName: Full=UBX domain-containing 
protein 12; AltName: Full=UBX domain-containing protein 3A; [Homo sapiens 
(Human)] - [FAF1_HUMAN] 4.56E+07 
Fatty acid-binding protein, epidermal OS=Homo sapiens GN=FABP5 PE=1 
SV=3 8.26E+07 
Ferritin heavy chain OS=Homo sapiens GN=FTH1 PE=1 SV=2 5.09E+06 
Ferritin light chain OS=Homo sapiens GN=FTL PE=1 SV=2 2.03E+07 
Glutathione S-transferase A1 OS=Homo sapiens GN=GSTA1 PE=1 SV=3 1.73E+07 
Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 1.82E+07 
Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH 
PE=1 SV=3 4.98E+07 
Glyoxalase domain-containing protein 4 OS=Homo sapiens GN=GLOD4 PE=1 
SV=1 1.54E+06 
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 1.04E+08 
Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2 4.31E+07 
Heme-binding protein 2; AltName: Full=Placental protein 23; Short=PP23; 
AltName: Full=Protein SOUL; [Homo sapiens (Human)] - [HEBP2_HUMAN] 1.49E+06 
Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 5.40E+07 
Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 2.04E+07 
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 1.89E+08 
Histone H3.3C; [Homo sapiens (Human)] - [H3C_HUMAN] 1.36E+07 
Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 2.72E+07 
Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 6.14E+08 
Ig alpha-2 chain C region; [Homo sapiens (Human)] - [IGHA2_HUMAN] 3.06E+08 
Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 3.30E+09 
Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2 2.57E+09 
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Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=1 SV=2 2.87E+09 
Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 2.57E+09 
Ig heavy chain V-I region HG3; Flags: Precursor; [Homo sapiens (Human)] - 
[HV102_HUMAN] 3.44E+07 
Ig heavy chain V-II region COR; [Homo sapiens (Human)] - [HV202_HUMAN] 2.14E+07 
Ig heavy chain V-II region NEWM OS=Homo sapiens PE=1 SV=1 9.45E+07 
Ig heavy chain V-III region BRO; [Homo sapiens (Human)] - [HV305_HUMAN] 5.36E+08 
Ig heavy chain V-III region BUT; [Homo sapiens (Human)] - [HV306_HUMAN] 4.98E+08 
Ig heavy chain V-III region CAM OS=Homo sapiens PE=1 SV=1   
Ig heavy chain V-III region GAL OS=Homo sapiens PE=1 SV=1 4.92E+08 
Ig heavy chain V-III region GAR; [Homo sapiens (Human)] - 
[HV322_HUMAN] 8.76E+07 
Ig heavy chain V-III region HIL; [Homo sapiens (Human)] - [HV310_HUMAN] 7.00E+08 
Ig heavy chain V-III region VH26 OS=Homo sapiens PE=1 SV=1 4.91E+08 
Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 1.07E+09 
Ig kappa chain V-I region DEE; [Homo sapiens (Human)] - [KV105_HUMAN] 1.54E+08 
Ig kappa chain V-I region EU OS=Homo sapiens PE=1 SV=1 7.39E+07 
Ig kappa chain V-I region WAT OS=Homo sapiens PE=1 SV=1   
Ig kappa chain V-II region RPMI 6410 OS=Homo sapiens PE=4 SV=1 4.64E+07 
Ig kappa chain V-III region POM; [Homo sapiens (Human)] - 
[KV306_HUMAN] 7.29E+07 
Ig kappa chain V-III region SIE OS=Homo sapiens PE=1 SV=1 1.24E+08 
Ig kappa chain V-III region Ti; [Homo sapiens (Human)] - [KV304_HUMAN] 9.42E+07 
Ig kappa chain V-III region VG (Fragment) OS=Homo sapiens PE=1 SV=1 5.54E+07 
Ig kappa chain V-IV region B17 OS=Homo sapiens PE=2 SV=1 6.10E+07 
Ig kappa chain V-IV region JI; Flags: Precursor; [Homo sapiens (Human)] - 
[KV403_HUMAN] 6.10E+07 
Ig kappa chain V-IV region Len; [Homo sapiens (Human)] - [KV402_HUMAN] 6.10E+07 
Ig lambda chain V region 4A; Flags: Precursor; [Homo sapiens (Human)] - 
[LV001_HUMAN] 1.78E+07 
Ig lambda chain V-I region HA; [Homo sapiens (Human)] - [LV102_HUMAN] 5.73E+07 
Ig lambda chain V-III region LOI OS=Homo sapiens PE=1 SV=1 6.55E+07 
Ig lambda chain V-III region SH OS=Homo sapiens PE=1 SV=1 1.01E+07 
Ig lambda chain V-IV region Bau; [Homo sapiens (Human)] - 
[LV401_HUMAN] 1.05E+07 
Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 SV=1 7.91E+08 
Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 4.18E+07 
Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 3.90E+07 
Immunoglobulin lambda-like polypeptide 5 OS=Homo sapiens GN=IGLL5 PE=2 
SV=2 4.43E+08 
Intercellular adhesion molecule 1 OS=Homo sapiens GN=ICAM1 PE=1 SV=2 4.60E+06 
Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2 1.76E+07 
Leukocyte elastase inhibitor OS=Homo sapiens GN=SERPINB1 PE=1 SV=1 2.61E+06 
Lysozyme C; EC=3.2.1.17; AltName: Full=1,4-beta-N-acetylmuramidase C; 
Flags: Precursor; [Homo sapiens (Human)] - [LYSC_HUMAN] 7.04E+05 
Myoglobin; [Homo sapiens (Human)] - [MYG_HUMAN] 1.97E+06 
Nicotinamide phosphoribosyltransferase; Short=NAmPRTase; Short=Nampt; 
EC=2.4.2.12; AltName: Full=Pre-B-cell colony-enhancing factor 1; Short=Pre-B 
cell-enhancing factor; AltName: Full=Visfatin; [Homo sapiens (Human)] - 
[NAMPT_HUMAN] 1.55E+07 
Olfactory receptor 2A2; AltName: Full=Olfactory receptor 2A17; AltName: 2.70E+08 
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Full=Olfactory receptor OR7-11; [Homo sapiens (Human)] - [OR2A2_HUMAN] 
Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 1.78E+06 
Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 SV=4 1.54E+08 
Pro-cathepsin H OS=Homo sapiens GN=CTSH PE=1 SV=4 1.14E+07 
Proactivator polypeptide; Contains: RecName: Full=Saposin-A; AltName: 
Full=Protein A; Contains: RecName: Full=Saposin-B-Val; Contains: RecName: 
Full=Saposin-B; AltName: Full=Cerebroside sulfate activator; Short=CSAct; 
AltName: Full=Dispersin; AltName: Full=Sphingolipid activator protein 1; 
Short=SAP-1; AltName: Full=Sulfatide/GM1 activator; Contains: RecName: 
Full=Saposin-C; AltName: Full=A1 activator; AltName: Full=Co-beta-
glucosidase; AltName: Full=Glucosylceramidase activator; AltName: 
Full=Sphingolipid activator protein 2; Short=SAP-2; Contains: RecName: 
Full=Saposin-D; AltName: Full=Component C; AltName: Full=Protein C; Flags: 
Precursor; [Homo sapiens (Human)] - [SAP_HUMAN] 1.35E+06 
Prostasin; EC=3.4.21.-; AltName: Full=Serine protease 8; Contains: RecName: 
Full=Prostasin light chain; Contains: RecName: Full=Prostasin heavy chain; 
Flags: Precursor; [Homo sapiens (Human)] - [PRSS8_HUMAN] 1.62E+06 
Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 7.89E+06 
Protein S100-A11 OS=Homo sapiens GN=S100A11 PE=1 SV=2 4.08E+06 
Protein S100-A6 OS=Homo sapiens GN=S100A6 PE=1 SV=1 4.87E+07 
Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 8.57E+08 
Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1 5.29E+08 
Protein S100-P; AltName: Full=Protein S100-E; AltName: Full=S100 calcium-
binding protein P; [Homo sapiens (Human)] - [S100P_HUMAN] 2.36E+06 
Protein Shroom3; AltName: Full=Shroom-related protein; Short=hShrmL; 
[Homo sapiens (Human)] - [SHRM3_HUMAN] 8.20E+07 
Pulmonary surfactant-associated protein A2 OS=Homo sapiens GN=SFTPA2 
PE=1 SV=1 2.82E+07 
Pulmonary surfactant-associated protein B OS=Homo sapiens GN=SFTPB PE=1 
SV=3   
Pulmonary surfactant-associated protein D; Short=PSP-D; Short=SP-D; 
AltName: Full=Collectin-7; AltName: Full=Lung surfactant protein D; Flags: 
Precursor; [Homo sapiens (Human)] - [SFTPD_HUMAN] 5.11E+06 
Putative V-set and immunoglobulin domain-containing protein 6 OS=Homo 
sapiens GN=VSIG6 PE=5 SV=2 8.23E+07 
Scavenger receptor cysteine-rich type 1 protein M130 OS=Homo sapiens 
GN=CD163 PE=1 SV=2 1.59E+07 
Selenium-binding protein 1 OS=Homo sapiens GN=SELENBP1 PE=1 SV=2 1.15E+07 
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 
3,420,000
,000 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 1.54E+09 
SH3 domain-binding glutamic acid-rich-like protein 3; AltName: Full=SH3 
domain-binding protein 1; Short=SH3BP-1; [Homo sapiens (Human)] - 
[SH3L3_HUMAN] 7.49E+06 
SH3 domain-binding glutamic acid-rich-like protein OS=Homo sapiens 
GN=SH3BGRL PE=1 SV=1 1.18E+06 
Sorting nexin-6; AltName: Full=TRAF4-associated factor 2; [Homo sapiens 
(Human)] - [SNX6_HUMAN] 2.48E+06 
Superoxide dismutase [Cu-Zn] OS=Homo sapiens GN=SOD1 PE=1 SV=2 7.11E+06 
Thioredoxin domain-containing protein 17; AltName: Full=14 kDa thioredoxin-
related protein; Short=TRP14; AltName: Full=Protein 42-9-9; AltName: 7.54E+05 
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Full=Thioredoxin-like protein 5; [Homo sapiens (Human)] - [TXD17_HUMAN] 
Thioredoxin; Short=Trx; AltName: Full=ATL-derived factor; Short=ADF; 
AltName: Full=Surface-associated sulphydryl protein; Short=SASP; [Homo 
sapiens (Human)] - [THIO_HUMAN] 1.29E+07 
Transaldolase OS=Homo sapiens GN=TALDO1 PE=1 SV=2 2.21E+07 
Transcriptional adapter 2-beta; AltName: Full=ADA2-like protein beta; 
Short=ADA2-beta; [Homo sapiens (Human)] - [TAD2B_HUMAN] 5.10E+07 
Transketolase-like protein 2; EC=2.2.1.1; [Homo sapiens (Human)] - 
[TKTL2_HUMAN] 1.26E+08 
Transmembrane protein 198; [Homo sapiens (Human)] - [TM198_HUMAN] 2.08E+07 
Transmembrane protein 200C; AltName: Full=Transmembrane protein TTMA; 
AltName: Full=Two transmembrane domain-containing family member A; 
[Homo sapiens (Human)] - [T200C_HUMAN] 2.06E+06 
Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 4.44E+07 
Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 1.81E+07 
Trypsin-3; EC=3.4.21.4; AltName: Full=Brain trypsinogen; AltName: 
Full=Mesotrypsinogen; AltName: Full=Serine protease 3; AltName: Full=Serine 
protease 4; AltName: Full=Trypsin III; AltName: Full=Trypsin IV; Flags: 
Precursor; [Homo sapiens (Human)] - [TRY3_HUMAN] 1.60E+06 
Uncharacterized protein C3orf38; [Homo sapiens (Human)] - [CC038_HUMAN] 1.62E+09 
Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=1 SV=1 8.73E+07 
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 1.16E+08 
Voltage-gated potassium channel subunit beta-1; AltName: Full=K(+) channel 
subunit beta-1; AltName: Full=Kv-beta-1; [Homo sapiens (Human)] - 
[KCAB1_HUMAN] 6.65E+07 
Xin actin-binding repeat-containing protein 2 OS=Homo sapiens GN=XIRP2 
PE=1 SV=2 1.77E+08 
Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 5.33E+07 
 
Table C.3: All alveolar proteins identified by 1D PAGE and nano LC MS/MS in COPD 
smoker RTLFs. The 234 proteins identified in COPD smoker subjects investigated, (n=5), 
alongside the mean of the three most abundant ion peaks of each respective protein 
identified. Accession numbers included according to entries in UniProtKB/Swiss-Prot.  
 
COPD smoker   
14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 3.26E+07 
14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 3.12E+07 
14-3-3 protein eta OS=Homo sapiens GN=YWHAH PE=1 SV=4 3.26E+07 
14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 3.26E+07 
14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 3.48E+07 
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase OS=Homo sapiens 
GN=CYP8B1 PE=2 SV=2 
2.87E+07 
Actin-related protein 2; AltName: Full=Actin-like protein 2; [Homo sapiens 
(Human)] - [ARP2_HUMAN] 
1.95E+07 
Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 5.36E+07 
Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 1.76E+07 
Aldehyde dehydrogenase, dimeric NADP-preferring OS=Homo sapiens 
GN=ALDH3A1 PE=1 SV=3 
2.75E+06 
Aldo-keto reductase family 1 member B10; EC=1.1.1.-; AltName: Full=ARL-1; 
AltName: Full=Aldose reductase-like; AltName: Full=Aldose reductase-related 




Short=SI reductase; [Homo sapiens (Human)] - [AK1BA_HUMAN] 
Aldo-keto reductase family 1 member C1; EC=1.1.1.-; AltName: Full=20-alpha-
hydroxysteroid dehydrogenase; Short=20-alpha-HSD; EC=1.1.1.149; AltName: 
Full=Chlordecone reductase homolog HAKRC; AltName: Full=Dihydrodiol 
dehydrogenase 1/2; Short=DD1/DD2; AltName: Full=High-affinity hepatic bile 
acid-binding protein; Short=HBAB; AltName: Full=Indanol dehydrogenase; 
EC=1.1.1.112; AltName: Full=Trans-1,2-dihydrobenzene-1,2-diol 
dehydrogenase; EC=1.3.1.20; [Homo sapiens (Human)] - [AK1C1_HUMAN] 
8.87E+06 
Aldose 1-epimerase; EC=5.1.3.3; AltName: Full=Galactose mutarotase; [Homo 
sapiens (Human)] - [GALM_HUMAN] 
1.50E+06 
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 2.76E+08 
Alpha-1-acid glycoprotein 2; Short=AGP 2; AltName: Full=Orosomucoid-2; 
Short=OMD 2; Flags: Precursor; [Homo sapiens (Human)] - [A1AG2_HUMAN] 
1.95E+08 
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 1.00E+08 
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 1.61E+09 
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 3.51E+07 
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 9.30E+07 
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 1.01E+07 
Alpha-amylase 1 OS=Homo sapiens GN=AMY1A PE=1 SV=2 3.66E+07 
Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 7.37E+06 
Angiotensin-converting enzyme OS=Homo sapiens GN=ACE PE=1 SV=1 2.81E+07 
Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 5.39E+07 
Ankyrin repeat domain-containing protein 56; [Homo sapiens (Human)] - 
[ANR56_HUMAN] 
4.43E+07 
Annexin A3; AltName: Full=35-alpha calcimedin; AltName: Full=Annexin III; 
AltName: Full=Annexin-3; AltName: Full=Inositol 1,2-cyclic phosphate 2-
phosphohydrolase; AltName: Full=Lipocortin III; AltName: Full=Placental 
anticoagulant protein III; Short=PAP-III; [Homo sapiens (Human)] - 
[ANXA3_HUMAN] 
9.75E+05 
Annexin A4; AltName: Full=35-beta calcimedin; AltName: Full=Annexin IV; 
AltName: Full=Annexin-4; AltName: Full=Carbohydrate-binding protein 
p33/p41; AltName: Full=Chromobindin-4; AltName: Full=Endonexin I; 
AltName: Full=Lipocortin IV; AltName: Full=P32.5; AltName: Full=PP4-X; 
AltName: Full=Placental anticoagulant protein II; Short=PAP-II; AltName: 
Full=Protein II; [Homo sapiens (Human)] - [ANXA4_HUMAN] 
3.12E+07 
Annexin A5 OS=Homo sapiens GN=ANXA5 PE=1 SV=2 7.53E+07 
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 1.82E+07 
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 5.68E+07 
Apolipoprotein A-II OS=Homo sapiens GN=APOA2 PE=1 SV=1 9.64E+06 
Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 SV=3 1.11E+07 
Arginase-1; EC=3.5.3.1; AltName: Full=Liver-type arginase; AltName: 
Full=Type I arginase; [Homo sapiens (Human)] - [ARGI1_HUMAN] 
1.90E+07 
Aspartate aminotransferase, cytoplasmic OS=Homo sapiens GN=GOT1 PE=1 
SV=3 
1.52E+06 
ATP-binding cassette sub-family C member 8; AltName: Full=Sulfonylurea 
receptor 1; [Homo sapiens (Human)] - [ABCC8_HUMAN] 
4.40E+07 
ATP-binding cassette sub-family F member 1; AltName: Full=ATP-binding 
cassette 50; AltName: Full=TNF-alpha-stimulated ABC protein; [Homo sapiens 
(Human)] - [ABCF1_HUMAN] 
4.47E+07 
Attractin OS=Homo sapiens GN=ATRN PE=1 SV=2 1.08E+07 
Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 3.80E+07 
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Beta-microseminoprotein; AltName: Full=Immunoglobulin-binding factor; 
Short=IGBF; AltName: Full=PN44; AltName: Full=Prostate secreted seminal 
plasma protein; AltName: Full=Prostate secretory protein of 94 amino acids; 
Short=PSP-94; Short=PSP94; AltName: Full=Seminal plasma beta-inhibin; 
Flags: Precursor; [Homo sapiens (Human)] - [MSMB_HUMAN] 
4.84E+07 
Calcineurin-like phosphoesterase domain-containing protein 1 OS=Homo sapiens 
GN=CPPED1 PE=1 SV=3 
3.70E+06 
Calcyphosin OS=Homo sapiens GN=CAPS PE=1 SV=1 1.32E+06 
Calmodulin OS=Homo sapiens GN=CALM1 PE=1 SV=2 2.48E+07 
Carbonic anhydrase 1 OS=Homo sapiens GN=CA1 PE=1 SV=2 5.50E+06 
Carbonic anhydrase 2 OS=Homo sapiens GN=CA2 PE=1 SV=2 1.05E+07 
Caspase recruitment domain-containing protein 6; [Homo sapiens (Human)] - 
[CARD6_HUMAN] 
1.73E+08 
Cathepsin B OS=Homo sapiens GN=CTSB PE=1 SV=3 4.12E+06 
Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 8.45E+08 
Cathepsin S OS=Homo sapiens GN=CTSS PE=1 SV=3 3.07E+07 
Cathepsin Z OS=Homo sapiens GN=CTSZ PE=1 SV=1 6.46E+06 
CD166 antigen OS=Homo sapiens GN=ALCAM PE=1 SV=2 6.34E+06 
CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=3 3.49E+07 
CD59 glycoprotein; AltName: Full=1F5 antigen; AltName: Full=20 kDa 
homologous restriction factor; Short=HRF-20; Short=HRF20; AltName: 
Full=MAC-inhibitory protein; Short=MAC-IP; AltName: Full=MEM43 antigen; 
AltName: Full=Membrane attack complex inhibition factor; Short=MACIF; 
AltName: Full=Membrane inhibitor of reactive lysis; Short=MIRL; AltName: 
Full=Protectin; AltName: CD_antigen=CD59; Flags: Precursor; [Homo sapiens 
(Human)] - [CD59_HUMAN] 
2.60E+06 
Cell adhesion molecule 2; AltName: Full=Immunoglobulin superfamily member 
4D; Short=IgSF4D; AltName: Full=Nectin-like protein 3; Short=NECL-3; Flags: 
Precursor; [Homo sapiens (Human)] - [CADM2_HUMAN] 
1.71E+07 
Centromere-associated protein E OS=Homo sapiens GN=CENPE PE=1 SV=2 1.43E+08 
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 2.38E+08 
Chitotriosidase-1 OS=Homo sapiens GN=CHIT1 PE=1 SV=1 2.82E+07 
Coactosin-like protein OS=Homo sapiens GN=COTL1 PE=1 SV=3 3.50E+07 
Coiled-coil domain-containing protein 37; [Homo sapiens (Human)] - 
[CCD37_HUMAN] 
6.25E+06 
Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2 1.87E+06 
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 7.33E+07 
Corticosteroid-binding globulin OS=Homo sapiens GN=SERPINA6 PE=1 SV=1 2.38E+07 
Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 1.51E+07 
Cytochrome c oxidase subunit 7B2, mitochondrial; AltName: Full=Cytochrome c 
oxidase polypeptide VIIb2; Flags: Precursor; [Homo sapiens (Human)] - 
[CX7B2_HUMAN] 
6.12E+06 
Cytoplasmic aconitate hydratase; Short=Aconitase; EC=4.2.1.3; AltName: 
Full=Citrate hydro-lyase; AltName: Full=Ferritin repressor protein; AltName: 
Full=Iron regulatory protein 1; Short=IRP1; AltName: Full=Iron-responsive 
element-binding protein 1; Short=IRE-BP 1; [Homo sapiens (Human)] - 
[ACOC_HUMAN] 
5.93E+07 
Deleted in malignant brain tumors 1 protein OS=Homo sapiens GN=DMBT1 
PE=1 SV=2 
2.80E+07 
Delta-like protein 4; AltName: Full=Drosophila Delta homolog 4; Short=Delta4; 




Dermcidin; AltName: Full=Preproteolysin; Contains: RecName: Full=Survival-
promoting peptide; Contains: RecName: Full=DCD-1; Flags: Precursor; [Homo 
sapiens (Human)] - [DCD_HUMAN] 
2.94E+06 
Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 5.04E+06 
Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 1.06E+08 
Dipeptidyl peptidase 4 OS=Homo sapiens GN=DPP4 PE=1 SV=2 1.99E+07 
Disintegrin and metalloproteinase domain-containing protein 2; Short=ADAM 2; 
AltName: Full=Cancer/testis antigen 15; Short=CT15; AltName: Full=Fertilin 
subunit beta; AltName: Full=PH-30; Short=PH30; AltName: Full=PH30-beta; 
Flags: Precursor; [Homo sapiens (Human)] - [ADAM2_HUMAN] 
1.48E+08 
DNA-directed RNA polymerase I subunit RPA34; AltName: Full=A34.5; 
AltName: Full=Antisense to ERCC-1 protein; Short=ASE-1; AltName: 
Full=CD3-epsilon-associated protein; Short=CAST; Short=CD3E-associated 
protein; AltName: Full=RNA polymerase I-associated factor PAF49; [Homo 
sapiens (Human)] - [RPA34_HUMAN] 
2.81E+07 
Endonuclease 8-like 1; EC=3.2.2.-; EC=4.2.99.18; AltName: Full=DNA 
glycosylase/AP lyase Neil1; AltName: Full=DNA-(apurinic or apyrimidinic site) 
lyase Neil1; AltName: Full=Endonuclease VIII-like 1; AltName: Full=FPG1; 
AltName: Full=Nei homolog 1; Short=NEH1; AltName: Full=Nei-like protein 1; 
[Homo sapiens (Human)] - [NEIL1_HUMAN] 
6.97E+06 
Endothelin-1 receptor; AltName: Full=Endothelin A receptor; Short=ET-A; 
Short=ETA-R; Short=hET-AR; Flags: Precursor; [Homo sapiens (Human)] - 
[EDNRA_HUMAN] 
1.31E+06 
Eosinophil lysophospholipase; EC=3.1.1.5; AltName: Full=Charcot-Leyden 
crystal protein; Short=CLC; AltName: Full=Galectin-10; Short=Gal-10; 
AltName: Full=Lysolecithin acylhydrolase; [Homo sapiens (Human)] - 
[LPPL_HUMAN] 
3.02E+06 
Epididymal secretory protein E1 OS=Homo sapiens GN=NPC2 PE=1 SV=1 3.19E+07 
Ester hydrolase C11orf54; EC=3.1.-.-; [Homo sapiens (Human)] - 
[CK054_HUMAN] 
9.28E+05 
Eukaryotic translation initiation factor 2-alpha kinase 1; EC=2.7.11.1; AltName: 
Full=Heme-controlled repressor; Short=HCR; AltName: Full=Heme-regulated 
eukaryotic initiation factor eIF-2-alpha kinase; AltName: Full=Heme-regulated 
inhibitor; AltName: Full=Hemin-sensitive initiation factor 2-alpha kinase; [Homo 
sapiens (Human)] - [E2AK1_HUMAN] 
5.75E+07 
FAS-associated factor 1; Short=hFAF1; AltName: Full=UBX domain-containing 
protein 12; AltName: Full=UBX domain-containing protein 3A; [Homo sapiens 
(Human)] - [FAF1_HUMAN] 
9.69E+07 
Fatty acid-binding protein, adipocyte OS=Homo sapiens GN=FABP4 PE=1 SV=3 7.13E+06 
Fatty acid-binding protein, epidermal; AltName: Full=Epidermal-type fatty acid-
binding protein; Short=E-FABP; AltName: Full=Fatty acid-binding protein 5; 
AltName: Full=Psoriasis-associated fatty acid-binding protein homolog; 
Short=PA-FABP; [Homo sapiens (Human)] - [FABP5_HUMAN] 
1.88E+06 
Fatty acid-binding protein, heart; AltName: Full=Fatty acid-binding protein 3; 
AltName: Full=Heart-type fatty acid-binding protein; Short=H-FABP; AltName: 
Full=Mammary-derived growth inhibitor; Short=MDGI; AltName: Full=Muscle 
fatty acid-binding protein; Short=M-FABP; [Homo sapiens (Human)] - 
[FABPH_HUMAN] 
3.50E+07 
Ferritin heavy chain OS=Homo sapiens GN=FTH1 PE=1 SV=2 1.41E+08 
Ferritin light chain OS=Homo sapiens GN=FTL PE=1 SV=2 3.93E+08 
Filaggrin-2; Short=FLG-2; AltName: Full=Intermediate filament-associated and 





Folate receptor alpha; Short=FR-alpha; AltName: Full=Adult folate-binding 
protein; Short=FBP; AltName: Full=Folate receptor 1; AltName: Full=Folate 
receptor, adult; AltName: Full=KB cells FBP; AltName: Full=Ovarian tumor-
associated antigen MOv18; Flags: Precursor; [Homo sapiens (Human)] - 
[FOLR1_HUMAN] 
4.15E+06 
Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1 8.21E+06 
Galectin-3; Short=Gal-3; AltName: Full=35 kDa lectin; AltName: 
Full=Carbohydrate-binding protein 35; Short=CBP 35; AltName: Full=Galactose-
specific lectin 3; AltName: Full=Galactoside-binding protein; Short=GALBP; 
AltName: Full=IgE-binding protein; AltName: Full=L-31; AltName: 
Full=Laminin-binding protein; AltName: Full=Lectin L-29; AltName: Full=Mac-
2 antigen; [Homo sapiens (Human)] - [LEG3_HUMAN] 
1.28E+06 
Gamma-glutamylcyclotransferase; EC=2.3.2.4; AltName: Full=Cytochrome c-
releasing factor 21; [Homo sapiens (Human)] - [GGCT_HUMAN] 
2.72E+06 
Ganglioside GM2 activator; AltName: Full=Cerebroside sulfate activator protein; 
AltName: Full=GM2-AP; AltName: Full=Shingolipid activator protein 3; 
Short=SAP-3; Contains: RecName: Full=Ganglioside GM2 activator isoform 
short; Flags: Precursor; [Homo sapiens (Human)] - [SAP3_HUMAN] 
7.81E+06 
Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 1.70E+06 
Glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 2; 
EC=2.6.1.16; AltName: Full=D-fructose-6-phosphate amidotransferase 2; 
AltName: Full=Glutamine:fructose 6 phosphate amidotransferase 2; Short=GFAT 
2; Short=GFAT2; AltName: Full=Hexosephosphate aminotransferase 2; [Homo 
sapiens (Human)] - [GFPT2_HUMAN] 
1.11E+08 
Glucose-6-phosphate isomerase OS=Homo sapiens GN=GPI PE=1 SV=4 8.09E+06 
Glutathione S-transferase A2 OS=Homo sapiens GN=GSTA2 PE=1 SV=4 9.67E+07 
Glutathione S-transferase omega-1 OS=Homo sapiens GN=GSTO1 PE=1 SV=2 9.80E+06 
Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 1.74E+07 
Glutathione synthetase; Short=GSH synthetase; Short=GSH-S; EC=6.3.2.3; 
AltName: Full=Glutathione synthase; [Homo sapiens (Human)] - 
[GSHB_HUMAN] 
3.37E+06 
Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH 
PE=1 SV=3 
4.28E+06 
Glyoxalase domain-containing protein 4 OS=Homo sapiens GN=GLOD4 PE=1 
SV=1 
3.60E+06 
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 2.64E+08 
Hemicentin-1; AltName: Full=Fibulin-6; Short=FIBL-6; Flags: Precursor; [Homo 
sapiens (Human)] - [HMCN1_HUMAN] 
1.02E+08 
Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 8.29E+07 
Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 7.32E+07 
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 3.48E+08 
HLA class II histocompatibility antigen, DRB1-1 beta chain OS=Homo sapiens 
GN=HLA-DRB1 PE=1 SV=2 
4.64E+06 
Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 2.68E+07 
Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 1.56E+09 
Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 8.21E+08 
Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 5.79E+09 
Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2 4.65E+09 
Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=1 SV=2 5.04E+09 




Ig heavy chain V-I region V35; Flags: Precursor; [Homo sapiens (Human)] - 
[HV103_HUMAN] 
3.54E+07 
Ig heavy chain V-II region ARH-77 OS=Homo sapiens PE=4 SV=1 7.16E+07 
Ig heavy chain V-II region NEWM; [Homo sapiens (Human)] - 
[HV207_HUMAN] 
1.15E+08 
Ig heavy chain V-II region OU; [Homo sapiens (Human)] - [HV201_HUMAN] 4.28E+07 
Ig heavy chain V-II region WAH; [Homo sapiens (Human)] - [HV206_HUMAN] 1.13E+07 
Ig heavy chain V-III region BRO; [Homo sapiens (Human)] - [HV305_HUMAN] 9.27E+08 
Ig heavy chain V-III region BUT; [Homo sapiens (Human)] - [HV306_HUMAN] 9.00E+08 
Ig heavy chain V-III region CAM OS=Homo sapiens PE=1 SV=1 9.16E+08 
Ig heavy chain V-III region GAL OS=Homo sapiens PE=1 SV=1 8.79E+08 
Ig heavy chain V-III region GAR; [Homo sapiens (Human)] - [HV322_HUMAN] 2.86E+08 
Ig heavy chain V-III region HIL; [Homo sapiens (Human)] - [HV310_HUMAN] 1.24E+09 
Ig heavy chain V-III region TUR; [Homo sapiens (Human)] - [HV318_HUMAN] 9.44E+08 
Ig heavy chain V-III region VH26; Flags: Precursor; [Homo sapiens (Human)] - 
[HV303_HUMAN] 
9.25E+08 
Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 2.92E+09 
Ig kappa chain V-I region CAR OS=Homo sapiens PE=1 SV=1 8.07E+07 
Ig kappa chain V-I region EU OS=Homo sapiens PE=1 SV=1 3.10E+08 
Ig kappa chain V-I region Kue OS=Homo sapiens PE=1 SV=1 2.80E+08 
Ig kappa chain V-I region Roy; [Homo sapiens (Human)] - [KV116_HUMAN] 1.88E+08 
Ig kappa chain V-I region Wes; [Homo sapiens (Human)] - [KV119_HUMAN] 3.60E+08 
Ig kappa chain V-II region FR OS=Homo sapiens PE=1 SV=1 3.16E+06 
Ig kappa chain V-II region TEW OS=Homo sapiens PE=1 SV=1 1.67E+08 
Ig kappa chain V-III region NG9; Flags: Precursor; Fragment; [Homo sapiens 
(Human)] - [KV303_HUMAN] 
2.30E+08 
Ig kappa chain V-III region POM OS=Homo sapiens PE=1 SV=1 1.58E+08 
Ig kappa chain V-III region SIE OS=Homo sapiens PE=1 SV=1 2.67E+08 
Ig kappa chain V-III region VG (Fragment) OS=Homo sapiens PE=1 SV=1 6.84E+07 
Ig kappa chain V-IV region JI OS=Homo sapiens PE=4 SV=1 1.08E+08 
Ig kappa chain V-IV region Len; [Homo sapiens (Human)] - [KV402_HUMAN] 1.49E+08 
Ig lambda chain V region 4A OS=Homo sapiens PE=4 SV=1 7.87E+06 
Ig lambda chain V-I region HA OS=Homo sapiens PE=1 SV=1 6.98E+07 
Ig lambda chain V-I region NIG-64 OS=Homo sapiens PE=1 SV=1 2.25E+07 
Ig lambda chain V-III region LOI OS=Homo sapiens PE=1 SV=1 6.09E+07 
Ig lambda chain V-III region SH; [Homo sapiens (Human)] - [LV301_HUMAN] 1.31E+07 
Ig lambda chain V-IV region Bau; [Homo sapiens (Human)] - [LV401_HUMAN] 5.41E+07 
Ig lambda chain V-IV region Hil; [Homo sapiens (Human)] - [LV403_HUMAN] 6.79E+07 
Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 SV=1 1.09E+09 
Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 3.88E+07 
Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 7.57E+07 
Immunoglobulin lambda-like polypeptide 5 OS=Homo sapiens GN=IGLL5 PE=2 
SV=2 
7.42E+08 
Intercellular adhesion molecule 1 OS=Homo sapiens GN=ICAM1 PE=1 SV=2 1.44E+07 
IQ domain-containing protein G; [Homo sapiens (Human)] - [IQCG_HUMAN] 6.79E+07 
Kazrin; [Homo sapiens (Human)] - [KAZRN_HUMAN] 2.75E+07 
Keratan sulfate proteoglycan lumican; Short=KSPG lumican; Flags: Precursor; 
[Homo sapiens (Human)] - [LUM_HUMAN] 
3.26E+06 
Keratinocyte proline-rich protein OS=Homo sapiens GN=KPRP PE=1 SV=1 1.15E+07 
Kininogen-1; AltName: Full=Alpha-2-thiol proteinase inhibitor; AltName: 1.20E+07 
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Full=Fitzgerald factor; AltName: Full=High molecular weight kininogen; 
Short=HMWK; AltName: Full=Williams-Fitzgerald-Flaujeac factor; Contains: 
RecName: Full=Kininogen-1 heavy chain; Contains: RecName: Full=T-kinin; 
AltName: Full=Ile-Ser-Bradykinin; Contains: RecName: Full=Bradykinin; 
AltName: Full=Kallidin I; Contains: RecName: Full=Lysyl-bradykinin; AltName: 
Full=Kallidin II; Contains: RecName: Full=Kininogen-1 light chain; Contains: 
RecName: Full=Low molecular weight growth-promoting factor; Flags: 
Precursor; [Homo sapiens (Human)] - [KNG1_HUMAN] 
Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2 3.29E+07 
Leukocyte elastase inhibitor OS=Homo sapiens GN=SERPINB1 PE=1 SV=1 6.74E+06 
Leukotriene A-4 hydrolase OS=Homo sapiens GN=LTA4H PE=1 SV=2 1.50E+07 
Liver carboxylesterase 1; EC=3.1.1.1; AltName: Full=Acyl-coenzyme 
A:cholesterol acyltransferase; Short=ACAT; AltName: Full=Brain 
carboxylesterase hBr1; AltName: Full=Cocaine carboxylesterase; AltName: 
Full=Egasyn; AltName: Full=HMSE; AltName: Full=Methylumbelliferyl-acetate 
deacetylase 1; EC=3.1.1.56; AltName: Full=Monocyte/macrophage serine 
esterase; AltName: Full=Retinyl ester hydrolase; Short=REH; AltName: 
Full=Serine esterase 1; AltName: Full=Triacylglycerol hydrolase; Short=TGH; 
Flags: Precursor; [Homo sapiens (Human)] - [EST1_HUMAN] 
1.49E+06 
Long palate, lung and nasal epithelium carcinoma-associated protein 1; AltName: 
Full=Von Ebner minor salivary gland protein; Short=VEMSGP; Flags: Precursor; 
[Homo sapiens (Human)] - [LPLC1_HUMAN] 
5.85E+06 
Long-chain fatty acid transport protein 6; Short=FATP-6; Short=Fatty acid 
transport protein 6; AltName: Full=Fatty-acid-coenzyme A ligase, very long-
chain 2; AltName: Full=Solute carrier family 27 member 6; AltName: Full=Very 
long-chain acyl-CoA synthetase homolog 1; Short=VLCSH1; Short=hVLCS-H1; 
[Homo sapiens (Human)] - [S27A6_HUMAN] 
2.86E+07 
Lysosomal alpha-glucosidase OS=Homo sapiens GN=GAA PE=1 SV=4 1.97E+07 
Matrix metalloproteinase-28; Short=MMP-28; EC=3.4.24.-; AltName: 
Full=Epilysin; Flags: Precursor; [Homo sapiens (Human)] - [MMP28_HUMAN] 
1.09E+07 
Methionyl-tRNA formyltransferase OS=Geobacillus sp. (strain WCH70) GN=fmt 
PE=3 SV=1 
9.01E+07 
Mucin-1 OS=Homo sapiens GN=MUC1 PE=1 SV=3 1.02E+07 
Myotubularin-related protein 14; EC=3.1.3.-; AltName: Full=HCV NS5A-
transactivated protein 4 splice variant A-binding protein 1; 
Short=NS5ATP4ABP1; AltName: Full=hJumpy; [Homo sapiens (Human)] - 
[MTMRE_HUMAN] 
3.66E+06 
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1; Short=DDAH-1; 
Short=Dimethylarginine dimethylaminohydrolase 1; EC=3.5.3.18; AltName: 
Full=DDAHI; AltName: Full=Dimethylargininase-1; [Homo sapiens (Human)] - 
[DDAH1_HUMAN] 
1.77E+06 
Napsin-A OS=Homo sapiens GN=NAPSA PE=1 SV=1 5.17E+06 
Nestin; [Homo sapiens (Human)] - [NEST_HUMAN] 1.23E+06 
Neutrophil gelatinase-associated lipocalin OS=Homo sapiens GN=LCN2 PE=1 
SV=2 
3.72E+06 
OTU domain-containing protein 4; AltName: Full=HIV-1-induced protein HIN-1; 
[Homo sapiens (Human)] - [OTUD4_HUMAN] 
1.21E+08 
Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2 7.32E+06 
Phosphatidylethanolamine-binding protein 1 OS=Homo sapiens GN=PEBP1 
PE=1 SV=3 
2.34E+06 
Phosphoglycerate mutase 1; EC=3.1.3.13; EC=5.4.2.1; EC=5.4.2.4; AltName: 




isozyme B; Short=PGAM-B; [Homo sapiens (Human)] - [PGAM1_HUMAN] 
Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 SV=4 2.83E+08 
Pro-cathepsin H OS=Homo sapiens GN=CTSH PE=1 SV=4 1.61E+07 
Proactivator polypeptide; Contains: RecName: Full=Saposin-A; AltName: 
Full=Protein A; Contains: RecName: Full=Saposin-B-Val; Contains: RecName: 
Full=Saposin-B; AltName: Full=Cerebroside sulfate activator; Short=CSAct; 
AltName: Full=Dispersin; AltName: Full=Sphingolipid activator protein 1; 
Short=SAP-1; AltName: Full=Sulfatide/GM1 activator; Contains: RecName: 
Full=Saposin-C; AltName: Full=A1 activator; AltName: Full=Co-beta-
glucosidase; AltName: Full=Glucosylceramidase activator; AltName: 
Full=Sphingolipid activator protein 2; Short=SAP-2; Contains: RecName: 
Full=Saposin-D; AltName: Full=Component C; AltName: Full=Protein C; Flags: 
Precursor; [Homo sapiens (Human)] - [SAP_HUMAN] 
6.97E+06 
Probable E3 ubiquitin-protein ligase HERC6; EC=6.3.2.-; AltName: Full=HECT 
domain and RCC1-like domain-containing protein 6; [Homo sapiens (Human)] - 
[HERC6_HUMAN] 
1.12E+09 
Probable histone-lysine N-methyltransferase NSD2; EC=2.1.1.43; AltName: 
Full=Multiple myeloma SET domain-containing protein; AltName: Full=Nuclear 
SET domain-containing protein 2; AltName: Full=Protein trithorax-5; AltName: 
Full=Wolf-Hirschhorn syndrome candidate 1 protein; [Homo sapiens (Human)] - 
[NSD2_HUMAN] 
8.55E+07 
Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 1.94E+08 
Prostaglandin-H2 D-isomerase; EC=5.3.99.2; AltName: Full=Beta-trace protein; 
AltName: Full=Cerebrin-28; AltName: Full=Glutathione-independent PGD 
synthase; AltName: Full=Lipocalin-type prostaglandin-D synthase; AltName: 
Full=Prostaglandin-D2 synthase; Short=PGD2 synthase; Short=PGDS; 
Short=PGDS2; Flags: Precursor; [Homo sapiens (Human)] - [PTGDS_HUMAN] 
4.62E+06 
Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1 3.11E+06 
Protein DJ-1 OS=Homo sapiens GN=PARK7 PE=1 SV=2 1.16E+07 
Protein kinase-like protein SgK196; AltName: Full=Sugen kinase 196; [Homo 
sapiens (Human)] - [SG196_HUMAN] 
1.67E+07 
Protein S100-A11 OS=Homo sapiens GN=S100A11 PE=1 SV=2 5.82E+06 
Protein S100-A6 OS=Homo sapiens GN=S100A6 PE=1 SV=1 1.14E+08 
Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 2.22E+06 
Protein S100-P; AltName: Full=Protein S100-E; AltName: Full=S100 calcium-
binding protein P; [Homo sapiens (Human)] - [S100P_HUMAN] 
2.63E+06 
Protein Shroom3; AltName: Full=Shroom-related protein; Short=hShrmL; [Homo 
sapiens (Human)] - [SHRM3_HUMAN] 
2.30E+08 
Protein-glutamine gamma-glutamyltransferase E; EC=2.3.2.13; AltName: 
Full=Transglutaminase E; Short=TG(E); Short=TGE; Short=TGase E; AltName: 
Full=Transglutaminase-3; Short=TGase-3; Contains: RecName: Full=Protein-
glutamine gamma-glutamyltransferase E 50 kDa non-catalytic chain; Contains: 
RecName: Full=Protein-glutamine gamma-glutamyltransferase E 27 kDa catalytic 
chain; Flags: Precursor; [Homo sapiens (Human)] - [TGM3_HUMAN] 
8.37E+06 
Pulmonary surfactant-associated protein A2 OS=Homo sapiens GN=SFTPA2 
PE=1 SV=1 
2.89E+07 
Pulmonary surfactant-associated protein B OS=Homo sapiens GN=SFTPB PE=1 
SV=3 
9.69E+06 
Pulmonary surfactant-associated protein D OS=Homo sapiens GN=SFTPD PE=1 
SV=3 
2.63E+07 
Putative annexin A2-like protein; AltName: Full=Annexin A2 pseudogene 2; 2.21E+07 
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AltName: Full=Lipocortin II pseudogene; [Homo sapiens (Human)] - 
[AXA2L_HUMAN] 
Putative golgin subfamily A member 8I; [Homo sapiens (Human)] - 
[GOG8I_HUMAN] 
4.68E+07 
Putative methyltransferase NSUN3; EC=2.1.1.-; AltName: 
Full=NOL1/NOP2/Sun domain family member 3; [Homo sapiens (Human)] - 
[NSUN3_HUMAN] 
1.55E+07 
Putative V-set and immunoglobulin domain-containing protein 6; Flags: 
Precursor; [Homo sapiens (Human)] - [VSIG6_HUMAN] 
1.42E+08 
Pyridoxal kinase OS=Homo sapiens GN=PDXK PE=1 SV=1 3.73E+06 
Retinoic acid-induced protein 3; AltName: Full=G-protein coupled receptor 
family C group 5 member A; AltName: Full=Orphan G-protein-coupling receptor 
PEIG-1; AltName: Full=Retinoic acid-induced gene 1 protein; Short=RAIG-1; 
[Homo sapiens (Human)] - [RAI3_HUMAN] 
1.88E+06 
Rho GDP-dissociation inhibitor 2 OS=Homo sapiens GN=ARHGDIB PE=1 
SV=3 
4.51E+06 
Ribonuclease P protein subunit p40; Short=RNaseP protein p40; EC=3.1.26.5; 
AltName: Full=RNase P subunit 1; [Homo sapiens (Human)] - 
[RPP40_HUMAN] 
1.55E+08 
Scavenger receptor cysteine-rich type 1 protein M130 OS=Homo sapiens 
GN=CD163 PE=1 SV=2 
5.07E+07 
Selenium-binding protein 1 OS=Homo sapiens GN=SELENBP1 PE=1 SV=2 8.65E+06 
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 4.56E+09 
Serpin B12; [Homo sapiens (Human)] - [SPB12_HUMAN] 1.84E+07 
Serpin B6; AltName: Full=Cytoplasmic antiproteinase; Short=CAP; AltName: 
Full=Peptidase inhibitor 6; Short=PI-6; AltName: Full=Placental thrombin 
inhibitor; [Homo sapiens (Human)] - [SPB6_HUMAN] 
2.74E+06 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 3.86E+09 
SH3 domain-binding glutamic acid-rich-like protein 3; AltName: Full=SH3 
domain-binding protein 1; Short=SH3BP-1; [Homo sapiens (Human)] - 
[SH3L3_HUMAN] 
1.22E+07 
SH3 domain-binding glutamic acid-rich-like protein OS=Homo sapiens 
GN=SH3BGRL PE=1 SV=1 
4.80E+06 
Sister chromatid cohesion protein PDS5 homolog B; AltName: Full=Androgen-
induced proliferation inhibitor; AltName: Full=Androgen-induced prostate 
proliferative shutoff-associated protein AS3; [Homo sapiens (Human)] - 
[PDS5B_HUMAN] 
2.25E+07 
Sorting nexin-6; AltName: Full=TRAF4-associated factor 2; [Homo sapiens 
(Human)] - [SNX6_HUMAN] 
4.91E+06 
Superoxide dismutase [Cu-Zn] OS=Homo sapiens GN=SOD1 PE=1 SV=2 1.08E+07 
Thioredoxin domain-containing protein 17; AltName: Full=14 kDa thioredoxin-
related protein; Short=TRP14; AltName: Full=Protein 42-9-9; AltName: 
Full=Thioredoxin-like protein 5; [Homo sapiens (Human)] - [TXD17_HUMAN] 
1.84E+06 
Thioredoxin; Short=Trx; AltName: Full=ATL-derived factor; Short=ADF; 
AltName: Full=Surface-associated sulphydryl protein; Short=SASP; [Homo 
sapiens (Human)] - [THIO_HUMAN] 
2.98E+07 
Thyroxine-binding globulin OS=Homo sapiens GN=SERPINA7 PE=1 SV=2 1.87E+07 
Transaldolase OS=Homo sapiens GN=TALDO1 PE=1 SV=2 3.90E+07 
Transcriptional adapter 2-beta; AltName: Full=ADA2-like protein beta; 
Short=ADA2-beta; [Homo sapiens (Human)] - [TAD2B_HUMAN] 
2.68E+07 




Transmembrane protein 198; [Homo sapiens (Human)] - [TM198_HUMAN] 4.78E+07 
Transmembrane protein 200C; AltName: Full=Transmembrane protein TTMA; 
AltName: Full=Two transmembrane domain-containing family member A; 
[Homo sapiens (Human)] - [T200C_HUMAN] 
1.94E+06 
Transmembrane protein ENSP00000382582; [Homo sapiens (Human)] - 
[YE031_HUMAN] 
3.19E+07 
Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 1.29E+08 
Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 3.25E+07 
Trypsin-1 OS=Homo sapiens GN=PRSS1 PE=1 SV=1 7.59E+06 
Trypsin-3; EC=3.4.21.4; AltName: Full=Brain trypsinogen; AltName: 
Full=Mesotrypsinogen; AltName: Full=Serine protease 3; AltName: Full=Serine 
protease 4; AltName: Full=Trypsin III; AltName: Full=Trypsin IV; Flags: 
Precursor; [Homo sapiens (Human)] - [TRY3_HUMAN] 
2.58E+06 
Uncharacterized protein C19orf68; [Homo sapiens (Human)] - 
[CS068_HUMAN] 
2.46E+07 
Uncharacterized protein C3orf38; [Homo sapiens (Human)] - [CC038_HUMAN] 1.83E+09 
Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=1 SV=1 1.99E+08 
V-set and immunoglobulin domain-containing protein 4; AltName: Full=Protein 
Z39Ig; Flags: Precursor; [Homo sapiens (Human)] - [VSIG4_HUMAN] 
1.28E+06 
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 1.52E+08 
Xaa-Pro dipeptidase; Short=X-Pro dipeptidase; EC=3.4.13.9; AltName: 
Full=Imidodipeptidase; AltName: Full=Peptidase D; AltName: Full=Proline 
dipeptidase; Short=Prolidase; [Homo sapiens (Human)] - [PEPD_HUMAN] 
1.34E+07 
Xin actin-binding repeat-containing protein 2 OS=Homo sapiens GN=XIRP2 
PE=1 SV=2 
1.76E+08 
Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 8.23E+07 
 
Table C.4: All alveolar proteins identified by 1D PAGE and nano LC MS/MS in COPD 
ex-smoker RTLFs. The 58 proteins identified in COPD ex-smoker subjects investigated, 
(n=5), alongside the mean of the three most abundant ion peaks of each respective 




Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 4.06E+08 
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 2.88E+06 
Alpha-1-acid glycoprotein 2; Short=AGP 2; AltName: Full=Orosomucoid-2; 
Short=OMD 2; Flags: Precursor; [Homo sapiens (Human)] - 
[A1AG2_HUMAN] 
1.95E+06 
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 3.86E+07 
Alpha-1B-glycoprotein; AltName: Full=Alpha-1-B glycoprotein; Flags: 
Precursor; [Homo sapiens (Human)] - [A1BG_HUMAN] 
1.24E+06 
Annexin A5; AltName: Full=Anchorin CII; AltName: Full=Annexin V; 
AltName: Full=Annexin-5; AltName: Full=Calphobindin I; Short=CBP-I; 
AltName: Full=Endonexin II; AltName: Full=Lipocortin V; AltName: 
Full=Placental anticoagulant protein 4; Short=PP4; AltName: Full=Placental 
anticoagulant protein I; Short=PAP-I; AltName: Full=Thromboplastin 
inhibitor; AltName: Full=Vascular anticoagulant-alpha; Short=VAC-alpha; 




Arginase-1; EC=3.5.3.1; AltName: Full=Liver-type arginase; AltName: 
Full=Type I arginase; [Homo sapiens (Human)] - [ARGI1_HUMAN] 
1.75E+06 
Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 5.86E+08 
Calmodulin-like protein 5; AltName: Full=Calmodulin-like skin protein; 
[Homo sapiens (Human)] - [CALL5_HUMAN] 
6.19E+06 
CD44 antigen; AltName: Full=CDw44; AltName: Full=Epican; AltName: 
Full=Extracellular matrix receptor III; Short=ECMR-III; AltName: Full=GP90 
lymphocyte homing/adhesion receptor; AltName: Full=HUTCH-I; AltName: 
Full=Heparan sulfate proteoglycan; AltName: Full=Hermes antigen; AltName: 
Full=Hyaluronate receptor; AltName: Full=Phagocytic glycoprotein 1; 
Short=PGP-1; AltName: Full=Phagocytic glycoprotein I; Short=PGP-I; 
AltName: CD_antigen=CD44; Flags: Precursor; [Homo sapiens (Human)] - 
[CD44_HUMAN] 
3.87E+07 
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 2.73E+06 
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 2.06E+08 
Complement C4-A; AltName: Full=Acidic complement C4; AltName: 
Full=C3 and PZP-like alpha-2-macroglobulin domain-containing protein 2; 
Contains: RecName: Full=Complement C4 beta chain; Contains: RecName: 
Full=Complement C4-A alpha chain; Contains: RecName: Full=C4a 
anaphylatoxin; Contains: RecName: Full=C4b-A; Contains: RecName: 
Full=C4d-A; Contains: RecName: Full=Complement C4 gamma chain; Flags: 
Precursor; [Homo sapiens (Human)] - [CO4A_HUMAN] 
5.65E+07 
Delta-like protein 4; AltName: Full=Drosophila Delta homolog 4; 
Short=Delta4; Flags: Precursor; [Homo sapiens (Human)] - [DLL4_HUMAN] 
4.85E+07 
Dermcidin; AltName: Full=Preproteolysin; Contains: RecName: 
Full=Survival-promoting peptide; Contains: RecName: Full=DCD-1; Flags: 
Precursor; [Homo sapiens (Human)] - [DCD_HUMAN] 
6.55E+06 
Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 3.75E+06 
Ferritin light chain OS=Homo sapiens GN=FTL PE=1 SV=2 1.51E+08 
G antigen family D member 2; AltName: Full=Cancer/testis antigen 12.1; 
Short=CT12.1; AltName: Full=Protein XAGE-1; [Homo sapiens (Human)] - 
[GAGD2_HUMAN] 
4.94E+06 
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 9.50E+06 
Hemoglobin subunit alpha; AltName: Full=Alpha-globin; AltName: 
Full=Hemoglobin alpha chain; [Homo sapiens (Human)] - [HBA_HUMAN] 
5.24E+08 
Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 1.66E+09 
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 4.16E+07 
Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 1.89E+07 
Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 3.55E+09 
Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2 5.64E+07 
Ig heavy chain V-III region CAM; [Homo sapiens (Human)] - 
[HV307_HUMAN] 
1.68E+07 
Ig heavy chain V-III region TIL; [Homo sapiens (Human)] - 
[HV304_HUMAN] 
1.60E+07 
Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 9.25E+09 
Ig kappa chain V-II region MIL; [Homo sapiens (Human)] - 
[KV203_HUMAN] 
2.22E+06 
Ig kappa chain V-III region B6; [Homo sapiens (Human)] - 
[KV301_HUMAN] 
1.63E+09 





Ig kappa chain V-III region VG (Fragment) OS=Homo sapiens PE=1 SV=1 2.65E+06 
Ig lambda chain V-III region LOI; [Homo sapiens (Human)] - 
[LV302_HUMAN] 
4.81E+08 
Ig lambda chain V-IV region Bau; [Homo sapiens (Human)] - 
[LV401_HUMAN] 
3.27E+07 
Ig lambda-1 chain C regions; [Homo sapiens (Human)] - [LAC1_HUMAN] 3.53E+09 
Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 SV=1 8.59E+06 
Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2 7.23E+05 
Lysozyme C; EC=3.2.1.17; AltName: Full=1,4-beta-N-acetylmuramidase C; 
Flags: Precursor; [Homo sapiens (Human)] - [LYSC_HUMAN] 
5.31E+08 
Myoglobin; [Homo sapiens (Human)] - [MYG_HUMAN] 2.39E+06 
Myotubularin-related protein 14; EC=3.1.3.-; AltName: Full=HCV NS5A-
transactivated protein 4 splice variant A-binding protein 1; 
Short=NS5ATP4ABP1; AltName: Full=hJumpy; [Homo sapiens (Human)] - 
[MTMRE_HUMAN] 
1.21E+06 
Olfactory receptor 2A2; AltName: Full=Olfactory receptor 2A17; AltName: 
Full=Olfactory receptor OR7-11; [Homo sapiens (Human)] - 
[OR2A2_HUMAN] 
2.34E+07 
Peptidyl-prolyl cis-trans isomerase A; Short=PPIase A; EC=5.2.1.8; AltName: 
Full=Cyclophilin A; AltName: Full=Cyclosporin A-binding protein; AltName: 
Full=Rotamase A; [Homo sapiens (Human)] - [PPIA_HUMAN] 
7.51E+07 
Peroxiredoxin-5, mitochondrial OS=Homo sapiens GN=PRDX5 PE=1 SV=4 2.13E+08 
Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein; 
Short=P-Rex1; Short=PtdIns(3,4,5)-dependent Rac exchanger 1; [Homo 
sapiens (Human)] - [PREX1_HUMAN] 
9.18E+06 
Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 
SV=4 
2.37E+09 
Protein kinase-like protein SgK196; AltName: Full=Sugen kinase 196; [Homo 
sapiens (Human)] - [SG196_HUMAN] 
1.36E+07 
Protein Shroom3; AltName: Full=Shroom-related protein; Short=hShrmL; 
[Homo sapiens (Human)] - [SHRM3_HUMAN] 
2.29E+07 
Pulmonary surfactant-associated protein A2; Short=PSP-A; Short=PSPA; 
Short=SP-A; Short=SP-A2; AltName: Full=35 kDa pulmonary surfactant-
associated protein; AltName: Full=Alveolar proteinosis protein; AltName: 
Full=Collectin-5; Flags: Precursor; [Homo sapiens (Human)] - 
[SFPA2_HUMAN] 
1.85E+06 
Putative annexin A2-like protein; AltName: Full=Annexin A2 pseudogene 2; 
AltName: Full=Lipocortin II pseudogene; [Homo sapiens (Human)] - 
[AXA2L_HUMAN] 
2.60E+07 
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 3.49E+07 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 5.49E+08 
Thioredoxin; Short=Trx; AltName: Full=ATL-derived factor; Short=ADF; 
AltName: Full=Surface-associated sulphydryl protein; Short=SASP; [Homo 
sapiens (Human)] - [THIO_HUMAN] 
1.54E+08 
Transcriptional adapter 2-beta; AltName: Full=ADA2-like protein beta; 
Short=ADA2-beta; [Homo sapiens (Human)] - [TAD2B_HUMAN] 
1.11E+06 
Transmembrane protein 200C; AltName: Full=Transmembrane protein 
TTMA; AltName: Full=Two transmembrane domain-containing family 
member A; [Homo sapiens (Human)] - [T200C_HUMAN] 
1.89E+06 
Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 7.84E+07 
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Trypsin-3; EC=3.4.21.4; AltName: Full=Brain trypsinogen; AltName: 
Full=Mesotrypsinogen; AltName: Full=Serine protease 3; AltName: 
Full=Serine protease 4; AltName: Full=Trypsin III; AltName: Full=Trypsin 
IV; Flags: Precursor; [Homo sapiens (Human)] - [TRY3_HUMAN] 
4.78E+06 
Uncharacterized protein C3orf38; [Homo sapiens (Human)] - 
[CC038_HUMAN] 
5.97E+08 
Uteroglobin OS=Homo sapiens GN=SCGB1A1 PE=1 SV=1 4.49E+09 
 
 
Table C.5 Alveolar proteins identified by 1D PAGE and nano LC MS/MS in healthy 
smoker and COPD smoker RTLFs. The 119 proteins common to both healthy smoker and 
COPD smoker subjects investigated n=5 for both subject groups, alongside the mean of 
the three most abundant ion peaks of each respective protein identified. Accession 
numbers included according to entries in UniProtKB/Swiss-Prot.  
 
COPD smoker Healthy Smoker 
14-3-3 protein beta/alpha 
OS=Homo sapiens 
GN=YWHAB PE=1 SV=3 
3.26E+07 
14-3-3 protein beta/alpha 
OS=Homo sapiens 
GN=YWHAB PE=1 SV=3 
6.47E+07 
14-3-3 protein zeta/delta 
OS=Homo sapiens 
GN=YWHAZ PE=1 SV=1 
3.48E+07 
14-3-3 protein zeta/delta 
OS=Homo sapiens 
GN=YWHAZ PE=1 SV=1 
4.51E+07 
Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 
5.36E+07 
Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 
SV=1 
1.38E+08 
Afamin OS=Homo sapiens 
GN=AFM PE=1 SV=1 
1.76E+07 
Afamin OS=Homo sapiens 
GN=AFM PE=1 SV=1 
5.45E+06 
Aldo-keto reductase family 1 







Full=Small intestine reductase; 
Short=SI reductase; [Homo 
sapiens (Human)] - 
[AK1BA_HUMAN] 
7.27E+05 
Aldo-keto reductase family 1 







Full=Small intestine reductase; 
Short=SI reductase; [Homo 
sapiens (Human)] - 
[AK1BA_HUMAN] 
5.19E+05 
Aldo-keto reductase family 1 
member C1 OS=Homo sapiens 
GN=AKR1C1 PE=1 SV=1 
8.87E+06 
Aldo-keto reductase family 1 
member C1 OS=Homo sapiens 















Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 
2.76E+08 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 
1.29E+08 
Alpha-1-acid glycoprotein 2; 
Short=AGP 2; AltName: 
Full=Orosomucoid-2; 
Short=OMD 2; Flags: 
Precursor; [Homo sapiens 
(Human)] - [A1AG2_HUMAN] 
1.95E+08 
Alpha-1-acid glycoprotein 2; 
Short=AGP 2; AltName: 
Full=Orosomucoid-2; 
Short=OMD 2; Flags: 
Precursor; [Homo sapiens 








GN=SERPINA3 PE=1 SV=2 
3.72E+07 
Alpha-1-antitrypsin OS=Homo 
































sapiens GN=ENO1 PE=1 SV=2 
7.37E+06 
Alpha-enolase OS=Homo 
sapiens GN=ENO1 PE=1 SV=2 
3.19E+07 
Angiotensinogen OS=Homo 
sapiens GN=AGT PE=1 SV=1 
5.39E+07 
Angiotensinogen OS=Homo 
sapiens GN=AGT PE=1 SV=1 
1.41E+06 
Annexin A3; AltName: 
Full=35-alpha calcimedin; 





Full=Lipocortin III; AltName: 
Full=Placental anticoagulant 
protein III; Short=PAP-III; 
[Homo sapiens (Human)] - 
[ANXA3_HUMAN] 
9.75E+05 
Annexin A3 OS=Homo sapiens 
GN=ANXA3 PE=1 SV=3 
2.81E+06 
Annexin A5 OS=Homo sapiens 
GN=ANXA5 PE=1 SV=2 
7.53E+07 
Annexin A5 OS=Homo sapiens 




Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 
SV=1 
5.68E+07 
Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 
SV=1 
7.56E+06 
Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 
1.08E+07 
Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 
4.53E+06 
Beta-2-microglobulin 










factor; Short=IGBF; AltName: 
Full=PN44; AltName: 
Full=Prostate secreted seminal 
plasma protein; AltName: 
Full=Prostate secretory protein 
of 94 amino acids; Short=PSP-
94; Short=PSP94; AltName: 
Full=Seminal plasma beta-
inhibin; Flags: Precursor; 






factor; Short=IGBF; AltName: 
Full=PN44; AltName: 
Full=Prostate secreted seminal 
plasma protein; AltName: 
Full=Prostate secretory protein 
of 94 amino acids; Short=PSP-
94; Short=PSP94; AltName: 
Full=Seminal plasma beta-
inhibin; Flags: Precursor; 
[Homo sapiens (Human)] - 
[MSMB_HUMAN] 
1.50E+07 
Calcyphosin OS=Homo sapiens 
GN=CAPS PE=1 SV=1 
1.32E+06 
Calcyphosin OS=Homo sapiens 
GN=CAPS PE=1 SV=1 
1.44E+07 
Calmodulin OS=Homo sapiens 
GN=CALM1 PE=1 SV=2 
2.48E+07 
Calmodulin OS=Homo sapiens 
GN=CALM1 PE=1 SV=2 
2.84E+06 
Carbonic anhydrase 2 
OS=Homo sapiens GN=CA2 
PE=1 SV=2 
1.05E+07 
Carbonic anhydrase 2 
OS=Homo sapiens GN=CA2 
PE=1 SV=2 
3.84E+06 
Cathepsin B OS=Homo sapiens 
GN=CTSB PE=1 SV=3 
4.12E+06 
Cathepsin B OS=Homo sapiens 
GN=CTSB PE=1 SV=3 
2.14E+06 
Cathepsin S OS=Homo sapiens 
GN=CTSS PE=1 SV=3 
3.07E+07 
Cathepsin S OS=Homo sapiens 
GN=CTSS PE=1 SV=3 
3.74E+06 
Cathepsin Z OS=Homo sapiens 
GN=CTSZ PE=1 SV=1 
6.46E+06 
Cathepsin Z OS=Homo sapiens 
GN=CTSZ PE=1 SV=1 
4.21E+06 
CD166 antigen OS=Homo 
sapiens GN=ALCAM PE=1 
SV=2 
6.34E+06 
CD166 antigen; AltName: 
Full=Activated leukocyte cell 
adhesion molecule; AltName: 
CD_antigen=CD166; Flags: 
Precursor; [Homo sapiens 
(Human)] - [CD166_HUMAN] 
2.77E+06 
CD44 antigen OS=Homo 
sapiens GN=CD44 PE=1 SV=3 
3.49E+07 
CD44 antigen OS=Homo 





sapiens GN=CP PE=1 SV=1 
2.38E+08 
Ceruloplasmin OS=Homo 
sapiens GN=CP PE=1 SV=1 
1.15E+08 
Coactosin-like protein 













GN=SERPINA6 PE=1 SV=1 
5.20E+06 
Cystatin-B OS=Homo sapiens 
GN=CSTB PE=1 SV=2 
1.51E+07 
Cystatin-B OS=Homo sapiens 
GN=CSTB PE=1 SV=2 
6.43E+06 
Deleted in malignant brain 
tumors 1 protein OS=Homo 
sapiens GN=DMBT1 PE=1 
SV=2 
2.80E+07 
Deleted in malignant brain 
tumors 1 protein OS=Homo 
sapiens GN=DMBT1 PE=1 
SV=2 
6.18E+06 
Delta-like protein 4; AltName: 
Full=Drosophila Delta homolog 
4; Short=Delta4; Flags: 
Precursor; [Homo sapiens 
(Human)] - [DLL4_HUMAN] 
5.48E+07 
Delta-like protein 4; AltName: 
Full=Drosophila Delta homolog 
4; Short=Delta4; Flags: 
Precursor; [Homo sapiens 





promoting peptide; Contains: 
RecName: Full=DCD-1; Flags: 
Precursor; [Homo sapiens 
(Human)] - [DCD_HUMAN] 
2.94E+06 
Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 
4.35E+06 
Desmoglein-1 OS=Homo 
sapiens GN=DSG1 PE=1 SV=2 
5.04E+06 
Desmoglein-1; AltName: 
Full=Cadherin family member 
4; AltName: Full=Desmosomal 
glycoprotein 1; Short=DG1; 
Short=DGI; AltName: 
Full=Pemphigus foliaceus 
antigen; Flags: Precursor; 




sapiens GN=DSP PE=1 SV=3 
1.06E+08 
Desmoplakin OS=Homo 
sapiens GN=DSP PE=1 SV=3 
9.94E+07 
Dipeptidyl peptidase 4 
OS=Homo sapiens GN=DPP4 
PE=1 SV=2 
1.99E+07 
Dipeptidyl peptidase 4 
OS=Homo sapiens GN=DPP4 
PE=1 SV=2 
3.08E+06 
Epididymal secretory protein E1 
OS=Homo sapiens GN=NPC2 
PE=1 SV=1 
3.19E+07 
Epididymal secretory protein 
E1 OS=Homo sapiens 




FAS-associated factor 1; 
Short=hFAF1; AltName: 
Full=UBX domain-containing 
protein 12; AltName: Full=UBX 
domain-containing protein 3A; 
[Homo sapiens (Human)] - 
[FAF1_HUMAN] 
9.69E+07 
FAS-associated factor 1; 
Short=hFAF1; AltName: 
Full=UBX domain-containing 
protein 12; AltName: 
Full=UBX domain-containing 
protein 3A; [Homo sapiens 
(Human)] - [FAF1_HUMAN] 
4.56E+07 




FABP; AltName: Full=Fatty 
acid-binding protein 5; 
AltName: Full=Psoriasis-
associated fatty acid-binding 
protein homolog; Short=PA-
FABP; [Homo sapiens 
(Human)] - [FABP5_HUMAN] 
1.88E+06 
Fatty acid-binding protein, 
epidermal OS=Homo sapiens 
GN=FABP5 PE=1 SV=3 
8.26E+07 
Ferritin heavy chain OS=Homo 
sapiens GN=FTH1 PE=1 SV=2 
1.41E+08 
Ferritin heavy chainOS=Homo 
sapiens GN=FTH1 PE=1 SV=2 
5.09E+06 
Ferritin light chain OS=Homo 
sapiens GN=FTL PE=1 SV=2 
3.93E+08 
Ferritin light chain OS=Homo 
sapiens GN=FTL PE=1 SV=2 
2.03E+07 
Glutathione S-transferase P 
OS=Homo sapiens GN=GSTP1 
PE=1 SV=2 
1.74E+07 
Glutathione S-transferase P 














protein 4 OS=Homo sapiens 
GN=GLOD4 PE=1 SV=1 
3.60E+06 
Glyoxalase domain-containing 
protein 4 OS=Homo sapiens 
GN=GLOD4 PE=1 SV=1 
1.54E+06 
Haptoglobin OS=Homo sapiens 
GN=HP PE=1 SV=1 
2.64E+08 
Haptoglobin OS=Homo sapiens 
GN=HP PE=1 SV=1 
1.04E+08 
Hemoglobin subunit alpha 
OS=Homo sapiens GN=HBA1 
PE=1 SV=2 
8.29E+07 
Hemoglobin subunit alpha 
OS=Homo sapiens GN=HBA1 
PE=1 SV=2 
5.40E+07 
Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB 
PE=1 SV=2 
7.32E+07 
Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB 
PE=1 SV=2 
2.04E+07 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 
3.48E+08 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 
1.89E+08 
Ig alpha-1 chain C region 
OS=Homo sapiens GN=IGHA1 
1.56E+09 Ig alpha-1 chain C region 




PE=1 SV=2 PE=1 SV=2 
Ig alpha-2 chain C region 
OS=Homo sapiens GN=IGHA2 
PE=1 SV=3 
8.21E+08 
Ig alpha-2 chain C region; 
[Homo sapiens (Human)] - 
[IGHA2_HUMAN] 
3.06E+08 
Ig gamma-1 chain C region 
OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 
5.79E+09 
Ig gamma-1 chain C region 
OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 
3.30E+09 
Ig gamma-2 chain C region 
OS=Homo sapiens GN=IGHG2 
PE=1 SV=2 
4.65E+09 
Ig gamma-2 chain C region 
OS=Homo sapiens GN=IGHG2 
PE=1 SV=2 
2.57E+09 
Ig gamma-3 chain C region 
OS=Homo sapiens GN=IGHG3 
PE=1 SV=2 
5.04E+09 
Ig gamma-3 chain C region 
OS=Homo sapiens GN=IGHG3 
PE=1 SV=2 
2.87E+09 
Ig heavy chain V-I region HG3; 
Flags: Precursor; [Homo sapiens 
(Human)] - [HV102_HUMAN] 
6.71E+07 
Ig heavy chain V-I region HG3; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[HV102_HUMAN] 
3.44E+07 
Ig heavy chain V-II region 
NEWM; [Homo sapiens 
(Human)] - [HV207_HUMAN] 
1.15E+08 
Ig heavy chain V-II region 
NEWM OS=Homo sapiens 
PE=1 SV=1 
9.45E+07 
Ig heavy chain V-III region 
BRO; [Homo sapiens (Human)] 
- [HV305_HUMAN] 
9.27E+08 
Ig heavy chain V-III region 
BRO; [Homo sapiens (Human)] 
- [HV305_HUMAN] 
5.36E+08 
Ig heavy chain V-III region 
BUT; [Homo sapiens (Human)] 
- [HV306_HUMAN] 
9.00E+08 
Ig heavy chain V-III region 
BUT; [Homo sapiens (Human)] 
- [HV306_HUMAN] 
4.98E+08 
Ig heavy chain V-III region 
CAM OS=Homo sapiens PE=1 
SV=1 
9.16E+08 
Ig heavy chain V-III region 
CAM OS=Homo sapiens PE=1 
SV=1 
  
Ig heavy chain V-III region 
GAL OS=Homo sapiens PE=1 
SV=1 
8.79E+08 
Ig heavy chain V-III region 
GAL OS=Homo sapiens PE=1 
SV=1 
4.92E+08 
Ig heavy chain V-III region 
GAR; [Homo sapiens (Human)] 
- [HV322_HUMAN] 
2.86E+08 
Ig heavy chain V-III region 
GAR; [Homo sapiens (Human)] 
- [HV322_HUMAN] 
8.76E+07 
Ig heavy chain V-III region 
HIL; [Homo sapiens (Human)] - 
[HV310_HUMAN] 
1.24E+09 
Ig heavy chain V-III region 
HIL; [Homo sapiens (Human)] 
- [HV310_HUMAN] 
7.00E+08 
Ig heavy chain V-III region 
VH26; Flags: Precursor; [Homo 
sapiens (Human)] - 
9.25E+08 
Ig heavy chain V-III region 






Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 
2.92E+09 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 
1.07E+09 
Ig kappa chain V-III region 
POM OS=Homo sapiens PE=1 
SV=1 
1.58E+08 
Ig kappa chain V-III region 
POM; [Homo sapiens 
(Human)] - [KV306_HUMAN] 
7.29E+07 
Ig kappa chain V-III region SIE 
OS=Homo sapiens PE=1 SV=1 
2.67E+08 
Ig kappa chain V-III region SIE 
OS=Homo sapiens PE=1 SV=1 
1.24E+08 
Ig kappa chain V-III region VG 
(Fragment) OS=Homo sapiens 
PE=1 SV=1 
6.84E+07 
Ig kappa chain V-III region VG 
(Fragment) OS=Homo sapiens 
PE=1 SV=1 
5.54E+07 
Ig kappa chain V-IV region JI 
OS=Homo sapiens PE=4 SV=1 
1.08E+08 
Ig kappa chain V-IV region JI; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[KV403_HUMAN] 
6.10E+07 
Ig kappa chain V-IV region 
Len; [Homo sapiens (Human)] - 
[KV402_HUMAN] 
1.49E+08 
Ig kappa chain V-IV region 
Len; [Homo sapiens (Human)] - 
[KV402_HUMAN] 
6.10E+07 
Ig lambda chain V region 4A 
OS=Homo sapiens PE=4 SV=1 
7.87E+06 
Ig lambda chain V region 4A; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[LV001_HUMAN] 
1.78E+07 
Ig lambda chain V-I region HA 
OS=Homo sapiens PE=1 SV=1 
6.98E+07 
Ig lambda chain V-I region HA; 
[Homo sapiens (Human)] - 
[LV102_HUMAN] 
5.73E+07 
Ig lambda chain V-III region 
LOI OS=Homo sapiens PE=1 
SV=1 
6.09E+07 
Ig lambda chain V-III region 
LOI OS=Homo sapiens PE=1 
SV=1 
6.55E+07 
Ig lambda chain V-III region 
SH; [Homo sapiens (Human)] - 
[LV301_HUMAN] 
1.31E+07 
Ig lambda chain V-III region 
SH OS=Homo sapiens PE=1 
SV=1 
1.01E+07 
Ig lambda chain V-IV region 
Bau; [Homo sapiens (Human)] - 
[LV401_HUMAN] 
5.41E+07 
Ig lambda chain V-IV region 
Bau; [Homo sapiens (Human)] 
- [LV401_HUMAN] 
1.05E+07 
Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 
1.09E+09 
Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 
7.91E+08 
Ig mu chain C region OS=Homo 
sapiens GN=IGHM PE=1 SV=3 
3.88E+07 
Ig mu chain C region 





Immunoglobulin J chain 
OS=Homo sapiens GN=IGJ 
PE=1 SV=4 
7.57E+07 
Immunoglobulin J chain 




polypeptide 5 OS=Homo 
sapiens GN=IGLL5 PE=2 SV=2 
7.42E+08 
Immunoglobulin lambda-like 
polypeptide 5 OS=Homo 
sapiens GN=IGLL5 PE=2 
SV=2 
4.43E+08 
Intercellular adhesion molecule 
1 OS=Homo sapiens 
GN=ICAM1 PE=1 SV=2 
1.44E+07 
Intercellular adhesion molecule 
1 OS=Homo sapiens 
GN=ICAM1 PE=1 SV=2 
4.60E+06 
Leucine-rich alpha-2-
glycoprotein OS=Homo sapiens 
GN=LRG1 PE=1 SV=2 
3.29E+07 
Leucine-rich alpha-2-
glycoprotein OS=Homo sapiens 
GN=LRG1 PE=1 SV=2 
1.76E+07 
Leukocyte elastase inhibitor 
OS=Homo sapiens 
GN=SERPINB1 PE=1 SV=1 
6.74E+06 
Leukocyte elastase inhibitor 
OS=Homo sapiens 
GN=SERPINB1 PE=1 SV=1 
2.61E+06 
Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
2.83E+08 
Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
1.54E+08 
Pro-cathepsin H OS=Homo 
sapiens GN=CTSH PE=1 SV=4 
1.61E+07 
Pro-cathepsin H OS=Homo 
























protein 2; Short=SAP-2; 
Contains: RecName: 
Full=Saposin-D; AltName: 
























protein 2; Short=SAP-2; 
Contains: RecName: 
Full=Saposin-D; AltName: 




Full=Protein C; Flags: 
Precursor; [Homo sapiens 
(Human)] - [SAP_HUMAN] 
Full=Protein C; Flags: 
Precursor; [Homo sapiens 
(Human)] - [SAP_HUMAN] 
Protein DJ-1 OS=Homo sapiens 
GN=PARK7 PE=1 SV=2 
1.16E+07 
Protein DJ-1 OS=Homo sapiens 
GN=PARK7 PE=1 SV=2 
7.89E+06 
Protein S100-A6 OS=Homo 
sapiens GN=S100A6 PE=1 
SV=1 
1.14E+08 
Protein S100-A6 OS=Homo 
sapiens GN=S100A6 PE=1 
SV=1 
4.87E+07 
Protein S100-A8 OS=Homo 
sapiens GN=S100A8 PE=1 
SV=1 
2.22E+06 
Protein S100-A8 OS=Homo 
sapiens GN=S100A8 PE=1 
SV=1 
8.57E+08 
Protein S100-P; AltName: 
Full=Protein S100-E; AltName: 
Full=S100 calcium-binding 
protein P; [Homo sapiens 
(Human)] - [S100P_HUMAN] 
2.63E+06 
Protein S100-P; AltName: 
Full=Protein S100-E; AltName: 
Full=S100 calcium-binding 
protein P; [Homo sapiens 
(Human)] - [S100P_HUMAN] 
2.36E+06 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 
Short=hShrmL; [Homo sapiens 
(Human)] - [SHRM3_HUMAN] 
2.30E+08 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 





protein A2 OS=Homo sapiens 
GN=SFTPA2 PE=1 SV=1 
2.89E+07 
Pulmonary surfactant-
associated protein A2 
OS=Homo sapiens 
GN=SFTPA2 PE=1 SV=1 
2.82E+07 
Pulmonary surfactant-associated 
protein B OS=Homo sapiens 
GN=SFTPB PE=1 SV=3 
9.69E+06 
Pulmonary surfactant-
associated protein B OS=Homo 




protein D OS=Homo sapiens 
GN=SFTPD PE=1 SV=3 
2.63E+07 
Pulmonary surfactant-
associated protein D; 
Short=PSP-D; Short=SP-D; 
AltName: Full=Collectin-7; 
AltName: Full=Lung surfactant 
protein D; Flags: Precursor; 
[Homo sapiens (Human)] - 
[SFTPD_HUMAN] 
5.11E+06 
Putative V-set and 
immunoglobulin domain-
containing protein 6; Flags: 
Precursor; [Homo sapiens 
(Human)] - [VSIG6_HUMAN] 
1.42E+08 
Putative V-set and 
immunoglobulin domain-
containing protein 6 OS=Homo 
sapiens GN=VSIG6 PE=5 
SV=2 
8.23E+07 
Scavenger receptor cysteine-rich 
type 1 protein M130 OS=Homo 
5.07E+07 Scavenger receptor cysteine-




sapiens GN=CD163 PE=1 
SV=2 
OS=Homo sapiens GN=CD163 
PE=1 SV=2 
Selenium-binding protein 1 
OS=Homo sapiens 
GN=SELENBP1 PE=1 SV=2 
8.65E+06 
Selenium-binding protein 1 
OS=Homo sapiens 
GN=SELENBP1 PE=1 SV=2 
1.15E+07 
Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=3 
4.56E+09 
Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=3 
3.42E+09 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
3.86E+09 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
1.54E+09 
SH3 domain-binding glutamic 
acid-rich-like protein 3; 
AltName: Full=SH3 domain-
binding protein 1; 
Short=SH3BP-1; [Homo 
sapiens (Human)] - 
[SH3L3_HUMAN] 
1.22E+07 
SH3 domain-binding glutamic 
acid-rich-like protein 3; 
AltName: Full=SH3 domain-
binding protein 1; 
Short=SH3BP-1; [Homo 
sapiens (Human)] - 
[SH3L3_HUMAN] 
7.49E+06 
SH3 domain-binding glutamic 
acid-rich-like protein OS=Homo 
sapiens GN=SH3BGRL PE=1 
SV=1 
4.80E+06 
SH3 domain-binding glutamic 
acid-rich-like protein 
OS=Homo sapiens 
GN=SH3BGRL PE=1 SV=1 
1.18E+06 
Sorting nexin-6; AltName: 
Full=TRAF4-associated factor 
2; [Homo sapiens (Human)] - 
[SNX6_HUMAN] 
4.91E+06 
Sorting nexin-6; AltName: 
Full=TRAF4-associated factor 
2; [Homo sapiens (Human)] - 
[SNX6_HUMAN] 
2.48E+06 
Superoxide dismutase [Cu-Zn] 
OS=Homo sapiens GN=SOD1 
PE=1 SV=2 
1.08E+07 
Superoxide dismutase [Cu-Zn] 




protein 17; AltName: Full=14 
kDa thioredoxin-related protein; 
Short=TRP14; AltName: 
Full=Protein 42-9-9; AltName: 
Full=Thioredoxin-like protein 5; 




protein 17; AltName: Full=14 
kDa thioredoxin-related 
protein; Short=TRP14; 
AltName: Full=Protein 42-9-9; 
AltName: Full=Thioredoxin-
like protein 5; [Homo sapiens 




factor; Short=ADF; AltName: 
Full=Surface-associated 
sulphydryl protein; 
Short=SASP; [Homo sapiens 




factor; Short=ADF; AltName: 
Full=Surface-associated 
sulphydryl protein; 
Short=SASP; [Homo sapiens 
(Human)] - [THIO_HUMAN] 
1.29E+07 
Transaldolase OS=Homo 
sapiens GN=TALDO1 PE=1 
3.90E+07 Transaldolase OS=Homo 





Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-beta; 
[Homo sapiens (Human)] - 
[TAD2B_HUMAN] 
2.68E+07 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-
beta; [Homo sapiens (Human)] 
- [TAD2B_HUMAN] 
5.10E+07 
Transketolase-like protein 2; 
EC=2.2.1.1; [Homo sapiens 
(Human)] - [TKTL2_HUMAN] 
1.32E+08 
Transketolase-like protein 2; 
EC=2.2.1.1; [Homo sapiens 
(Human)] - [TKTL2_HUMAN] 
1.26E+08 
Transmembrane protein 198; 
[Homo sapiens (Human)] - 
[TM198_HUMAN] 
4.78E+07 
Transmembrane protein 198; 
[Homo sapiens (Human)] - 
[TM198_HUMAN] 
2.08E+07 
Transmembrane protein 200C; 
AltName: Full=Transmembrane 
protein TTMA; AltName: 
Full=Two transmembrane 
domain-containing family 
member A; [Homo sapiens 
(Human)] - [T200C_HUMAN] 
1.94E+06 
Transmembrane protein 200C; 
AltName: Full=Transmembrane 
protein TTMA; AltName: 
Full=Two transmembrane 
domain-containing family 
member A; [Homo sapiens 
(Human)] - [T200C_HUMAN] 
2.06E+06 
Transthyretin OS=Homo 
sapiens GN=TTR PE=1 SV=1 
1.29E+08 
Transthyretin OS=Homo 
sapiens GN=TTR PE=1 SV=1 
4.44E+07 
Triosephosphate isomerase 











AltName: Full=Serine protease 
3; AltName: Full=Serine 
protease 4; AltName: 
Full=Trypsin III; AltName: 
Full=Trypsin IV; Flags: 
Precursor; [Homo sapiens 






AltName: Full=Serine protease 
3; AltName: Full=Serine 
protease 4; AltName: 
Full=Trypsin III; AltName: 
Full=Trypsin IV; Flags: 
Precursor; [Homo sapiens 
(Human)] - [TRY3_HUMAN] 
1.60E+06 
Uncharacterized protein 
C3orf38; [Homo sapiens 
(Human)] - [CC038_HUMAN] 
1.83E+09 
Uncharacterized protein 
C3orf38; [Homo sapiens 
(Human)] - [CC038_HUMAN] 
1.62E+09 
Uteroglobin OS=Homo sapiens 
GN=SCGB1A1 PE=1 SV=1 
1.99E+08 
Uteroglobin OS=Homo sapiens 
GN=SCGB1A1 PE=1 SV=1 
8.73E+07 
Vitamin D-binding protein 
OS=Homo sapiens GN=GC 
PE=1 SV=1 
1.52E+08 
Vitamin D-binding protein 






containing protein 2 OS=Homo 
sapiens GN=XIRP2 PE=1 SV=2 
1.76E+08 
Xin actin-binding repeat-
containing protein 2 OS=Homo 









GN=AZGP1 PE=1 SV=2 
5.33E+07 
 
Table C.6: Alveolar proteins identified by 1D PAGE and nano LC MS/MS in healthy 
aged and COPD smoker RTLFs. The 126 proteins common to both healthy aged and 
COPD smoker subjects investigated n=5 for both subject groups, alongside the mean of 
the three most abundant ion peaks of each respective protein identified. Accession 
numbers included according to entries in UniProtKB/Swiss-Prot.  
 
COPD smoker Healthy Aged Control 
14-3-3 protein beta/alpha 
OS=Homo sapiens 
GN=YWHAB PE=1 SV=3 
3.26E+07 
14-3-3 protein beta/alpha 
OS=Homo sapiens 
GN=YWHAB PE=1 SV=3 
1.46E+07 
14-3-3 protein zeta/delta 
OS=Homo sapiens 
GN=YWHAZ PE=1 SV=1 
3.48E+07 
14-3-3 protein zeta/delta 
OS=Homo sapiens 










GN=CYP8B1 PE=2 SV=2 
4.20E+07 
Actin-related protein 2; 
AltName: Full=Actin-like 
protein 2; [Homo sapiens 
(Human)] - [ARP2_HUMAN] 
1.95E+07 
Actin-related protein 2; 
AltName: Full=Actin-like 
protein 2; [Homo sapiens 
(Human)] - [ARP2_HUMAN] 
1.97E+07 
Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 
5.36E+07 
Actin, cytoplasmic 1 
OS=Homo sapiens GN=ACTB 
PE=1 SV=1 
6.89E+07 
Afamin OS=Homo sapiens 
GN=AFM PE=1 SV=1 
1.76E+07 
Afamin OS=Homo sapiens 
GN=AFM PE=1 SV=1 
2.54E+07 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 
2.76E+08 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 
3.39E+08 
Alpha-1-acid glycoprotein 2; 
Short=AGP 2; AltName: 
Full=Orosomucoid-2; 
Short=OMD 2; Flags: Precursor; 
[Homo sapiens (Human)] - 
[A1AG2_HUMAN] 
1.95E+08 
Alpha-1-acid glycoprotein 2 









GN=SERPINA3 PE=1 SV=2 
8.21E+07 
Alpha-1-antitrypsin OS=Homo 


































sapiens GN=ENO1 PE=1 SV=2 
7.37E+06 
Alpha-enolase OS=Homo 











carboxypeptidase I; AltName: 




enzyme, soluble form; Flags: 
Precursor; [Homo sapiens 
(Human)] - [ACE_HUMAN] 
1.46E+07 
Angiotensinogen OS=Homo 
sapiens GN=AGT PE=1 SV=1 
5.39E+07 
Angiotensinogen OS=Homo 
sapiens GN=AGT PE=1 SV=1 
4.94E+07 
Annexin A5 OS=Homo sapiens 
GN=ANXA5 PE=1 SV=2 
7.53E+07 
Annexin A5 OS=Homo 








sapiens GN=SERPINC1 PE=1 
SV=1 
1.84E+07 
Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 
SV=1 
5.68E+07 
Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 
SV=1 
1.38E+08 
Apolipoprotein A-II OS=Homo 





GN=APOA2 PE=1 SV=1 
7.40E+07 
Apolipoprotein A-IV OS=Homo 





GN=APOA4 PE=1 SV=3 
2.74E+07 
ATP-binding cassette sub-family 
F member 1; AltName: 
Full=ATP-binding cassette 50; 
AltName: Full=TNF-alpha-
stimulated ABC protein; [Homo 




family F member 1; AltName: 
Full=ATP-binding cassette 50; 
AltName: Full=TNF-alpha-
stimulated ABC protein; 
[Homo sapiens (Human)] - 
[ABCF1_HUMAN] 
1.17E+07 
Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 
1.08E+07 
Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 
5.23E+06 
Beta-2-microglobulin 
OS=Homo sapiens GN=B2M 
3.80E+07 
Beta-2-microglobulin 




PE=1 SV=1 PE=1 SV=1 
Calmodulin OS=Homo sapiens 
GN=CALM1 PE=1 SV=2 
2.48E+07 
Calmodulin OS=Homo sapiens 
GN=CALM1 PE=1 SV=2 
2.68E+06 
Carbonic anhydrase 1 
OS=Homo sapiens GN=CA1 
PE=1 SV=2 
5.50E+06 
Carbonic anhydrase 1 
OS=Homo sapiens GN=CA1 
PE=1 SV=2 
3.91E+06 
CD166 antigen OS=Homo 
sapiens GN=ALCAM PE=1 
SV=2 
6.34E+06 
CD166 antigen; AltName: 
Full=Activated leukocyte cell 
adhesion molecule; AltName: 
CD_antigen=CD166; Flags: 
Precursor; [Homo sapiens 
(Human)] - [CD166_HUMAN] 
1.35E+07 
CD44 antigen OS=Homo 
sapiens GN=CD44 PE=1 SV=3 
3.49E+07 
CD44 antigen OS=Homo 
sapiens GN=CD44 PE=1 
SV=3 
2.73E+07 
CD59 glycoprotein; AltName: 
Full=1F5 antigen; AltName: 
Full=20 kDa homologous 
restriction factor; Short=HRF-
20; Short=HRF20; AltName: 
Full=MAC-inhibitory protein; 
Short=MAC-IP; AltName: 
Full=MEM43 antigen; AltName: 
Full=Membrane attack complex 
inhibition factor; Short=MACIF; 
AltName: Full=Membrane 




Precursor; [Homo sapiens 
(Human)] - [CD59_HUMAN] 
2.60E+06 
CD59 glycoprotein; AltName: 
Full=1F5 antigen; AltName: 
Full=20 kDa homologous 
restriction factor; Short=HRF-





attack complex inhibition 
factor; Short=MACIF; 
AltName: Full=Membrane 




Precursor; [Homo sapiens 
(Human)] - [CD59_HUMAN] 
3.54E+06 
Cell adhesion molecule 2; 
AltName: Full=Immunoglobulin 
superfamily member 4D; 
Short=IgSF4D; AltName: 
Full=Nectin-like protein 3; 
Short=NECL-3; Flags: 
Precursor; [Homo sapiens 
(Human)] - [CADM2_HUMAN] 
1.71E+07 
Cell adhesion molecule 2; 
AltName: 
Full=Immunoglobulin 
superfamily member 4D; 
Short=IgSF4D; AltName: 
Full=Nectin-like protein 3; 
Short=NECL-3; Flags: 





sapiens GN=CP PE=1 SV=1 
2.38E+08 
Ceruloplasmin OS=Homo 
sapiens GN=CP PE=1 SV=1 
3.67E+08 
Coactosin-like protein 





GN=COTL1 PE=1 SV=3 
5.15E+06 
Complement C2 OS=Homo 
sapiens GN=C2 PE=1 SV=2 
1.87E+06 
Complement C2 OS=Homo 
sapiens GN=C2 PE=1 SV=2 
3.41E+07 
Complement C3 OS=Homo 
sapiens GN=C3 PE=1 SV=2 
7.33E+07 
Complement C3 OS=Homo 






GN=SERPINA6 PE=1 SV=1 
2.38E+07 
Corticosteroid-binding 
globulin OS=Homo sapiens 
GN=SERPINA6 PE=1 SV=1 
3.95E+07 
Deleted in malignant brain 
tumors 1 protein OS=Homo 
sapiens GN=DMBT1 PE=1 
SV=2 
2.80E+07 
Deleted in malignant brain 
tumors 1 protein OS=Homo 
sapiens GN=DMBT1 PE=1 
SV=2 
3.69E+07 
Delta-like protein 4; AltName: 
Full=Drosophila Delta homolog 
4; Short=Delta4; Flags: 
Precursor; [Homo sapiens 
(Human)] - [DLL4_HUMAN] 
5.48E+07 
Delta-like protein 4; AltName: 
Full=Drosophila Delta 
homolog 4; Short=Delta4; 
Flags: Precursor; [Homo 






promoting peptide; Contains: 
RecName: Full=DCD-1; Flags: 
Precursor; [Homo sapiens 
(Human)] - [DCD_HUMAN] 
2.94E+06 
Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 
2.13E+06 
Desmoplakin OS=Homo sapiens 
GN=DSP PE=1 SV=3 
1.06E+08 
Desmoplakin OS=Homo 
sapiens GN=DSP PE=1 SV=3 
1.40E+08 
Dipeptidyl peptidase 4 
OS=Homo sapiens GN=DPP4 
PE=1 SV=2 
1.99E+07 
Dipeptidyl peptidase 4 





containing protein 2; 
Short=ADAM 2; AltName: 
Full=Cancer/testis antigen 15; 
Short=CT15; AltName: 










containing protein 2; 
Short=ADAM 2; AltName: 
Full=Cancer/testis antigen 15; 
Short=CT15; AltName: 








Epididymal secretory protein E1 
OS=Homo sapiens GN=NPC2 
PE=1 SV=1 
3.19E+07 
Epididymal secretory protein 
E1 OS=Homo sapiens 
GN=NPC2 PE=1 SV=1 
1.37E+07 
FAS-associated factor 1; 
Short=hFAF1; AltName: 
Full=UBX domain-containing 
protein 12; AltName: Full=UBX 
domain-containing protein 3A; 
[Homo sapiens (Human)] - 
[FAF1_HUMAN] 
9.69E+07 
FAS-associated factor 1; 
Short=hFAF1; AltName: 
Full=UBX domain-containing 
protein 12; AltName: 
Full=UBX domain-containing 
protein 3A; [Homo sapiens 
(Human)] - [FAF1_HUMAN] 
4.89E+08 
Ferritin heavy chain OS=Homo 
sapiens GN=FTH1 PE=1 SV=2 
1.41E+08 
Ferritin heavy chain; 






inducing gene 15 protein; 
[Homo sapiens (Human)] - 
[FRIH_HUMAN] 
Ferritin light chain OS=Homo 
sapiens GN=FTL PE=1 SV=2 
3.93E+08 
Ferritin light chain; 
Short=Ferritin L subunit; 









membrane autoantigen p105; 
AltName: Full=Lectin 
galactoside-binding soluble 3-




associated antigen 90K; Flags: 





AltName: Full=35 kDa lectin; 
AltName: Full=Carbohydrate-
binding protein 35; Short=CBP 
35; AltName: Full=Galactose-




protein; AltName: Full=L-31; 
AltName: Full=Laminin-binding 
protein; AltName: Full=Lectin 
L-29; AltName: Full=Mac-2 
antigen; [Homo sapiens 
(Human)] - [LEG3_HUMAN] 
1.28E+06 
Galectin-3; Short=Gal-3; 
AltName: Full=35 kDa lectin; 
AltName: Full=Carbohydrate-
binding protein 35; Short=CBP 
35; AltName: Full=Galactose-




protein; AltName: Full=L-31; 
AltName: Full=Laminin-
binding protein; AltName: 
Full=Lectin L-29; AltName: 
Full=Mac-2 antigen; [Homo 
sapiens (Human)] - 
[LEG3_HUMAN] 
2.03E+06 
Glutathione S-transferase A2 
OS=Homo sapiens GN=GSTA2 
PE=1 SV=4 
9.67E+07 
Glutathione S-transferase A2 
OS=Homo sapiens 
GN=GSTA2 PE=1 SV=4 
4.18E+07 
Glutathione S-transferase P 
OS=Homo sapiens GN=GSTP1 
PE=1 SV=2 
1.74E+07 
Glutathione S-transferase P 
OS=Homo sapiens 
GN=GSTP1 PE=1 SV=2 
8.51E+06 
Haptoglobin OS=Homo sapiens 
GN=HP PE=1 SV=1 
2.64E+08 
Haptoglobin OS=Homo 
sapiens GN=HP PE=1 SV=1 
1.26E+08 
Hemoglobin subunit alpha 
OS=Homo sapiens GN=HBA1 
PE=1 SV=2 
8.29E+07 
Hemoglobin subunit alpha 
OS=Homo sapiens GN=HBA1 
PE=1 SV=2 
1.49E+08 
Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB 
PE=1 SV=2 
7.32E+07 
Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB 
PE=1 SV=2 
1.28E+08 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 
3.48E+08 
Hemopexin OS=Homo sapiens 




Ig alpha-1 chain C region 
OS=Homo sapiens GN=IGHA1 
PE=1 SV=2 
1.56E+09 
Ig alpha-1 chain C region 
OS=Homo sapiens 
GN=IGHA1 PE=1 SV=2 
2.42E+09 
Ig alpha-2 chain C region 
OS=Homo sapiens GN=IGHA2 
PE=1 SV=3 
8.21E+08 
Ig alpha-2 chain C region 
OS=Homo sapiens 
GN=IGHA2 PE=1 SV=3 
1.79E+09 
Ig gamma-1 chain C region 
OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 
5.79E+09 
Ig gamma-1 chain C region 
OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 
8.92E+09 
Ig gamma-2 chain C region 
OS=Homo sapiens GN=IGHG2 
PE=1 SV=2 
4.65E+09 
Ig gamma-2 chain C region 
OS=Homo sapiens 
GN=IGHG2 PE=1 SV=2 
5.60E+09 
Ig gamma-3 chain C region 
OS=Homo sapiens GN=IGHG3 
PE=1 SV=2 
5.04E+09 
Ig gamma-3 chain C region 
OS=Homo sapiens 
GN=IGHG3 PE=1 SV=2 
6.71E+09 
Ig heavy chain V-II region 
NEWM; [Homo sapiens 
(Human)] - [HV207_HUMAN] 
1.15E+08 
Ig heavy chain V-II region 
NEWM OS=Homo sapiens 
PE=1 SV=1 
1.47E+08 
Ig heavy chain V-II region OU; 
[Homo sapiens (Human)] - 
[HV201_HUMAN] 
4.28E+07 
Ig heavy chain V-II region 
OU; [Homo sapiens (Human)] 
- [HV201_HUMAN] 
1.44E+08 
Ig heavy chain V-III region 
BRO; [Homo sapiens (Human)] 
- [HV305_HUMAN] 
9.27E+08 
Ig heavy chain V-III region 




Ig heavy chain V-III region 
BUT; [Homo sapiens (Human)] 
- [HV306_HUMAN] 
9.00E+08 
Ig heavy chain V-III region 




Ig heavy chain V-III region 
CAM OS=Homo sapiens PE=1 
SV=1 
9.16E+08 
Ig heavy chain V-III region 
CAM OS=Homo sapiens PE=1 
SV=1 
1.05E+09 
Ig heavy chain V-III region 
GAL OS=Homo sapiens PE=1 
SV=1 
8.79E+08 
Ig heavy chain V-III region 
GAL OS=Homo sapiens PE=1 
SV=1 
1.05E+09 
Ig heavy chain V-III region 
GAR; [Homo sapiens (Human)] 
- [HV322_HUMAN] 
2.86E+08 
Ig heavy chain V-III region 




Ig heavy chain V-III region HIL; 
[Homo sapiens (Human)] - 
[HV310_HUMAN] 
1.24E+09 
Ig heavy chain V-III region 
HIL; [Homo sapiens (Human)] 
- [HV310_HUMAN] 
1.47E+09 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 
2.92E+09 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 
3.47E+09 
Ig kappa chain V-I region CAR 
OS=Homo sapiens PE=1 SV=1 
8.07E+07 
Ig kappa chain V-I region 




Ig kappa chain V-I region EU 
OS=Homo sapiens PE=1 SV=1 
3.10E+08 
Ig kappa chain V-I region EU 
OS=Homo sapiens PE=1 SV=1 
2.41E+08 
Ig kappa chain V-I region Kue 2.80E+08 Ig kappa chain V-I region Kue 1.89E+08 
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OS=Homo sapiens PE=1 SV=1 OS=Homo sapiens PE=1 SV=1 
Ig kappa chain V-I region Wes; 
[Homo sapiens (Human)] - 
[KV119_HUMAN] 
3.60E+08 
Ig kappa chain V-I region 
Wes; [Homo sapiens (Human)] 
- [KV119_HUMAN] 
2.71E+08 
Ig kappa chain V-II region FR 
OS=Homo sapiens PE=1 SV=1 
3.16E+06 
Ig kappa chain V-II region FR 
OS=Homo sapiens PE=1 SV=1 
8.51E+07 
Ig kappa chain V-III region 
POM OS=Homo sapiens PE=1 
SV=1 
1.58E+08 
Ig kappa chain V-III region 
POM OS=Homo sapiens PE=1 
SV=1 
9.77E+07 
Ig kappa chain V-III region SIE 
OS=Homo sapiens PE=1 SV=1 
2.67E+08 
Ig kappa chain V-III region 
SIE OS=Homo sapiens PE=1 
SV=1 
2.40E+08 
Ig kappa chain V-III region VG 
(Fragment) OS=Homo sapiens 
PE=1 SV=1 
6.84E+07 
Ig kappa chain V-III region 
VG; Flags: Precursor; 




Ig kappa chain V-IV region JI 
OS=Homo sapiens PE=4 SV=1 
1.08E+08 
Ig kappa chain V-IV region JI 
OS=Homo sapiens PE=4 SV=1 
3.74E+07 
Ig kappa chain V-IV region Len; 
[Homo sapiens (Human)] - 
[KV402_HUMAN] 
1.49E+08 
Ig kappa chain V-IV region 
Len OS=Homo sapiens PE=1 
SV=2 
9.86E+07 
Ig lambda chain V region 4A 
OS=Homo sapiens PE=4 SV=1 
7.87E+06 
Ig lambda chain V region 4A 
OS=Homo sapiens PE=4 SV=1 
5.01E+07 
Ig lambda chain V-I region HA 
OS=Homo sapiens PE=1 SV=1 
6.98E+07 
Ig lambda chain V-I region HA 
OS=Homo sapiens PE=1 SV=1 
1.91E+08 
Ig lambda chain V-I region 
NIG-64 OS=Homo sapiens 
PE=1 SV=1 
2.25E+07 
Ig lambda chain V-I region 
NIG-64 OS=Homo sapiens 
PE=1 SV=1 
7.21E+07 
Ig lambda chain V-III region 
LOI OS=Homo sapiens PE=1 
SV=1 
6.09E+07 
Ig lambda chain V-III region 
LOI OS=Homo sapiens PE=1 
SV=1 
1.57E+08 
Ig lambda chain V-III region 
SH; [Homo sapiens (Human)] - 
[LV301_HUMAN] 
1.31E+07 
Ig lambda chain V-III region 
SH; [Homo sapiens (Human)] - 
[LV301_HUMAN] 
3.09E+07 
Ig lambda chain V-IV region 
Bau; [Homo sapiens (Human)] - 
[LV401_HUMAN] 
5.41E+07 
Ig lambda chain V-IV region 
Bau; [Homo sapiens (Human)] 
- [LV401_HUMAN] 
1.58E+08 
Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 
1.09E+09 
Ig lambda-2 chain C regions 
OS=Homo sapiens 
GN=IGLC2 PE=1 SV=1 
2.31E+09 
Ig mu chain C region OS=Homo 
sapiens GN=IGHM PE=1 SV=3 
3.88E+07 
Ig mu chain C region 
OS=Homo sapiens GN=IGHM 
PE=1 SV=3 
4.16E+07 
Immunoglobulin J chain 
OS=Homo sapiens GN=IGJ 
PE=1 SV=4 
7.57E+07 
Immunoglobulin J chain 




polypeptide 5 OS=Homo 
sapiens GN=IGLL5 PE=2 SV=2 
7.42E+08 
Immunoglobulin lambda-like 
polypeptide 5 OS=Homo 
sapiens GN=IGLL5 PE=2 
SV=2 
1.44E+09 
Intercellular adhesion molecule 1.44E+07 Intercellular adhesion molecule 1.15E+07 
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1 OS=Homo sapiens 
GN=ICAM1 PE=1 SV=2 
1 OS=Homo sapiens 
GN=ICAM1 PE=1 SV=2 
Leucine-rich alpha-2-
glycoprotein OS=Homo sapiens 













Full=Acid maltase; AltName: 
Full=Aglucosidase alfa; 
Contains: RecName: Full=76 
kDa lysosomal alpha-
glucosidase; Contains: 
RecName: Full=70 kDa 
lysosomal alpha-glucosidase; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[LYAG_HUMAN] 
1.40E+06 
Mucin-1 OS=Homo sapiens 
GN=MUC1 PE=1 SV=3 
1.02E+07 
Mucin-1 OS=Homo sapiens 
GN=MUC1 PE=1 SV=3 
1.18E+07 
Myotubularin-related protein 14; 
EC=3.1.3.-; AltName: 
Full=HCV NS5A-transactivated 
protein 4 splice variant A-
binding protein 1; 
Short=NS5ATP4ABP1; 
AltName: Full=hJumpy; [Homo 




14; EC=3.1.3.-; AltName: 
Full=HCV NS5A-
transactivated protein 4 splice 
variant A-binding protein 1; 
Short=NS5ATP4ABP1; 
AltName: Full=hJumpy; 




isomerase A OS=Homo sapiens 
GN=PPIA PE=1 SV=2 
7.32E+06 
Peptidyl-prolyl cis-trans 
isomerase A; Short=PPIase A; 
EC=5.2.1.8; AltName: 
Full=Cyclophilin A; AltName: 
Full=Cyclosporin A-binding 
protein; AltName: 
Full=Rotamase A; [Homo 




receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
2.83E+08 
Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
1.94E+08 
Pro-cathepsin H OS=Homo 
sapiens GN=CTSH PE=1 SV=4 
1.61E+07 
Pro-cathepsin H OS=Homo 
































protein 2; Short=SAP-2; 
Contains: RecName: 
Full=Saposin-D; AltName: 
Full=Component C; AltName: 
Full=Protein C; Flags: 
Precursor; [Homo sapiens 
(Human)] - [SAP_HUMAN] 
Protein DJ-1 OS=Homo sapiens 
GN=PARK7 PE=1 SV=2 
1.16E+07 
Protein DJ-1 OS=Homo 
sapiens GN=PARK7 PE=1 
SV=2 
1.23E+07 
Protein S100-A6 OS=Homo 
sapiens GN=S100A6 PE=1 
SV=1 
1.14E+08 
Protein S100-A6 OS=Homo 
sapiens GN=S100A6 PE=1 
SV=1 
2.38E+07 
Protein S100-A8 OS=Homo 
sapiens GN=S100A8 PE=1 
SV=1 
2.22E+06 
Protein S100-A8 OS=Homo 
sapiens GN=S100A8 PE=1 
SV=1 
3.59E+07 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 
Short=hShrmL; [Homo sapiens 
(Human)] - [SHRM3_HUMAN] 
2.30E+08 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 














glutamyltransferase E 50 kDa 
non-catalytic chain; Contains: 
RecName: Full=Protein-
glutamine gamma-
glutamyltransferase E 27 kDa 
catalytic chain; Flags: Precursor; 












glutamyltransferase E 50 kDa 
non-catalytic chain; Contains: 
RecName: Full=Protein-
glutamine gamma-
glutamyltransferase E 27 kDa 
catalytic chain; Flags: 




[TGM3_HUMAN] (Human)] - [TGM3_HUMAN] 
Pulmonary surfactant-associated 
protein A2 OS=Homo sapiens 
GN=SFTPA2 PE=1 SV=1 
2.89E+07 
Pulmonary surfactant-
associated protein A2 
OS=Homo sapiens 
GN=SFTPA2 PE=1 SV=1 
3.74E+07 
Pulmonary surfactant-associated 
protein B OS=Homo sapiens 
GN=SFTPB PE=1 SV=3 
9.69E+06 
Pulmonary surfactant-
associated protein B; 
Short=SP-B; AltName: 
Full=18 kDa pulmonary-
surfactant protein; AltName: 
Full=6 kDa protein; AltName: 
Full=Pulmonary surfactant-
associated proteolipid 
SPL(Phe); Flags: Precursor; 




protein D OS=Homo sapiens 
GN=SFTPD PE=1 SV=3 
2.63E+07 
Pulmonary surfactant-
associated protein D 
OS=Homo sapiens 
GN=SFTPD PE=1 SV=3 
1.53E+07 
Putative V-set and 
immunoglobulin domain-
containing protein 6; Flags: 
Precursor; [Homo sapiens 
(Human)] - [VSIG6_HUMAN] 
1.42E+08 
Putative V-set and 
immunoglobulin domain-
containing protein 6 
OS=Homo sapiens 
GN=VSIG6 PE=5 SV=2 
2.00E+08 
Ribonuclease P protein subunit 
p40; Short=RNaseP protein p40; 
EC=3.1.26.5; AltName: 
Full=RNase P subunit 1; [Homo 
sapiens (Human)] - 
[RPP40_HUMAN] 
1.55E+08 
Ribonuclease P protein subunit 
p40; Short=RNaseP protein 
p40; EC=3.1.26.5; AltName: 
Full=RNase P subunit 1; 
[Homo sapiens (Human)] - 
[RPP40_HUMAN] 
5.47E+07 
Selenium-binding protein 1 
OS=Homo sapiens 
GN=SELENBP1 PE=1 SV=2 
8.65E+06 
Selenium-binding protein 1 
OS=Homo sapiens 
GN=SELENBP1 PE=1 SV=2 
1.67E+07 
Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=3 
4.56E+09 
Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=3 
7.62E+09 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
3.86E+09 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
2.77E+09 
SH3 domain-binding glutamic 
acid-rich-like protein 3; 
AltName: Full=SH3 domain-
binding protein 1; 
Short=SH3BP-1; [Homo sapiens 
(Human)] - [SH3L3_HUMAN] 
1.22E+07 
SH3 domain-binding glutamic 
acid-rich-like protein 3; 
AltName: Full=SH3 domain-
binding protein 1; 
Short=SH3BP-1; [Homo 
sapiens (Human)] - 
[SH3L3_HUMAN] 
3.66E+06 
Sorting nexin-6; AltName: 
Full=TRAF4-associated factor 
2; [Homo sapiens (Human)] - 
[SNX6_HUMAN] 
4.91E+06 
Sorting nexin-6; AltName: 
Full=TRAF4-associated factor 















Short=SASP; [Homo sapiens 
(Human)] - [THIO_HUMAN] 
Full=Surface-associated 
sulphydryl protein; 
Short=SASP; [Homo sapiens 
(Human)] - [THIO_HUMAN] 
Thyroxine-binding globulin 
OS=Homo sapiens 




GN=SERPINA7 PE=1 SV=2 
5.25E+06 
Transaldolase OS=Homo 




sapiens GN=TALDO1 PE=1 
SV=2 
4.47E+07 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-beta; 
[Homo sapiens (Human)] - 
[TAD2B_HUMAN] 
2.68E+07 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-
beta; [Homo sapiens (Human)] 
- [TAD2B_HUMAN] 
2.22E+07 
Transmembrane protein 198; 
[Homo sapiens (Human)] - 
[TM198_HUMAN] 
4.78E+07 
Transmembrane protein 198; 
[Homo sapiens (Human)] - 
[TM198_HUMAN] 
2.62E+07 
Transmembrane protein 200C; 
AltName: Full=Transmembrane 
protein TTMA; AltName: 
Full=Two transmembrane 
domain-containing family 
member A; [Homo sapiens 
(Human)] - [T200C_HUMAN] 
1.94E+06 
Transmembrane protein 200C; 
AltName: 
Full=Transmembrane protein 
TTMA; AltName: Full=Two 
transmembrane domain-
containing family member A; 
[Homo sapiens (Human)] - 
[T200C_HUMAN] 
3.59E+06 
Transthyretin OS=Homo sapiens 
GN=TTR PE=1 SV=1 
1.29E+08 
Transthyretin OS=Homo 
sapiens GN=TTR PE=1 SV=1 
2.53E+08 
Triosephosphate isomerase 








C3orf38; [Homo sapiens 
(Human)] - [CC038_HUMAN] 
1.83E+09 
Uncharacterized protein 
C3orf38; [Homo sapiens 
(Human)] - [CC038_HUMAN] 
2.73E+09 
Uteroglobin OS=Homo sapiens 
GN=SCGB1A1 PE=1 SV=1 
1.99E+08 
Uteroglobin OS=Homo 
sapiens GN=SCGB1A1 PE=1 
SV=1 
1.74E+08 
Vitamin D-binding protein 
OS=Homo sapiens GN=GC 
PE=1 SV=1 
1.52E+08 
Vitamin D-binding protein 




containing protein 2 OS=Homo 
sapiens GN=XIRP2 PE=1 SV=2 
1.76E+08 
Xin actin-binding repeat-
containing protein 2 









GN=AZGP1 PE=1 SV=2 
1.24E+08 
14-3-3 protein epsilon 
OS=Homo sapiens 
GN=YWHAE PE=1 SV=1 
3.12E+07 
14-3-3 protein epsilon 
OS=Homo sapiens 
GN=YWHAE PE=1 SV=1 
1.86E+07 
HLA class II histocompatibility 
antigen, DRB1-1 beta chain 
4635000 






DRB1 PE=1 SV=2 




Table C.7 Alveolar proteins identified by 1D PAGE and nano LC MS/MS in healthy aged 
and COPD ex-smoker RTLFs. The 45 proteins common to both healthy aged (n=5) and 
COPD ex-smoker (n=10) subjects investigated, alongside the mean of the three most 
abundant ion peaks of each respective protein identified. Accession numbers included 
according to entries in UniProtKB/Swiss-Prot.  
COPD ex-smoker Healthy Aged Control 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 
9.25E+09 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 
3.47E+09 
Ig alpha-1 chain C region 
OS=Homo sapiens GN=IGHA1 
PE=1 SV=2 
6.04E+09 
Ig alpha-1 chain C region 
OS=Homo sapiens 
GN=IGHA1 PE=1 SV=2 
2.42E+09 
Uteroglobin OS=Homo sapiens 
GN=SCGB1A1 PE=1 SV=1 
4.49E+09 
Uteroglobin OS=Homo 
sapiens GN=SCGB1A1 PE=1 
SV=1 
1.74E+08 
Ig gamma-1 chain C region 
OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 
3.55E+09 
Ig gamma-1 chain C region 
OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 
8.92E+09 
Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
2.37E+09 
Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
1.94E+08 
Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB 
PE=1 SV=2 
1.66E+09 
Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB 
PE=1 SV=2 
1.28E+08 
RecName: Full=Ig kappa chain 
V-III region B6; [Homo sapiens 
(Human)] - [KV301_HUMAN] 
1.63E+09 
Ig kappa chain V-III region 




sapiens GN=TF PE=1 SV=3 
1.10E+09 
Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=3 
7.62E+09 
Uncharacterized protein 
C3orf38; [Homo sapiens 
(Human)] - [CC038_HUMAN] 
5.97E+08 
Uncharacterized protein 
C3orf38; [Homo sapiens 
(Human)] - [CC038_HUMAN] 
2.73E+09 
Beta-2-microglobulin 




OS=Homo sapiens GN=B2M 
PE=1 SV=1 
2.59E+07 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
5.49E+08 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
2.77E+09 
Lysozyme C; EC=3.2.1.17; 
AltName: Full=1,4-beta-N-
acetylmuramidase C; Flags: 
Precursor; [Homo sapiens 
(Human)] - [LYSC_HUMAN] 
5.31E+08 
Lysozyme C; EC=3.2.1.17; 
AltName: Full=1,4-beta-N-
acetylmuramidase C; Flags: 
Precursor; [Homo sapiens 
(Human)] - [LYSC_HUMAN] 
1.48E+06 
Hemoglobin subunit alpha; 
AltName: Full=Alpha-globin; 
AltName: Full=Hemoglobin 
alpha chain; [Homo sapiens 
(Human)] - [HBA_HUMAN] 
5.24E+08 
Hemoglobin subunit alpha 





Ig lambda chain V-III region 
LOI; [Homo sapiens (Human)] - 
[LV302_HUMAN] 
4.81E+08 
Ig lambda chain V-III region 
LOI OS=Homo sapiens PE=1 
SV=1 
1.57E+08 
Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 
4.06E+08 
Actin, cytoplasmic 1 
OS=Homo sapiens GN=ACTB 
PE=1 SV=1 
6.89E+07 
Complement C3 OS=Homo 
sapiens GN=C3 PE=1 SV=2 
2.06E+08 
Complement C3 OS=Homo 
sapiens GN=C3 PE=1 SV=2 
2.66E+06 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 
1.75E+08 
Hemopexin OS=Homo sapiens 




factor; Short=ADF; AltName: 
Full=Surface-associated 
sulphydryl protein; 
Short=SASP; [Homo sapiens 




factor; Short=ADF; AltName: 
Full=Surface-associated 
sulphydryl protein; 
Short=SASP; [Homo sapiens 
(Human)] - [THIO_HUMAN] 
8.21E+06 
Ferritin light chain OS=Homo 
sapiens GN=FTL PE=1 SV=2 
1.51E+08 
Ferritin light chain; 
Short=Ferritin L subunit; 
[Homo sapiens (Human)] - 
[FRIL_HUMAN] 
4.73E+06 
Annexin A5; AltName: 
Full=Anchorin CII; AltName: 




Full=Endonexin II; AltName: 
Full=Lipocortin V; AltName: 
Full=Placental anticoagulant 
protein 4; Short=PP4; AltName: 
Full=Placental anticoagulant 





[Homo sapiens (Human)] - 
[ANXA5_HUMAN] 
9.47E+07 
Annexin A5 OS=Homo 




sapiens GN=TTR PE=1 SV=1 
7.84E+07 
Transthyretin OS=Homo 
sapiens GN=TTR PE=1 SV=1 
2.53E+08 
Peptidyl-prolyl cis-trans 
isomerase A; Short=PPIase A; 
EC=5.2.1.8; AltName: 
Full=Cyclophilin A; AltName: 
Full=Cyclosporin A-binding 
protein; AltName: 
Full=Rotamase A; [Homo 




isomerase A; Short=PPIase A; 
EC=5.2.1.8; AltName: 
Full=Cyclophilin A; AltName: 
Full=Cyclosporin A-binding 
protein; AltName: 
Full=Rotamase A; [Homo 
sapiens (Human)] - 
[PPIA_HUMAN] 
6.43E+06 
Ig gamma-2 chain C region 
OS=Homo sapiens GN=IGHG2 
5.64E+07 





PE=1 SV=2 GN=IGHG2 PE=1 SV=2 
Delta-like protein 4; AltName: 
Full=Drosophila Delta homolog 
4; Short=Delta4; Flags: 
Precursor; [Homo sapiens 
(Human)] - [DLL4_HUMAN] 
4.85E+07 
Delta-like protein 4; AltName: 
Full=Drosophila Delta 
homolog 4; Short=Delta4; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[DLL4_HUMAN] 
1.23E+07 









AltName: Full=Heparan sulfate 
proteoglycan; AltName: 
Full=Hermes antigen; AltName: 
Full=Hyaluronate receptor; 
AltName: Full=Phagocytic 
glycoprotein 1; Short=PGP-1; 
AltName: Full=Phagocytic 
glycoprotein I; Short=PGP-I; 
AltName: CD_antigen=CD44; 
Flags: Precursor; [Homo sapiens 
(Human)] - [CD44_HUMAN] 
3.87E+07 
CD44 antigen OS=Homo 








sapiens GN=SERPINA1 PE=1 
SV=3 
3.20E+09 
RecName: Full=Ig lambda chain 
V-IV region Bau; [Homo 
sapiens (Human)] - 
[LV401_HUMAN] 
3.27E+07 
Ig lambda chain V-IV region 
Bau; [Homo sapiens (Human)] 
- [LV401_HUMAN] 
1.58E+08 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 
Short=hShrmL; [Homo sapiens 
(Human)] - [SHRM3_HUMAN] 
2.29E+07 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 




Ig heavy chain V-III region 
CAM; [Homo sapiens (Human)] 
- [HV307_HUMAN] 
1.68E+07 
Ig heavy chain V-III region 
CAM OS=Homo sapiens PE=1 
SV=1 
1.05E+09 
Ig heavy chain V-III region TIL; 
[Homo sapiens (Human)] - 
[HV304_HUMAN] 
1.60E+07 
Ig heavy chain V-III region 
TIL OS=Homo sapiens PE=1 
SV=1 
1.06E+09 
Haptoglobin OS=Homo sapiens 
GN=HP PE=1 SV=1 
9.50E+06 
Haptoglobin OS=Homo 
sapiens GN=HP PE=1 SV=1 
1.26E+08 
Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 
8.59E+06 
Ig lambda-2 chain C regions 
OS=Homo sapiens 





Dermcidin OS=Homo sapiens 





promoting peptide; Contains: 
RecName: Full=DCD-1; Flags: 
Precursor; [Homo sapiens 
(Human)] - [DCD_HUMAN] 
Calmodulin-like protein 5; 
AltName: Full=Calmodulin-like 
skin protein; [Homo sapiens 
(Human)] - [CALL5_HUMAN] 
6.19E+06 
Calmodulin-like protein 5; 
AltName: Full=Calmodulin-
like skin protein; [Homo 




sapiens GN=DSP PE=1 SV=3 
3.75E+06 
Desmoplakin OS=Homo 
sapiens GN=DSP PE=1 SV=3 
1.40E+08 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 
2.88E+06 
Alpha-1-acid glycoprotein 1 




sapiens GN=CP PE=1 SV=1 
2.73E+06 
Ceruloplasmin OS=Homo 
sapiens GN=CP PE=1 SV=1 
3.67E+08 
Alpha-1-acid glycoprotein 2; 
Short=AGP 2; AltName: 
Full=Orosomucoid-2; 
Short=OMD 2; Flags: 
Precursor; [Homo sapiens 
(Human)] - [A1AG2_HUMAN] 
1.95E+06 
Alpha-1-acid glycoprotein 2 
OS=Homo sapiens GN=ORM2 
PE=1 SV=2 
2.40E+08 
Transmembrane protein 200C; 
AltName: Full=Transmembrane 
protein TTMA; AltName: 
Full=Two transmembrane 
domain-containing family 
member A; [Homo sapiens 
(Human)] - [T200C_HUMAN] 
1.89E+06 
Transmembrane protein 200C; 
AltName: 
Full=Transmembrane protein 
TTMA; AltName: Full=Two 
transmembrane domain-
containing family member A; 
[Homo sapiens (Human)] - 
[T200C_HUMAN] 
3.59E+06 
Ig kappa chain V-III region SIE; 
[Homo sapiens (Human)] - 
[KV302_HUMAN] 
1.85E+06 
Ig kappa chain V-III region 




protein A2; Short=PSP-A; 
Short=PSPA; Short=SP-A; 
Short=SP-A2; AltName: 
Full=35 kDa pulmonary 
surfactant-associated protein; 
AltName: Full=Alveolar 
proteinosis protein; AltName: 
Full=Collectin-5; Flags: 
Precursor; [Homo sapiens 
(Human)] - [SFPA2_HUMAN] 
1.85E+06 
Pulmonary surfactant-
associated protein A2 
OS=Homo sapiens 




glycoprotein; Flags: Precursor; 








14; EC=3.1.3.-; AltName: 
1.21E+06 
Myotubularin-related protein 





Table C.8: Alveolar proteins identified by 1D PAGE and nano LC MS/MS in healthy 
smoker and COPD ex-smoker RTLFs. The 40 proteins common to both healthy smoker 
(n=5) and COPD ex-smoker (n=10) subjects investigated, alongside the mean of the 
three most abundant ion peaks of each respective protein identified. Accession numbers 
included according to entries in UniProtKB/Swiss-Prot.  
 
COPD ex-smoker Healthy Smoker 
Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=3 
1.10E+09 
Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=3 
3.42E+09 
Ig gamma-1 chain C region 
OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 
3.55E+09 
Ig gamma-1 chain C region 
OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 
3.30E+09 
Ig gamma-2 chain C region 
OS=Homo sapiens 
GN=IGHG2 PE=1 SV=2 
5.64E+07 
Ig gamma-2 chain C region 
OS=Homo sapiens 




C3orf38; [Homo sapiens 
(Human)] - [CC038_HUMAN] 
5.97E+08 
Uncharacterized protein 




Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
5.49E+08 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
1.54E+09 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 
9.25E+09 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 
1.07E+09 
Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 
8.59E+06 
Ig lambda-2 chain C regions 
OS=Homo sapiens 
GN=IGLC2 PE=1 SV=1 
7.91E+08 
Ig alpha-1 chain C region 
OS=Homo sapiens 
GN=IGHA1 PE=1 SV=2 
6.04E+09 
Ig alpha-1 chain C region 
OS=Homo sapiens 
GN=IGHA1 PE=1 SV=2 
6.14E+08 
Alpha-1-antitrypsin OS=Homo 




sapiens GN=SERPINA1 PE=1 
SV=3 
2.75E+08 
Olfactory receptor 2A2; 
AltName: Full=Olfactory 
2.34E+07 




protein 4 splice variant A-
binding protein 1; 
Short=NS5ATP4ABP1; 
AltName: Full=hJumpy; [Homo 
sapiens (Human)] - 
[MTMRE_HUMAN] 
Full=HCV NS5A-
transactivated protein 4 splice 
variant A-binding protein 1; 
Short=NS5ATP4ABP1; 
AltName: Full=hJumpy; 
[Homo sapiens (Human)] - 
[MTMRE_HUMAN] 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-beta; 
[Homo sapiens (Human)] - 
[TAD2B_HUMAN] 
1.11E+06 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-




glycoprotein OS=Homo sapiens 









receptor 2A17; AltName: 
Full=Olfactory receptor OR7-
11; [Homo sapiens (Human)] - 
[OR2A2_HUMAN] 
receptor 2A17; AltName: 
Full=Olfactory receptor OR7-
11; [Homo sapiens (Human)] - 
[OR2A2_HUMAN] 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 
2.83E+08 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 
1.89E+08 
Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
2.37E+09 
Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
1.54E+08 
Actin, cytoplasmic 1 
OS=Homo sapiens GN=ACTB 
PE=1 SV=1 
4.06E+08 
Actin, cytoplasmic 1 
OS=Homo sapiens GN=ACTB 
PE=1 SV=1 
1.38E+08 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 
2.88E+06 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens 
GN=ORM1 PE=1 SV=1 
1.29E+08 
Ceruloplasmin OS=Homo 
sapiens GN=CP PE=1 SV=1 
2.73E+06 
Ceruloplasmin OS=Homo 
sapiens GN=CP PE=1 SV=1 
1.15E+08 
Alpha-1-acid glycoprotein 2; 
Short=AGP 2; AltName: 
Full=Orosomucoid-2; 
Short=OMD 2; Flags: 




Alpha-1-acid glycoprotein 2; 
Short=AGP 2; AltName: 
Full=Orosomucoid-2; 
Short=OMD 2; Flags: 





sapiens GN=HP PE=1 SV=1 
9.50E+06 
Haptoglobin OS=Homo 
sapiens GN=HP PE=1 SV=1 
1.04E+08 
Uteroglobin OS=Homo sapiens 
GN=SCGB1A1 PE=1 SV=1 
4.49E+09 
Uteroglobin OS=Homo 
sapiens GN=SCGB1A1 PE=1 
SV=1 
8.73E+07 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 




Protein Shroom3; AltName: 
Full=Shroom-related protein; 
Short=hShrmL; [Homo 
sapiens (Human)] - 
[SHRM3_HUMAN] 
8.20E+07 
Ig kappa chain V-III region 
VG (Fragment) OS=Homo 
sapiens PE=1 SV=1 
2.65E+06 
Ig kappa chain V-III region 
VG (Fragment) OS=Homo 
sapiens PE=1 SV=1 
5.54E+07 
RecName: Full=Hemoglobin 
subunit alpha; AltName: 
Full=Alpha-globin; AltName: 
Full=Hemoglobin alpha chain; 
[Homo sapiens (Human)] - 
[HBA_HUMAN] 
5.24E+08 
Hemoglobin subunit alpha 
OS=Homo sapiens GN=HBA1 
PE=1 SV=2 
5.40E+07 
RecName: Full=Annexin A5; 
AltName: Full=Anchorin CII; 
AltName: Full=Annexin V; 
AltName: Full=Annexin-5; 
AltName: Full=Calphobindin I; 
Short=CBP-I; AltName: 
Full=Endonexin II; AltName: 
Full=Lipocortin V; AltName: 
Full=Placental anticoagulant 
9.47E+07 
Annexin A5 OS=Homo 





protein 4; Short=PP4; 
AltName: Full=Placental 






sapiens (Human)] - 
[ANXA5_HUMAN] 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-
beta; [Homo sapiens (Human)] 
- [TAD2B_HUMAN] 
1.11E+06 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-




sapiens GN=TTR PE=1 SV=1 
7.84E+07 
Transthyretin OS=Homo 
sapiens GN=TTR PE=1 SV=1 
4.44E+07 















1; Short=PGP-1; AltName: 
Full=Phagocytic glycoprotein 
I; Short=PGP-I; AltName: 
CD_antigen=CD44; Flags: 
Precursor; [Homo sapiens 
(Human)] - [CD44_HUMAN] 
3.87E+07 
CD44 antigen OS=Homo 




associated protein A2; 
Short=PSP-A; Short=PSPA; 
Short=SP-A; Short=SP-A2; 
AltName: Full=35 kDa 
pulmonary surfactant-




Precursor; [Homo sapiens 
(Human)] - [SFPA2_HUMAN] 
1.85E+06 
Pulmonary surfactant-
associated protein A2 
OS=Homo sapiens 










glycoprotein; Flags: Precursor; 
[Homo sapiens (Human)] - 
[A1BG_HUMAN] 
PE=1 SV=4 
Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB 
PE=1 SV=2 
1.66E+09 
Transmembrane protein 198; 
[Homo sapiens (Human)] - 
[TM198_HUMAN] 
2.08E+07 
Ferritin light chain OS=Homo 
sapiens GN=FTL PE=1 SV=2 
1.51E+08 
Ferritin light chain OS=Homo 


















Short=SASP; [Homo sapiens 




factor; Short=ADF; AltName: 
Full=Surface-associated 
sulphydryl protein; 
Short=SASP; [Homo sapiens 
(Human)] - [THIO_HUMAN] 
1.29E+07 
RecName: Full=Ig lambda 
chain V-IV region Bau; [Homo 
sapiens (Human)] - 
[LV401_HUMAN] 
3.27E+07 
Ig lambda chain V-IV region 














promoting peptide; Contains: 
RecName: Full=DCD-1; Flags: 
Precursor; [Homo sapiens 
(Human)] - [DCD_HUMAN] 
6.55E+06 
Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 
4.35E+06 
Transmembrane protein 200C; 
AltName: 
Full=Transmembrane protein 
TTMA; AltName: Full=Two 
transmembrane domain-
containing family member A; 
[Homo sapiens (Human)] - 
[T200C_HUMAN] 
1.89E+06 
Transmembrane protein 200C; 
AltName: 
Full=Transmembrane protein 
TTMA; AltName: Full=Two 
transmembrane domain-
containing family member A; 
[Homo sapiens (Human)] - 
[T200C_HUMAN] 
2.06E+06 
Myoglobin; [Homo sapiens 
(Human)] - [MYG_HUMAN] 
2.39E+06 
Myoglobin; [Homo sapiens 







AltName: Full=Serine protease 
3; AltName: Full=Serine 






AltName: Full=Serine protease 
3; AltName: Full=Serine 
protease 4; AltName: 




Full=Trypsin III; AltName: 
Full=Trypsin IV; Flags: 
Precursor; [Homo sapiens 
(Human)] - [TRY3_HUMAN] 
Full=Trypsin IV; Flags: 
Precursor; [Homo sapiens 
(Human)] - [TRY3_HUMAN] 
RecName: Full=Lysozyme C; 
EC=3.2.1.17; AltName: 
Full=1,4-beta-N-
acetylmuramidase C; Flags: 
Precursor; [Homo sapiens 
(Human)] - [LYSC_HUMAN] 
5.31E+08 
Lysozyme C; EC=3.2.1.17; 
AltName: Full=1,4-beta-N-
acetylmuramidase C; Flags: 
Precursor; [Homo sapiens 
(Human)] - [LYSC_HUMAN] 
7.04E+05 
Ig heavy chain V-III region 
CAM; [Homo sapiens 
(Human)] - [HV307_HUMAN] 
1.68E+07 
Ig heavy chain V-III region 
CAM OS=Homo sapiens 
PE=1 SV=1 
 
Delta-like protein 4; AltName: 
Full=Drosophila Delta 
homolog 4; Short=Delta4; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[DLL4_HUMAN] 
4.85E+07 
Delta-like protein 4; AltName: 
Full=Drosophila Delta 
homolog 4; Short=Delta4; 
Flags: Precursor; [Homo 




Table C.9: Alveolar proteins identified by 1D PAGE and nano LC MS/MS in COPD 
smoker and COPD ex-smoker RTLFs. The 45 proteins common to both COPD smoker 
(n=5) and COPD ex-smoker (n=10) subjects investigated, alongside the mean of the 
three most abundant ion peaks of each respective protein identified. Accession numbers 
included according to entries in UniProtKB/Swiss-Prot 
COPD smoker   COPD ex-smoker   
Ig gamma-1 chain C region 
OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 
5.79E+09 
Ig gamma-1 chain C region 
OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 
3.55E+09 
Ig alpha-1 chain C region 
OS=Homo sapiens 
GN=IGHA1 PE=1 SV=2 
1.56E+09 
Ig alpha-1 chain C region 
OS=Homo sapiens 
GN=IGHA1 PE=1 SV=2 
1.89E+07 
Uteroglobin OS=Homo sapiens 
GN=SCGB1A1 PE=1 SV=1 
1.99E+08 
Uteroglobin OS=Homo 




receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
2.83E+08 
Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 
2.37E+09 
Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB 
PE=1 SV=2 
7.32E+07 
Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB 
PE=1 SV=2 
1.66E+09 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 
2.92E+09 
Ig kappa chain C region 






sapiens GN=TF PE=1 SV=3 
4.56E+09 
Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=3 
3.80E+07 
Uncharacterized protein 
C3orf38; [Homo sapiens 




C3orf38; [Homo sapiens 
(Human)] - [CC038_HUMAN] 
5.97E+08 
Beta-2-microglobulin 




OS=Homo sapiens GN=B2M 
PE=1 SV=1 
5.86E+08 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
3.86E+09 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
5.49E+08 
Hemoglobin subunit alpha 




subunit alpha; AltName: 
Full=Alpha-globin; AltName: 
Full=Hemoglobin alpha chain; 
[Homo sapiens (Human)] - 
[HBA_HUMAN] 
5.24E+08 
Ig lambda chain V-III region 
LOI OS=Homo sapiens PE=1 
SV=1 
6.09E+07 
RecName: Full=Ig lambda 
chain V-III region LOI; [Homo 
sapiens (Human)] - 
[LV302_HUMAN] 
4.81E+08 
Actin, cytoplasmic 1 
OS=Homo sapiens GN=ACTB 
PE=1 SV=1 
5.36E+07 
Actin, cytoplasmic 1 
OS=Homo sapiens GN=ACTB 
PE=1 SV=1 
4.06E+08 
Complement C3 OS=Homo 
sapiens GN=C3 PE=1 SV=2 
7.33E+07 
Complement C3 OS=Homo 
sapiens GN=C3 PE=1 SV=2 
2.06E+08 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 
3.48E+08 
Hemopexin OS=Homo sapiens 




factor; Short=ADF; AltName: 
Full=Surface-associated 
sulphydryl protein; 
Short=SASP; [Homo sapiens 








Short=SASP; [Homo sapiens 
(Human)] - [THIO_HUMAN] 
1.54E+08 
Ferritin light chain OS=Homo 
sapiens GN=FTL PE=1 SV=2 
3.93E+08 
Ferritin light chain OS=Homo 
sapiens GN=FTL PE=1 SV=2 
1.51E+08 
Annexin A5 OS=Homo 
sapiens GN=ANXA5 PE=1 
SV=2 
7.53E+07 
RecName: Full=Annexin A5; 
AltName: Full=Anchorin CII; 
AltName: Full=Annexin V; 
AltName: Full=Annexin-5; 
AltName: Full=Calphobindin 
I; Short=CBP-I; AltName: 
Full=Endonexin II; AltName: 
Full=Lipocortin V; AltName: 
Full=Placental anticoagulant 
protein 4; Short=PP4; 
AltName: Full=Placental 









sapiens (Human)] - 
[ANXA5_HUMAN] 
Transthyretin OS=Homo 
sapiens GN=TTR PE=1 SV=1 
1.29E+08 
Transthyretin OS=Homo 
sapiens GN=TTR PE=1 SV=1 
7.84E+07 
Peptidyl-prolyl cis-trans 
isomerase A OS=Homo 
sapiens GN=PPIA PE=1 SV=2 
7.32E+06 
RecName: Full=Peptidyl-
prolyl cis-trans isomerase A; 
Short=PPIase A; EC=5.2.1.8; 
AltName: Full=Cyclophilin A; 
AltName: Full=Cyclosporin A-
binding protein; AltName: 
Full=Rotamase A; [Homo 
sapiens (Human)] - 
[PPIA_HUMAN] 
7.51E+07 
Ig gamma-2 chain C region 
OS=Homo sapiens 
GN=IGHG2 PE=1 SV=2 
4.65E+09 
Ig gamma-2 chain C region 
OS=Homo sapiens 
GN=IGHG2 PE=1 SV=2 
5.64E+07 
Delta-like protein 4; AltName: 
Full=Drosophila Delta 
homolog 4; Short=Delta4; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[DLL4_HUMAN] 
5.48E+07 
Delta-like protein 4; AltName: 
Full=Drosophila Delta 
homolog 4; Short=Delta4; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[DLL4_HUMAN] 
4.85E+07 
CD44 antigen OS=Homo 
sapiens GN=CD44 PE=1 SV=3 
3.49E+07 















1; Short=PGP-1; AltName: 
Full=Phagocytic glycoprotein 
I; Short=PGP-I; AltName: 
CD_antigen=CD44; Flags: 
Precursor; [Homo sapiens 
(Human)] - [CD44_HUMAN] 
3.87E+07 
Alpha-1-antitrypsin OS=Homo 




sapiens GN=SERPINA1 PE=1 
SV=3 
3.86E+07 
Ig lambda chain V-IV region 
Bau; [Homo sapiens (Human)] 
5.41E+07 
RecName: Full=Ig lambda 




- [LV401_HUMAN] sapiens (Human)] - 
[LV401_HUMAN] 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 




Protein Shroom3; AltName: 
Full=Shroom-related protein; 




Ig heavy chain V-III region 
CAM OS=Homo sapiens PE=1 
SV=1 
9.16E+08 
Ig heavy chain V-III region 





sapiens GN=HP PE=1 SV=1 
2.64E+08 
Haptoglobin OS=Homo 
sapiens GN=HP PE=1 SV=1 
9.50E+06 
Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 
1.09E+09 
Ig lambda-2 chain C regions 
OS=Homo sapiens 





promoting peptide; Contains: 
RecName: Full=DCD-1; Flags: 
Precursor; [Homo sapiens 





promoting peptide; Contains: 
RecName: Full=DCD-1; Flags: 
Precursor; [Homo sapiens 






AltName: Full=Serine protease 
3; AltName: Full=Serine 
protease 4; AltName: 
Full=Trypsin III; AltName: 
Full=Trypsin IV; Flags: 
Precursor; [Homo sapiens 







AltName: Full=Serine protease 
3; AltName: Full=Serine 
protease 4; AltName: 
Full=Trypsin III; AltName: 
Full=Trypsin IV; Flags: 
Precursor; [Homo sapiens 
(Human)] - [TRY3_HUMAN] 
4.78E+06 
Desmoplakin OS=Homo 
sapiens GN=DSP PE=1 SV=3 
1.06E+08 
Desmoplakin OS=Homo 
sapiens GN=DSP PE=1 SV=3 
3.75E+06 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 
2.76E+08 
Alpha-1-acid glycoprotein 1 




sapiens GN=CP PE=1 SV=1 
2.38E+08 
Ceruloplasmin OS=Homo 
sapiens GN=CP PE=1 SV=1 
2.73E+06 
Ig kappa chain V-III region 
VG (Fragment) OS=Homo 
sapiens PE=1 SV=1 
6.84E+07 
Ig kappa chain V-III region 
VG (Fragment) OS=Homo 




Alpha-1-acid glycoprotein 2; 
Short=AGP 2; AltName: 
Full=Orosomucoid-2; 
Short=OMD 2; Flags: 




Alpha-1-acid glycoprotein 2; 
Short=AGP 2; AltName: 
Full=Orosomucoid-2; 
Short=OMD 2; Flags: 




Transmembrane protein 200C; 
AltName: 
Full=Transmembrane protein 
TTMA; AltName: Full=Two 
transmembrane domain-
containing family member A; 
[Homo sapiens (Human)] - 
[T200C_HUMAN] 
1.94E+06 
Transmembrane protein 200C; 
AltName: 
Full=Transmembrane protein 
TTMA; AltName: Full=Two 
transmembrane domain-
containing family member A; 
[Homo sapiens (Human)] - 
[T200C_HUMAN] 
1.89E+06 
Ig kappa chain V-III region 
SIE OS=Homo sapiens PE=1 
SV=1 
2.67E+08 
Ig kappa chain V-III region 




associated protein A2 
OS=Homo sapiens 
GN=SFTPA2 PE=1 SV=1 
2.89E+07 
Pulmonary surfactant-
associated protein A2; 
Short=PSP-A; Short=PSPA; 
Short=SP-A; Short=SP-A2; 
AltName: Full=35 kDa 
pulmonary surfactant-




Precursor; [Homo sapiens 




arginase; AltName: Full=Type 
I arginase; [Homo sapiens 




arginase; AltName: Full=Type 





14; EC=3.1.3.-; AltName: 
Full=HCV NS5A-
transactivated protein 4 splice 
variant A-binding protein 1; 
Short=NS5ATP4ABP1; 
AltName: Full=hJumpy; 




14; EC=3.1.3.-; AltName: 
Full=HCV NS5A-
transactivated protein 4 splice 
variant A-binding protein 1; 
Short=NS5ATP4ABP1; 
AltName: Full=hJumpy; 
[Homo sapiens (Human)] - 
[MTMRE_HUMAN] 
1.21E+06 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-
beta; [Homo sapiens (Human)] 
- [TAD2B_HUMAN] 
2.68E+07 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-












sapiens GN=LRG1 PE=1 
SV=2 
7.23E+05 
Putative annexin A2-like 
protein; AltName: 
Full=Annexin A2 pseudogene 
2; AltName: Full=Lipocortin II 




Putative annexin A2-like 
protein; AltName: 
Full=Annexin A2 pseudogene 
2; AltName: Full=Lipocortin II 




Protein kinase-like protein 
SgK196; AltName: Full=Sugen 
kinase 196; [Homo sapiens 
(Human)] - [SG196_HUMAN] 
1.67E+07 
Protein kinase-like protein 
SgK196; AltName: 
Full=Sugen kinase 196; [Homo 




Table C.10: Alveolar proteins identified by 1D PAGE and nano LC MS/MS in Healthy 
smoker and Healthy aged RTLFs. The 105 proteins common to both healthy smoker 
(n=5) and Healthy aged (n=5) subjects investigated, alongside the mean of the three most 
abundant ion peaks of each respective protein identified. Accession numbers included 
according to entries in UniProtKB/Swiss-Prot 
Healthy Smoker Healthy Aged Control 
14-3-3 protein beta/alpha 
OS=Homo sapiens 
GN=YWHAB PE=1 SV=3 6.47E+07 
14-3-3 protein beta/alpha 
OS=Homo sapiens 
GN=YWHAB PE=1 SV=3 1.46E+07 
14-3-3 protein zeta/delta 
OS=Homo sapiens 
GN=YWHAZ PE=1 SV=1 4.51E+07 
14-3-3 protein zeta/delta 
OS=Homo sapiens 
GN=YWHAZ PE=1 SV=1 1.57E+07 
Actin, cytoplasmic 1 
OS=Homo sapiens GN=ACTB 
PE=1 SV=1 1.38E+08 
Actin, cytoplasmic 1 
OS=Homo sapiens GN=ACTB 
PE=1 SV=1 6.89E+07 
Afamin OS=Homo sapiens 
GN=AFM PE=1 SV=1 5.45E+06 
Afamin OS=Homo sapiens 
GN=AFM PE=1 SV=1 2.54E+07 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 1.29E+08 
Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 3.39E+08 
Alpha-1-acid glycoprotein 2; 
Short=AGP 2; AltName: 
Full=Orosomucoid-2; 
Short=OMD 2; Flags: 
Precursor; [Homo sapiens 
(Human)] - 
[A1AG2_HUMAN] 1.14E+08 
Alpha-1-acid glycoprotein 2 
OS=Homo sapiens GN=ORM2 
PE=1 SV=2 2.40E+08 
Alpha-1-antichymotrypsin 
OS=Homo sapiens 
GN=SERPINA3 PE=1 SV=2 3.72E+07 
Alpha-1-antichymotrypsin 
OS=Homo sapiens 
GN=SERPINA3 PE=1 SV=2 8.21E+07 
Alpha-1-antitrypsin OS=Homo 
sapiens GN=SERPINA1 PE=1 
SV=3 2.75E+08 
Alpha-1-antitrypsin OS=Homo 





OS=Homo sapiens GN=A1BG 
PE=1 SV=4 2.29E+07 
Alpha-1B-glycoprotein 
OS=Homo sapiens GN=A1BG 
PE=1 SV=4 1.33E+08 
Alpha-2-HS-glycoprotein 
OS=Homo sapiens GN=AHSG 
PE=1 SV=1 2.99E+07 
Alpha-2-HS-glycoprotein 
OS=Homo sapiens GN=AHSG 
PE=1 SV=1 1.16E+08 
Alpha-2-macroglobulin 
OS=Homo sapiens GN=A2M 
PE=1 SV=3 4.14E+06 
Alpha-2-macroglobulin 
OS=Homo sapiens GN=A2M 
PE=1 SV=3 1.66E+08 
Alpha-enolase OS=Homo 
sapiens GN=ENO1 PE=1 
SV=2 3.19E+07 
Alpha-enolase OS=Homo 
sapiens GN=ENO1 PE=1 
SV=2 4.14E+06 
Angiotensinogen OS=Homo 
sapiens GN=AGT PE=1 SV=1 1.41E+06 
Angiotensinogen OS=Homo 
sapiens GN=AGT PE=1 SV=1 4.94E+07 
Annexin A5 OS=Homo 
sapiens GN=ANXA5 PE=1 
SV=2 5.18E+07 
Annexin A5 OS=Homo 
sapiens GN=ANXA5 PE=1 
SV=2 1.36E+06 
Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 
SV=1 7.56E+06 
Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 
SV=1 1.38E+08 
Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 4.53E+06 
Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 5.23E+06 
Beta-2-microglobulin 
OS=Homo sapiens GN=B2M 
PE=1 SV=1 1.03E+07 
Beta-2-microglobulin 
OS=Homo sapiens GN=B2M 
PE=1 SV=1 2.59E+07 
C2 calcium-dependent domain-
containing protein 4B; 
AltName: Full=Nuclear-
localized factor 2; AltName: 
Full=Protein FAM148B; 
[Homo sapiens (Human)] - 
[C2C4B_HUMAN] 7.49E+06 
C2 calcium-dependent domain-
containing protein 4B; 
AltName: Full=Nuclear-
localized factor 2; AltName: 
Full=Protein FAM148B; 
[Homo sapiens (Human)] - 
[C2C4B_HUMAN] 8.25E+07 
Calmodulin OS=Homo sapiens 
GN=CALM1 PE=1 SV=2 2.84E+06 
Calmodulin OS=Homo sapiens 
GN=CALM1 PE=1 SV=2 2.68E+06 
CD166 antigen; AltName: 
Full=Activated leukocyte cell 
adhesion molecule; AltName: 
CD_antigen=CD166; Flags: 
Precursor; [Homo sapiens 
(Human)] - [CD166_HUMAN] 2.77E+06 
CD166 antigen; AltName: 
Full=Activated leukocyte cell 
adhesion molecule; AltName: 
CD_antigen=CD166; Flags: 
Precursor; [Homo sapiens 
(Human)] - [CD166_HUMAN] 1.35E+07 
CD44 antigen OS=Homo 
sapiens GN=CD44 PE=1 SV=3 3.34E+07 
CD44 antigen OS=Homo 
sapiens GN=CD44 PE=1 
SV=3 2.73E+07 
Ceruloplasmin OS=Homo 
sapiens GN=CP PE=1 SV=1 1.15E+08 
Ceruloplasmin OS=Homo 
sapiens GN=CP PE=1 SV=1 3.67E+08 
Coactosin-like protein 
OS=Homo sapiens 
GN=COTL1 PE=1 SV=3 6.78E+06 
Coactosin-like protein 
OS=Homo sapiens 
GN=COTL1 PE=1 SV=3 5.15E+06 
Corticosteroid-binding 
globulin OS=Homo sapiens 
GN=SERPINA6 PE=1 SV=1 5.20E+06 
Corticosteroid-binding 
globulin OS=Homo sapiens 
GN=SERPINA6 PE=1 SV=1 3.95E+07 
Deleted in malignant brain 6.18E+06 Deleted in malignant brain 3.69E+07 
344 
 
tumors 1 protein OS=Homo 
sapiens GN=DMBT1 PE=1 
SV=2 
tumors 1 protein OS=Homo 
sapiens GN=DMBT1 PE=1 
SV=2 
Delta-like protein 4; AltName: 
Full=Drosophila Delta 
homolog 4; Short=Delta4; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[DLL4_HUMAN] 1.12E+07 
Delta-like protein 4; AltName: 
Full=Drosophila Delta 
homolog 4; Short=Delta4; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[DLL4_HUMAN] 1.23E+07 
Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 4.35E+06 
Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 2.13E+06 
Desmoplakin OS=Homo 
sapiens GN=DSP PE=1 SV=3 9.94E+07 
Desmoplakin OS=Homo 
sapiens GN=DSP PE=1 SV=3 1.40E+08 
Dipeptidyl peptidase 4 
OS=Homo sapiens GN=DPP4 
PE=1 SV=2 3.08E+06 
Dipeptidyl peptidase 4 
OS=Homo sapiens GN=DPP4 
PE=1 SV=2 6.17E+07 
Ecto-ADP-ribosyltransferase 4; 
EC=2.4.2.31; AltName: 
Full=Dombrock blood group 
carrier molecule; AltName: 
Full=Mono(ADP-





Precursor; [Homo sapiens 
(Human)] - [NAR4_HUMAN] 2.69E+07 
Ecto-ADP-ribosyltransferase 
4; EC=2.4.2.31; AltName: 
Full=Dombrock blood group 





ribosyltransferase 4; AltName: 
CD_antigen=CD297; Flags: 
Precursor; [Homo sapiens 
(Human)] - [NAR4_HUMAN] 5.81E+07 
Elongation factor 1-alpha 1 
OS=Homo sapiens 
GN=EEF1A1 PE=1 SV=1   
Elongation factor 1-alpha 1 
OS=Homo sapiens 
GN=EEF1A1 PE=1 SV=1 2.16E+07 
Epididymal secretory protein 
E1 OS=Homo sapiens 
GN=NPC2 PE=1 SV=1 1.32E+07 
Epididymal secretory protein 
E1 OS=Homo sapiens 
GN=NPC2 PE=1 SV=1 1.37E+07 
FAS-associated factor 1; 
Short=hFAF1; AltName: 
Full=UBX domain-containing 
protein 12; AltName: 
Full=UBX domain-containing 
protein 3A; [Homo sapiens 
(Human)] - [FAF1_HUMAN] 4.56E+07 
FAS-associated factor 1; 
Short=hFAF1; AltName: 
Full=UBX domain-containing 
protein 12; AltName: 
Full=UBX domain-containing 
protein 3A; [Homo sapiens 
(Human)] - [FAF1_HUMAN] 4.89E+08 
Ferritin heavy chain OS=Homo 
sapiens GN=FTH1 PE=1 SV=2 5.09E+06 
Ferritin heavy chain; 
Short=Ferritin H subunit; 
EC=1.16.3.1; AltName: 
Full=Cell proliferation-
inducing gene 15 protein; 
[Homo sapiens (Human)] - 
[FRIH_HUMAN] 2.34E+06 
Ferritin light chain OS=Homo 
sapiens GN=FTL PE=1 SV=2 2.03E+07 
Ferritin light chain; 
Short=Ferritin L subunit; 




Glutathione S-transferase P 
OS=Homo sapiens 
GN=GSTP1 PE=1 SV=2 1.82E+07 
Glutathione S-transferase P 
OS=Homo sapiens 
GN=GSTP1 PE=1 SV=2 8.51E+06 
Haptoglobin OS=Homo 
sapiens GN=HP PE=1 SV=1 1.04E+08 
Haptoglobin OS=Homo 
sapiens GN=HP PE=1 SV=1 1.26E+08 
Heat shock protein beta-1 
OS=Homo sapiens 
GN=HSPB1 PE=1 SV=2 4.31E+07 
Heat shock protein beta-1 
OS=Homo sapiens 
GN=HSPB1 PE=1 SV=2 8.93E+06 
Hemoglobin subunit alpha 
OS=Homo sapiens GN=HBA1 
PE=1 SV=2 5.40E+07 
Hemoglobin subunit alpha 
OS=Homo sapiens GN=HBA1 
PE=1 SV=2 1.49E+08 
Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB 
PE=1 SV=2 2.04E+07 
Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB 
PE=1 SV=2 1.28E+08 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 1.89E+08 
Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 2.71E+08 
Histone H3.3C; [Homo sapiens 
(Human)] - [H3C_HUMAN] 1.36E+07 
Histone H3.3C; [Homo sapiens 
(Human)] - [H3C_HUMAN] 1.79E+07 
Histone H4 OS=Homo sapiens 
GN=HIST1H4A PE=1 SV=2 2.72E+07 
Histone H4 OS=Homo sapiens 
GN=HIST1H4A PE=1 SV=2 2.45E+07 
Ig alpha-1 chain C region 
OS=Homo sapiens 
GN=IGHA1 PE=1 SV=2 6.14E+08 
Ig alpha-1 chain C region 
OS=Homo sapiens 
GN=IGHA1 PE=1 SV=2 2.42E+09 
Ig gamma-1 chain C region 
OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 3.30E+09 
Ig gamma-1 chain C region 
OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 8.92E+09 
Ig gamma-2 chain C region 
OS=Homo sapiens 
GN=IGHG2 PE=1 SV=2 2.57E+09 
Ig gamma-2 chain C region 
OS=Homo sapiens 
GN=IGHG2 PE=1 SV=2 5.60E+09 
Ig gamma-3 chain C region 
OS=Homo sapiens 
GN=IGHG3 PE=1 SV=2 2.87E+09 
Ig gamma-3 chain C region 
OS=Homo sapiens 
GN=IGHG3 PE=1 SV=2 6.71E+09 
Ig gamma-4 chain C region 
OS=Homo sapiens 
GN=IGHG4 PE=1 SV=1 2.57E+09 
Ig gamma-4 chain C region 
OS=Homo sapiens 
GN=IGHG4 PE=1 SV=1 5.60E+09 
Ig heavy chain V-II region 
NEWM OS=Homo sapiens 
PE=1 SV=1 9.45E+07 
Ig heavy chain V-II region 
NEWM OS=Homo sapiens 
PE=1 SV=1 1.47E+08 
Ig heavy chain V-III region 
BRO; [Homo sapiens 
(Human)] - [HV305_HUMAN] 5.36E+08 
Ig heavy chain V-III region 
BRO; [Homo sapiens 
(Human)] - 
[HV305_HUMAN] 1.02E+09 
Ig heavy chain V-III region 
BUT; [Homo sapiens 
(Human)] - [HV306_HUMAN] 4.98E+08 
Ig heavy chain V-III region 
BUT; [Homo sapiens 
(Human)] - 
[HV306_HUMAN] 1.03E+09 
Ig heavy chain V-III region 
CAM OS=Homo sapiens PE=1 
SV=1   
Ig heavy chain V-III region 
CAM OS=Homo sapiens PE=1 
SV=1 1.05E+09 
Ig heavy chain V-III region 
GAL OS=Homo sapiens PE=1 
SV=1 4.92E+08 
Ig heavy chain V-III region 




Ig heavy chain V-III region 
GAR; [Homo sapiens 
(Human)] - [HV322_HUMAN] 8.76E+07 
Ig heavy chain V-III region 
GAR; [Homo sapiens 
(Human)] - 
[HV322_HUMAN] 1.05E+08 
Ig heavy chain V-III region 
HIL; [Homo sapiens (Human)] 
- [HV310_HUMAN] 7.00E+08 
Ig heavy chain V-III region 
HIL; [Homo sapiens (Human)] 
- [HV310_HUMAN] 1.47E+09 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 1.07E+09 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 3.47E+09 
Ig kappa chain V-I region 
DEE; [Homo sapiens 
(Human)] - [KV105_HUMAN] 1.54E+08 
Ig kappa chain V-I region 
DEE; [Homo sapiens 
(Human)] - 
[KV105_HUMAN] 2.73E+08 
Ig kappa chain V-I region EU 
OS=Homo sapiens PE=1 SV=1 7.39E+07 
Ig kappa chain V-I region EU 
OS=Homo sapiens PE=1 SV=1 2.41E+08 
Ig kappa chain V-II region 
RPMI 6410 OS=Homo sapiens 
PE=4 SV=1 4.64E+07 
Ig kappa chain V-II region 
RPMI 6410 OS=Homo sapiens 
PE=4 SV=1 1.62E+08 
Ig kappa chain V-III region 
POM; [Homo sapiens 
(Human)] - [KV306_HUMAN] 7.29E+07 
Ig kappa chain V-III region 
POM OS=Homo sapiens PE=1 
SV=1 9.77E+07 
Ig kappa chain V-III region 
SIE OS=Homo sapiens PE=1 
SV=1 1.24E+08 
Ig kappa chain V-III region 
SIE OS=Homo sapiens PE=1 
SV=1 2.40E+08 
Ig kappa chain V-III region 
VG (Fragment) OS=Homo 
sapiens PE=1 SV=1 5.54E+07 
Ig kappa chain V-III region 
VG; Flags: Precursor; 
Fragment; [Homo sapiens 
(Human)] - 
[KV309_HUMAN] 1.46E+08 
Ig kappa chain V-IV region JI; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[KV403_HUMAN] 6.10E+07 
Ig kappa chain V-IV region JI 
OS=Homo sapiens PE=4 SV=1 3.74E+07 
Ig kappa chain V-IV region 
Len; [Homo sapiens (Human)] 
- [KV402_HUMAN] 6.10E+07 
Ig kappa chain V-IV region 
Len OS=Homo sapiens PE=1 
SV=2 9.86E+07 
Ig lambda chain V region 4A; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[LV001_HUMAN] 1.78E+07 
Ig lambda chain V region 4A 
OS=Homo sapiens PE=4 SV=1 5.01E+07 
Ig lambda chain V-I region 
HA; [Homo sapiens (Human)] 
- [LV102_HUMAN] 5.73E+07 
Ig lambda chain V-I region HA 
OS=Homo sapiens PE=1 SV=1 1.91E+08 
Ig lambda chain V-III region 
LOI OS=Homo sapiens PE=1 
SV=1 6.55E+07 
Ig lambda chain V-III region 
LOI OS=Homo sapiens PE=1 
SV=1 1.57E+08 
Ig lambda chain V-III region 
SH OS=Homo sapiens PE=1 
SV=1 1.01E+07 
Ig lambda chain V-III region 
SH; [Homo sapiens (Human)] - 
[LV301_HUMAN] 3.09E+07 
Ig lambda chain V-IV region 
Bau; [Homo sapiens (Human)] 1.05E+07 
Ig lambda chain V-IV region 
Bau; [Homo sapiens (Human)] 1.58E+08 
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- [LV401_HUMAN] - [LV401_HUMAN] 
Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 7.91E+08 
Ig lambda-2 chain C regions 
OS=Homo sapiens 
GN=IGLC2 PE=1 SV=1 2.31E+09 
Ig mu chain C region 
OS=Homo sapiens GN=IGHM 
PE=1 SV=3 4.18E+07 
Ig mu chain C region 
OS=Homo sapiens GN=IGHM 
PE=1 SV=3 4.16E+07 
Immunoglobulin lambda-like 
polypeptide 5 OS=Homo 
sapiens GN=IGLL5 PE=2 
SV=2 4.43E+08 
Immunoglobulin lambda-like 
polypeptide 5 OS=Homo 
sapiens GN=IGLL5 PE=2 
SV=2 1.44E+09 
Intercellular adhesion molecule 
1 OS=Homo sapiens 
GN=ICAM1 PE=1 SV=2 4.60E+06 
Intercellular adhesion molecule 
1 OS=Homo sapiens 
GN=ICAM1 PE=1 SV=2 1.15E+07 
Leucine-rich alpha-2-
glycoprotein OS=Homo 




sapiens GN=LRG1 PE=1 
SV=2 4.46E+07 
Lysozyme C; EC=3.2.1.17; 
AltName: Full=1,4-beta-N-
acetylmuramidase C; Flags: 
Precursor; [Homo sapiens 
(Human)] - [LYSC_HUMAN] 7.04E+05 
Lysozyme C; EC=3.2.1.17; 
AltName: Full=1,4-beta-N-
acetylmuramidase C; Flags: 
Precursor; [Homo sapiens 
(Human)] - [LYSC_HUMAN] 1.48E+06 
Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 1.54E+08 
Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 1.94E+08 
Pro-cathepsin H OS=Homo 
sapiens GN=CTSH PE=1 
SV=4 1.14E+07 
Pro-cathepsin H OS=Homo 





Full=Protein A; Contains: 
RecName: Full=Saposin-B-

















protein 2; Short=SAP-2; 1.35E+06 
Proactivator polypeptide 
OS=Homo sapiens GN=PSAP 





Full=Component C; AltName: 
Full=Protein C; Flags: 
Precursor; [Homo sapiens 
(Human)] - [SAP_HUMAN] 
Prostasin; EC=3.4.21.-; 
AltName: Full=Serine protease 
8; Contains: RecName: 
Full=Prostasin light chain; 
Contains: RecName: 
Full=Prostasin heavy chain; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[PRSS8_HUMAN] 1.62E+06 
Prostasin; EC=3.4.21.-; 
AltName: Full=Serine protease 
8; Contains: RecName: 
Full=Prostasin light chain; 
Contains: RecName: 
Full=Prostasin heavy chain; 
Flags: Precursor; [Homo 
sapiens (Human)] - 
[PRSS8_HUMAN] 1.22E+06 
Protein DJ-1 OS=Homo 
sapiens GN=PARK7 PE=1 
SV=2 7.89E+06 
Protein DJ-1 OS=Homo 
sapiens GN=PARK7 PE=1 
SV=2 1.23E+07 
Protein S100-A6 OS=Homo 
sapiens GN=S100A6 PE=1 
SV=1 4.87E+07 
Protein S100-A6 OS=Homo 
sapiens GN=S100A6 PE=1 
SV=1 2.38E+07 
Protein S100-A8 OS=Homo 
sapiens GN=S100A8 PE=1 
SV=1 8.57E+08 
Protein S100-A8 OS=Homo 
sapiens GN=S100A8 PE=1 
SV=1 3.59E+07 
Protein S100-A9 OS=Homo 
sapiens GN=S100A9 PE=1 
SV=1 5.29E+08 
Protein S100-A9 OS=Homo 
sapiens GN=S100A9 PE=1 
SV=1 1.13E+07 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 
Short=hShrmL; [Homo sapiens 
(Human)] - 
[SHRM3_HUMAN] 8.20E+07 
Protein Shroom3; AltName: 
Full=Shroom-related protein; 




associated protein A2 
OS=Homo sapiens 
GN=SFTPA2 PE=1 SV=1 2.82E+07 
Pulmonary surfactant-
associated protein A2 
OS=Homo sapiens 
GN=SFTPA2 PE=1 SV=1 3.74E+07 
Pulmonary surfactant-
associated protein B 
OS=Homo sapiens 
GN=SFTPB PE=1 SV=3   
Pulmonary surfactant-
associated protein B; 
Short=SP-B; AltName: 
Full=18 kDa pulmonary-
surfactant protein; AltName: 
Full=6 kDa protein; AltName: 
Full=Pulmonary surfactant-
associated proteolipid 
SPL(Phe); Flags: Precursor; 
[Homo sapiens (Human)] - 
[PSPB_HUMAN] 3.26E+06 
Pulmonary surfactant-
associated protein D; 
Short=PSP-D; Short=SP-D; 
AltName: Full=Collectin-7; 
AltName: Full=Lung surfactant 5.11E+06 
Pulmonary surfactant-
associated protein D 
OS=Homo sapiens 
GN=SFTPD PE=1 SV=3 1.53E+07 
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protein D; Flags: Precursor; 
[Homo sapiens (Human)] - 
[SFTPD_HUMAN] 
Putative V-set and 
immunoglobulin domain-
containing protein 6 OS=Homo 
sapiens GN=VSIG6 PE=5 
SV=2 8.23E+07 
Putative V-set and 
immunoglobulin domain-
containing protein 6 
OS=Homo sapiens 
GN=VSIG6 PE=5 SV=2 2.00E+08 
Selenium-binding protein 1 
OS=Homo sapiens 
GN=SELENBP1 PE=1 SV=2 1.15E+07 
Selenium-binding protein 1 
OS=Homo sapiens 
GN=SELENBP1 PE=1 SV=2 1.67E+07 
Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=3 3.42E+09 
Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=3 7.62E+09 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 1.54E+09 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 2.77E+09 
SH3 domain-binding glutamic 
acid-rich-like protein 3; 
AltName: Full=SH3 domain-
binding protein 1; 
Short=SH3BP-1; [Homo 
sapiens (Human)] - 
[SH3L3_HUMAN] 7.49E+06 
SH3 domain-binding glutamic 
acid-rich-like protein 3; 
AltName: Full=SH3 domain-
binding protein 1; 
Short=SH3BP-1; [Homo 
sapiens (Human)] - 
[SH3L3_HUMAN] 3.66E+06 
Sorting nexin-6; AltName: 
Full=TRAF4-associated factor 
2; [Homo sapiens (Human)] - 
[SNX6_HUMAN] 2.48E+06 
Sorting nexin-6; AltName: 
Full=TRAF4-associated factor 




factor; Short=ADF; AltName: 
Full=Surface-associated 
sulphydryl protein; 
Short=SASP; [Homo sapiens 
(Human)] - [THIO_HUMAN] 1.29E+07 
Thioredoxin; Short=Trx; 
AltName: Full=ATL-derived 
factor; Short=ADF; AltName: 
Full=Surface-associated 
sulphydryl protein; 
Short=SASP; [Homo sapiens 
(Human)] - [THIO_HUMAN] 8.21E+06 
Transaldolase OS=Homo 
sapiens GN=TALDO1 PE=1 
SV=2 2.21E+07 
Transaldolase OS=Homo 
sapiens GN=TALDO1 PE=1 
SV=2 4.47E+07 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-
beta; [Homo sapiens (Human)] 
- [TAD2B_HUMAN] 5.10E+07 
Transcriptional adapter 2-beta; 
AltName: Full=ADA2-like 
protein beta; Short=ADA2-
beta; [Homo sapiens (Human)] 
- [TAD2B_HUMAN] 2.22E+07 
Transmembrane protein 198; 
[Homo sapiens (Human)] - 
[TM198_HUMAN] 2.08E+07 
Transmembrane protein 198; 
[Homo sapiens (Human)] - 
[TM198_HUMAN] 2.62E+07 
Transmembrane protein 200C; 
AltName: 
Full=Transmembrane protein 
TTMA; AltName: Full=Two 
transmembrane domain-
containing family member A; 
[Homo sapiens (Human)] - 
[T200C_HUMAN] 2.06E+06 
Transmembrane protein 200C; 
AltName: 
Full=Transmembrane protein 
TTMA; AltName: Full=Two 
transmembrane domain-
containing family member A; 





sapiens GN=TTR PE=1 SV=1 4.44E+07 
Transthyretin OS=Homo 
sapiens GN=TTR PE=1 SV=1 2.53E+08 
Triosephosphate isomerase 
OS=Homo sapiens GN=TPI1 
PE=1 SV=3 1.81E+07 
Triosephosphate isomerase 
OS=Homo sapiens GN=TPI1 
PE=1 SV=3 4.37E+07 
Uncharacterized protein 
C3orf38; [Homo sapiens 
(Human)] - [CC038_HUMAN] 1.62E+09 
Uncharacterized protein 
C3orf38; [Homo sapiens 
(Human)] - [CC038_HUMAN] 2.73E+09 
Uteroglobin OS=Homo sapiens 
GN=SCGB1A1 PE=1 SV=1 8.73E+07 
Uteroglobin OS=Homo 
sapiens GN=SCGB1A1 PE=1 
SV=1 1.74E+08 
Vitamin D-binding protein 
OS=Homo sapiens GN=GC 
PE=1 SV=1 1.16E+08 
Vitamin D-binding protein 
OS=Homo sapiens GN=GC 
PE=1 SV=1 4.91E+08 
Xin actin-binding repeat-
containing protein 2 OS=Homo 
sapiens GN=XIRP2 PE=1 
SV=2 1.77E+08 
Xin actin-binding repeat-
containing protein 2 
OS=Homo sapiens GN=XIRP2 
PE=1 SV=2 2.05E+08 
Zinc-alpha-2-glycoprotein 
OS=Homo sapiens 
GN=AZGP1 PE=1 SV=2 5.33E+07 
Zinc-alpha-2-glycoprotein 
OS=Homo sapiens 
GN=AZGP1 PE=1 SV=2 1.24E+08 
 
Table. C.11: The 32 common alveolar proteins identified by 1D PAGE and nano LC 
MS/MS in Healthy Aged, Healthy Smoker, COPD smoker, smoker and COPD ex-smoking 
RTLFs. The 32 proteins common across all groups are listed for Healthy Aged (n=5) , 
Healthy Smoker (n=5), COPD smoker (n=5), smoker and COPD ex-smoker (n=10), 
subjects investigated, alongside the mean of the three most abundant ion peaks of each 
respective protein identified. Accession numbers included according to entries in 
UniProtKB/Swiss-Prot 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table C.12: The biological process classification of Inflammation/immunity according to 
Gene Ontology annotation of proteins identified. Data shown is a comparison of the 
mean of the three most abundant ion peaks of each protein identified, in Healthy Aged 
Non-Smokers, n=5, Healthy Aged Smokers, n=5, COPD Ex-Smokers, n = 10  , and 










Alpha-1-acid glycoprotein 1 3.39E+08 1.29E+08 X 2.76E+08 
Alpha-1-antichymotrypsin 8.21E+07 3.72E+07 X 1.00E+08 
Alpha-1-antichymotrypsin 8.21E+07 3.72E+07 X 1.00E+08 
Alpha-2-HS-glycoprotein 
(fetuin A) 1.16E+08 2.99E+07 
X 
9.30E+07 
Annexin A3 X 2.81E+06 X 9.75E+05 
Antithrombin-III 1.84E+07 X X 1.82E+07 
Beta-2-microglobulin 2.59E+07 1.03E+07 5.86E+08 3.80E+07 
Beta-microseminoprotein X 1.50E+07 X 4.84E+07 
Cell adhesion molecule 2 X X X 1.71E+07 
Complement C2 3.41E+07 X   1.87E+06 
Complement C3 2.66E+06 X 2.06E+08 7.33E+07 
Complement C4-A X X 7.09E+07 X 
Complement decay-




Complement factor B 7.63E+06 X X X 
Deleted in malignant brain 
tumors 1 protein 2.73E+07 3.34E+07 1.13E+06 3.49E+07 
Dipeptidyl peptidase 4 X X X 1.99E+07 
Galectin-3 binding protein 2.34E+06 5.09E+06 X 1.41E+08 
Haptoglobin X X X 8.21E+06 
HLA class II 





HLA class II 
histocompatibility antigen, 
DRB1-15 beta chain 
1.69E+06 X X X 
Ig alpha-1 chain C region  X X X 4.64E+06 
Ig alpha-2 chain C region  2.42E+09 6.14E+08 6.04E+09 1.56E+09 
Ig delta chain C region  1.79E+09 3.06E+08 X 8.21E+08 
Ig gamma-1 chain C region  1.10E+07 X X X 
Ig gamma-2 chain C region  8.92E+09 3.30E+09 3.55E+09 5.79E+09 
Ig gamma-3 chain C region  5.60E+09 2.57E+09 5.64E+07 4.65E+09 











Ig heavy chain V-I region V35 X 3.44E+07 X 6.71E+07 
Ig heavy chain V-II region 
ARH-77  
X X X 3.54E+07 
Ig heavy chain V-III region 
CAM 
X X X 7.16E+07 












Ig kappa chain C region  X X 1.60E+07 X 





Ig kappa chain V-I region Kue  2.73E+08 1.54E+08 X X 
Ig kappa chain V-II region 
RPMI 6410 
1.89E+08 X X 2.80E+08 





Ig kappa chain V-III region B6 X X X 1.67E+08 










Ig kappa chain V-III region 
VG (Fragment) 1.46E+08 5.54E+07 2.65E+06 6.84E+07 





Ig lambda chain V region 4A 9.86E+07 6.10E+07 X 1.49E+08 










Ig lambda chain V-III region 
LOI  
7.21E+07 X X 2.25E+07 










Ig lambda-2 chain C regions X X 3.53E+09 X 
Ig mu chain C region 2.31E+09 7.91E+08 8.59E+06 1.09E+09 
IgBF 4.16E+07 4.18E+07 X 3.88E+07 
IgGFc-binding protein X 1.50E+07 X 4.84E+07 
Immunoglobulin lambda-like 














Lactotransferrin 9.06E+05 X X X 
Leukocyte elastase inhibitor 9.47E+08 X X X 
Lysozyme C 3.69E+07 2.61E+06 X 6.74E+06 
Neutrophil defensin 1 X X 1.54E+08 X 
Plasma protease C1 inhibitor X X 7.51E+07 7.32E+06 
Polymeric immunoglobulin 
receptor 1.94E+08 1.54E+08 2.37E+09 2.83E+08 
Pulmonary surfactant-













Table C.12: The biological process classification of Oxidant/antioxidant balance 
according to Gene Ontology annotation of proteins identified. Data shown is a 
comparison of the mean of the three most abundant ion peaks of each protein identified, 
in Healthy Aged Non-Smokers, n=5, Healthy Aged Smokers, n=5, COPD Ex-Smokers, n 
= 10  , and COPD Smokers, n = 5, respectively.  
 
Table C.13: The biological process classification of Protease/antiprotease balance 
according to Gene Ontology annotation of proteins identified. Data shown is a 
comparison of the mean of the three most abundant ion peaks of each protein identified, , 
in Healthy Aged Non-Smokers, n=5, Healthy Aged Smokers, n=5, COPD Ex-Smokers, n 
= 10  , and COPD Smokers, n = 5, respectively. 
Sushi domain-containing 
protein 2 
1.63E+06 X X X 
V-set and immunoglobulin 




V-set and immunoglobulin 















Glutathione peroxidase 3  1.19E+06 X X X 
Glutathione S-transferase 
A1 X 1.73E+07 X X 
Glutathione S-transferase 
A2 4.18E+07 X X 9.67E+07 
Glutathione S-transferase 
omega-1 X X X 9.80E+06 
Glutathione S-transferase P 8.51E+06 1.82E+07 3.52E+08 1.74E+07 
Peroxiredoxin-5, 
mitochondrial X X 2.13E+08 2.13E+08 
Peroxiredoxin-6  X 1.78E+06 X X 
Protein DJ-1  1.23E+07 7.89E+06 X 1.16E+07 
Superoxide dismutase [Cu-
Zn] X 7.11E+06 X 1.08E+07 











Alpha-1-antichymotrypsin 8.21E+07 3.72E+07 X 1.00E+08 
Alpha-1-antitrypsin 3.20E+09 2.75E+08 2.31E+09 1.61E+09 
Alpha-2-macroglobulin 1.66E+08 4.14E+06 X 1.01E+07 
Alpha-amylase 1 X X X 3.66E+07 
Angiotensin-converting 
enzyme; Dipeptidyl 
carboxypeptidase I 1.46E+07 
X X 
2.81E+07 
Antithrombin-III 1.84E+07 X X 1.82E+07 




Cathepsin Z X 4.21E+06 X 6.46E+06 
Complement C2 3.41E+07 X X 1.87E+06 
Cystatin-B 4.33E+06 6.43E+06 X 1.51E+07 
Dermcidin 2.13E+06 4.35E+06 6.19E+06 2.94E+06 
Dipeptidyl peptidase 1 X X X 1.99E+07 
Dipeptidyl peptidase 4 6.17E+07 3.08E+06 X 1.99E+07 
Haptoglobin 1.26E+08 1.04E+08 9.50E+06 2.64E+08 
Kininogen-1; Alpha-2-thiol 
proteinase inhibitor 
X X X 
1.20E+07 




elastase inhibitor 3.69E+07 2.61E+06 
X 
6.74E+06 
Leukotriene A-4 hydrolase X X X 1.50E+07 
Matrix metalloproteinase-
28 
X X X 
1.09E+07 
Napsin-A X X X 5.17E+06 
Pancreatic alpha-amylase 1.35E+07 X X X 
Pro-cathepsin H 1.06E+07 1.14E+07 X 1.61E+07 
Prostasin 1.22E+06 1.62E+06 X X 
Protein DJ-1 1.23E+07 7.89E+06 X 1.16E+07 
Serpin B6 X X X 2.74E+06 
Trypsin-3 X 1.60E+06 X 2.58E+06 
Xaa-Pro dipeptidase X X X 1.34E+07 
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Table C.14: The biological process classification of Metal handling according to Gene 
Ontology annotation of proteins identified. Data shown is a comparison of the mean of 
the three most abundant ion peaks of each protein identified, in Healthy Aged Non-
Smokers, n=5, Healthy Aged Smokers, n=5, COPD Ex-Smokers, n = 10  , and COPD 
Smokers, n = 5, respectively 
 





















Annexin A5 1.36E+06 5.18E+07 X 7.53E+07 
Calcineurin-like 
phosphoesterase domain-





Calcyphosin X 1.44E+07 X 1.32E+06 
Calmodulin 2.68E+06 2.84E+06 X 2.48E+07 
Calmodulin-like protein 3 X 1.93E+07 X X 
Calmodulin-like protein 5 X 2.40E+07 X X 
Carbonic anhydrase 1 3.91E+06 X X 5.50E+06 
Carbonic anhydrase 2 X 3.84E+06 X 1.05E+07 






Ferritin heavy chain 6.17E+07 3.08E+06 X 1.99E+07 
Ferritin light chain 4.73E+06 2.03E+07 1.51E+08 3.93E+08 
Gelsolin X X X 1.70E+06 
Glutathione peroxidase 3 1.19E+06 X X X 
Glutathione synthetase X 8.00E+06 X 3.37E+06 
Hemoglobin subunit alpha 1.49E+08 5.40E+07 5.24E+08 8.29E+07 
Hemoglobin subunit beta 1.28E+08 2.04E+07 1.66E+09 7.32E+07 
Hemoglobin subunit delta 7.65E+07   X X 
Hemopexin 2.71E+08 1.89E+08 X 3.48E+08 
Hornerin X X X 2.68E+07 
Lactotransferrin 9.06E+05 X X   
Leukotriene A-4 
hydrolase 
X X X 
1.50E+07 
Protein S100-A11 X 4.08E+06 X 5.82E+06 
Protein S100-A6 X X X 1.14E+08 
Protein S100-A7 1.37E+07 8.42E+07 X X 
Protein S100-A8 3.59E+07 8.57E+08 2.33E+07 2.22E+06 
Protein S100-A9 1.13E+07 X X X 
Pyridoxal kinase X X X 3.73E+06 
Selenium-binding protein 
1 1.67E+07 1.15E+07 
X 
8.65E+06 
Serotransferrin 7.62E+09 3.42E+09 1.10E+09 4.56E+09 
Serum albumin 2.77E+09 1.54E+09 2.62E+10 3.86E+09 
Superoxide dismutase 
[Cu-Zn] X 7.11E+06 X 1.08E+07 






Figure D.1: TEM images acquired for concentrated BAL fluids investigated. 
Representative TEM images of Concentrated BAL, respectively. TEM images were 
acquired with an AMT 16000M camera using a FEI Tecnai 12 transmission microscope 
operated at 120 kV, Negative staining of liposomes with 2% PTA  pH 6.5 and  0.1%  








Figure D.2: TEM images acquired for  simulant: Protein and DPPC in HEPES  
investigated. Representative TEM images of Concentrated BAL, respectively. TEM 
images were acquired with an AMT 16000M camera using a FEI Tecnai 12 transmission 
microscope operated at 120 kV, Negative staining of liposomes with 2% PTA  pH 6.5 and  











Figure D.3: TEM images acquired for simulant: Protein and DPPC, PG, Chol in HEPES 
investigated. Representative TEM images of Concentrated BAL, respectively. TEM 
images were acquired with an AMT 16000M camera using a FEI Tecnai 12 transmission 
microscope operated at 120 kV, Negative staining of liposomes with 2% PTA  pH 6.5 and  





Figure D.4: The average intensity distribution measurements for  50nm polystyrene 
particles in simulant variants (A) simulant: Protein and DPPC in HEPES; (B) simulant: 
Protein and DPPC, PG, Chol in HEPES respectively. All distribution curves as 






Figure D.5: The average intensity distribution measurements for  50nm polystyrene 
particles in (A) Hepes (B) HBSS and (C) CCM FBS 2% respectively. All distribution 









Figure D.6: The average intensity distribution measurements and respective TEM 
images acquired for  50nm polystyrene particles in simulant variants and concentrated 
BAL fluids investigated. (A) simulant: Protein and DPPC, PG, Chol; (B)  simulant: 
Protein and DPPC in HEPES and (C) Concentrated BAL, respectively. TEM images 
were acquired with an AMT 16000M camera using a FEI Tecnai 12 transmission 
microscope operated at 120 kV, Negative staining of liposomes with 2% PTA  pH 6.5 and  
0.1%  trehalose was employed. 
 
 
Figure D.7: The average intensity distribution measurements for 200nm polystyrene 
particles in simulant variants (A) simulant: Protein and DPPC in HEPES; (B) simulant: 
Protein and DPPC, PG, Chol in HEPES respectively. All distribution curves as 





Figure D.8: The average intensity distribution measurements for 200nm polystyrene 
particles in (A) HEPES (B) HBSS and (C) CCM FBS 2% respectively. All distribution 
curves as measured by DLS are representative of at n = 3 at 37 °C at t=0 h. 
 
Figure D.9: The average intensity distribution measurements and respective TEM 
images acquired for 200nm polystyrene particles in simulant variants and concentrated 
BAL fluids investigated. (A) simulant: Protein and DPPC, PG, Chol; (B)  simulant: 
Protein and DPPC in HEPES and (C) Concentrated BAL, respectively. TEM images 
were acquired with an AMT 16000M camera using a FEI Tecnai 12 transmission 
microscope operated at 120 kV, Negative staining of liposomes with 2% PTA  pH 6.5 and  




Figure D.10: The average intensity distribution measurements for 50nm carboxylated 
polystyrene particles in (A) HEPES (B) HBSS and (C) CCM FBS 2% respectively. All 




Figure D.11: The average intensity distribution measurements for 50nm carboxylated 
polystyrene particles in simulant variants (A) simulant: Protein and DPPC in HEPES; 
(B) simulant: Protein and DPPC, PG, Chol in HEPES respectively. All distribution 





Figure D.12: The average intensity distribution measurements and respective TEM 
images acquired for 50nm carboxylated polystyrene particles in simulant variants and 
concentrated BAL fluids investigated (A) simulant: Protein and DPPC, PG, Chol; (B)  
simulant: Protein and DPPC in HEPES and (C) Concentrated BAL, respectively. TEM 
images were acquired with an AMT 16000M camera using a FEI Tecnai 12 transmission 
microscope operated at 120 kV, Negative staining of liposomes with 2% PTA  pH 6.5 and  






Figure D.13: The average intensity distribution measurements for  50nm , 200nm and 50nm carboxylated 
polystyrene particles in simulant: Protein and DPPC in HEPES. All distribution curves as measured by DLS 




 Figure D.14: The average intensity distribution measurements for  50nm , 200nm and 50nm carboxylated polystyrene 
particles in simulant: Protein and DPPC, PG ,chol in HEPES. All distribution curves as measured by DLS are 





Figure D. 15: The effect of simulant (Protein and DPPC) on the proliferation of J774 
cell monolayers. The influence of simulant on cell proliferation was calculated as a 
percentage of the control (CCM 2%) versus simulant. The effect of a series of dilutions of 
simulant (concentrations of 1.1, 2.2, 4.3, 6.5, 8.7, 10.8 mg/ml protein respectively) was 
assessed over a 12 hour periodsof incubation with cells respectively. Cellular metabolic 
activity was measured spectrophotometrically at 570nm, data represents the mean±SD, , 
n = 3 experiments, four replicates per experiment at each dilution 
 
Table D.1: Hanks’ Balanced Salt Solution incorporated with simulant: HBSS Modified, 










Ionic constituent Concentration (mg/L) 
Inorganic salts   
Calcium chloride dihydrate  185.4 
Magnesium sulfate heptahydrate  200 
Potassium chloride  400 
Potassium phosphate monobasic anhydrous  60 
Sodium bicarbonate  350 
Sodium chloride 8000 
Sodium phosphate dibasic heptahydrate  90 
OTHER Concentration (mg/L) 
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